

- (51) International Patent Classification:

C07D 241/44 (2006.01)

C07D 401/04 (2006.01)

C07D 401/12 (2006.01)

C07D 401/14 (2006.01)

C07D 403/04 (2006.01)

C07D 417/12 (2006.01)

C07D 491/18 (2006.01)

C07D 491/20 (2006.01)

C07D 498/20 (2006.01)

A61P 35/00 (2006.01)

A61K 31/498 (2006.01)
- (21) International Application Number:

PCT/US2024/028261
- (22) International Filing Date:

08 May 2024 (08.05.2024)
- (25) Filing Language:

English
- (26) Publication Language:

English
- (30) Priority Data:

63/501,970

12 May 2023 (12.05.2023)

US

63/522,325

21 June 2023 (21.06.2023)

US

63/578,523

24 August 2023 (24.08.2023)

US
- (71) Applicant: MIRATI THERAPEUTICS, INC. [US/US];

3545 Cray Court, San Diego, CA 92121 (US).
- (72) Inventors: MARX, Matthew, Arnold; 10231 Lone Dove

Street, San Diego, CA 92127 (US). SMITH, Christopher,

Ronald; 3316 Windbreak Court, San Diego, CA 92130

(US). KETCHAM, John, Michael; 7447 Baltic Street,

San Diego, CA 92111 (US). HARWOOD, Stephen; 4263

Felton Street, Apartment 7, San Diego, CA 92104 (US).

BURNS, Aaron, Craig; 16954 Manresa Court, San Diego,

CA 92128 (US). LAWSON, John, David; 6755 Xana Way,

Carlsbad, CA 92009 (US). CADDELL-HAATVEIT, Ker-

sti; 3760 3rd Avenue, Apartment 2, San Diego, CA 92103

(US).
- (74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hul-

bert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL

60606 (US).
- (81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,

ZA, ZM, ZW.

(54) Title: SUBSTITUTED QUINOXALINES

(57) Abstract: Disclosed herein are substituted quinoxalines, methods for their preparation, and use thereof.

WO 2024/238221 A1



Substituted QuinoxalinesCross-reference to related applications

[0001] This application claims priority from U.S. Provisional Application No. 63/501,970, filed May 12, 2023, U.S. Provisional Application No. 63/522,325, filed June 21, 2023, and U.S. Provisional Application No. 63/578,523, filed August 24, 2023, the disclosure of each of which is hereby incorporated by reference in its entirety

Field

[0002] This disclosure is directed to substituted quinoxalines, and more particularly to such compounds that are inhibitors of phosphoinositide 3-kinase (PI3K) and therefore useful in the treatment of diseases or disorders associated with PI3K modulation. The disclosure is directed toward compounds and compositions which inhibit PI3K, methods of treating a disease or disorder associated with PI3K (e.g., CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), PIK3CA-related overgrowth syndrome (PROS), breast cancer, brain cancer, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer), and methods of using PI3K inhibitors in combination with one or more additional disorder or cancer therapy.

Background

[0003] The activity of cells can be regulated by external signals that stimulate or inhibit intracellular events. The process by which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response is referred to as signal transduction. Over the past decades, cascades of signal transduction events have been elucidated and found to play a central role in a variety of biological responses. Defects in various components of signal transduction pathways have been found to account for a vast number of diseases, including numerous forms of cancer, inflammatory disorders, metabolic disorders, vascular and neuronal diseases.

[0004] Kinases represent a class of important signaling molecules. Kinases can generally be classified into protein kinases and lipid kinases, and certain kinases exhibit dual specificities. Protein kinases are enzymes that phosphorylate other proteins and/or themselves (i.e., autophosphorylation). Protein kinases can be generally classified into three major groups based upon their substrate utilization: tyrosine kinases which predominantly phosphorylate substrates on tyrosine residues (e.g., erb2, PDGF receptor, EGF receptor, VEGF receptor, src, abl), serine/threonine kinases which predominantly phosphorylate substrates on serine and/or threonine residues (e.g., mTORC1, mTORC2, ATM, ATR, DNA-PK, Akt), and

dual-specificity kinases which phosphorylate substrates on tyrosine, serine and/or threonine residues.

[0005] Lipid kinases are enzymes that catalyze the phosphorylation of lipids within cells. These enzymes, and the resulting phosphorylated lipids and lipid-derived biologically active organic molecules, play a role in many different physiological processes, including cell proliferation, migration, adhesion, and differentiation. A particular group of lipid kinases comprises membrane lipid kinases, i.e., kinases that catalyze the phosphorylation of lipids contained in or associated with cell membranes. Examples of such enzymes include phosphoinositide(s) kinases (such as PI3 -kinases, PI4-Kinases), diacylglycerol kinases, and sphingosine kinases.

[0006] The phosphoinositide 3 -kinases (PI3Ks) signaling pathway is one of the most highly mutated systems in human cancers. PI3K signaling is involved in many other disease states including allergic contact dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, asthma, disorders related to diabetic complications, and inflammatory complications of the cardiovascular system such as acute coronary syndrome.

[0007] PI3Ks are members of a unique and conserved family of intracellular lipid kinases that phosphorylate the 3' -OH group on phosphatidylinositols or phosphoinositides. The PI3K family comprises 15 kinases with distinct substrate specificities, expression patterns, and modes of regulation. The class I PI3Ks (pi 10a, pi 10b, pi 10c, and pi 10g) are typically activated by tyrosine kinases or G-protein coupled receptors to generate PIP3, which engages downstream effectors such as those in the pathways of Akt/PDK1, mTOR, the Tec family kinases, and the Rho family GTPases. The class II and III PI3-Ks play a key role in intracellular trafficking through the synthesis of PI(3)P and PI(3,4)P2.

[0008] The PI3K isoforms have been implicated, for example, in a variety of human cancers and disorders. Mutations in the gene coding for PI3K isoforms or mutations which lead to upregulation of a PI3K isoform are believed to occur in many human cancers. Mutations in the gene coding for a PI3K isoform are point mutations clustered within several hotspots in helical and kinase domains. Because of the high rate of PI3K mutations, targeting of this pathway may provide valuable therapeutic opportunities.

[0009] Genetic alterations in genes in PI3K signaling are believed to be involved in a range of cancers such as endometrial cancer, breast cancer, esophageal squamous-cell cancer, cervical squamous-cell carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, bladder urothelial carcinoma, glioblastoma, ovarian cancer, non-small-cell lung cancer, esophagogastric cancer, nerve-sheath tumor, head and neck squamous-cell carcinoma, melanoma, esophagogastric adenocarcinoma, soft-tissue sarcoma, prostate cancer,

fibrolamellar carcinoma, hepatocellular carcinoma, diffuse glioma, colorectal cancer, pancreatic cancer, cholangiocarcinoma, B-cell lymphoma, mesothelioma, adrenocortical carcinoma, renal non- clear-cell carcinoma, renal clear-cell carcinoma, germ-cell carcinoma, thymic tumor, pheochromocytoma, miscellaneous neuroepithelial tumor, thyroid cancer, leukemia, and encapsulated glioma.

[0010] The alpha (α) isoform of PI3K has been implicated, for example, in a variety of human cancers. Angiogenesis has been shown to selectively require the alpha (α) isoform of PI3K in the control of endothelial cell migration. Mutations in the gene coding for PI3K α or mutations which lead to upregulation of PI3K α are believed to occur in many human cancers such as lung, stomach, endometrial, ovarian, bladder, breast, colon, brain, prostate, and skin cancers. Mutations in the gene coding for PI3K α are point mutations clustered within several hotspots in helical and kinase domains, such as E542K, E545K, and H1047R. Many of these mutations have been shown to be oncogenic gain-of-function mutations. Because of the high rate of PI3K α mutations, targeting of this pathway may provide valuable therapeutic opportunities. While other PI3K isoforms such as PI3K δ or PI3K γ are expressed primarily in hematopoietic cells, PI3K α , along with PI3K β , is expressed constitutively.

[0011] Due to the central role of PI3K α in regulating organismal glucose homeostasis, PI3K inhibition in patients often gives rise to hyperglycemia and/or hyperinsulinemia. High levels of circulating insulin could potentially be mitogenic and/or antiapoptotic for cancer cells and thus negate the antiproliferative effects of PI3K inhibitors.


[0012] In the setting of cancer with mutated PI3K α , one way to overcome the problem of compensatory production of insulin and/or glucose upon systemic PI3K α inhibition would be to develop inhibitors with enhanced selectivity for mutant PI3K α over wild-type PI3K α . This would create an increased window for drug dosing to selectively inhibit the pathologic signaling of mutant PI3K α in the cancer cells without affecting the wild-type PI3K α in the host tissues that control systemic metabolism, thus limiting toxicities and permitting higher doses and more complete inhibition of the drug target.

[0013] Existing PI3K α inhibitors are nearly equipotent to wild-type and mutant PI3K α . Mutant selective inhibitors have been elusive due to the PI3K α mutations location far from the active site. As such, inhibitors which target a second, peripheral binding pocket near a known mutation (e.g., H1047R) may provide a route to selective PI3K α inhibition. Thus, targeting a mutated, peripheral binding pocket of PI3K α , may in turn provide a valuable therapeutic target for drug development.

[0014] As such, kinases, for example lipid kinases such as PI3Ks, are prime targets for drug development.

Summary

[0015] In one aspect, the present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, and prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof:



(I)

or a pharmaceutically acceptable salt or deuterated form thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3$ alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, tetrazolyl or halogen;

each R^A is independently H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or 2-carboxy-3,4,5-trihydroxytetrahydro-2H-pyran-6-yl;

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^5 is hydrogen, $-OR^{20}$, $-SR^{20}$, C_1 - C_6 alkyl, halogen, hydroxy, cyano, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy(C_1 - C_6)alkyl, cyano, amino, mono- or di(C_1 - C_3) alkyl amino, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), 3-8 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, phenyl, 3-8 membered heterocyclyl and heteroaryl is optionally independently substituted with 1-3 of halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, oxo, cyano, amino, mono- or di(C_1 - C_3) alkyl amino,

wherein each R^{20} is aryl, aryl(C_1 - C_6)alkyl, 5-7 membered heteroaryl or 5-7 membered heteroaryl(C_1 - C_6)alkyl, wherein each aryl and heteroaryl is optionally

independently substituted with one to four of C₁-C₆ alkyl, halogen, hydroxy, cyano, haloC₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy(C₁-C₆)alkyl, cyano, amino, or mono- or di(C₁-C₃) alkyl amino;

R^{5A} represents NR⁷R⁸, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl, or 5-6 membered heteroaryl, wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl and heteroaryl is optionally independently substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, oxo, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₆ alkanoyl, cyano, amino, or mono- or di(C₁-C₃) alkyl amino;

R⁷ represents H or C₁-C₃ alkyl;

R⁸ represents H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), 3-8 membered heterocyclyl, 3-8 membered heterocyclyl(C₁-C₆) alkyl, phenyl(C₁-C₆)alkyl or 5-6 membered heteroaryl(C₁-C₆)alkyl, wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl, heteroaryl and 3-8 membered heterocyclyl is optionally independently substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, oxo, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, mono- or di(C₁-C₃) alkyl amino, amino- or mono- or di(C₁-C₃) alkylaminocarbonyl, -SO₂R¹⁶, -SO₂(NR¹⁶)₂, or -NR¹⁷SO₂R¹⁶ wherein each R¹⁶ is independently C₁-C₆ alkyl and R¹⁷ is C₁-C₆ alkyl; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group or fused ring system and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁-C₆ alkyl optionally substituted with C₁-C₃ alkoxy, (ii) C₁-C₆ alkoxy, (iii) C₃-C₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁-C₃ alkyl, (ix) hydroxy C₁-C₆ alkyl, (x) amino, (xi) mono- or di-(C₁-C₆ alkyl) amino where one alkyl is optionally substituted with oxo, (xii) C₁-C₆ alkanoyl optionally substituted with 1 or 2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, C₃-C₆ cycloalkyl, phenyl, 5-6 membered heteroaryl, wherein each C₁-C₃ alkyl and C₃-C₆ cycloalkyl

on the alkanoyl is optionally substituted with halogen, hydroxy or amino, and wherein each cycloalkyl, phenyl and heteroaryl on the alkanoyl is optionally substituted with C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, amino, hydroxy, or cyano, (xii) C₃-C₆ cycloalkyloxy, (xiii) phenyl, (xiv) phenyl(C₁-C₃ alkanoyl), (xv) 5-7 membered heterocyclyl, or (xvi) 5-6 membered heteroaryl, wherein each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, mono- or di(C₁-C₃ alkyl)amino, amino(C₁-C₃) alkyl, mono- or di(C₁-C₃ alkyl)amino(C₁-C₃) alkyl, or amino- or mono- or di(C₁-C₃) alkylaminocarbonyl.

[0016] In another aspect, the present disclosure provides for a pharmaceutical composition comprising a compound or salt as otherwise described herein together with a pharmaceutically acceptable carrier, excipient or diluent.

[0017] In another aspect, the present disclosure provides for a method of treating a disease or disorder associated with modulation of phosphoinositide 3-kinase (PI3K), comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any as otherwise described herein or a pharmaceutical composition as otherwise described herein.

[0018] In another aspect, the present disclosure provides for a method of inhibiting phosphoinositide 3-kinase (PI3K), comprising administering to a patient in need thereof a therapeutically effective amount of a compound as otherwise described herein or a pharmaceutical composition as otherwise described herein.

[0019] In another aspect, the present disclosure provides for a method of treating cancer or a disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound as otherwise described herein or a pharmaceutical composition as otherwise described herein.

[0020] The compounds disclosed herein selectively bind to H1047R-mutated PI3K α and not to wild-type PI3K α .

[0021] In another aspect, the present disclosure provides intermediates as described herein, such intermediates being suitable for use in a process for preparing a compound as described herein.

[0022] Other aspects and embodiments of the disclosure are evident in view of the detailed description provided herein.

DETAILED DESCRIPTION OF THE INVENTION

[0023] The present invention relates to inhibitors of PI3K α . In particular, the present invention relates to compounds that inhibit PI3K α activity, pharmaceutical compositions comprising a therapeutically effective amount of the compounds, and methods of use therefor.

DEFINITIONS

[0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, patent applications, and publications referred to herein are incorporated by reference to the extent they are consistent with the present disclosure. Terms and ranges have their generally defined definition unless expressly defined otherwise.

[0025] For simplicity, chemical moieties are defined and referred to throughout primarily as univalent chemical moieties (e.g., alkyl, aryl, etc.). Nevertheless, such terms may also be used to convey corresponding multivalent moieties under the appropriate structural circumstances clear to those skilled in the art. For example, while an "alkyl" moiety generally refers to a monovalent radical (e.g. CH₃-CH₂-), in certain circumstances a bivalent linking moiety can be "alkyl," in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH₂-CH₂-), which is equivalent to the term "alkylene." (Similarly, in circumstances in which a divalent moiety is required and is stated as being "aryl," those skilled in the art will understand that the term "aryl" refers to the corresponding divalent moiety, arylene.) All atoms are understood to have their normal number of valences for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of the S).

[0026] The term "amino" refers to -NH₂.

[0027] The term "acetyl" refers to -C(O)CH₃.

[0028] As herein employed, the term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent wherein the alkyl and aryl portions are as defined herein.

[0029] The term "alkyl" as employed herein refers to saturated straight and branched chain aliphatic groups having from 1 to 12 carbon atoms. As such, "alkyl" encompasses C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁ and C₁₂ groups. Alkyl groups may be branched or unbranched. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

[0030] The term "alkenyl" as used herein means an unsaturated straight or branched chain aliphatic group with one or more carbon-carbon double bonds, having from 2 to 12 carbon atoms. As such, "alkenyl" encompasses C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁ and C₁₂ groups. Examples of alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl, and


hexenyl.

[0031] The term "alkynyl" as used herein means an unsaturated straight or branched chain aliphatic group with one or more carbon-carbon triple bonds, having from 2 to 12 carbon atoms. As such, "alkynyl" encompasses C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁ and C₁₂ groups. Examples of alkynyl groups include, without limitation, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0032] An "alkylene," "alkenylene," or "alkynylene" group is an alkyl, alkenyl, or alkynyl group, as defined hereinabove, that is positioned between and serves to connect two other chemical groups. Examples of alkylene groups include, without limitation, methylene, ethylene, propylene, and butylene. Representative alkenylene groups include, without limitation, ethenylene, propenylene, and butenylene. Representative alkynylene groups include, without limitation, ethynylene, propynylene, and butynylene.

[0033] The term "alkoxy" refers to -O(C₁-C₆ alkyl).

[0034] The term "amino- or mono- or di(C₁-C₃) alkylaminocarbonyl" refers to carbamoyl groups, i.e., groups of the formula



wherein R¹⁴ and R¹⁵ independently represent hydrogen and C₁-C₃ alkyl.

[0035] The term "cycloalkyl" as employed herein is a saturated and partially unsaturated cyclic hydrocarbon group having 3 to 12 carbons. As such, "cycloalkyl" includes C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁ and C₁₂ cyclic hydrocarbon groups. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. The term "cycloalkyl" also encompasses bridged ring systems such as as bicyclo[1.1.1]pentan-2-yl, bicyclo[1.1.1]pentan-1-yl, and bicyclo[2.2.2]octan-2-yl.

[0036] The term "C₃-C₆ cycloalkyloxy" refers to groups of the formula -O(C₃-C₆ cycloalkyl).

[0037] The term "heteroalkyl" refers to an alkyl group, as defined hereinabove, wherein one or more carbon atoms in the chain are independently replaced O, S, or NR^x, wherein R^x is hydrogen or C₁ - C₃ alkyl. Examples of heteroalkyl groups include methoxymethyl, methoxyethyl and methoxypropyl.

[0038] An "aryl" group is a C₆-C₁₄ aromatic moiety comprising one to three aromatic rings. As such, "aryl" includes C₆, C₁₀, C₁₃, and C₁₄ cyclic hydrocarbon groups. A representative aryl group is a C₆-C₁₀ aryl group. Particular aryl groups include, without limitation, phenyl, naphthyl,

anthracenyl, and fluorenyl. An "aryl" group also includes fused multicyclic (e.g., bicyclic) ring systems in which one or more of the fused rings is non-aromatic, provided that at least one ring is aromatic, such as indenyl.

[0039] An "aralkyl" or "arylalkyl" group comprises an aryl group covalently linked to an alkyl group wherein the moiety is linked to another group via the alkyl moiety. An representative aralkyl group is $-(C_1-C_6)alkyl(C_6-C_{10})aryl$, including, without limitation, benzyl, phenethyl, and naphthylmethyl. For example, an arC_1-C_3alkyl is an aryl group covalently linked to a C_1-C_3 alkyl.

[0040] As used herein, the term "fused" when used to define rings, e.g., bicyclic fused ring systems, refers to bicyclic, tricyclic, etc. ring systems sharing 2 or more atoms. Examples of such fused ring systems are (1S,4R)-2-azabicyclo[2.2.1]heptane; 2-azabicyclo[2.2.2]octane, 2,5-diazabicyclo[2.2.2]octane; 2-oxa-5-azabicyclo[2.2.2]octane; isoindoline; 1,2,3,4-tetrahydro-2,6-naphthyridine, 1,2,3,4-tetrahydroisoquinoline; 1,2,3,4-tetrahydro-1,4-(epiminomethano)naphthalene; and 3-azabicyclo[3.1.0]hexane.

[0041] A "heterocyclyl" or "heterocyclic" or "heterocycloalkyl" group is a mono- or bicyclic (fused or spiro) ring structure having from 3 to 12 atoms, (3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 atoms), for example 4 to 8 atoms, wherein one or more ring atoms are independently $-C(O)-$, N, NR^d , O, or S, and the remainder of the ring atoms are quaternary or carbonyl carbons. Examples of heterocyclic groups include, without limitation, epoxy, oxiranyl, oxetanyl, azetidiny, aziridiny, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, pyrrolidiny, piperidiny, piperaziny, imidazolidiny, thiazolidiny, thiatanyl, dithianyl, trithianyl, azathianyl, oxathianyl, dioxolanyl, oxazolidiny, oxazolidinonyl, decahydroquinoliny, piperidonyl, 4-piperidonyl, thiomorpholiny, dimethyl-morpholiny, and morpholiny. Examples of heterocyclic groups that are spiro ring systems are 6-azaspiro[2.5]octan-6-yl, 5-azaspiro[2.4]heptan-5-yl, 6-azaspiro[3.4]octan-6-yl, 5-oxa-7-azaspiro[3.4]octan-7-yl, 5,5-dimethyl-4-oxa-7-azaspiro[2.5]octan-7-yl, 2-oxa-6-azaspiro[3.3]heptan-6-yl, 1-oxa-6-azaspiro[3.4]octan-6-yl and 7,7-dimethyl-5-azaspiro[2.5]octan-5-yl. Specifically excluded from the scope of this term are compounds having adjacent ring O and/or S atoms. The heterocyclic groups can be attached to a parent group (i.e., the point of attachment) via any ring atom, including one of the heteroatoms or one of the carbon atoms, in the heterocyclic ring group. As chemically required, the heterocyclic ring may be attached to one or more other groups, for instance if operating as a bridging group. Thus, the term "heterocyclyl" includes groups such as azabicyclo[2.1.1]hexan-2-yl, azabicyclo[2.2.1]heptan-7-yl, 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl, diazabicyclo[3.1.1]heptan-6-yl and hexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl. The term "heterocyclyl" also includes fused multicyclic (e.g., bicyclic) ring systems in which one or more of the fused rings is aromatic or non-aromatic, provided that at least one ring is non-aromatic contains an N, O,

or S ring atom. Examples of such fused multicyclic ring systems are indolinyl, indolin-2-yl, 2,3-dihydrobenzofuran-2-yl and 2,3,4,5-tetrahydrobenzo[d]oxazol-2-yl. Each of these examples is a 9-membered heterocyclyl.

[0042] As used herein, the term "heteroaryl" refers to a group having 5 to 14 ring atoms, preferably 5, 6, 10, 13 or 14 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to three heteroatoms that are each independently N, O, or S. "Heteroaryl" also includes fused multicyclic (e.g., bicyclic) ring systems in which one or more of the fused rings is non-aromatic, provided that at least one ring is aromatic and at least one ring contains an N, O, or S ring atom. The heteroaryl groups can be attached to a parent group (i.e., the point of attachment) via any ring atom, including one of the heteroatoms or one of the carbon atoms, in the heteroaryl ring group. As chemically required, the heteroaryl may be attached to one or more other groups, for instance if operating as a bridging group.

[0043] Examples of heteroaryl groups include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzo[d]oxazol-2(3H)-one, 2H-benzo[b][1,4]oxazin-3(4H)-one, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, furanyl, furazanyl, imidazolyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenaziny, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizyl, quinoxalyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[0044] An "arylene," "heteroarylene," or "heterocyclylene" group is a bivalent aryl, heteroaryl, or heterocyclyl group, respectively, as defined hereinabove, that is positioned between and serves to connect two other chemical groups.

[0045] As employed herein, when a moiety (e.g., cycloalkyl, aryl, heteroaryl, heterocyclyl, urea, etc.) is described as "optionally substituted" without expressly stating the substituents it is meant that the group optionally has multiple non-hydrogen substituents, for example from one

to five, or from one to four, or from one to three, or one or two, non-hydrogen substituents.

[0046] The term "halogen" or "halo" as employed herein refers to chlorine, bromine, fluorine, or iodine.

[0047] The term "haloalkyl" refers to an alkyl chain in which one or more hydrogens have been replaced by a halogen. Representative haloalkyls are trifluoromethyl, difluoromethyl, fluorochloromethyl, chloromethyl, and fluoromethyl.

[0048] The term "hydroxyalkyl" refers to -alkylene-OH.

[0049] It is to be understood that each individual atom present in Formula (I) and the compounds within formula (I), may be present in the form of any of its naturally occurring isotopes, with the most abundant isotope(s) being preferred. Thus, by way of example, each individual hydrogen atom present in formula (I), or in the formulae depicted hereinafter, may be present as a 1H , 2H (deuterium; D) or 3H (tritium; T) atom, preferably 1H . Similarly, by way of example, each individual carbon atom present in formula (I), or in the formulae depicted hereinafter, may be present as a 12C , 13C or 14C atom, preferably 12C .

[0050] Particular deuterated compounds of this disclosure are those wherein $\text{R}^{5\text{A}}$ has one or more hydrogen atoms replaced with a deuterium. Representative deuterated $\text{R}^{5\text{A}}$ groups are pyrrolidin-1-yl- d_8 , morpholino- d_8 , (piperazin-1-yl-2,2,3,3,5,5,6,6- d_8), and piperidine-1-yl- d_{10} .

[0051] As used herein, "an effective amount" of a compound is an amount that is sufficient to negatively modulate or inhibit the activity of PI3K α .


[0052] As used herein, a "therapeutically effective amount" of a compound is an amount that is sufficient to ameliorate or in some manner reduce a symptom or stop or reverse progression of a condition, or negatively modulate or inhibit the activity of PI3K α . Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective.

[0053] As used herein, "treatment" means any manner in which the symptoms or pathology of a condition, disorder or disease in a patient are ameliorated or otherwise beneficially altered.

[0054] As used herein, "amelioration of the symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition" refers to any lessening, whether permanent or temporary, lasting or transient, that can be attributed to or associated with administration of the composition.

COMPOUNDS

[0055] In one aspect, the present disclosure provides compounds of Formula (I):



(I)

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R¹ is H, C₁-C₃ alkyl, or C₃-C₆ cycloalkyl;

R² is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R¹²;

each R¹² is independently C₁-C₄ alkyl, -OR^A, -C(O)OR^A, (C₁-C₃ alkyl)-OR^A, -C(O)N(R^A)₂, cyano, tetrazolyl or halogen;

each R^A is independently H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, cycloalkyl or 2-carboxy-3,4,5-trihydroxytetrahydro-2H-pyran-6-yl;

R³ is C₁-C₃ alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl;

R⁴ is H, halogen, C₁-C₃ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl or cyano, wherein each C₁-C₃ alkyl and C₃-C₆ cycloalkyl is optionally substituted with 1-5 halo groups;

R⁶ and R^{6A} independently represent H or C₁-C₆ alkyl;

R⁵ is hydrogen, -OR²⁰, -SR²⁰, C₁-C₆ alkyl, halogen, hydroxy, cyano, haloC₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy(C₁-C₆)alkyl, cyano, amino, mono- or di(C₁-C₃) alkyl amino, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), 3-8 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, phenyl, 3-8 membered heterocyclyl and heteroaryl is optionally independently substituted with 1-3 of halogen, hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, haloC₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, oxo, cyano, amino, mono- or di(C₁-C₃) alkyl amino,

wherein R²⁰ is aryl, aryl(C₁-C₆)alkyl, 5-7 membered heteroaryl or 5-7 membered heteroaryl(C₁-C₆)alkyl, wherein each aryl and heteroaryl is optionally independently substituted with one to four of C₁-C₆ alkyl, halogen, hydroxy, cyano,

haloC₁₋₃ alkyl, hydroxy C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, cyano, amino, or mono- or di(C₁₋₃) alkyl amino;

R^{5A} represents NR⁷R⁸, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), phenyl, or 5-6 membered heteroaryl, wherein each C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), phenyl and heteroaryl is optionally independently substituted with 1-3 of halogen, halo(C₁₋₃ alkyl), hydroxy, oxo, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₆ alkanoyl, cyano, amino, or mono- or di(C₁₋₃) alkyl amino;

R⁷ represents H or C₁₋₃ alkyl;

R⁸ represents H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), 3-8 membered heterocyclyl, 3-8 membered heterocyclyl(C₁₋₆) alkyl, phenyl(C₁₋₆)alkyl or 5-6 membered heteroaryl(C₁₋₆)alkyl, wherein each C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), phenyl, heteroaryl and 3-8 membered heterocyclyl is optionally independently substituted with 1-3 of halogen, halo(C₁₋₃ alkyl), hydroxy, oxo, C₁₋₃ alkyl, C₁₋₃ alkoxy, cyano, amino, mono- or di(C₁₋₃) alkyl amino, amino- or mono- or di(C₁₋₃) alkylaminocarbonyl, -SO₂R¹⁶, -SO₂(NR¹⁶)₂, or -NR¹⁷SO₂R¹⁶ wherein each R¹⁶ is independently C₁₋₆ alkyl and R¹⁷ is C₁₋₆ alkyl; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group


is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group or fused ring system and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and wherein each ring Q is optionally substituted, on an aromatic or non-aromatic

portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁₋₆ alkyl optionally substituted with C₁₋₃ alkoxy, (ii) C₁₋₆ alkoxy, (iii) C₃₋₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁₋₃ alkyl, (ix) hydroxy C₁₋₆ alkyl, (x) amino, (xi) mono- or di-(C₁₋₆ alkyl) amino where one alkyl is optionally substituted with oxo, (xii) C₁₋₆ alkanoyl optionally substituted with 1 or 2 of C₁₋₃ alkyl, C₁₋₃ alkoxy, C₃₋₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁₋₃ alkyl, hydroxy C₁₋₃ alkyl, amino, mono- or di-(C₁₋₆ alkyl) amino, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl, wherein each C₁₋₃ alkyl and C₃₋₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino,

and wherein each cycloalkyl, phenyl and heteroaryl on the alkanoyl is optionally substituted with C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, amino, hydroxy, or cyano, (xii) C₃-C₆ cycloalkyloxy, (xiii) phenyl, (xiv) phenyl(C₁-C₃ alkanoyl), (xv) 5-7 membered heterocyclyl, or (xvi) 5-6 membered heteroaryl, wherein each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, mono- or di(C₁-C₃ alkyl)amino, amino(C₁-C₃) alkyl, mono- or di(C₁-C₃ alkyl)amino(C₁-C₃) alkyl, or amino- or mono- or di(C₁-C₃) alkylaminocarbonyl.

[0056] In another aspect, the present disclosure provides compounds of Formula (IV):



(IV)

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R¹ is H, C₁-C₃ alkyl, or C₃-C₆ cycloalkyl;

R² is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R¹²;

each R¹² is independently C₁-C₄ alkyl, -OR^A, -C(O)OR^A, (C₁-C₃ alkyl)-OR^A, -C(O)N(R^A)₂, cyano, tetrazolyl, or halogen;

each R^A is independently H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl; and

R³ is C₁-C₃ alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl;

R⁴ is H, halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl or cyano, wherein each C₁-C₃ alkyl and C₃-C₆ cycloalkyl is optionally substituted with 1-5 halo groups;

R⁶ and R^{6A} independently represent H or C₁-C₆ alkyl;

R⁵ is C₁-C₂ alkyl, cyclopropyl, bromo, chloro, fluoro, cyano, or trifluoromethyl;

R^{5A} represents NR⁷R⁶, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl or 5-6 membered heteroaryl, wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of

halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino;

R⁷ represents H or C₁-C₃ alkyl;

R⁸ represent H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl) wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl and C₃-C₆ cycloalkyl(C₁-C₃ alkyl) is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁-C₆ alkyl, (ii) C₁-C₆ alkoxy, (iii) C₃-C₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁-C₃ alkyl, (ix) amino, (x) mono- or di-(C₁-C₆ alkyl) amino, (xi) C₂-C₆ alkanoyl optionally substituted with 1 or 2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C₃-C₆ cycloalkyloxy, or (xiii) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

[0057] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁶ and R^{6A} represent hydrogen.

[0058] In certain embodiments of formula (I) or formula (IV) as otherwise described herein one of R⁶ and R^{6A} represents hydrogen and the other represents C₁-C₆ alkyl.

[0059] In certain embodiments of formula (I) or formula (IV) as otherwise described herein one

of R⁶ and R^{6A} represents hydrogen and the other represents C₁-C₆ alkyl.

[0060] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁶ and R^{6A} independently represent C₁-C₆ alkyl.

[0061] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R¹ is H.

[0062] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R¹ is CH₃.

[0063] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R¹ is H or CH₃.

[0064] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups.

[0065] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A.

[0066] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A, where R^A is H, methyl or ethyl.

[0067] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A, where R^A is H.

[0068] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A, where R^A is methyl or ethyl.

[0069] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A, where R^A is 2-carboxy-3,4,5-trihydroxytetrahydro-2H-pyran-6-yl. A suitable compound to prepare compounds with such R^A groups is (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid.

[0070] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A.

[0071] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups,

and at least one R¹² group is a tetrazolyl, particularly 1*H*-tetrazol-5-yl.

[0072] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl, pyridinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl or pyrimidinyl, each of which is optionally substituted with 1-5 R¹².

[0073] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R¹².

[0074] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A.

[0075] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A, where R^A is H, methyl or ethyl.

[0076] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A, where R^A is H.

[0077] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A, where R^A is methyl or ethyl.

[0078] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl which is optionally substituted with 1-5 R¹².

[0079] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A.

[0080] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A, where R^A is H, methyl or ethyl.

[0081] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A, where R^A is H.

[0082] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is phenyl which is optionally substituted with 1-5 R¹², and at least one R¹² group is -C(O)OR^A, where R^A is methyl or ethyl.

[0083] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is pyridinyl which is optionally substituted with 1-5 R¹².

[0084] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$.

[0085] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H, methyl or ethyl.

[0086] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H.

[0087] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is methyl or ethyl.

[0088] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyrimidinyl which is optionally substituted with 1-5 R^{12} .

[0089] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyrimidinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$.

[0090] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyrimidinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H, methyl or ethyl.

[0091] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyrimidinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H.

[0092] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^2 is pyrimidinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is methyl or ethyl.

[0093] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^3 is C_1 - C_3 alkyl, wherein the alkyl group is unsubstituted, substituted with 1-5 halo groups, or perfluorinated.

[0094] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^3 is C_1 - C_3 alkyl, wherein the alkyl group is unsubstituted, substituted with 1-5 halo groups, or perfluorinated.

[0095] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^3 is C_1 - C_3 alkyl.

[0096] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R³ is ethyl or R³ is methyl.

[0097] In certain embodiments of formula (I) as otherwise described herein R⁵ is hydrogen, C₁-C₃ alkyl, haloC₁-C₃ alkyl, halogen, cyano, C₃-C₆ cycloalkyl, or C₃-C₆ cycloalkyl(C₁-C₃ alkyl).

[0098] In certain embodiments of formula (I) as otherwise described herein R⁵ is haloC₁-C₃ alkyl, particularly, fluoromethyl, difluoromethyl or trifluoromethyl.

[0099] In certain embodiments of formula (I) as otherwise described herein R⁵ is phenyl or 5-6 membered heteroaryl, wherein each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1-3 of halogen, hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino.

[00100] In certain embodiments of formula (I) as otherwise described herein R⁵ is hydrogen, C₁-C₃ alkyl, haloC₁-C₃ alkyl, halogen, cyano, cyclopropyl, or cyclopropyl(C₁-C₂ alkyl).

[00101] In certain embodiments of formula (I) as otherwise described herein R⁵ is methyl, ethyl, cyclopropyl or cyano.

[00102] In certain embodiments of formula (I) as otherwise described herein R⁵ is methyl or cyano.

[00103] In certain embodiments of formula (I) as otherwise described herein R⁵ is C₁-C₃ alkyl, haloC₁-C₃ alkyl, halogen, cyano, cyclopropyl, or cyclopropyl(C₁-C₂ alkyl).

[00104] In certain embodiments of formula (I) as otherwise described herein R⁵ is hydrogen, halogen, hydroxy, cyano or amino.

[00105] In certain embodiments of formula (I) as otherwise described herein R⁵ is cycloalkyl, phenyl or 5-6 membered heteroaryl, where each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1-3 of halogen, hydroxy, C₁-C₂ alkyl, C₁-C₂ alkoxy, cyano, amino, or mono- or di(C₁-C₂) alkylamino.

[00106] In certain embodiments of formula (I) as otherwise described herein R⁵ is phenyl or 5-6 membered heteroaryl, where each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1 or 2 of halogen, hydroxy, C₁-C₂ alkyl, C₁-C₂ alkoxy, cyano, amino, or mono- or di(C₁-C₂) alkylamino.

[00107] In certain embodiments of formula (I) as otherwise described herein R⁵ is heterocyclyl connected to the parent ring system at a carbon atom and which heterocyclyl is optionally substituted with 1-3 of halogen, hydroxy, C₁-C₂ alkyl, C₁-C₂ alkoxy, cyano, amino, or mono- or di(C₁-C₂) alkylamino.

[00108] In certain embodiments of formula (IV) as otherwise described herein R⁵ is

methyl.

[00109] In certain embodiments of formula (IV) as otherwise described herein R⁵ is ethyl.

[00110] In certain embodiments of formula (IV) as otherwise described herein R⁵ is cyano.

[00111] In certain embodiments of formula (IV) as otherwise described herein R⁵ is cyclopropyl.

[00112] In certain embodiments of formula (IV) as otherwise described herein R⁵ is bromo.

[00113] In certain embodiments of formula (IV) as otherwise described herein R⁵ is fluoro.

[00114] In certain embodiments of formula (IV) as otherwise described herein R⁵ is chloro.

[00115] In certain embodiments of formula (IV) as otherwise described herein R⁵ is trifluoromethyl.

[00116] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is optionally substituted phenyl.

[00117] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R² is optionally substituted pyridinyl.

[00118] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁴ is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl or cyano.

[00119] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁴ is hydrogen, fluoro, chloro, methyl, trifluoromethyl or cyano.

[00120] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁴ is fluoro, chloro, methyl, cyclopropyl or cyano.

[00121] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁴ is fluoro, chloro, methyl, cyclopropyl, trifluoromethyl or cyano.

[00122] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁴ is fluoro, methyl, trifluoromethyl or cyano.

[00123] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁴ is fluoro, methyl or cyano.

[00124] In certain embodiments of formula (I) or formula (IV) as otherwise described

herein R^{5A} represents C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl);

[00125] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^{5A} represents NR⁷R⁸.

[00126] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁷ is hydrogen and R⁸ represents hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl).

[00127] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-7 membered monocyclic heterocyclyl group, and

the heterocyclyl group is optionally substituted with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, or phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00128] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-7 membered monocyclic heterocyclyl group, and

the heterocyclyl group is fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen atoms and the remainder carbons, wherein

the fused heterocyclyl group is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, or phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00129] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R⁷ and R⁸ together with the nitrogen to which they are attached form a 3-7 membered monocyclic heterocyclyl group, and

the heterocyclyl group forms a spirocyclic ring system having up to 10 total ring members with a carbon atom from the monocyclic heterocyclyl group and additional carbon, nitrogen, sulfur or oxygen atoms, wherein


wherein the spirocyclic ring system is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.

[00130] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.

[00131] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_3 alkyl, amino, or mono- or di-(C_1 - C_3 alkyl) amino.

[00132] In certain embodiments of formula (I) or formula (IV) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently methyl, ethyl, methoxy, ethoxy, cyano, fluoro, chloro, trifluoromethyl, cyclopropyl, or cyclopropylmethyl.

[00133] In another aspect, the present disclosure provides compounds of Formula (IV-A):



(IV-A)

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3$ alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^{5A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;

R^7 represents H or C_1 - C_3 alkyl;

R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or

R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group


is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1 - C_6 alkyl, (ii) C_1 - C_6 alkoxy, (iii) C_3 - C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vi)

halogen, (vii) halo C₁-C₃ alkyl, (viii) hydroxy C₁-C₆ alkyl, (ix) amino, (x) mono- or di-(C₁-C₆ alkyl) amino, (xi) C₂-C₆ alkanoyl optionally substituted with 1 or 2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C₃-C₆ cycloalkyloxy, or (xiii) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00134] In another aspect, the present disclosure provides compounds of Formula (IV-B):



(IV-B)

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R¹ is H, C₁-C₃ alkyl, or C₃-C₆ cycloalkyl;

R² is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R¹²;

each R¹² is independently C₁-C₄ alkyl, -OR^A, -C(O)OR^A, (C₁-C₃ alkyl)-OR^A, -C(O)N(R^A)₂, cyano, or halogen;

each R^A is independently H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl; and

R³ is C₁-C₃ alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl;

R⁴ is H, halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl or cyano, wherein each C₁-C₃ alkyl and C₃-C₆ cycloalkyl is optionally substituted with 1-5 halo groups;

R⁶ and R^{6A} independently represent H or C₁-C₆ alkyl;

R^{5A} represents NR⁷R⁸, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl or 5-6 membered heteroaryl, wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆

cycloalkyl(C₁-C₃ alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino;

R⁷ represents H or C₁-C₃ alkyl;

R⁸ represent H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl) wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl and C₃-C₆ cycloalkyl(C₁-C₃ alkyl) is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is


a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁-C₆ alkyl, (ii) C₁-C₆ alkoxy, (iii) C₃-C₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁-C₃ alkyl, (ix) amino, (x) mono- or di-(C₁-C₆ alkyl) amino, (xi) C₂-C₆ alkanoyl optionally substituted with 1 or 2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C₃-C₆ cycloalkyloxy, or (xiii) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00135] In another aspect, the present disclosure provides compounds of Formula (IV-C):



(IV-C)

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3 \text{ alkyl})-OR^A$, $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^{6A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;

R^7 represents H or C_1 - C_3 alkyl;

R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or


R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or
 with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

[00136] wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1-C_6 alkyl, (ii) C_1-C_6 alkoxy, (iii) C_3-C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C_1-C_3 alkyl, (ix) hydroxy C_1-C_6 alkyl, (x) amino, (xi) mono- or di- (C_1-C_6) alkyl amino, (xii) C_2-C_6 alkanoyl optionally substituted with 1 or 2 of C_1-C_3 alkyl, C_1-C_3 alkoxy, C_3-C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1-C_3 alkyl, hydroxy C_1-C_3 alkyl, amino, or mono- or di- (C_1-C_6) alkyl amino, wherein each C_1-C_3 alkyl or C_3-C_6 cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xiii) C_3-C_6 cycloalkyloxy, or (xiv) phenyl, phenyl(C_1-C_3 alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C_1-C_3 alkyl, C_1-C_3 alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di- (C_1-C_3) alkyl amino.

[00137] In another aspect, the present disclosure provides compounds of Formula (IV-D):



(IV-D)


and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R^1 is H, C_1-C_3 alkyl, or C_3-C_6 cycloalkyl;

- R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;
- each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3 \text{ alkyl})-OR^A$, $-C(O)N(R^A)_2$, cyano, or halogen;
- each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and
- R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;
- R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;
- R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;
- R^{5A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;
- R^7 represents H or C_1 - C_3 alkyl;
- R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or
- R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is
- a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or
- with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and
- wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1 - C_6 alkyl, (ii) C_1 - C_6 alkoxy, (iii) C_3 - C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C_1 - C_3 alkyl, (ix) hydroxy C_1 - C_6 alkyl, (x) amino, (xi) mono- or di-(C_1 - C_6 alkyl) amino, (xii) C_2 - C_6 alkanoyl optionally substituted with 1 or 2 of C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo,

halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C₃-C₆ cycloalkyloxy, or (xiii) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00138] In another aspect, the present disclosure provides compounds of Formula (IV-E):



(IV-E)

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, deuterated forms, and tautomers thereof, wherein:

R¹ is H, C₁-C₃ alkyl, or C₃-C₆ cycloalkyl;

R² is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R¹²;

each R¹² is independently C₁-C₄ alkyl, -OR^A, -C(O)OR^A, (C₁-C₃ alkyl)-OR^A, -C(O)N(R^A)₂, cyano, or halogen;

each R^A is independently H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl; and

R³ is C₁-C₃ alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl;

R⁴ is H, halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl or cyano, wherein each C₁-C₃ alkyl and C₃-C₆ cycloalkyl is optionally substituted with 1-5 halo groups;

R^H is bromo, chloro or fluoro, preferably chloro;

R⁶ and R^{6A} independently represent H or C₁-C₆ alkyl;

R^{5A} represents NR⁷R⁸, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl or 5-6 membered heteroaryl, wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆

cycloalkyl(C₁-C₃ alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino;

R⁷ represents H or C₁-C₃ alkyl;

R⁸ represent H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl) wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl and C₃-C₆ cycloalkyl(C₁-C₃ alkyl) is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

[00139] wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁-C₆ alkyl, (ii) C₁-C₆ alkoxy, (iii) C₃-C₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁-C₃ alkyl, (ix) hydroxy C₁-C₆ alkyl, (x) amino, (xi) mono- or di-(C₁-C₆ alkyl) amino, (xii) C₂-C₆ alkanoyl optionally substituted with 1 or 2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xiii) C₃-C₆ cycloalkyloxy, or (xiv) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00140] In certain embodiments of formula (IV-A)-formula (IV-E) as otherwise described herein R^{5A} represents NR⁷R⁸, and R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-7 membered monocyclic heterocyclyl group, and

the heterocyclyl group is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di-(C_1 - C_3 alkyl)amino (Embodiment (IV-AE-1)).

[00141] In certain embodiments of formula (IV-A)-formula (IV-E) as otherwise described herein R^{5A} represents piperidiny, piperaziny, or morpholiny, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di-(C_1 - C_3 alkyl)amino (Embodiment (IV-AE-2)).

[00142] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl or pyridiny, each of which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H, methyl or ethyl.

[00143] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl or pyridiny, each of which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H.

[00144] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl or pyridiny, each of which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is methyl or ethyl.

[00145] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl which is optionally substituted with 1-5 R^{12} .

[00146] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$.

[00147] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H, methyl or ethyl.

[00148] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is phenyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H.

[00149] In particular embodiments of Embodiments (IV-AE-1) and (IV-AE-2), R^2 is

phenyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is methyl or ethyl.

[00150] In particular embodiments of Embodiments (IV-AE-1)) and (IV-AE-2), R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} .


[00151] In particular embodiments of Embodiments (IV-AE-1)) and (IV-AE-2), R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$.

[00152] In particular embodiments of Embodiments (IV-AE-1)) and (IV-AE-2), R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H, methyl or ethyl.

[00153] In particular embodiments of Embodiments (IV-AE-1)) and (IV-AE-2), R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is H.

[00154] In particular embodiments of Embodiments (IV-AE-1)) and (IV-AE-2), R^2 is pyridinyl which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$, where R^A is methyl or ethyl.

[00155] In particular embodiments of Embodiments (IV-AE-1)) and (IV-AE-2), R^2 is a group of the formula



wherein

each R^{13} is independently C_1 - C_4 alkyl, $-OR^B$, $-C(O)OR^B$, $(C_1$ - C_3 alkyl)- OR^B , $-C(O)N(R^B)_2$, cyano, or halogen;

each R^B is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl;

R^{12} is hydrogen, C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1$ - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;


each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl;

n is 0, 1, 2 or 3; and

m is 0, 1 or 2.

[00156] In certain embodiments of formula (4-AE-B) and formula (4-AE-P), R^{12} is cyano or halogen. In other embodiments of formula (4-AE-B) and formula (4-AE-P), R^{12} is cyano. In other embodiments of formula (4-AE-B) or (4-AE-P), R^{12} is fluoro, chloro or bromo. In other embodiments of formula (4-AE-B) or (4-AE-P), R^{12} is fluoro or chloro. In other embodiments of formula (4-AE-B) or (4-AE-P), R^{12} is methyl. In other embodiments of formula (4-AE-B) or (4-AE-P), R^{12} is hydrogen.


[00157] In certain embodiments of formula (I) or formula (IV) as otherwise described herein the compound is of formula (II) or (III)




wherein n is 0, 1, 2, 3 or 4; and

m is 0, 1, 2 or 3.

[00158] In certain embodiments of formula (II) or formula (III) as otherwise described herein the compound is of formula (II-A)



[00159] In certain embodiments of formula (II) or formula (III) as otherwise described herein the compound is of formula (III-A)



[00160] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

each R^{12} is independently C_1 - C_4 alkyl; $-OR^A$, $-C(O)OR^A$, (C_1 - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl; and

R^4 is H, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, cyano, or halo, wherein each C_1 - C_3 alkyl is optionally substituted with 1-5 halo groups.

[00161] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^3 is C_1 - C_3 alkyl.

[00162] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^3 is methyl.

[00163] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^4 is H, C_1 - C_3 alkyl, C_3 - C_4 cycloalkyl or cyano.

[00164] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^7 is hydrogen and R^8 represents hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl).

[00165] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^{5A} represents NR^7R^8 and R^7 and R^8 together with the nitrogen to which they are attached form ring Q, and ring Q is a C_1 - C_6 heterocyclyl


[00166] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^{5A} represents NR^7R^8 and R^7 and R^8 together with the nitrogen to which they are attached form ring Q, and ring Q is aziridinyl, azetidiny, pyrrolidinyl, piperazinyl, morpholinyl, piperidinyl, or azepanyl, each of which is optionally substituted with 1-

2 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di- (C_1 - C_6 alkyl) amino, phenyl, 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.

[00167] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^{5A} represents NR^7R^8 and R^7 and R^8 together with the nitrogen to which they are attached form ring Q, and ring Q is aziridinyl, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or azepanyl, each of which is optionally substituted with 1, 2, 3 or 4 halogens.

[00168] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^{5A} represents NR^7R^8 and R^7 and R^8 together with the nitrogen to which they are attached form ring Q, and ring Q is a 5-6 membered monocyclic heterocyclyl group fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen atoms and the remainder carbons, and the fused ring system is optionally substituted, on either ring, with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, or mono- or di- (C_1 - C_6 alkyl) amino.

[00169] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^{5A} represents NR^7R^8 and R^7 and R^8 together with the nitrogen to which they are attached form ring Q, where ring Q is a group of the formula:



wherein

each ring A is a 3-6 membered carbocyclic ring or 3-6 membered heterocyclic ring,
m is 0, 1, 2, 3, or 4;

n is 0, 1 or 2;

p and r are independently 1 or 2, provided that the sum of p and r is 2 or 3;

each R^{10} and R^{11} is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogen, cyano,


hydroxy, hydroxy C_1 - C_6 alkyl, amino, mono- or di(C_1 - C_6 alkyl) amino, C_3 - C_6 cycloalkyl, phenyl or 5-6 membered heteroaryl, where each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1-3 of halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino.

[00170] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.

[00171] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_3 alkyl, amino, or mono- or di-(C_1 - C_3 alkyl) amino.

[00172] In certain embodiments of formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently methyl, ethyl, methoxy, ethoxy, cyano, fluoro, chloro, trifluoromethyl, cyclopropyl, or cyclopropylmethyl.

[00173] In certain embodiments of formula (I), formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q represents a nitrogen-containing ring selected from




wherein each v represents 0, 1, 2, 3 or 4.

[00174] In certain embodiments, the nitrogen-containing ring is substituted independently with 1, 2 or 3 halogens. In certain embodiments, the halogens are independently fluorine atoms or chlorine atoms.

[00175] In certain embodiments, the nitrogen-containing ring is substituted with phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00176] In certain embodiments of formula (I), formula (II), formula (III), formula (II-A) or formula (III-A) as otherwise described herein R^{5A} represents a group of the formula



wherein

each v represents 0, 1, 2, 3 or 4; and

R¹⁸ represents H or C₁-C₆ alkyl.

[00177] In certain embodiments, the nitrogen-containing ring is substituted independently with 1, 2 or 3 halogens. In certain embodiments, the halogens are independently fluorine atoms or chlorine atoms.

[00178] In certain embodiments, the nitrogen-containing ring is substituted with phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00179] In certain embodiments of formula (I) or formula (IV) as otherwise described herein, R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is


a 3-7 membered monocyclic heterocyclyl group containing one or two ring nitrogens and only nitrogen heteroatoms, and


the heterocyclyl group is fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen atoms and the remainder carbons, wherein

the fused heterocyclyl group is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃

alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, or phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C₁-C₃ alkyl)amino.

[00180] In certain embodiments of formula (I) or formula (IV) as otherwise described herein, R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q represents a fused bicyclic group selected from





wherein each v represents 0, 1, 2, 3 or 4 and the R^9 groups can be on either ring.

[00181] In certain embodiments, the fused bicyclic group is substituted independently with 1, 2, 3 or 4 of C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 haloalkyl or halogen.

[00182] In certain embodiments, the fused bicyclic group is substituted independently with 1, 2, 3 or 4 halogens. In certain embodiments, the halogens are independently fluorine atoms or chlorine atoms. In other embodiments, the halogens are fluorine atoms.

[00183] In other embodiments, the fused bicyclic group is substituted with phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.


[00184] In certain embodiments of formula (I) or formula (IV) as otherwise described herein, R^7 and R^8 together with the nitrogen to which they are attached form a 3-7 membered monocyclic heterocyclyl group containing one or two ring nitrogens and only nitrogen heteroatoms, and

the heterocyclyl group forms a spirocyclic ring system having up to 10 total ring members with a carbon atom from the monocyclic heterocyclyl group and additional carbon, nitrogen, oxygen or sulfur atoms, wherein

wherein the spirocyclic ring system is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.

[00185] In certain embodiments of formula (I) or formula (IV) as otherwise described herein, R^7 and R^8 together with the nitrogen to which they are attached represent a spirocyclic ring system having one or two heteroatoms selected from nitrogen, oxygen and sulfur, preferably nitrogen and oxygen, and up to 10 total ring members. The spirocyclic ring system

is optionally substituted with up to 4 R^9 groups. Examples of such optionally substituted spirocyclic ring systems are



wherein each v represents 0, 1, 2, 3 or 4 and the R^9 groups can be on either ring.

[00186] In certain embodiments, the spirocyclic ring system is substituted independently with 1, 2, 3 or 4 of C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 haloalkyl or halogen.


[00187] In certain embodiments, the spirocyclic ring system is substituted independently with 1, 2, 3 or 4 halogens. In certain embodiments, the halogens are independently fluorine atoms or chlorine atoms. In other embodiments, the halogens are fluorine atoms.

[00188] In certain embodiments, the spirocyclic ring system is substituted with phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.

[00189] In certain embodiments of formula (I), formula (II), formula (III), formula (IV), formula (II-A) or formula (III-A) as otherwise described herein R^9 is an optionally substituted 5-

6 membered heteroaryl group. Examples of suitable heteroaryl groups are pyrazolyl, thiazolyl, imidazolyl, pyridinyl, oxazolyl, and isoxazolyl, each of which is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.


[00190] In certain embodiments, the stereochemical orientation at R³ is such that the compound will have an "R" stereochemical designation at that position according to the Cahn–Ingold–Prelog priority rules. Thus, for example, the compound is of formula (I-1):




(I-1)

where the groups are defined as above for formula (I).

[00191] In certain embodiments of formula (I) or formula (IV) as otherwise described herein the compound is of formula (II-A-1) or (III-A-1)




(II-A-1)




(III-A-1)

wherein n is 0, 1, 2, 3 or 4; and
m is 0, 1, 2 or 3.

[00192] In certain embodiments of formula (I), the compound is of formula (II-A-1.1) or (III-A-1.1)



II-A-1.1)



(III-A-1.1)

wherein

each R^{13} is independently C_1 - C_4 alkyl, $-OR^B$, $-C(O)OR^B$, $(C_1$ - C_3 alkyl)- OR^B , $-C(O)N(R^B)_2$, cyano, or halogen;

each R^B is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl;

R^{12} is hydrogen, C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1$ - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl;

n is 0, 1, 2 or 3; and

m is 0, 1 or 2.

[00193] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^{12} is cyano or halogen. In other embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^{12} is cyano. In other embodiments of formula (II-A-1.1) or (III-A-1.1), R^{12} is fluoro, chloro or bromo. In other embodiments of formula (II-A-1.1) or (III-A-1.1), R^{12} is fluoro or chloro. In other embodiments of formula (II-A-1.1) or (III-A-1.1), R^{12} is methyl. In other embodiments of formula (II-A-1.1) or (III-A-1.1), R^{12} is hydrogen.

[00194] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), n and m are 1, R^{13} is hydrogen, methyl or ethyl, and R^{12} is cyano or halogen. In other embodiments of formula (II-A-1.1) and formula (III-A-1.1), n and m are 1, R^{13} is hydrogen, methyl or ethyl, and R^{12} is cyano. In other embodiments of formula (II-A-1.1) or (III-A-1.1), n and m are 1, R^{13} is hydrogen, methyl or ethyl, and R^{12} is fluoro, chloro or bromo. In other embodiments of formula (II-A-1.1) or (III-A-1.1), n and m are 1, R^{13} is hydrogen, methyl or ethyl, and R^{12} is fluoro or chloro.

[00195] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^5 is methyl, n and m are 1, R^{13} is hydrogen, methyl or ethyl,

and

- i. R^{12} is cyano or halogen;
- ii. R^{12} is cyano;
- iii. R^{12} is fluoro, chloro or bromo; or
- iv. R^{12} is fluoro or chloro.

[00196] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^5 is ethyl, n and m are 1, R^{13} is hydrogen, methyl or ethyl, and

- i. R^{12} is cyano or halogen;
- ii. R^{12} is cyano;
- iii. R^{12} is fluoro, chloro or bromo; or
- iv. R^{12} is fluoro or chloro.

[00197] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^5 is cyano, n and m are 1, R^{13} is hydrogen, methyl or ethyl, and

- i. R^{12} is cyano or halogen;
- ii. R^{12} is cyano;
- iii. R^{12} is fluoro, chloro or bromo; or
- iv. R^{12} is fluoro or chloro.

[00198] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^5 is cyclopropyl, n and m are 1, R^{13} is hydrogen, methyl or ethyl, and

- i. R^{12} is cyano or halogen;
- ii. R^{12} is cyano;
- iii. R^{12} is fluoro, chloro or bromo; or
- iv. R^{12} is fluoro or chloro.

[00199] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^5 is bromo, n and m are 1, R^{13} is hydrogen, methyl or ethyl, and

- i. R^{12} is cyano or halogen;
- ii. R^{12} is cyano;
- iii. R^{12} is fluoro, chloro or bromo; or
- iv. R^{12} is fluoro or chloro.

[00200] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R^5 is fluoro,

n and m are 1, R¹³ is hydrogen, methyl or ethyl, and

- i. R¹² is cyano or halogen;
- ii. R¹² is cyano;
- iii. R¹² is fluoro, chloro or bromo; or
- iv. R¹² is fluoro or chloro.

[00201] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R⁵ is chloro, n and m are 1, R¹³ is hydrogen, methyl or ethyl, and


- i. R¹² is cyano or halogen;
- ii. R¹² is cyano;
- iii. R¹² is fluoro, chloro or bromo; or
- iv. R¹² is fluoro or chloro.







[00202] In certain embodiments of formula (II-A-1.1) and formula (III-A-1.1), R⁵ is trifluoromethyl, n and m are 1, R¹³ is hydrogen, methyl or ethyl, and







- i. R¹² is cyano or halogen;
- ii. R¹² is cyano;
- iii. R¹² is fluoro, chloro or bromo; or
- iv. R¹² is fluoro or chloro.






[00203] In certain embodiments of formula (I), R⁵ is a 3-8 membered heterocyclyl group. In these embodiments, the heterocyclyl group can be connected to the parent ring system via a carbon atom in the heterocyclyl ring. Examples of such groups are tetrahydrofuran-3-yl, tetrahydro-2H-pyran-2-yl, morpholin-2-yl, piperidin-4-yl, 3,6-dihydro-2H-pyran-4-yl, and tetrahydro-2H-pyran-4-yl.







[00204] In one embodiment, the compound of Formula (I) or Formula (IV) is selected from:






Name	Structure
2-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	







2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(((2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid	
2-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	







6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






6-chloro-3-((1-(2-cyano-3-(5-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-7-fluoro-3-(4-fluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2,7-dicyano-3-(4-fluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	






2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid	







2-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methoxyquinoxalin-5-yl)ethyl)amino)benzoic acid	
5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid	
2-chloro-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid	
2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid	






3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-2-carboxylic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(3-(difluoromethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(1-(fluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






6-chloro-3-((1-(2-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	






3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid	
2-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	






2-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

6-chloro-3-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	






6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






2-((1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

6-chloro-3-((1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

6-chloro-3-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

6-chloro-3-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	







6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	

6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-(2-oxopiperidin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
or a pharmaceutically acceptable salt thereof.	

[00205] In one embodiment, the compound of Formula (I) is selected from:







Name	Structure
(<i>R</i>)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>S</i>)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1 <i>S</i> ,4 <i>S</i>)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1 <i>R</i> ,4 <i>R</i>)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1 <i>R</i> ,4 <i>S</i>)-6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1 <i>S</i> ,4 <i>R</i>)-6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(((<i>S</i>)-2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(((<i>R</i>)-2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	







6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyano-3-(((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	







(R)-6-chloro-3-((1-(2-cyano-3-(5-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid	
(S)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid	
(S)-2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	







(R)-2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(S)-2-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-2-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-6-chloro-3-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid	







(R)-2-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-2-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methoxyquinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid	
(R)-2-chloro-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid	
(R)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid	
(R)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-2-carboxylic acid	







6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((R)-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((S)-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-((1 <i>S</i>)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	






6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(((1 <i>R</i>)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(2-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-2-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-6-chloro-3-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






(R)-2-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid	
(R)-2-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-6-chloro-3-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(R)-2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)benzoic acid	
(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	







(<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	

(<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	






(<i>R</i>)-2-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
2-(((1<i>R</i>)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-(((1<i>R</i>)-1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	




(<i>R</i>)-6-chloro-3-(((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-(((1<i>R</i>)-1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-(((1<i>R</i>)-1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	

2-(((1 <i>R</i>)-1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
2-(((1 <i>R</i>)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
2-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
2-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

2-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
6-chloro-3-(((1 <i>R</i>)-1-(2-cyano-7-methyl-3-(3-(2-oxopiperidin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	

(<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
(<i>R</i>)-2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
or a pharmaceutically acceptable salt thereof.	

PHARMACEUTICAL COMPOSITIONS

[00206] The compounds of Formula I may be formulated into pharmaceutical compositions.

[00207] In another aspect, the invention provides pharmaceutical compositions comprising a PI3K α inhibitor according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent. Compounds of the invention may be formulated by any method well known in the art and may be prepared for administration by any route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal. In certain embodiments, compounds of the invention are administered intravenously in a hospital setting. In certain other embodiments, administration may preferably be by the oral route.

[00208] The characteristics of the carrier will depend on the route of administration. As used herein, the term "pharmaceutically acceptable" means a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism, and that does not interfere with the effectiveness of the biological activity of the active ingredient(s). Thus, compositions according to the invention may contain, in addition to the inhibitor, diluents,

fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The preparation of pharmaceutically acceptable formulations is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.

[00209] As used herein, the term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds can also be administered as pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula $-NR^+Z^-$, wherein R is hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzyloate, and diphenylacetate).

[00210] The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount without causing serious toxic effects in the patient treated. A dose of the active compound for all of the above-mentioned conditions is in the range from about 0.01 to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient per day. A typical topical dosage will range from 0.01-3% wt/wt in a suitable carrier. The effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.

[00211] The pharmaceutical compositions comprising compounds of the present invention may be used in the methods described herein.

[00212] METHODS OF USE

[00213] In another aspect, the present disclosure generally relates to methods for treating cancer. These methods comprise administering to a subject in need thereof, a therapeutically effective amount of a PI3K inhibitor (e.g., PI3K α inhibitor or PI3K α H1047R mutant inhibitor).

[00214] In some embodiments, the PI3K inhibitor (e.g., PI3K α inhibitor or PI3K α H1047R mutant inhibitor) is a compound of Formula (I), (IIa), (IIb), (IIc) or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof. In particular embodiments, the PI3K inhibitor comprises a compound selected from Table 1.

[00215] In another aspect, the present disclosure provides a compound obtainable by, or obtained by, a method for preparing a compound as described herein (e.g., a method comprising one or more steps described in the Schemes).

[00216] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I), (IIa), (IIb), (IIc), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, and a pharmaceutically acceptable diluent or carrier.

[00217] In another aspect, the present disclosure provides an intermediate as described herein, being suitable for use in a method for preparing a compound as described herein (e.g., the intermediate is selected from the intermediates described in the Examples).

[00218] In another aspect, the present disclosure provides a method of modulating PI3K (e.g., PI3K α) activity (e.g., in vitro or in vivo), comprising contacting a cell with a therapeutically effective amount of a compound of Formula (I), (IIa), (IIb), (IIc), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

[00219] In particular embodiments, the PI3K-associated with the disease or disorder has a H1047R mutation. For example, in certain embodiments as otherwise described herein, the compounds have a high selectivity for inhibiting H1047R-mutated PI3K α compared to wild-type PI3K α . This unexpected finding suggests that certain compounds may allow targeted inhibition of PI3K α with a novel binding mechanism compared to conventional wild-type PI3K α inhibitors. Without wishing to be bound by theory, the H1047R-mutated PI3K α has a modification distant from the wild-type PI3K α active site. Accordingly, compounds which are selective for H1047R-mutated PI3K α over wild-type PI3K α are not believed to strongly bind at the PI3K α active site, but rather advantageously are believed to target other binding pockets. As the active site of PI3K-type proteins is thought to be better conserved among different variants, compounds that effectively bind at a position different than the active site may provide high selectivity for PI3K α inhibition over other PI3K proteins, such as PI3K β .

[00220] In another aspect, methods of treating cancer comprising administering to a patient having cancer a therapeutically effective amount of a compound of Formula I, pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the compound or pharmaceutically acceptable salts thereof are provided.

[00221] The compositions and methods provided herein may be used for the treatment of a wide variety of cancer including tumors such as prostate, breast, brain, skin, cervical carcinomas, testicular carcinomas, etc. More particularly, cancers that may be treated by the compositions and methods of the invention include, but are not limited to tumor types such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate and thyroid carcinomas and sarcomas. More specifically, these compounds can be used to treat: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell

carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. In certain embodiments, the cancer is diffuse large B-cell lymphoma (DLBCL).

[00222] In one embodiment, the cancer is selected from hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, and head and neck cancer,

[00223] In another embodiment, the cancer is selected from breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

[00224] Thus, in certain embodiments, this disclosure provides methods of treating cancer comprising administering a compound of Formula (I) a pharmaceutical composition thereof and KRAS inhibitor to a patient in need thereof, wherein the cancer is breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

[00225] In other embodiments, this disclosure provides a methods of treating cancer comprising administering a compound of Formula (I) a pharmaceutical composition thereof and a mutant selective KRAS inhibitor to a patient in need thereof, wherein the cancer is breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

[00226] In another embodiment, this disclosure provides a compound of Formula (I) a pharmaceutical composition thereof for use in the treatment of cancer in combination with a KRAS inhibitor, wherein the cancer is breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

[00227] The concentration and route of administration to the patient will vary depending on the cancer to be treated. The compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds and salts also may be co-administered with other anti-neoplastic compounds, e.g., chemotherapy, or used in combination with other treatments, such as radiation or surgical intervention, either as an adjuvant prior to surgery or post-operatively.

[00228] The present disclosure provides methods of treating, preventing, or ameliorating a disease or disorder in which PI3K plays a role by administering to a patient in need thereof a therapeutically effective amount of a PI3K inhibitor. The methods of the present disclosure can be used in the treatment of a variety of PI3K-dependent diseases and disorders.

[00229] In some embodiments, the disease or disorder is a cancer (e.g., breast cancer, brain cancers, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, and head and neck cancer). In some embodiments, the disease or disorder associated with PI3K includes, but is not limited to, CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), PIK3CA-related overgrowth syndrome (PROS), endometrial cancer, breast cancer, esophageal squamous-cell cancer, cervical squamous-cell carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, bladder urothelial carcinoma, glioblastoma, ovarian cancer, non-small-cell lung cancer, esophagogastric cancer, nerve-sheath tumor, head and neck squamous-cell carcinoma, melanoma, esophagogastric adenocarcinoma, soft-tissue sarcoma, prostate cancer, fibrolamellar carcinoma, hepatocellular carcinoma, diffuse glioma, colorectal cancer, pancreatic cancer, cholangiocarcinoma, B-cell lymphoma, mesothelioma, adrenocortical carcinoma, renal non-clear-cell carcinoma, renal clear-cell carcinoma, germ-cell carcinoma, thymic tumor, pheochromocytoma, miscellaneous neuroepithelial tumor, thyroid cancer, leukemia, and encapsulated glioma.

[00230] The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be

used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.


GENERAL REACTION SCHEMES, INTERMEDIATES AND EXAMPLES

[00231] The compounds of the present invention may be prepared using commercially available reagents and intermediates in the synthetic methods and reaction schemes described herein, or may be prepared using other reagents and conventional methods well known to those skilled in the art.

[00232] Where reference is made to "first eluting enantiomer" or "second eluting enantiomer", unless otherwise specifically indicated, the specific stereochemistry of such enantiomers has not been determined and any stereochemistry depicted in the corresponding compound structures has been arbitrarily assigned.


[00233] For instance, intermediates for preparing compounds and compounds of Formula (I) of the present invention may be prepared according to General Reaction Schemes 1 and 2:

General Reaction Scheme 1




[00234] For General Reaction Scheme I, Compound 9 is an example of Formula (I). In this General Reaction Scheme I, 1 can undergo amide bond formation with an activated acid or acid chloride in the presence of a suitable base such as triethylamine or diisopropylethylamine to provide compound 2. In the presence of a suitable base such as sodium ethoxide under heating, condensation to the quinoxaline N-oxide can be accomplished followed by reduction of the N-oxide with a suitable reagent such as phosphorus tribromide and protection to provide compound 3. The aryl bromide can be converted to an acyl group through a palladium catalyzed reaction such as a Heck reaction or Stille with a vinyl ether and subsequent treatment with aqueous acid to provide compound 4. Ammonolysis can be accomplished under heating in a suitable solvent such as ammonia in methanol to prepare compound 5. Condensation of the aryl ketone with an amine bearing a chiral auxiliary followed by reduction to the benzylic amine can be effected by dehydrating reagents such as titanium (IV) ethoxide and hydride transfer reagents such as sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, diisobutylaluminum hydride, or zirconocene hydrochloride. Alternatively, compound 6 can be accessed through an asymmetric hydrogenation or transfer hydrogenation or resolution of the racemic amine. The terminal amide can be converted to the nitrile through the action of a dehydrating reagent such as phosphorous oxychloride or Burgess's reagent and deprotection of the benzylic amine can be accomplished under Brønsted or Lewis acidic reagents such as hydrochloric acid or trimethylsilyl trifluoromethanesulfonate, for example, to access compound 7. The benzylic amine can be substituted to access compound 8 through the action of palladium or copper catalysis under Buchwald-Hartwig, Ullmann-Goldberg, or Chan-Evans-Lam reaction conditions with a suitable electrophile or boronic acid, solvent and base. Additionally, compound 8 can be accessed through uncatalyzed nucleophilic aromatic substitution reactions with suitable electrophiles at elevated temperatures in the presence of a suitable base, such as diisopropylethylamine. Finally, compounds such as 9 can be accessed after deprotection under acidic conditions such as through the action of trifluoroacetic acid and subsequent activation through the action of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate, phosphorous oxychloride or other activating reagent and reaction with a substituted amine in the presence of a base at ambient or elevated temperatures.

General Reaction Scheme 2



[00235] For General Reaction Scheme 2, Compound 15 is an example of Formula (I). In this General Reaction Scheme 2, 10 can be reacted with an activated alpha-keto acid, acid halide, or 2-oxomalonate in a condensation reaction to access compound 11. In the event R_5 is an ester, an aminolysis using a suitable solvent such as ammonia in methanol at elevated temperatures can be used to provide the free amide. Upon treatment of a suitable chlorinating reagent such as phosphorous oxychloride compound 12 can be prepared. Under such conditions, the terminal amide will be dehydrated to provide a nitrile at R_5 . Aryl chloride 12 can be reacted with an amine and suitable base, such as diisopropylethylamine, at ambient or elevated temperatures to prepare compound 13. A palladium catalyzed transformation such as a Heck reaction or Stille coupling with a suitable vinyl ether partner and subsequent treatment with an aqueous acid, for example, hydrochloric acid, can provide compound 14. A reductive amination of this ketone and an amine can be effected with a suitable Lewis acid and hydride donor, such as trimethylsilyl trifluoromethanesulfonate and borane, or other common hydride reductant to access compound 15. Alternatively, a sequence analogous to General Reaction Scheme 1 can be used to access a chiral benzylic amine through condensation of a chiral amine reagent and subsequent reduction and carbon-nitrogen bond formation reaction such as a Buchwald-Hartwig reaction, Ullmann-Goldberg Coupling, Chan-Evans-Lam coupling, alkylation, nucleophilic aromatic substitution or reductive amination to provide compound 15.

INTERMEDIATE A



[00236] Step A: To a solution of 2-bromo-4-methyl-6-nitroaniline (540 g, 2.34 mol, 1.00 eq.) in toluene (650 mL) was added ethyl 3-chloro-3-oxopropanoate (422 g, 2.80 mol, 353 mL, 1.20 eq.) at 0 °C, then the reaction was stirred at 110 °C for 1 hour. After completion of the reaction, the mixture was cooled to 25°C and poured into petroleum ether (3.00 L). The mixture was filtered and the filtered cake was collected to give ethyl 3-((2-bromo-4-methyl-6-nitrophenyl)amino)-3-oxopropanoate (790 g, 2.29 mol, 97.9% yield) as a yellow solid. LCMS $[M+1]^+ = 344.9$.

[00237] ^1H NMR (400 MHz, CDCl_3) δ = 9.70 (br s, 1H), 7.70 (d, J = 2.0 Hz, 2H), 4.30 (q, J = 7.2 Hz, 2H), 3.51 (s, 2H), 2.41 (s, 3H), 1.35 (t, J = 7.2 Hz, 3H).

[00238] Step B: To a solution of sodium ethoxide (734 mL, 2.17 M, 2.20 eq.) in ethanol (500 mL) and tetrahydrofuran (1.50 L) was added a solution of ethyl 3-((2-bromo-4-methyl-6-nitrophenyl)amino)-3-oxopropanoate (250 g, 724 mmol, 1.00 eq.) in tetrahydrofuran (1.00 L) dropwise at $-30\text{ }^\circ\text{C}$. Then the reaction was stirred at $-30\text{ }^\circ\text{C}$ for 15 minutes. After completion of the reaction, the mixture was poured into ice water (5.00 L) slowly at $0\text{ }^\circ\text{C}$. Then the pH of the mixture was adjusted with hydrogen chloride (4 M in water) to pH ~4. The resulting suspension was filtered and the filtered cake was collected to give a crude product. The crude product was triturated with acetonitrile (750 mL) at room temperature for 30 minutes. Then the mixture was filtered, and the filter cake was collected, dried over under reduced pressure to give 5-bromo-2-(ethoxycarbonyl)-3-hydroxy-7-methylquinoxaline 1-oxide (190 g, 542 mmol, 74.9% yield, 93.4% purity) as a yellow solid. LCMS $[\text{M}+3]^+ = 328.9$.

[00239] ^1H NMR (400 MHz, CDCl_3) δ = 9.67 (br s, 1H), 8.09 (s, 1H), 7.71 (d, J = 1.2 Hz, 1H), 4.52 (q, J = 7.2 Hz, 2H), 2.46 (s, 3H), 1.43 (t, J = 6.8 Hz, 3H).

[00240] Step C: To a solution of 5-bromo-2-(ethoxycarbonyl)-3-hydroxy-7-methylquinoxaline 1-oxide (200 g, 581 mmol, 1.00 eq.) in DMF (2.50 L) was added phosphorus tribromide (314 g, 1.16 mol, 110 mL, 2.00 eq.) dropwise at $0\text{ }^\circ\text{C}$. Then the reaction was stirred at $60\text{ }^\circ\text{C}$ for 2 hours. The mixture was then cooled to $25\text{ }^\circ\text{C}$ and poured into ice water (4.00 L). The resulting mixture was filtered and the filter cake was collected. The filter cake was triturated with acetonitrile (500 mL) at $15\text{ }^\circ\text{C}$ for 30 minutes. Then the mixture was filtered, and the filter cake was collected, dried over under reduced pressure to give ethyl 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxylate (150 g, 465 mmol, 80.1% yield, 96.5% purity) as a yellow solid. LCMS $[\text{M}+1]^+ = 310.9$.

[00241] ^1H NMR (400 MHz, CDCl_3) δ = 9.54 (br s, 1H), 7.71 (s, 1H), 7.66 (s, 1H), 4.51 (q, J = 7.2 Hz, 2H), 2.45 (s, 3H), 1.44 (t, J = 7.2 Hz, 3H).

[00242] Step D: To a solution of ethyl 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxylate (300 g, 964 mmol, 1.00 eq.) and potassium carbonate (400 g, 2.89 mol, 3.000 eq.) in DMF (2.40 L) was added PMBCl (151 g, 964 mmol, 131 mL, 1.00 eq.), and the reaction was stirred at $50\text{ }^\circ\text{C}$ for 8 hours. The mixture was then cooled to $25\text{ }^\circ\text{C}$ and then poured into ice water (4.00 L). Then the mixture was filtered, and the filter cake was collected. The filter cake was triturated with acetonitrile (800 mL) at $20\text{ }^\circ\text{C}$ for 20 minutes, then filtered and the filter cake was again collected, and dried over under reduced pressure to give ethyl 5-bromo-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxylate (380 g, 819 mmol, 85.0% yield, 93.0 % purity) as a yellow solid. LCMS $[\text{M}+23]^+ = 453.1$.

[00243] ^1H NMR (400 MHz, CDCl_3) δ = 7.86 (s, 1H), 7.79 (s, 1H), 7.56 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 5.61 (s, 2H), 4.49 (q, J = 6.8 Hz, 2H), 3.78 (s, 3H), 2.49 (s, 3H), 1.41 (t, J = 7.2 Hz, 3H).

[00244] Step E: A mixture of ethyl 5-bromo-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxylate (1.00 kg, 2.16 mol, 1.00 eq.), tributyl(1-ethoxyvinyl)tin (1.00 kg, 2.77 mol, 935 mL, 1.28 eq.), $\text{Pd}_2(\text{dba})_3$ (98.7 g, 108 mmol, 0.050 eq.) and XPhos (51.4 g, 108 mmol, 0.050 eq.) in toluene (16.0 L) was degassed and purged with nitrogen 3 times. The reaction was then stirred at 100 °C for 5 hours under a nitrogen atmosphere. After completion of the reaction, the mixture was cooled to 25 °C and then the solution of ethyl 5-(1-ethoxyvinyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxylate (911 g, crude) in toluene (16.0 L) was obtained as a black liquid, which was used directly in the next step. LCMS $[\text{M}+1]^+ = 423.2$.

[00245] Step F: A solution of ethyl 5-(1-ethoxyvinyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxylate (911 g, crude) in toluene (16.0 L) was cooled to 20 °C and tetrahydrofuran (14.0 L) was added. To this mixture was added hydrogen chloride (1.94 L, 1.00 M, 0.900 eq.) dropwise at 0 °C, and the mixture was stirred at 0 °C for 30 minutes. After this time, the pH of the mixture was adjusted with sodium hydrogen carbonate (saturated in water) to pH ~7. To this mixture was added potassium fluoride (4.31 L, 4.00 M in water). After 1 hour, the mixture was diluted with water (6.00 L) and ethyl acetate (6.00 L). The mixture was then filtered, and the filtrate was extracted with ethyl acetate (5.00 L $\times$ 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with (dichloromethane: ethyl acetate = 1: 2, 500 mL) and then further triturated with (petroleum ether: ethyl acetate = 3 : 1, 500 mL) at 20 °C for 30 minutes. The mixture was then filtered and the filter cake was collected, and dried under reduced pressure to give ethyl 5-acetyl-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxylate (640 g, 1.51 mol, 70.0% yield) as a yellow solid. LCMS $[\text{M}+23]^+ = 417.1$.

[00246] ^1H NMR (400 MHz, CDCl_3) δ = 8.04 (d, J = 0.8 Hz, 1H), 7.99 (d, J = 2.0 Hz, 1H), 7.42 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 5.53 (s, 2H), 4.51 (q, J = 6.8 Hz, 2H), 3.82 (s, 3H), 2.93 (s, 3H), 2.57 (s, 3H), 1.41 (t, J = 7.2 Hz, 3H).

[00247] Step G: Ammonia (130 g, 7.62 mol, 14.6 eq.) was bubbled into a solvent of methanol (1.00 L) at 15 °C for 1 hour. Then the above solution was added to a mixture of ethyl 5-acetyl-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxylate (206 g, 522 mmol, 1.00 eq.) in methanol (2.00 L). The reaction was stirred at 25 °C for 16 hours., then concentrated at 30 °C under reduced pressure to give 5-acetyl-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (210 g, 466 mmol, 89.1% yield, 81.0% purity) as a yellow solid. LCMS $[\text{M}+1]^+ = 366.3$.

[00248] Step H: To a mixture of 5-acetyl-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (89.0 g, 244 mmol, 1.00 eq.) and (*R*)-2-methylpropane-2-sulfinamide (148 g, 1.22 mol, 5.00 eq.) in 2-methyltetrahydrofuran (3.00 L) was added titanium (IV) ethoxide (278 g, 1.22 mol, 253 mL, 5.00 eq.), and the reaction was stirred at 70 °C for 24 hours. The mixture was then cooled to 25 °C, diluted with ethyl acetate (2.00 L) and quenched using sodium hydrogen carbonate (saturated in water, 1.50 L) at 0 °C. The mixture was then filtered and the filtrate was washed with water (1.00 L × 2), followed by brine (500 mL × 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with ethyl acetate (100 mL) at 20 °C for 1 hour. Then the mixture was filtered and the filter cake was collected, dried over under reduced pressure to give (*R*)-5-(1-((*tert*-butylsulfinyl)imino)ethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (101 g, 174 mmol, 71.4% yield, 80.7% purity) as a yellow solid. LCMS [M+1]⁺ = 469.2.

[00249] ¹H NMR (400 MHz, CDCl₃) δ = 7.98 (s, 1H), 7.73 (s, 1H), 7.59 (br s, 1H), 7.45 - 7.42 (m, 2H), 6.91 (br d, *J* = 6.8 Hz, 2H), 6.23 (br s, 1H), 5.55 (s, 2H), 3.81 (s, 3H), 2.94 (d, *J* = 1.6 Hz, 3H), 2.57 (s, 3H), 1.23 (s, 9H).

[00250] Step I: To a solution of (*R*)-5-(1-((*tert*-butylsulfinyl)imino)ethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (155 g, 257 mmol, 1.00 eq.) in dichloromethane (1.50 L) and methanol (1.50 L) were added acetic acid (77.1 g, 1.28 mol, 73.5 mL, 5.00 eq.) and sodium cyanoborohydride (64.5 g, 1.03 mol, 4.00 eq.) at 0 °C. The reaction was then stirred at 20 °C for 12 hours. After this time, the mixture was washed with water (1.00 L) and the organic phase was treated with sodium hydrogen carbonate (saturated in water, 800 mL) slowly at 0 °C. The resultant mixture was washed with water (1.00 L) and brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-((*R*)-1-(((*R*)-*tert*-butylsulfinyl)amino)ethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (155 g, crude) as a yellow solid. LCMS [M+1]⁺ = 471.2.

[00251] Step J: To a solution of 5-((*R*)-1-(((*R*)-*tert*-butylsulfinyl)amino)ethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (190 g, 299 mmol, 1.00 eq.) in THF (2.00 L) was added hydrogen chloride (380 mL, 1.00 M in water, 1.27 eq.) dropwise at 0 °C, and the mixture was stirred at 15 °C for 7 hours. After the reaction was completed the solution of (*R*)-5-(1-aminoethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (160 g, crude) in THF (2.00 L) was obtained as yellow liquid, which was used directly in the next step. LCMS [M+1]⁺ = 367.1.

[00252] Step K: To a solution of ((*R*)-5-(1-aminoethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carboxamide (160 g, 288 mmol, 1.00 eq.) in THF (2.00 L) was added sodium hydroxide (34.6 g, 865 mmol, 3.00 eq.) in water (1.00 L) and Boc₂O (75.5 g, 346 mmol, 79.4 mL, 1.20 eq.), and the reaction was stirred at 50 °C for 1 hour. After this time, the mixture

was diluted with ethyl acetate (1.00 L), washed with brine (500 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give *tert*-butyl (*R*)-(1-(2-carbamoyl-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)carbamate (160 g, crude) as a yellow solid. LCMS [M+1]⁺ = 467.3.

[00253] Step L: To a solution of *tert*-butyl (*R*)-(1-(2-carbamoyl-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)carbamate (215 g, 277 mmol, 1.00 eq.) in THF (3.00 L) was added Burgess reagent (198 g, 830 mmol, 3.00 eq.) at 0 °C. The reaction was stirred at 0 °C for 1 hour, then diluted with ethyl acetate (1.00 L), washed with water (500 mL) and brine (500 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with acetonitrile (180 mL) at 20 °C for 30 minutes, then filtered and the filter cake was collected, and dried over reduced pressure to give *tert*-butyl (*R*)-(1-(2-cyano-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)carbamate (125 g, 234 mmol, 84.7% yield, 84% purity) as a yellow solid. LCMS [M+23]⁺ = 471.3.

[00254] ¹H NMR (400 MHz, CDCl₃) δ = 7.73 (d, *J* = 0.8 Hz, 1H), 7.60 (d, *J* = 1.6 Hz, 1H), 7.52 - 7.47 (m, 2H), 6.97 - 6.91 (m, 2H), 5.69 - 5.40 (m, 4H), 3.82 (s, 3H), 2.54 (s, 3H), 1.53 (d, *J* = 6.8 Hz, 3H), 1.44 (br s, 9H).

[00255] Step M: To a solution of *tert*-butyl (*R*)-(1-(2-cyano-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)carbamate (300 g, 562 mmol, 1.00 eq.) in dichloromethane (3.00 L) was added 2,6-dimethylpyridine (482 g, 4.49 mol, 524 mL, 8.00 eq.) and trimethylsilyl trifluoromethanesulfonate (500 g, 2.25 mol, 406 mL, 4.00 eq.), then the mixture was stirred at 40 °C for 1 hour, followed by dilution with water (2.50 L) at 0 °C. The resulting mixture was washed with brine (500 mL × 2) and then citric acid (1 N in water, 1000 mL × 4). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with acetonitrile (450 mL) at 20 °C for 10 minutes. Then the mixture was filtered, and the filter cake was collected, and dried under reduced pressure to give the crude product. The crude product was purified by reversed phase flash (column: Sfar C18 1800 g D Duo 30 um; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 35%-65% phase B) to give (*R*)-5-(1-aminoethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carbonitrile (195 g, 535 mmol, 95.2% yield, 95.6% purity) as a yellow solid. LCMS [M+1]⁺ = 349.1.

[00256] ¹H NMR (400 MHz, CDCl₃) δ = 7.71 (s, 2H), 7.47 (d, *J* = 8.4 Hz, 2H), 6.92 (d, *J* = 8.4 Hz, 2H), 5.55 (s, 2H), 5.01 (q, *J* = 6.8 Hz, 1H), 3.81 (s, 3H), 2.69 (br s, 2H), 2.54 (s, 3H), 1.55 (d, *J* = 6.8 Hz, 3H).


[00257] Step N: A mixture of (*R*)-5-(1-aminoethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carbonitrile (40.0 g, 115 mmol, 1.00 eq.), methyl 2-iodobenzoate (45.1 g, 172 mmol, 25.3 mL, 1.50 eq.), Pd₂(dba)₃ (5.26 g, 5.74 mmol, 0.050 eq.), XantPhos (3.32 g, 5.74 mmol, 0.050 eq.) and cesium carbonate (112 g, 344 mmol, 3.00 eq.) in 1,4-dioxane (400 mL) was degassed and purged with nitrogen 3 times. The mixture was then stirred at 100 °C for 5 hours under a nitrogen atmosphere. After completion of the reaction, the mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was triturated with a mixture solvent of petroleum ether:ethyl acetate:acetonitrile = 3:1:1 (80.0 mL) at 20 °C for 10 minutes, then the mixture was filtered and the filter cake was collected, dried under reduced pressure to give methyl (*R*)-2-((1-(2-cyano-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (38.0 g, 74.8 mmol, 65.2% yield, 95.0% purity) as a yellow solid. LCMS [M+23]⁺ = 505.2.

[00258] ¹H NMR (400 MHz, CDCl₃) δ = 8.38 (d, *J* = 6.0 Hz, 1H), 7.94 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.70 (s, 1H), 7.69 (s, 1H), 7.52 (d, *J* = 8.8 Hz, 2H), 7.13 - 7.04 (m, 1H), 6.94 - 6.86 (m, 2H), 6.56 (t, *J* = 7.2 Hz, 1H), 6.24 (d, *J* = 8.4 Hz, 1H), 5.68 - 5.57 (m, 3H), 3.94 (s, 3H), 3.79 (s, 3H), 2.47 (s, 3H), 1.66 (d, *J* = 6.8 Hz, 3H).

[00259] Step O: To a solution of methyl (*R*)-2-((1-(2-cyano-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (38.0 g, 74.8 mmol, 1.00 eq.) in dichloromethane (380 mL) was added 2,2,2-trifluoroacetic acid (127 g, 1.12 mol, 83.0 mL, 14.9 eq.) at 0 °C, and the mixture was left to stir at 0 °C for 1 hour. The mixture was then poured into sodium hydrogen carbonate (saturated in water, 500 mL) slowly at 0 °C, then the mixture was extracted with dichloromethane (400 mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash (column: Sfar C18 330 g D Duo 30 μm; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 45%-80% phase B) to give methyl (*R*)-2-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl) ethyl)amino)benzoate (22.6 g, 60.1 mmol, 80.4% yield, 96.4% purity) as a yellow solid. LCMS [M+1]⁺ = 363.0.

[00260] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 12.89 (br s, 1H), 8.18 (br d, *J* = 5.6 Hz, 1H), 7.81 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.52 (s, 1H), 7.44 (d, *J* = 1.6 Hz, 1H), 7.24 - 7.14 (m, 1H), 6.56 (t, *J* = 7.6 Hz, 1H), 6.31 (d, *J* = 8.4 Hz, 1H), 5.35 (quin, *J* = 6.0 Hz, 1H), 3.86 (s, 3H), 2.29 (s, 3H), 1.46 (d, *J* = 6.4 Hz, 3H).

INTERMEDIATE B



[00261] Step A: To a solution of 2-bromo-4-methyl-6-nitroaniline (30.0 g, 130 mmol, 1.00 eq.) in ethyl acetate (300 mL) was added tin (II) chloride dihydrate (147 g, 649 mmol, 5.00 eq.), and the mixture was left to stir at 80 °C for 3 hours. The reaction mixture was then cooled to 25 °C, and the pH of the mixture was adjusted with sodium bicarbonate (saturated solution in water) to pH ~8. The mixture was then filtered, and the filter cake was washed with ethyl acetate (300 mL × 3). The filtrate was further diluted with water (300 mL) and extracted with ethyl acetate (300 mL), and the combined organic layers were washed with brine (500 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude product 3-bromo-5-methylbenzene-1,2-diamine (22.5 g, 112 mmol, 86.2% yield) was obtained as a yellow solid and used without further purification. LCMS $[\text{M} + \text{H}]^+ = 201.1$.

[00262] Step B: To a solution of 3-bromo-5-methylbenzene-1,2-diamine (22.5 g, 112 mmol, 1.00 eq.) in ethanol (300 mL) was added diethyl 2-oxomalonate (23.4 g, 134 mmol, 20.7 mL, 1.20 eq.), and the mixture was left to stir at 80 °C for 4 hours. The mixture was then cooled to 25 °C, filtered, and the filter cake was dried under vacuum to give ethyl 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxylate (31.5 g, 92.9 mmol, 83.1% yield) as a yellow solid. LCMS $[\text{M} + 3]^+ = 313.1$.


[00263] Step C: To a solution of ethyl 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxylate (31.5 g, 101 mmol, 1.00 eq.) in methanol (300 mL) was added ammonium hydroxide (63.4 g, 506 mmol, 69.6 mL, 28.0% purity, 5.00 eq.), and the mixture was stirred at 25 °C for 12 hours. The mixture was then filtered, and the filter cake concentrated under reduced pressure to give 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxamide (26.4 g, crude) as a yellow solid. LCMS $[\text{M} + 3]^+ = 284.0$.

[00264] Step D: To a solution of 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxamide (1.00 g, 3.54 mmol, 1.00 eq.) in POCl_3 (10.0 mL) was added diisopropylethylamine (2.29 g, 17.7 mmol, 3.09 mL, 5.00 eq.) at 0 °C, and the mixture was left to stir at 120 °C for 12 hours.

The mixture was then cooled to 25 °C, concentrated in vacuo, and the residue was diluted with ethyl acetate (50.0 mL × 2) at 0 °C. The pH of the mixture was then adjusted to pH=7 with sodium bicarbonate (saturated solution in water) slowly, and the organic phase was washed with brine (50.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude product. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate = 50/1 to 20/1) to give 5-bromo-3-chloro-7-methylquinoxaline-2-carbonitrile (1.40 g, 4.86 mmol, 68.5% yield, 98.0% purity) as a yellow solid. LCMS [M+3]⁺ = 284.1.

[00265] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.37 (d, *J* = 1.6 Hz, 1H), 8.30 (d, *J* = 1.6 Hz, 1H), 8.06 (s, 1H), 7.96 (s, 1H), 2.61 (s, 3H).

INTERMEDIATE B – Alternative Synthesis



[00266] Step A: To A mixture of 2-bromo-4-methyl-6-nitroaniline (26.0 g, 113 mmol, 1.00 eq.) in toluene (250 mL) was added ethyl 3-chloro-3-oxopropanoate (18.6 g, 124 mmol, 15.6 mL, 1.10 eq.) at 0°C, then the reaction was heat to 90°C and left to stir for 4 hours. The mixture was then cooled to 25°C, and diisopropyl ether (250 mL) was added, at which point a white precipitate was formed. The suspension was filtered, and the cake was collected and dried under reduced pressure to give ethyl 3-((2-bromo-4-methyl-6-nitrophenyl)amino)-3-oxopropanoate (33.0 g, 95.6 mmol, 85.0% yield) as a yellow solid. LCMS [M+3]⁺ = 347.2.

[00267] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.33 (s, 1H), 7.93 (d, *J* = 1.2 Hz, 1H), 7.81 (d, *J* = 1.2 Hz, 1H), 4.11 (q, *J* = 6.8 Hz, 2H), 3.46 (s, 2H), 2.40 (s, 3H), 1.21 (t, *J* = 7.2 Hz, 3H).

[00268] Step B: To a solution of sodium ethoxide (81.3 g, 239 mmol, 75.0 mL, 20% purity, 2.50 eq.) in tetrahydrofuran (250 mL) and DMF (250 mL) was added a solution of ethyl 3-((2-bromo-4-methyl-6-nitrophenyl)amino)-3-oxopropanoate (33.0 g, 95.6 mmol, 1.00 eq.) in a mixed solvent of DMF (50.0 mL) and tetrahydrofuran (50.0 mL) dropwise at -30°C over one hour. The mixture was then warmed to 0°C and poured into cold water (80.0 mL), then 4N HCl (in water, 30.0 mL) was added. The pH of the mixture was adjusted to pH >7, and the mixture

was extracted with ethyl acetate (100 mL $\times$ 2), and the combined organic layers were washed with saturated brine (100 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with diisopropylether (35.0 mL) to give the 5-bromo-2-(ethoxycarbonyl)-3-hydroxy-7-methylquinoxaline 1-oxide (25.0 g, 76.4 mmol, 79.9% yield) as a yellow solid which was used without further purification. LCMS $[M+3]^+ = 329.2$.

[00269] Step C: To a solution of 5-bromo-2-(ethoxycarbonyl)-3-hydroxy-7-methylquinoxaline 1-oxide (23.0 g, 70.3 mmol, 1.00 eq.) in DMF (200 mL) was added PBr_3 (38.1 g, 141 mmol, 2.00 eq.) dropwise, then the solution was stirred at 65°C for 1.5 hours. The mixture was then cooled to 25°C, poured into sodium bicarbonate solution (saturated in water, 400 mL), and extracted with ethyl acetate (400 mL $\times$ 3). The combined organic layers were washed with saturated brine (100 mL $\times$ 3), dried over magnesium sulfate, filtered, and concentrated to give a residue. The residue was purified by trituration with *n*-hexane (300 mL) to give ethyl 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxylate (19.0 g, 61.1 mmol, 86.9 % yield) as yellow solid which was without further purification. LCMS $[M+H]^+ = 311.0$.


[00270] 1H NMR (400 MHz, $DMSO-d_6$) δ = 12.65 - 11.74 (m, 1H), 7.85 (s, 1H), 7.70 (s, 1H), 4.39 (q, J = 7.2 Hz, 2H), 2.41 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H).

[00271] Step D: To a solution of ethyl 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxylate (5.70 g, 18.3 mmol, 1.00 eq.) in tetrahydrofuran (60.0 mL) was added ammonium hydroxide (6.88 g, 55.0 mmol, 7.56 mL, 28% purity, 3.00 eq.), and the mixture was stirred at 45 °C for 12 hours. Upon completion, the mixture was cooled to 25°C and the mixture was concentrated under reduced pressure to give 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxamide (5.10 g, 18.1 mmol, 98.7% yield) as a yellow solid which was used without further purification. LCMS $[M+3]^+ = 283.7$.

[00272] Step E: To a solution of 5-bromo-3-hydroxy-7-methylquinoxaline-2-carboxamide (4.0 g, 14.2 mmol, 1.00 eq.) in $POCl_3$ (40.0 mL) was added diisopropylethylamine (9.16 g, 70.9 mmol, 12.4 mL, 5.0 eq.) at 0°C. The mixture was then warmed to 120 °C and left to stir for 12 hours. The mixture was then cooled to 0 °C, diluted with ethyl acetate (150 mL $\times$ 2), and the solution was poured into aqueous sodium bicarbonate slowly, and the pH was adjusted to pH>7. The organic phase was washed with brine (100 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-bromo-3-chloro-7-methylquinoxaline-2-carbonitrile (4.42 g, crude) as brown solid which was used without further purification.

[00273] 1H NMR (400 MHz, $CDCl_3$) δ = 8.05 (d, J = 1.6 Hz, 1H), 7.84 (dd, J = 0.8, 1.6 Hz, 1H), 2.56 (s, 3H).

INTERMEDIATE C




[00274] Step A: A mixture of (*R*)-5-(1-aminoethyl)-3-((4-methoxybenzyl)oxy)-7-methylquinoxaline-2-carbonitrile (2.67 g, 7.66 mmol, 1.00 eq.), methyl 6-chloro-3-fluoropicolinate (2.03 g, 10.7 mmol, 1.40 eq.), diisopropylethylamine (4.95 g, 38.3 mmol, 6.67 mL, 5.00 eq.) in *N,N*-dimethylformamide (30.0 mL) was degassed and purged with dinitrogen for 3 times, and then the mixture was stirred at 100 °C for 12 hours under dinitrogen atmosphere. After completion, the mixture was cooled to 20 °C. The mixture was poured into water aqueous solution (10.0 mL) and extracted with ethyl acetate (30.0 mL×3). The combined organic layer was washed with brine (10.0 mL), dried over anhydrous sodium sulfate, then the mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 3/1) to give methyl (*R*)-6-chloro-3-((1-(2-cyano-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (2.30 g, 4.00 mmol, 52.2% yield, 90% purity) as a yellow solid. LCMS [*M*+23]⁺ = 540.2.

[00275] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.40 (d, *J* = 7.20 Hz, 1H), 7.88 - 7.76 (m, 2H), 7.52 (d, *J* = 8.40 Hz, 2H), 7.28 (d, *J* = 9.20 Hz, 1H), 7.05 (d, *J* = 9.20 Hz, 1H), 6.98 (d, *J* = 8.80 Hz, 2H), 5.74 - 5.48 (m, 3H), 3.87 (s, 3H), 3.76 (s, 3H), 2.48 (s, 3H), 1.67 (d, *J* = 6.40 Hz, 3H).

[00276] Step B: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-((4-methoxybenzyl)oxy)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (1.30 g, 2.51 mmol, 1.00 eq.) in dichloromethane (10.0 mL) was added trifluoroacetic acid (4.61 g, 40.4 mmol, 3.00 mL, 16.1 eq.) at 0 °C. The mixture was stirred at 25 °C for 1 hour. After completion, the mixture was concentrated to give methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (2.50 g crude) as a yellow solid. LCMS [*M*+1]⁺ = 398.2.

[00277] Example 1

2-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid



[00278] Step A: To a solution of 5-bromo-3-chloro-7-methylquinoxaline-2-carbonitrile (1.20 g, 4.25 mmol, 1.00 eq.) in dimethyl sulfoxide (12.0 mL) was added cesium fluoride (968 mg, 6.37 mmol, 235 μ L, 1.50 eq.) and piperidine (723 mg, 8.49 mmol, 839 μ L, 2.00 eq.). The mixture was stirred at 130 °C for 1 hour. After completion of the reaction, the mixture was cooled to 25°C, the mixture was diluted with water (20.0 mL), then extracted with ethyl acetate (20.0 mL $\times$ 3). The combined the organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 50/1, 5/1) to give 5-bromo-7-methyl-3-(piperidin-1-yl)quinoxaline-2-carbonitrile (180 mg, 543 μ mol, 12.8% yield) as a yellow solid. LCMS $[M+H]^+ = 331.2$.

[00279] ^1H NMR (400 MHz, DMSO- d_6) δ = 7.80 (d, J = 1.6 Hz, 1H), 7.52 (s, 1H), 3.70 (br d, J = 5.2 Hz, 4H), 2.48 (br s, 3H), 1.68 (br s, 6H).

[00280] Step B: A mixture of 5-bromo-7-methyl-3-(piperidin-1-yl)quinoxaline-2-carbonitrile (300 mg, 906 μ mol, 1.00 eq.), *n*-butyl vinyl ether (363 mg, 3.62 mmol, 466 μ L, 4.00 eq.), Pd(dppf)Cl₂ (66.3 mg, 90.6 μ mol, 0.10 eq.), and diisopropylethylamine (351 mg, 2.72 mmol, 473 μ L, 3.00 eq.) in *n*-butyl alcohol (6.00 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 120 °C for 8 hours under nitrogen atmosphere. After completion of the reaction, the mixture was added water (5.00 mL) and extracted with ethyl acetate (5.00 mL $\times$ 3). Combined the organic layers were dried over anhydrous sodium sulfate and concentrated in vacuum to give 5-(1-butoxyvinyl)-7-methyl-3-(piperidin-1-yl)quinoxaline-2-carbonitrile (300 mg, crude) as a black solid. LCMS $[M+H]^+ = 351.2$.

[00281] Step C: To a solution of 5-(1-butoxyvinyl)-7-methyl-3-(piperidin-1-yl)quinoxaline-2-carbonitrile (300 mg, 856 μ mol, 1.00 eq.) in tetrahydrofuran (3.00 mL) was added hydrochloric acid (4.00 M in dioxane, 1.07 mL, 5.00 eq.). The mixture was stirred at 25 °C for 2 hours. The mixture was added water (20.00 mL) and extracted with ethyl acetate (20.00 mL $\times$ 3). Combined the organic layers were dried over anhydrous sodium sulfate and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 50/1, 1/1) to give 5-acetyl-7-methyl-3-(piperidin-1-yl)quinoxaline-2-carbonitrile (140 mg, 441 μ mol, 51.7% yield, 92.8% purity) as a yellow solid. LCMS $[M+H]^+ = 294.9$.


[00282] Step D: To a solution of 5-acetyl-7-methyl-3-(piperidin-1-yl)quinoxaline-2-carbonitrile (80.0 mg, 272 μ mol, 1.00 eq.) in *N,N*-dimethylformamide (0.50 mL) under nitrogen was added *tert*-butyl 2-aminobenzoate (63.0 mg, 326 μ mol, 59.0 μ L, 1.20 eq.) and trimethylsilyl trifluoromethanesulfonate (151 mg, 679 μ mol, 123 μ L, 2.50 eq.) at 0 °C. Then a solution of borane tetrahydrofuran complex (1.00 M, 272 μ L, 1.00 eq.) was added. The mixture was stirred at 0 °C for 3 hours. The mixture was quenched with methanol (3.00 mL) at 0 °C. Next, the mixture was diluted with ethyl acetate 5.00 mL and washed with brine (3.00 mL $\times$ 3), the separated organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The mixture was purified by prep-TLC (petroleum ether/ethyl acetate 10:1) to give *tert*-butyl 2-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoate (40.0 mg, 84.8 μ mol, 31.2% yield) as a yellow solid. LCMS $[M+H]^+ = 472.5$.

[00283] Step E: To a solution of *tert*-butyl 2-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoate (40.0 mg, 84.8 μ mol, 1.00 eq.) was added trifluoroacetic acid (29.0 mg, 254 μ mol, 18.9 μ L, 3.00 eq.). The mixture was stirred at 25 °C for 2 hours. The reaction was concentrated under reduced pressure to remove trifluoroacetic acid and the residue was neutralized with ammonium hydroxide. The mixture was purified by prep-HPLC (column: YMC-Actus Triart C18 150 $\times$ 30mm $\times$ 7 μ m; mobile phase: mobile phase A: 0.225% formic acid in water, mobile phase B: acetonitrile; gradient B%: 80%-100%, 10min) to give 2-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid (11.2 mg, 26.0 μ mol, 30.7% yield, 96.6% purity) as a yellow solid. LCMS $[M+H]^+ = 279.2$.

[00284] ^1H NMR (400 MHz, DMSO- d_6) δ = 8.47 (br d, J = 3.2 Hz, 1H), 7.78 (dd, J = 1.6, 8.0 Hz, 1H), 7.63 (s, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.19 - 7.13 (m, 1H), 6.50 (t, J = 7.6 Hz, 1H), 6.42 (d, J = 8.4 Hz, 1H), 5.51 - 5.45 (m, 1H), 3.71 (br d, J = 6.0 Hz, 4H), 2.41 (s, 3H), 1.78 - 1.67 (m, 6H), 1.61 (d, J = 6.8 Hz, 3H).

[00285] Example 2

2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid



[00286] Step A: To a solution of isoindoline (2.80 g, 23.5 mmol, 2.67 mL, 4.74 eq.) in dimethyl sulfoxide (2.50 mL) was added 5-bromo-3-chloro-7-methylquinoxaline-2-carbonitrile (1.40 g, 4.96 mmol, 1.00 eq.) portion-wise. The mixture was stirred at 15°C for 1 hour. Upon completion, the reaction mixture was poured into water (20.0 mL), during this period, yellow precipitate was formed, the suspension was filtered, the cake was collected and dried under reduced pressure to give the crude product. The crude product was triturated with a mixture solvent of petroleum ether (3.00 mL) and ethyl acetate (9.00 mL), then filtered and collected the cake 5-bromo-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (1.60 g, 4.38 mmol, 88.4% yield) as a yellow solid which was use directly. LCMS $[M+3]^+ = 367.1$.

[00287] ^1H NMR (400 MHz, CDCl_3) δ = 7.81 (d, J = 1.6 Hz, 1H), 7.59 (s, 1H), 7.42 - 7.32 (m, 2H), 7.31 - 7.26 (m, 2H), 7.16 - 7.01 (m, 2H), 5.35 - 5.07 (m, 4H), 2.42 (s, 3H).

[00288] Step B: A mixture of 5-bromo-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (1.60 g, 4.38 mmol, 1.00 eq.), tributyl(1-ethoxyvinyl)tin (2.21 g, 6.12 mmol, 2.07 mL, 1.40 eq.), $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (307 mg, 438 μmol , 0.10 eq.) in dioxane (15.0 mL) was stirred at 100 °C for 4 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was cooled to 20 °C, then the reaction mixture was quenched by addition KF solution 40 mL at 25

°C and stirred for 1 hour, the solution was extracted with ethyl acetate 150 mL (50.0 mL × 3). The combined organic layers were washed with water 60.0 mL (30.0 mL × 2), dried over, filtered and concentrated under reduced pressure to give 5-(1-ethoxyvinyl)-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (1.50 g, crude) as a yellow solid. LCMS [M+1]⁺ = 357.2.

[00289] Step C: To a solution of 5-(1-ethoxyvinyl)-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (1.50 g, 4.21 mmol, 1.00 eq.) in acetonitrile (20.0 mL) at 10 °C was added HCl (3 M in water, 1.40 mL, 1.00 eq.). The mixture was stirred at 10 °C for 1 hour. Upon completion, the mixture was quenched by saturated sodium bicarbonate solution to pH = 7 slowly. The suspension was precipitated with ethyl acetate (8.00 mL) and the yellow cake was collected by filtration, the solid was washed with ethyl acetate (2.00 mL × 2), then dried to give 5-acetyl-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (1.10 g, 3.35 mmol, 79.6% yield) as a yellow solid which was used directly. LCMS [M+1]⁺ = 329.1.

[00290] Step D: To a solution 5-acetyl-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (250 mg, 761 μmol, 1.00 eq.), 2-methylpropane-2-sulfinamide (185 mg, 1.52 mmol, 2.00 eq.) in a mixture of tetrahydrofuran (2.10 mL) and 1,2-dimethoxyethane (0.36 mL) was added titanium (IV) ethoxide (521 mg, 2.28 mmol, 474 μL, 3.00 eq.). The mixture was stirred at 80 °C for 16 hours. Upon completion, the mixture was cooled to 25 °C, water (0.50 mL) was added to the reaction, then the suspension was filtered, the solid was washed by ethyl acetate 160 mL (40.0 mL × 4, the combined organics were washed with brine 15.0 mL (5.0 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give *N*-(1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide (320 mg, crude) as yellow solid which was used directly. LCMS [M+1]⁺ = 432.1.

[00291] Step E: To a solution of *N*-(1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide (320 mg, 742 μmol, 1.00 eq.) in dichloromethane (3.00 mL) at 0 °C was added zirconocene hydrochloride (792 mg, 2.97 mmol, 4.00 eq.) portion-wise. The mixture was stirred at 0 °C, and then warmed to 25 °C stirred for 3 hours. Upon completion, the mixture was quenched by water 2.00 mL and stirred for 20 min. The suspension was filtered and extracted with dichloromethane (30.0 mL × 3). The organic phase was separated, washed with brine 4.00 mL, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=5/1 to 1/1) to give *N*-(1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)-2-methylpropane-2-sulfinamide (110 mg, 233 μmol, 31.4% yield, 91.8% purity) as a yellow solid. LCMS [M+1]⁺ = 434.1.

[00292] ¹H NMR (400 MHz, CDCl₃) δ = 7.64 (s, 1H), 7.55 (d, *J* = 1.6 Hz, 1H), 7.49 - 7.41 (m, 2H), 7.41 - 7.34 (m, 2H), 5.42 - 5.27 (m, 4H), 5.23 (quin, *J* = 6.4 Hz, 1H), 4.54 (br d, *J* = 6.0 Hz,

1H), 2.53 (s, 3H), 1.72 (d, $J = 6.8$ Hz, 3H), 1.26 (s, 9H).


[00293] Step F: To a solution of *N*-(1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)-2-methylpropane-2-sulfonamide (110 mg, 233 μ mol, 1.00 eq.) in acetonitrile (1.50 mL) was added HCl (4 M in dioxane, 116 μ L, 2.00 eq.). The mixture was stirred at 0 °C for 30 minutes. Upon completion, the reaction mixture was directly concentrated to give a crude product. The crude product was triturated with ethyl acetate (1.00 mL) and dried to give 5-(1-aminoethyl)-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (80.0 mg, 219 μ mol, 93.9% yield, hydrochloride salt) as a green solid which was used directly. LCMS $[M+1]^+ = 330.1$.

[00294] Step G: A mixture of 5-(1-aminoethyl)-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (80.0 mg, 219 μ mol, 1.00 eq., hydrochloride salt), 2-carboxyphenylboronic acid (109 mg, 656 μ mol, 3.00 eq.), 1,8-diazabicyclo[5.4.0]undec-7-ene (166 mg, 1.09 mmol, 165 μ L, 5.00 eq.), copper (II) acetate (59.6 mg, 328 μ mol, 1.50 eq.) and 4Å molecular sieves (30.0 mg) in dimethylformamide (1.50 mL) was stirred at 25 °C for 16 hours. Upon completion, the mixture was filtered, the filtrate was diluted with water (2.00 mL), ethyl acetate (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with ethyl acetate (15.0 mL $\times$ 3). Combined extracts were washed with brine (3.00 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 68% - 98% phase B) to give 2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid (12.5 mg, 25.5 μ mol, 11.7% yield, 91.6% purity) as a yellow solid. LCMS $[M+1]^+ = 450.2$.

[00295] ^1H NMR (400 MHz, DMSO- d_6) δ = 12.95 - 12.19 (m, 1H), 8.69 - 8.38 (m, 1H), 7.78 (br d, $J = 7.2$ Hz, 1H), 7.60 (s, 2H), 7.50 (br dd, $J = 3.2, 5.2$ Hz, 2H), 7.36 (br dd, $J = 3.2, 5.6$ Hz, 2H), 7.18 (br t, $J = 7.6$ Hz, 1H), 6.60 - 6.44 (m, 2H), 5.64 - 5.48 (m, 1H), 5.36 - 5.23 (m, 4H), 2.40 (s, 3H), 1.68 (br d, $J = 6.8$ Hz, 3H).

[00296] Examples 3 and 4

(*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate and
(*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate



[00297] Step A: To a solution of 5-bromo-3-chloro-7-methylquinoxaline-2-carbonitrile (4.42 g, 15.6 mmol, 1.00 eq.) in dimethyl sulfoxide (30.0 mL) was added CsF (3.56 g, 23.5 mmol, 866 μL , 1.50 eq.) and 4,4-difluoropiperidine (3.22 g, 26.6 mmol, 1.70 eq.). The mixture was stirred at 130 °C for 2 hours. Upon completion, the mixture was cooled to 20 °C, the reaction mixture was added to water (80.0 mL) slowly, during this period, yellow precipitate was formed, the suspension was filtered, the cake was collected and dried under reduced pressure to give the crude product. The crude product was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=20/1 to 10/1) to give 5-bromo-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (4.87 g, 13.26 mmol, 84.8% yield) as a yellow solid. LCMS $[\text{M}+1]^+ = 366.9$.

[00298] ^1H NMR (400 MHz, CDCl_3) δ = 7.85 (d, J = 1.6 Hz, 1H), 7.63 (d, J = 0.8 Hz, 1H), 3.98 - 3.80 (m, 4H), 2.45 (s, 3H), 2.26 - 2.08 (m, 4H).

[00299] Step B: A mixture of 5-bromo-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (4.80 g, 13.07 mmol, 1 eq), tributyl(1-ethoxyvinyl)tin (6.10 g, 16.9 mmol, 5.71 mL, 1.29 eq.), $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (918 mg, 1.31 mmol, 0.10 eq.) in dioxane (50.0 mL) was stirred at 100

°C for 2 hours under a nitrogen atmosphere. After completion, the reaction mixture was warmed to 0 °C, then the reaction mixture was quenched by addition KF solution 100 mL at 25 °C and stirred for 1 hour, the solution was extracted with ethyl acetate (80.0 mL × 2). The combined organic layers were washed with water (30.0 mL × 2), dried over, filtered and concentrated under reduced pressure to give 3-(4,4-difluoropiperidin-1-yl)-5-(1-ethoxyvinyl)-7-methylquinoxaline-2-carbonitrile (4.68 g, 13.06 mmol, crude) as a white solid which was used next step directly. LCMS $[M+1]^+ = 359.1$.

[00300] Step C: To a solution of 3-(4,4-difluoropiperidin-1-yl)-5-(1-ethoxyvinyl)-7-methylquinoxaline-2-carbonitrile (4.65 g, 13.0 mmol, 1.00 eq.) in acetonitrile (40.0 mL) at 10 °C was added HCl (3 M in water, 5.19 mL, 1.20 eq.). The mixture was stirred at 10 °C for 1 hours. Upon completion, the mixture was quenched by saturated sodium bicarbonate solution to pH =7 and then extracted with ethyl acetate (100 mL × 3). The combined organic phase was washed with saturated brine (40.0 mL ×2), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, the crude product was triturated with a mixed solvent of petroleum ether (30.0 mL) and ethyl acetate (10.0 mL) to give 5-acetyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (3.90 g, 11.8 mmol, 91.0% yield) as a yellow solid which used next step directly.

[00301] ¹H NMR (400 MHz, CDCl₃) δ = 7.96 (d, *J* = 2.0 Hz, 1H), 7.84 (dd, *J* = 0.8, 2.0 Hz, 1H), 3.88 - 3.70 (m, 4H), 2.80 (s, 3H), 2.50 (s, 3H), 2.28 - 2.10 (m, 4H)

[00302] Step D: A dry 100 mL three neck flask with magnetic stirring bar was charged consecutively with 5-acetyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (500 mg, 1.51 mmol, 1.00 eq.), *tert*-butyl 2-aminobenzoate (322 mg, 1.67 mmol, 304 μL, 1.10 eq.), *N,N*-dimethylformamide (5.00 mL), and trimethylsilyl trifluoromethanesulfonate (841 mg, 3.78 mmol, 684 μL, 2.50 eq.) under a nitrogen atmosphere. The reaction mixture was cooled to 0 °C, then a solution of borane tetrahydrofuran complex (1 M in tetrahydrofuran, 1.82 mL, 1.20 eq.) was added slowly with a syringe over a period of 10–20 min. the reaction mixture was kept stirring at 0 °C and stirred for 12 hours. Upon completion, the mixture was quenched water (5.0 mL) and the mixture was stirred for 20 min, the solution was extracted with ethyl acetate (20.0 mL), followed by saturated sodium carbonate solution (12.0 mL). The two phase mixture was kept stirring until the gas evolution had ceased. The phases were separated, and the aqueous layer was extracted with ethyl acetate (20 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, and the solvents were removed under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 10/1) to give the crude product. The crude product was further purified by prep-TLC (SiO₂, petroleum ether/ethyl acetate=1/0 to 10/1) give *tert*-butyl 2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (90.0 mg,

177 μ mol, 11.7% yield) as a yellow solid. LCMS $[M+1]^+ = 508.1$

Separation of *tert*-butyl (*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate and *tert*-butyl (*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate

[00303] 85 mg of *tert*-butyl 2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate was purified by prep-HPLC (column: DAICEL CHIRALPAK IG(250 mm $\times$ 50mm, 10 μ m); mobile phase: phase A: CO₂, phase B: 0.1% ammonium hydroxide in *i*-PrOH; phase B%: 10%, isocratic elution mode) to give *tert*-butyl (*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (40.0 mg, 78.8 μ mol, 47.1% yield) (first eluting isomer) as a yellow oil. *Tert*-butyl (*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (35.0 mg, 69.0 μ mol, 41.2% yield) (second eluting isomer) as a yellow oil.

[00304] Step E: To a solution of *tert*-butyl (*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (40.0 mg, 78.8 μ mol, 1.00 eq.) in dichloromethane (1.00 mL) was added trifluoroacetic acid (0.50 mL). The mixture was stirred at 25 °C for 8 hours. After completion of the reaction, the mixture was adjusted to pH=7 with aqueous sodium hydroxide, then concentrated to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: mobile phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 60%-90% B) to give (*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid (8.10 mg, 17.48 μ mol, 22.2% yield, 97.4% purity) as a yellow solid. LCMS $[M+H]^+ = 452.2$.

[00305] ¹H NMR (400 MHz, CD₃OD) δ = 7.90 (d, *J* = 8.0 Hz, 1H), 7.72 - 7.62 (m, 2H), 7.18 - 7.07 (m, 1H), 6.52 (t, *J* = 7.4 Hz, 1H), 6.41 (d, *J* = 8.4 Hz, 1H), 5.60 (q, *J* = 6.4 Hz, 1H), 3.93 (br t, *J* = 5.6 Hz, 4H), 2.47 (s, 3H), 2.33 - 2.19 (m, 4H), 1.69 (d, *J* = 6.8 Hz, 3H).


[00306] Step F: To a solution of *tert*-butyl (*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (35.0 mg, 69.0 μ mol, 1.00 eq.) in dichloromethane (1.00 mL) was added trifluoroacetic acid (0.50 mL). The mixture was stirred at 25 °C for 8 hours. After completion of the reaction, the mixture was adjusted to pH=7 with sodium hydroxide, then concentrated to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient :65%-95% phase B) to give (*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid (15.5 mg, 34.16 μ mol, 49.5% yield, 99.5% purity) as a yellow solid. LCMS $[M+H]^+ = 452.3$.

[00307] ¹H NMR (400 MHz, CD₃OD) δ = 7.79 (dd, *J* = 1.4, 7.9 Hz, 1H), 7.57 - 7.55 (m, 2H), 7.08 - 6.94 (m, 1H), 6.41 (t, *J* = 7.6 Hz, 1H), 6.30 (d, *J* = 8.4 Hz, 1H), 5.49 (q, *J* = 6.4 Hz, 1H),

3.81 (t, $J = 5.6$ Hz, 4H), 2.36 (s, 3H), 2.23 - 2.08 (m, 4H), 1.57 (d, $J = 6.8$ Hz, 3H)

[00308] Example 5

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00309] Step A: To a solution of 5-acetyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (1.50 g, 4.54 mmol, 1.00 eq.), (*R*)-2-methylpropane-2-sulfinamide (1.10 g, 9.08 mmol, 2.00 eq.) in a mixture of tetrahydrofuran (15.0 mL) and 1,2-dimethoxyethane (3.00 mL) was added titanium (IV) ethoxide (3.11 g, 13.6 mmol, 2.82 mL, 3.00 eq.). The mixture was stirred at 75 °C for 16 hours. Upon completion of the reaction, the mixture was cooled to 25 °C, the reaction mixture was added water (2.00 mL) and stirred for 0.5 hour at 25°C. The reaction mixture was filtered, the cake was washed with ethyl acetate (50.0 mL × 4), the combined organic layers were washed with brine 60.0 mL (20.0 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give (*R*)-*N*-(1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide (1.80 g, 4.15 mmol, 91.4% yield) as yellow oil which was used directly.

[00310] Step B: To a solution of (*R*)-*N*-(1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide, in dichloromethane (30.0

mL) was added zirconocene hydrochloride (2.94 g, 11.0 mmol, 4.0 eq.) portion-wise. The mixture was stirred at 25 °C stirred for 12 hours. Upon completion, the mixture was quenched by water (10 mL) and stirred for 20 min. Next, the suspension was filtered and diluted with dichloromethane (30.0 mL × 3). The organic phase was separated, washed with brine 20.0 mL, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=10/1 to 1/1) to give (*R*)-*N*-((*R*)-1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)-2-methylpropane-2-sulfonamide (1.24 g, 2.57 mmol, 67.6% yield, 90.3% purity) as a yellow solid. LCMS [M+1]⁺ = 436.1.

[00311] ¹H NMR (400 MHz, CDCl₃) δ = 7.62 (d, *J* = 0.8 Hz, 1H), 7.53 (d, *J* = 1.6 Hz, 1H), 5.13 (quin, *J* = 6.8 Hz, 1H), 4.21 (br d, *J* = 6.8 Hz, 1H), 3.77 (br t, *J* = 5.6 Hz, 4H), 2.47 (s, 3H), 2.30 - 2.09 (m, 4H), 1.57 (d, *J* = 6.8 Hz, 3H), 1.23 - 1.10 (m, 9H).

[00312] Step C: To a solution of (*R*)-*N*-((*R*)-1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)-2-methylpropane-2-sulfonamide (330 mg, 722.84 μmol, 1.00 eq.) in acetonitrile (3.00 mL) at 0 °C was added HCl (4 M in dioxane, 361.42 μL, 2.00 eq.) dropwise. The mixture was stirred at 0 °C for 1 hour. The reaction mixture was directly concentrated to give a crude product. The crude product was triturated with ethyl acetate (1.00 mL), collected the cake and dried to give (*R*)-5-(1-aminoethyl)-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (205 mg, 557.33 μmol, 77.1% yield, hydrochloride salt) as a yellow solid. LCMS [M+1]⁺ = 332.1.

[00313] Step D: A mixture of (*R*)-5-(1-aminoethyl)-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (195 mg, 530 μmol, 1.00 eq, hydrochloride salt), methyl 6-chloro-3-fluoro-pyridine-2-carboxylate (241 mg, 1.27 mmol, 2.40 eq.), diisopropylethylamine (480 mg, 3.71 mmol, 646 μL, 7.00 eq.) in dimethylformamide (1.50 mL) was stirred at 80 °C for 9 hours. Upon completion, the mixture was cooled to 25 °C, the reaction mixture was diluted with water (20.0 mL) and extracted with ethyl acetate (40.0 mL × 2). The combined organic layers were washed with saturate sodium bicarbonate solution (20.0 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (280 mg, 430 μmol, 81.2% yield, 77% purity) as yellow oil which was used directly. LCMS [M+1]⁺ = 501.2.


[00314] Step E: A mixture of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (90.0 mg, 138 μmol, 1.00 eq.), lithium chloride (58.7 mg, 1.38 mmol, 28.4 μL, 10.0 eq.) in dimethyl sulfoxide (0.50 mL) was stirred at 130 °C for 3 hours. Upon completion, the mixture was cooled to 25 °C, the reaction mixture was filtered. The filtrate was purified by prep-HPLC (column: YMC-Actus Triart C18 150 ×

30mm × 7um; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient 63% - 93% phase B) to give (*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (22.2 mg, 45.2 μmol, 32.7% yield, 99.2% purity) as a yellow solid. LCMS $[M+23]^+ = 509.1$

[00315] ^1H NMR (400 MHz, CDCl_3) δ = 11.07 - 10.33 (m, 1H), 8.38 (br d, J = 6.4 Hz, 1H), 7.70 (s, 1H), 7.58 (d, J = 1.6 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.77 (d, J = 8.8 Hz, 1H), 5.51 (quin, J = 6.4 Hz, 1H), 3.99 - 3.83 (m, 4H), 2.50 (s, 3H), 2.39 - 2.17 (m, 4H), 1.73 (d, J = 6.8 Hz, 3H).

[00316] Example 6

(*R*)-2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid



[00317] Step A: To a solution of 5-acetyl-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (500 mg, 1.52 mmol, 1.00 eq.), (*R*)-2-methylpropane-2-sulfonamide (369 mg, 3.05 mmol, 2.00 eq.) in a mixture of tetrahydrofuran (4.20 mL) and 1,2-dimethoxyethane (0.72 mL) was added tetraethoxytitanium (1.04 g, 4.57 mmol, 947 μL, 3.00 eq.). The mixture was stirred at 80 °C stirred for 16 hours. Upon completion, the mixture was cooled to 25 °C, the reaction mixture was quenched with water (0.50 mL), then the suspension was filtered, the cake was washed by ethyl acetate (20.0 mL × 4), the combined organics were washed with brine (2.00 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give (*R*)-*N*-(1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethylidene)-2-

methylpropane-2-sulfonamide (680 mg, crude) as yellow solid which was used directly. LCMS $[M+1]^+ = 432.2$

[00318] Step B: To a solution of (*R*)-*N*-(1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethylidene)-2-methylpropane-2-sulfonamide (600 mg, 1.39 mmol, 1.00 eq.) in dichloromethane (9.00 mL) at 0 °C was added zirconocene hydrochloride (1.48 g, 5.56 mmol, 4.00 eq.) portion-wise. The mixture was stirred at 0 °C, and then warmed to 25 °C stirred for 3 hours. Upon completion, the mixture was quenched by water 5 mL and stirred for 20 min. The suspension filtered and extracted with dichloromethane (30.0 mL × 3). The organic phase was separated, washed with brine 10.0 mL, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=5/1 to 1/1) to give (*R*)-*N*-((*R*)-1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)-2-methylpropane-2-sulfonamide (286 mg, 641 μmol, 46.1% yield, 97.2% purity) as a yellow solid.

[00319] ¹H NMR (400 MHz, CDCl₃) δ = 7.66 (s, 1H), 7.57 (d, *J* = 1.6 Hz, 1H), 7.51 - 7.43 (m, 2H), 7.43 - 7.37 (m, 2H), 5.43 - 5.29 (m, 4H), 5.24 (quin, *J* = 6.4 Hz, 1H), 4.56 (br d, *J* = 6.4 Hz, 1H), 2.67 - 2.50 (m, 1H), 2.54 (s, 2H), 1.73 (d, *J* = 6.8 Hz, 3H), 1.28 (s, 9H).

[00320] Step C: To a solution of (*R*)-*N*-((*R*)-1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)-2-methylpropane-2-sulfonamide (130 mg, 291 μmol, 1.00 eq.) in acetonitrile (1.50 mL) at 0 °C was added HCl (4 M in dioxane, 146 μL, 2.00 eq.), the mixture was stirred at 0 °C for 1 hour. Upon completion, the reaction mixture was directly concentrated to give a crude product. The crude product was triturated with ethyl acetate (1.00 mL) and dried to give (*R*)-5-(1-aminoethyl)-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (70.0 mg, 191 μmol, 65.7 % yield, hydrochloride salt) as a yellow solid. LCMS $[M+1]^+ = 330.2$.


[00321] Step D: A mixture of (*R*)-5-(1-aminoethyl)-3-(isoindolin-2-yl)-7-methylquinoxaline-2-carbonitrile (70.0 mg, 191 μmol, 1.00 eq., hydrochloride salt), 2-carboxyphenylboronic acid (95.3 mg, 574 μmol, 3.00 eq.), 1,8-diazabicyclo[5.4.0]undec-7-ene (146 mg, 957 μmol, 144 μL, 5.00 eq.), copper (II) acetate (52.1 mg, 287 μmol, 1.50 eq.) and 4Å molecular sieve (50.0 mg, 13.7 μmol) in *N,N*-dimethylformamide (1.00 mL) was stirred at 25 °C for 16 hours. Upon completion, the mixture was filtered and the filtrate was diluted water (2.00 mL). Next, ethyl acetate (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with ethyl acetate (15.0 mL × 3). The combined organics were washed with brine (3.00 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 150 × 25 mm × 10 μm; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 68%-98% phase B) to give (*R*)-2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid (17.0 mg, 37.7 μmol, 19.7% yield, 99.6%

purity) as a yellow solid. LCMS $[M+1]^+ = 450.2$.

[00322] ^1H NMR (400 MHz, CDCl_3) δ = 8.45 - 8.11 (m, 1H), 7.99 (dd, J = 1.2, 8.0 Hz, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.50 - 7.41 (m, 2H), 7.40 - 7.34 (m, 2H), 7.25 - 7.12 (m, 1H), 6.59 (t, J = 7.2 Hz, 1H), 6.43 (d, J = 8.4 Hz, 1H), 5.72 - 5.54 (m, 1H), 5.36 (s, 4H), 2.46 (s, 3H), 1.76 (d, J = 6.8 Hz, 3H).

[00323] Example 7

6-chloro-3-(((1*R*)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00324] Step A: To a solution of methyl (*R*)-6-chloro-3-(((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (100 mg, 251 μmol , 1.00 eq.) in dimethyl sulfoxide (1.00 mL) was added benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (196 mg, 377 μmol , 1.50 eq.), 6,6-difluoro-3-azabicyclo[3.1.1]heptane hydrochloride (77.7 mg, 377 μmol , 1.50 eq.) and diisopropylethylamine (162 mg, 1.26 mmol, 219 μL , 5.00 eq.). The mixture was stirred at 20 °C for 1 hour. After completion, the mixture was poured into saturated water aqueous solution (1.00 mL) and extracted with ethyl acetate (3 $\times$ 5.00 mL). The combined organics were washed with brine (1.00 mL), the organic layers were collected and concentrated to give a residue. The residue was purified by prep-TLC (SiO_2 , petroleum ether/ethyl acetate=3/1) to give methyl 6-chloro-3-(((1*R*)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (50.0 mg, 87.7 μmol , 34.9% yield, 75% purity) as a white solid. LCMS $[M+1]^+ = 513.3$.

[00325] Step B: To a solution of methyl 6-chloro-3-(((1*R*)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (40.0 mg, 82.9 μmol , 1.00 eq.) in dimethyl sulfoxide (0.50 mL) was added lithium chloride (35.1 mg, 829 μmol , 10.0 eq.). The reaction was stirred at 170 °C for 1 hour. After completion, the mixture was cooled to 20 °C. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Waters Xbridge 150 $\times$ 25 mm $\times$ 5 μm ; mobile phase: phase A: water(10mmol/L NH_4HCO_3),


phase B: acetonitrile; gradient: 10%-40% phase B) and further purified by prep-HPLC (column: Phenomenex luna C18 150 × 25 mm × 10 μm; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 15%-45% phase B) to give 6-chloro-3-(((1*R*)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (5.36 mg, 11.0 μmol, 13.3% yield, 96.1% purity) as a yellow solid. LCMS [M+23]⁺ = 521.3.


[00326] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.66 - 8.31 (m, 1H), 7.63 (t, *J* = 6.40 Hz, 2H), 7.29 (d, *J* = 8.80 Hz, 1H), 7.17 - 6.91 (m, 1H), 5.54 - 5.37 (m, 1H), 4.53 (br dd, *J* = 4.00, 12.4 Hz, 1H), 4.36 - 4.20 (m, 1H), 3.80 - 3.64 (m, 2H), 3.63 - 3.50 (m, 1H), 3.12 - 2.98 (m, 1H), 2.96 - 2.78 (m, 1H), 2.52 (br s, 1H), 2.41 (d, *J* = 2.00 Hz, 3H), 1.66 (t, *J* = 7.20 Hz, 3H)

[00327] ¹⁹F NMR (400 MHz, DMSO-*d*₆) δ = -92.47, -93.84, -94.83.

[00328] Examples 8 and 9

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*S*,4*S*)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (Example 8) and 6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,4*R*)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (Example 9)





[00329] Step A: To a solution of methyl (R)-6-chloro-3-(((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (150 mg, 377 μ mol, 1.00 eq.) in *N,N*-dimethylformamide (1.50 mL) was added diisopropylethylamine (244 mg, 1.89 mmol, 328 μ L, 5.00 eq.) and benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (294 mg, 565 μ mol, 1.50 eq.). The reaction was stirred at 20 °C for 15 minutes. And then 5,5-difluoro-2-azabicyclo[2.2.1]heptane hydrochloride (95.9 mg, 565 μ mol, 1.50 eq.) was added to the above mixture and the mixture was stirred at 20 °C for 1 hour. After completion, the reaction mixture was diluted with water (5.00 mL) and extracted with ethyl acetate (3 $\times$ 5.00 mL). The organic layers were combined and concentrated to give a residue. The residue was purified by *prep*-TLC (petroleum ether: ethyl acetate=3/1) to give methyl 6-chloro-3-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (180 mg, 316 μ mol, 83.8% yield, 90% purity) as a yellow solid. LCMS $[M+1]^+ = 513.1$.

[00330] Step B The mixture of methyl 6-chloro-3-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (180 mg, 316 μ mol, 1.00 eq.) was purified by Supercritical Fluid Chromatography (SFC) (column: DAICEL CHIRALCEL OX (250 mm $\times$ 30 mm, 10 μ m); mobile phase: phase A: CO₂, phase B: 0.1% ammonium hydroxide in MeOH; 40% phase B isocratic elution mode). The desired fractions of the first peak were collected and concentrated to give the methyl ester of Example 8 (30.0 mg, 42.7 μ mol, 12.2% yield, 73% purity) as a yellow solid (first eluting isomer). LCMS $[M+1]^+ = 513.2$. The desired fractions of the second peak were collected and concentrated to give the methyl ester of Example 9 (30.0 mg, 40.4 μ mol, 11.5% yield, 69% purity) as a yellow solid (second eluting isomer). LCMS $[M+1]^+ = 513.2$.

[00331] Saponification of the methyl esters of Examples 8 and 9

[00332] To a solution of the methyl ester of Example 8 (25.0 mg, 48.7 μ mol, 1.00 eq.) in dimethyl sulfoxide (0.50 mL) was added lithium chloride (20.7 mg, 487 μ mol, 10.0 eq.). The mixture was stirred at 130 °C for 4 hours. After completion, the mixture was cooled to 20 °C and filtered. The filtrate was purified by *prep*-HPLC (column: Welch Xtimate C18 150 * 25 mm * 5 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 55%-85% phase B) to give Example 8 (9.45 mg, 18.7 μ mol, 38.3% yield, 98.5% purity) as a yellow solid. LCMS $[M+23]^+ = 521.2$.

[00333] ^1H NMR (400 MHz, CDCl_3 -*d*) δ = 10.71 (s, 1H), 8.37 (br d, J = 6.0 Hz, 1H), 7.61 (s, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 5.44 - 5.34 (m, 1H), 5.10 (br s, 1H), 4.14 - 4.05 (m, 1H), 3.92 (d, J = 10.4 Hz, 1H), 3.11 - 3.02 (m, 1H), 2.44 (s, 3H), 2.41 - 2.27 (m, 2H), 2.20 - 2.07 (m, 2H), 1.70 (d, J = 6.8 Hz, 3H).

[00334] ^{19}F NMR (400 MHz, CDCl_3 -*d*) δ = -89.30, -89.91, -108.36, -108.96.


[00335] To a solution of the methyl ester of Example 9 (30.0 mg, 58.5 μ mol, 1.00 eq.) in dimethyl sulfoxide (0.50 mL) was added lithium chloride (24.8 mg, 585 μ mol, 10.0 eq.). The reaction was stirred at 130 °C for 4 hours. After completion, the mixture was cooled to 20 °C and filtered. The filtrate was purified by *prep*-HPLC (column: Welch Xtimate C18 150 * 25 mm * 5 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 55%-85% phase B) to give Example 9 (6.22 mg, 12.3 μ mol, 21.0% yield, 98.6% purity) as a yellow solid. LCMS $[M+23]^+ = 521.2$.

[00336] ^1H NMR (400 MHz, CDCl_3 -*d*) δ = 8.40 - 8.31 (d, J = 5.6 Hz, 1H), 7.61 (s, 1H), 7.50 (s, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.71 (d, J = 8.8 Hz, 1H), 5.47 - 5.37 (m, 1H), 5.06 (br s, 1H), 4.15 - 4.07 (m, 1H), 3.91 (d, J = 10.4 Hz, 1H), 3.11 - 3.03 (m, 1H), 2.44 (s, 3H), 2.41 - 2.27 (m, 2H), 2.20 - 2.07 (m, 2H), 1.69 (d, J = 6.8 Hz, 3H).

[00337] ^{19}F NMR (400 MHz, CDCl_3 -*d*) δ = -89.32, -89.92, -108.53, -109.13.

[00338] Examples 10 and 11

6-chloro-3-(((*R*)-1-(2-cyano-3-(((1*R*,4*S*)-6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (Example 11) and 6-chloro-3-(((*R*)-1-(2-cyano-3-(((1*S*,4*R*)-6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (Example 10)



[00339] Step A: To a solution of methyl (R)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (200 mg, 502 μ mol, 1.00 eq.) in *N,N*-dimethylformamide (4.00 mL) were added benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (392 mg, 754 μ mol, 1.50 eq.) and diisopropylethylamine (162 mg, 1.26 mmol, 219 μ L, 5.00 eq.). The reaction was stirred at 25 °C for 30 minutes. Then, to the above mixture was added 6,6-difluoro-2-azabicyclo[2.2.1]heptane hydrochloride (128 mg, 754 μ mol, 1.50 eq.) at 25 °C, the reaction was stirred at 25 °C for 48 hours. After completion, the mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3 $\times$ 20.0 mL). The combined organic layers were washed with brine (3 $\times$ 10.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by *prep*-TLC (SiO_2 , petroleum ether : ethyl acetate = 2:1) to give methyl 6-chloro-3-(((1R)-1-(2-cyano-3-(6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (90.0 mg, 175 μ mol, 34.9% yield) as a yellow solid.

[00340] Step B: 6-chloro-3-(((1R)-1-(2-cyano-3-(6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-

yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (90.0 mg, 175 μ mol) was purified by SFC (column: DAICEL CHIRALCEL OX (250 mm $\times$ 30 mm, 10 μ m); mobile phase: phase A: CO₂, phase B: ammonium hydroxide in MeOH; phase B%:40%, isocratic elution mode) to give methyl ester of Example 10 (25 mg, 48.7 μ mol, 27.8% yield) as a yellow solid (first eluting isomer) and the methyl ester of Example 11 (40.0 mg, 78.0 μ mol, 44.4% yield) as a yellow solid was isolated as the second eluting isomer.

[00341] Saponification of the methyl esters of Examples 10 and 11

[00342] To a solution of methyl ester of Example 10 (25.0 mg, 48.7 μ mol, 1.00 eq.) in dimethyl sulfoxide (0.20 mL) was added lithium chloride (10.3 mg, 244 μ mol, 5.00 eq.). The reaction was stirred at 130 °C for 1 hour. After completion, the mixture was cooled to 20 °C and purified by *prep*-HPLC (column: Waters Xbridge 150 $\times$ 25 mm $\times$ 5 μ m; mobile phase: phase A: water(10 mmol/L NH₄HCO₃), phase B: acetonitrile; gradient: 22%-52% phase B) to give Example 10 (9.22 mg, 17.9 μ mol, 36.6 % yield, 96.6% purity) as a yellow solid. LCMS [M+23]⁺ = 521.2.

[00343] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.24 (br s, 1H), 7.61 (s, 1H), 7.58 (s, 1H), 7.06 (br d, *J* = 8.4 Hz, 1H), 6.84 (br d, *J* = 6.8 Hz, 1H), 5.39 (s, 2H), 4.01 - 3.93 (m, 1H), 3.75 (d, *J* = 9.6 Hz, 1H), 2.90 (br s, 1H), 2.40 (s, 3H), 2.30 - 2.17 (m, 1H), 2.12 - 1.90 (m, 3H), 1.61 (d, *J* = 6.4 Hz, 3H).

[00344] ¹⁹F NMR (377 MHz, DMSO-*d*₆) δ = -89.18, -89.76, -110.69, -111.27.


[00345] Step D: To a solution of methyl ester of Example 11 (40.0 mg, 78.0 μ mol, 1.00 eq.) in dimethyl sulfoxide (0.40 mL) was added lithium chloride (16.5 mg, 390 μ mol, 5.00 eq.). The reaction was stirred at 130 °C for 1 hour. After completion, the mixture was cooled to 20 °C and purified by *prep*-HPLC (column: Waters Xbridge 150 $\times$ 25 mm $\times$ 5 μ m; mobile phase: phase A: water(10 mmol/L NH₄HCO₃), phase B: acetonitrile; gradient: 22%-52% phase B) to give Example 11 (7.38 mg, 14.51 μ mol, 18.6 % yield, 98.1% purity) as a yellow solid. LCMS [M+23]⁺ = 521.2.

[00346] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.20 (br s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 1.6 Hz, 1H), 7.08 (d, *J* = 8.8 Hz, 1H), 6.71 (br d, *J* = 8.8 Hz, 1H), 5.39 (br d, *J* = 6.4 Hz, 1H), 5.33 (s, 1H), 4.00 (br d, *J* = 8.0 Hz, 1H), 3.68 (d, *J* = 9.6 Hz, 1H), 2.89 (br s, 1H), 2.37 (s, 3H), 2.30 - 2.16 (m, 1H), 2.11 - 1.88 (m, 3H), 1.58 (d, *J* = 6.8 Hz, 3H).

[00347] ¹⁹F NMR (400 MHz, DMSO-*d*₆) δ = -89.67, -90.26, -110.71, -111.28.

[00348] Example 12

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00349] Step A: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (90.0 mg, 226 μmol , 1.00 eq.) in *N,N*-dimethylformamide (0.20 mL) were added benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (177 mg, 339 μmol , 1.50 eq.) and diisopropylethylamine (146 mg, 1.213 mmol, 197 μL , 5.00 eq.). The reaction was stirred at 25 °C for 30 minutes. Then, to above mixture was added 3,3-difluoropiperidine hydrochloride (41.1 mg, 261 μmol , 1.15 eq.) at 25 °C. The reaction was stirred at 25 °C for 11.5 hours. After completion, the mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (10.0 mL $\times$ 3). The combined organics were washed with brine (10.0 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by *prep*-TLC (SiO_2 , petroleum ether: ethyl acetate = 2: 1) to give methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (30.0 mg, 46.1 μmol , 20.4% yield) as a yellow solid. LCMS $[\text{M}+1]^+ = 501.1$.

[00350] Step B: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (20.0 mg, 39.9 μmol , 1.00 eq.) in dimethyl sulfoxide (0.20 mL) was added lithium chloride (8.46 mg, 200 μmol , 5.00 eq.). The reaction was stirred at 130 °C for 5 hours. After completion, the mixture was cooled to 20 °C and purified by *prep*-HPLC (column: Phenomenex Luna C18 150 $\times$ 25 mm $\times$ 10 μm ; mobile phase: phase A: water(10 mmol/L NH_4HCO_3), phase B: acetonitrile; gradient: 26%-56% phase B) to give (*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (12.7 mg, 25.5 μmol , 63.8 % yield, 97.3% purity) as a yellow solid. LCMS $[\text{M}+23]^+ = 509.2$.


[00351] ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 9.38 (br s, 1H), 7.68 (s, 1H), 7.64 (s, 1H), 7.03 (br d, J = 8.8 Hz, 1H), 6.75 (br d, J = 8.0 Hz, 1H), 5.53 - 5.35 (m, 1H), 4.15 - 3.90 (m, 2H), 3.86 - 3.64 (m, 2H), 2.44 - 2.39 (s, 3H), 2.22 - 2.09 (m, 2H), 2.01 - 1.84 (m, 2H), 1.59 (br d, J = 6.8

Hz, 3H)

[00352] ^{19}F NMR (400 MHz, DMSO- d_6) δ = -99.17, -99.22.

[00353] Examples 13 and 14

6-chloro-3-(((*R*)-1-(2-cyano-3-(((*S*)-2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (Example 13) and 6-chloro-3-(((*R*)-1-(2-cyano-3-(((*R*)-2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (Example 14)



[00354] Step A: A solution of methyl (*R*)-6-chloro-3-(((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (200 mg, 503 μmol , 1.00 eq.) in *N,N*-dimethylformamide (2.00 mL) were added benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (392 mg, 754 μmol , 1.50 eq.) and diisopropylethylamine (325 mg, 2.51 mmol, 438 μL , 5.00 eq.). The reaction was stirred at 15 $^{\circ}\text{C}$ for 20 minutes. To the above mixture was added (2,2-difluorocyclopropyl)methanamine hydrochloride (108 mg, 75 μmol , 1.50 eq.).

The reaction was stirred at 15 °C for 1 hour. After completion, the mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (10.0 mL × 3). The combined organics were washed with brine (30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 5/1) and *prep*-HPLC (column: Phenomenex Luna C18 150 × 25 mm × 10 µm; mobile phase: phase A: water(10 mmol/L NH₄HCO₃), phase B: acetonitrile; gradient: 64%-94% phase B over 10 min) to give methyl 6-chloro-3-(((1*R*)-1-(2-cyano-3-(((2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (30.0 mg, 61.6 µmol, 12.3% yield) as a yellow solid. LCMS [M+1]⁺ = 487.2.

[00355] Step B: To a mixture of methyl 6-chloro-3-(((1*R*)-1-(2-cyano-3-(((2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (30.0 mg, 61.6 µmol, 1.00 eq.) was purified by SFC (column: DAICEL CHIRALPAK AD (250 mm × 50 mm, 10 µm); mobile phase: phase A: hexanes, phase B: 0.1% ammonia in isopropanol; phase B%: 12%, isocratic elution mode). The desired fractions were collected and concentrated to give the methyl ester of Example 13 (11.0 mg, 22.4 µmol, 36.3% yield, 99.0% purity) as a yellow solid (first eluting isomer LCMS [M+1]⁺ = 487.3) and the methyl ester of Example 14 (11.0 mg, 21.9 µmol, 35.6% yield, 97.1% purity) was isolated as a yellow solid (second eluting isomer, LCMS [M+1]⁺ = 487.3).

[00356] Saponification of the methyl esters of Examples 13 and 14

[00357] To a solution of the methyl ester of Example 13 (10.0 mg, 20.5 µmol, 1.00 eq.) in dimethyl sulfoxide (0.50 mL) was added lithium chloride (8.71 mg, 205 µmol, 10.0 eq.). The reaction was stirred at 130 °C for 5 hours. After completion, the mixture was cooled to 20 °C. The mixture was filtered and the filtrate was purified by *prep*-HPLC (column: Phenomenex Luna C18 150 × 25 mm × 10 µm; mobile phase: phase A: water(10 mmol/L NH₄HCO₃), phase B: acetonitrile; gradient: 22%-52% phase B over 10 min) to give Example 13 (4.12 mg, 8.60 µmol, 41.9% yield, 98.7% purity) as a yellow solid. LCMS [M-1]⁻ = 471.2.

[00358] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.25 (br s, 1H), 8.00 (t, *J* = 5.6 Hz, 1H), 7.55 (s, 2H), 7.06 (br d, *J* = 8.4 Hz, 1H), 6.73 (br d, *J* = 7.2 Hz, 1H), 5.49 - 5.35 (m, 1H), 3.82 - 3.70 (m, 1H), 3.54 - 3.44 (m, 1H), 2.37 (s, 3H), 2.27 - 2.13 (m, 1H), 1.67 - 1.60 (m, 1H), 1.56 (d, *J* = 6.8 Hz, 3H), 1.48 - 1.35 (m, 1H).

[00359] ¹⁹F NMR (400 MHz, DMSO-*d*₆) δ = -126.46, -126.87, -141.37, -141.79.

[00360] To a solution of the methyl ester of Example 14 (10.0 mg, 20.5 µmol, 1.00 eq.) in dimethyl sulfoxide (0.50 mL) was added lithium chloride (8.71 mg, 205 µmol, 10.0 eq.). The reaction was stirred at 130 °C for 5 hours. After completion, the mixture was cooled to 20 °C. The mixture was filtered and the filtrate was purified by *prep*-HPLC (column: Phenomenex Luna


C18 150 × 25 mm×10 μm; mobile phase: phase A: water(10 mmol/L NH₄HCO₃), phase B: acetonitrile; gradient: 24%-54% phase B over 10 min) to give Example 14 (5.15 mg, 10.8 μmol, 52.5% yield, 99.0% purity) as a yellow solid. LCMS [M-1]⁻ = 471.2.

[00361] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.25 (br s, 1H), 8.00 (t, *J* = 5.6 Hz, 1H), 7.56 (s, 2H), 7.05 (br d, *J* = 8.8 Hz, 1H), 6.71 (br d, *J* = 8.4 Hz, 1H), 5.49 - 5.37 (m, 1H), 3.71 (m, 1H), 3.54 - 3.47 (m, 1H), 2.37 (s, 3H), 2.28 - 2.14 (m, 1H), 1.64 - 1.58 (m, 1H), 1.56 (d, *J* = 6.8 Hz, 3H), 1.46 - 1.33 (m, 1H).

[00362] ¹⁹F NMR (400 MHz, DMSO-*d*₆) δ = -126.40, -126.81, -141.44, -141.52.

[00363] Example 15

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid



[00364] Step A: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (100 mg, 251 μmol, 1.00 eq.), (1-(trifluoromethyl)cyclopropyl)methanamine hydrochloride (53.3 mg, 251 μmol, 1.00 eq., HCl) in *N,N*-dimethylformamide (1.00 mL) was added benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (157 mg, 302 μmol, 1.20 eq.) and diisopropylethylamine (162 mg, 1.26 mmol, 219 μL, 5.00 eq.). The mixture was stirred at 25 °C for 12 hours. After completion of the reaction, the mixture was cooled to 15 °C and added to water (2.00 mL) slowly, during this period, yellow precipitate was formed, the suspension was filtered, the cake was collected and dried under reduced pressure to give methyl (*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinate (45.0 mg, 71.1 μmol, 28.3% yield, 82% purity) as a yellow solid. LCMS [M+1]⁺ = 519.2.


[00365] Step B: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinate (45.0 mg, 71.1 μmol, 1.00 eq.) in dimethyl sulfoxide (1.00 mL) was added lithium chloride (30.1 mg, 711 μmol, 14.6 μL, 10.0 eq.). The mixture was stirred at 120 °C for 6 hours. After completion of the

reaction, the mixture was cooled to 25 °C, and then purified by prep-HPLC (column: Phenomenex luna C18 150 × 25mm × 10um; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 62%-92% phase B) to give (*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid (4.26 mg, 8.40 μmol, 11.8% yield, 99.6% purity) as a yellow solid. LCMS [M+1]⁺ = 505.2.

[00366] ¹H NMR (400 MHz, CD₃OD) δ = 7.57 (s, 2H), 7.17 (d, *J* = 8.8 Hz, 1H), 6.92 (d, *J* = 9.2 Hz, 1H), 5.65 - 5.54 (m, 1H), 4.14 - 3.91 (m, 2H), 2.42 (s, 3H), 1.68 (d, *J* = 6.4 Hz, 3H), 1.04 - 0.93 (m, 4H).

[00367] Example 16

(*R*)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00368] Step A: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (50.0 mg, 126 μmol, 1.00 eq.), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (98.1 mg, 188 μmol, 1.50 eq.) and diisopropylethylamine (81.2 mg, 628 μmol, 109 μL, 5.00 eq.) in *N,N*-dimethylformamide (1.00 mL) was stirred at 20 °C for 20 minutes. To the above mixture was added 1 1,1-difluoro-5-azaspiro[2.3]hexane hydrochloride (29.3 mg, 188 μmol, 1.50 eq.) at 20 °C. The reaction was stirred at 20 °C for 1 hour. After completion, the mixture was diluted with water (3.00 mL) and extracted with ethyl acetate (3 × 3.00 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give a residue. The residue was purified by prep-TLC (SiO₂, petroleum ether: ethyl acetate = 1:3) to give methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (55.0 mg, 75.0 μmol, 59.6% yield, 68.0% purity) as a yellow solid. LCMS [M+1]⁺ = 499.2.

[00369] Step B: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (50.0 mg, 90.2 μmol, 1.00 eq.) in dimethyl sulfoxide (1.00 mL) was added lithium chloride (38.2 mg, 902 μmol, 10.0


eq.). The reaction was stirred at 130 °C for 2 hours. After completion, the mixture was cooled to 20 °C. The mixture was filtered and the filtrate was purified by *prep*-HPLC (column: YMC-Actus Triart C18 150*30mm*7um; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 63%-93% phase B) to give (*R*)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (14.4 mg, 29.7 μmol, 32.9% yield, 99.9 % purity) as a yellow solid. LCMS [M-1]⁻ = 483.0.

[00370] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 12.96 (br s, 1H), 8.57 (br d, *J* = 7.2 Hz, 1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.30 (d, *J* = 8.8 Hz, 1H), 7.09 (d, *J* = 8.8 Hz, 1H), 5.41 (quin, *J* = 12.8 Hz, 1H), 4.66 - 4.51 (m, 4H), 2.41 (s, 3H), 1.88 (br t, *J* = 8.8 Hz, 2H), 1.66 (d, *J* = 6.8 Hz, 3H).

[00371] ¹⁹F NMR (400 MHz, DMSO-*d*₆) δ = -137.62.

[00372] Example 17

(*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid



[00373] Step A: To a solution of (*R*)-5-(1-aminoethyl)-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxaline-2-carbonitrile (100 mg, 272 μmol, 1.00 eq, hydrochloride salt), methyl 3-bromo-6-methylpicolinate (125 mg, 544 μmol, 2.00 eq.), Xantphos (31.5 mg, 54.4 μmol, 0.20 eq.), cesium carbonate (354 mg, 1.09 mmol, 4.00 eq.) in dioxane (2.00 mL) was added tris(dibenzylideneacetone)dipalladium(0) (24.9 mg, 27.2 μmol, 0.10 eq.). The mixture was stirred at 100 °C for 12 hours under a nitrogen atmosphere. After completion of the reaction, the mixture was cooled to 25 °C, and then directly concentrated to give a residue. The residue was purified by *prep*-TLC (SiO₂, petroleum ether/ethyl acetate = 3:1) to give methyl (*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinate (100 mg, 208 μmol, 76.6% yield) as a yellow solid. LCMS [M+1]⁺ = 481.2.

[00374] Step B: A mixture of methyl (*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinate in dimethyl sulfoxide (0.5 mL) was added lithium chloride (79.4 mg, 1.87 mmol, 38.4 μL, 10.0 eq.). The reaction was stirred at 120


°C for 8 hours. After completion of the reaction, the mixture was cooled to 25°C, and then directly concentrated to give a residue. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (20.0 mL × 2). The combined organic layers were washed with saturate sodium bicarbonate solution (10.0 mL × 2), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/1 to 0/1) to give (*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid (25.6 mg, 53.7 μmol, 28.7% yield, 97.9% purity) as a yellow solid. LCMS [M+1]⁺ = 467.1.




[00375] ¹H NMR (400 MHz, CDCl₃) δ = 8.09 (br d, *J* = 5.2 Hz, 1H), 7.58 (s, 1H), 7.53 (s, 1H), 6.92 (d, *J* = 8.8 Hz, 1H), 6.61 (d, *J* = 8.8 Hz, 1H), 5.43 (quin, *J* = 6.6 Hz, 1H), 3.88 - 3.75 (m, 4H), 2.39 (s, 3H), 2.31 (s, 3H), 2.24 - 2.14 (m, 4H), 1.61 (d, *J* = 6.8 Hz, 3H).




[00376] Examples 18-105




[00377] The compounds in Table 1 are prepared essentially according to the procedures set forth in the above schemes and examples, or as set forth in schemes and examples immediately below Table 1.




Table 1.




Examp le No.	Structure	Spectral Data
18	 (<i>R</i>)-2-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.22 (br s, 1H), 7.99 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.56 (s, 2H), 7.18 (ddd, <i>J</i> = 1.6, 7.2, 8.4 Hz, 1H), 6.58 (t, <i>J</i> = 7.6 Hz, 1H), 6.38 (d, <i>J</i> = 8.4 Hz, 1H), 5.69 - 5.46 (m, 2H), 3.54 - 3.44 (m, 2H), 2.43 (s, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H), 1.26 - 1.18 (m, 1H), 0.71 - 0.59 (m, 2H), 0.38 (q, <i>J</i> = 4.8 Hz, 2H). LCMS [M+1] ⁺ = 402.2.




19	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.95 (br s, 1H), 8.56 - 8.44 (m, 1H), 7.72 - 7.64 (m, 2H), 7.32 - 7.25 (m, 1H), 7.10 - 6.95 (m, 1H), 5.51 - 5.39 (m, 1H), 4.50 (br t, <i>J</i> = 9.2 Hz, 1H), 4.42 - 4.31 (m, 1H), 3.25 - 3.14 (m, 2H), 2.91 - 2.74 (m, 1H), 2.43 (d, <i>J</i> = 2.0 Hz, 3H), 2.07 - 2.00 (m, 1H), 1.93 - 1.84 (m, 1H), 1.76 - 1.62 (m, 5H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -71.01. LCMS [M+23] ⁺ = 541.2.
20	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.57 - 8.46 (m, 1H), 8.30 (d, <i>J</i> = 1.2 Hz, 1H), 8.02 (d, <i>J</i> = 2.0 Hz, 1H), 7.30 (d, <i>J</i> = 8.8 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 5.58 - 5.46 (m, 1H), 4.11 - 3.93 (m, 4H), 2.35 - 2.09 (m, 5H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -60.93, -94.78. LCMS [M+1] ⁺ = 541.1.
21	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 9.02 - 8.78 (m, 1H), 7.59 (s, 2H), 7.17 (d, <i>J</i> = 8.8 Hz, 1H), 6.87 (d, <i>J</i> = 8.8 Hz, 1H), 5.39 (br d, <i>J</i> = 4.0 Hz, 1H), 4.38 - 4.12 (m, 4H), 2.83 (br d, <i>J</i> = 10.4 Hz, 2H), 2.39 (s, 3H), 1.62 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -129.01, -129.43, -154.05, -154.48




		LCMS [M+23] ⁺ = 507.2.
22	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, DMSO-<i>d</i>₆) δ = 9.05 - 8.81 (br s, 1H), 7.70 (s, 1H), 7.67 (d, <i>J</i> = 1.6 Hz, 1H), 7.15 (d, <i>J</i> = 8.8 Hz, 1H), 6.89 (br d, <i>J</i> = 8.8 Hz, 1H), 5.47 - 5.44 (m, 1H), 4.11 - 4.01 (m, 2H), 3.94 - 3.79 (m, 2H), 2.43 (s, 3H), 1.94 - 1.79 (m, 2H), 1.63 (d, <i>J</i> = 6.4 Hz, 3H), 0.94 - 0.86 (m, 2H), 0.63 (br s, 2H). ¹⁹F NMR (400 MHz, DMSO-<i>d</i>₆) δ = -110.16, -110.40. LCMS [M+23]⁺ = 535.2.
23	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.57 (dd, <i>J</i> = 2.0, 6.8 Hz, 2H), 7.16 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (d, <i>J</i> = 9.2 Hz, 1H), 5.56 (q, <i>J</i> = 6.8 Hz, 1H), 4.19 (dd, <i>J</i> = 14.8, 18.8 Hz, 1H), 3.97 (dd, <i>J</i> = 14.8, 21.6 Hz, 1H), 2.42 (s, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H), 1.14 - 0.97 (m, 2H), 0.93 - 0.78 (m, 2H). ¹⁹F NMR (400 MHz, methanol-<i>d</i>₄) δ = -186.97. LCMS [M+H]⁺ = 455.1.
24	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(5-fluoroisoindolin-1-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, DMSO-<i>d</i>₆) δ = 13.15 - 12.80 (m, 1H), 8.55 (br d, <i>J</i> = 7.6 Hz, 1H), 7.63 (d, <i>J</i> = 7.6 Hz, 2H), 7.53 (dd, <i>J</i> = 5.2, 8.4 Hz, 1H), 7.43 - 7.29 (m, 2H), 7.25 - 7.15 (m, 1H), 7.11 (d, <i>J</i> = 9.2 Hz, 1H), 5.51 (quin, <i>J</i> = 6.8 Hz, 1H), 5.39 -





	2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 5.09 (m, 4H), 2.41 (s, 3H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -115.29. LCMS [M+1] ⁺ = 503.2.
25	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.66 - 8.46 (br s, 1H), 7.82 (t, <i>J</i> = 5.6 Hz, 1H), 7.55 (s, 2H), 7.27 (d, <i>J</i> = 9.2 Hz, 1H), 6.95 (d, <i>J</i> = 9.2 Hz, 1H), 5.51 - 5.40 (m, 1H), 3.47 - 3.39 (m, 2H), 2.37 (s, 3H), 1.61 (d, <i>J</i> = 6.8 Hz, 3H), 1.27 - 1.20 (m, 1H), 0.49 - 0.41 (m, 2H), 0.34 - 0.26 (m, 2H). LCMS [M+23] ⁺ = 459.3.
26	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.05 (br s, 1H), 8.45 (br d, <i>J</i> = 6.8 Hz, 1H), 7.77 (d, <i>J</i> = 9.2 Hz, 2H), 7.29 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.60 - 5.45 (m, 1H), 3.90 (s, 4H), 2.29 - 2.15 (m, 4H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -94.71, -111.49. LCMS [M+1] ⁺ = 491.2.
27	 (<i>S</i>)-2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 8.28 (d, <i>J</i> = 1.6 Hz, 1H), 7.96 - 7.86 (m, 2H), 7.14 (t, <i>J</i> = 7.2 Hz, 1H), 6.56 (t, <i>J</i> = 7.6 Hz, 1H), 6.39 (d, <i>J</i> = 8.4 Hz, 1H), 5.57 (q, <i>J</i> = 6.8 Hz, 1H), 4.17 - 4.03 (m, 4H), 2.35 - 2.19 (m, 4H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz,




		CD3OD) δ = -98.62. LCMS [M+H] ⁺ = 463.1.
28	 (<i>R</i>)-2-((1-((2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 8.28 (d, <i>J</i> = 1.6 Hz, 1H), 7.96 - 7.86 (m, 2H), 7.14 (t, <i>J</i> = 7.2 Hz, 1H), 6.56 (t, <i>J</i> = 7.6 Hz, 1H), 6.39 (d, <i>J</i> = 8.4 Hz, 1H), 5.57 (q, <i>J</i> = 6.8 Hz, 1H), 4.17 - 4.03 (m, 4H), 2.35 - 2.19 (m, 4H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, CD3OD) δ = -98.62. LCMS [M+H] ⁺ = 463.1.
29	 (<i>S</i>)-2-((1-((7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.78 (dd, <i>J</i> = 1.2, 7.6 Hz, 1H), 7.70 (d, <i>J</i> = 2.4 Hz, 1H), 7.59 (d, <i>J</i> = 2.4 Hz, 1H), 7.04 - 6.94 (m, 1H), 6.40 (t, <i>J</i> = 7.6 Hz, 1H), 6.24 (d, <i>J</i> = 8.4 Hz, 1H), 5.45 (q, <i>J</i> = 6.8 Hz, 1H), 3.92 - 3.78 (m, 4H), 2.21 - 2.04 (m, 4H), 1.57 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, methanol- <i>d</i> ₄) δ = -98.51. LCMS [M+H] ⁺ = 472.3.
30	 (<i>R</i>)-2-((1-((7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.78 (dd, <i>J</i> = 1.2, 7.6 Hz, 1H), 7.70 (d, <i>J</i> = 2.4 Hz, 1H), 7.59 (d, <i>J</i> = 2.4 Hz, 1H), 7.04 - 6.94 (m, 1H), 6.40 (t, <i>J</i> = 7.6 Hz, 1H), 6.24 (d, <i>J</i> = 8.4 Hz, 1H), 5.45 (q, <i>J</i> = 6.8 Hz, 1H), 3.92 - 3.78 (m, 4H), 2.21 - 2.04 (m, 4H), 1.57 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400




		MHz, CD ₃ OD) δ = -98.51. LCMS [M+H] ⁺ = 472.3.
31	 (<i>S</i>)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ 7.90 (br d, <i>J</i> = 8.4 Hz, 1H), 7.59 (dd, <i>J</i> = 9.6, 2.4 Hz, 1H), 7.47 - 7.55 (m, 1H), 7.04 - 7.16 (m, 1H), 6.53 (br t, <i>J</i> = 7.2 Hz, 1H), 6.34 (d, <i>J</i> = 8.4 Hz, 1H), 5.60 (q, <i>J</i> = 6.4 Hz, 1H), 3.89 - 3.97 (m, 4H), 2.14 - 2.34 (m, 4H), 1.68 (d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -98.53, -112.81. LCMS [M+1] ⁺ = 456.1.
32	 (<i>R</i>)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ 7.90 (br d, <i>J</i> = 8.0 Hz, 1H), 7.59 (br d, <i>J</i> = 9.6 Hz, 1H), 7.46 - 7.55 (m, 1H), 7.02 - 7.15 (m, 1H), 6.53 (br t, <i>J</i> = 7.2 Hz, 1H), 6.33 (d, <i>J</i> = 8.4 Hz, 1H), 5.60 (q, <i>J</i> = 6.4 Hz, 1H), 3.89 - 3.97 (m, 4H), 2.13 - 2.36 (m, 4H), 1.68 (br d, <i>J</i> = 6.8 Hz, 3H). ¹⁹ F NMR (400 MHz, DMSO- <i>d</i> ₆) δ = -98.53, -112.81. LCMS [M+1] ⁺ = 456.1.
33	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 10.69 (br s, 1H), 8.37 (br d, <i>J</i> = 6.4 Hz, 1H), 7.53 (d, <i>J</i> = 2.0 Hz, 1H), 7.49 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.8 Hz, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 5.48 (quin, <i>J</i> = 6.8 Hz, 1H), 4.01 - 3.80 (m, 4H), 2.36 - 2.18 (m, 4H), 2.05 - 1.93 (m, 1H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H), 1.16 - 1.03 (m, 2H),




		0.85 - 0.76 (m, 1H), 0.76 - 0.66 (m, 1H). LCMS [M+1] ⁺ : 513.1.
34	 (<i>R</i>)-6-chloro-3-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)ethyl)amino)picolinic acid	LCMS [M+1] ⁺ : 507.1.
35	 (<i>R</i>)-6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.94 (br s, 1H), 8.49 (d, <i>J</i> = 6.8 Hz, 1H), 7.56 (s, 1H), 7.44 (d, <i>J</i> = 1.6 Hz, 1H), 7.30 (d, <i>J</i> = 9.2 Hz, 1H), 7.06 (d, <i>J</i> = 9.2 Hz, 1H), 5.52 (quin, <i>J</i> = 6.8 Hz, 1H), 3.57 - 3.45 (m, 4H), 2.67 (s, 3H), 2.41 (s, 3H), 2.28 - 2.13 (m, 4H), 1.66 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 476.1.
36	 (<i>R</i>)-2-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.64 (br s, 1H), 8.47 (d, <i>J</i> = 6.0 Hz, 1H), 7.77 (dd, <i>J</i> = 2.8 Hz, 1.6 Hz, 1H), 7.54 (s, 1H), 7.42 (s, 1H), 7.19 - 7.10 (m, 1H), 6.54 - 6.40 (m, 2H), 5.56 (m, 1H), 3.52 (m, 4H), 2.68 (s, 3H), 2.40 (s, 3H), 2.28 - 2.14 (m, 4H), 1.61 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 441.2.




37	 (<i>R</i>)-2-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.24 (br s, 1H), 8.03 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 7.61 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (d, <i>J</i> = 2.0 Hz, 1H), 7.26 - 7.18 (m, 1H), 6.62 (t, <i>J</i> = 7.2 Hz, 1H), 6.37 (d, <i>J</i> = 8.4 Hz, 1H), 5.62 - 5.52 (m, 1H), 4.01 - 3.83 (m, 4H), 2.36 - 2.19 (m, 4H), 2.07 - 1.96 (m, 1H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H), 1.08 (dd, <i>J</i> = 1.6, 8.4 Hz, 2H), 0.88 - 0.80 (m, 1H), 0.77 - 0.69 (m, 1H). LCMS [M+1] ⁺ : 478.2.
38	 (<i>R</i>)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methoxyquinoxalin-5-yl)ethyl)amino)benzoic acid	
39	 (<i>R</i>)-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.03 (br d, <i>J</i> = 7.6 Hz, 1H), 7.73 (s, 1H), 7.71 (s, 1H), 7.59 (d, <i>J</i> = 1.6 Hz, 1H), 5.16 (quin, <i>J</i> = 6.8 Hz, 1H), 3.97 - 3.80 (m, 4H), 2.52 (s, 3H), 2.32 - 2.22 (m, 4H), 1.79 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 459.1.




40	 (<i>R</i>)-2-chloro-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.10 (br d, <i>J</i> = 7.6 Hz, 1H), 7.73 (d, <i>J</i> = 0.8 Hz, 1H), 7.57 (d, <i>J</i> = 2.0 Hz, 1H), 5.08 (quin, <i>J</i> = 6.8 Hz, 1H), 3.96 - 3.82 (m, 4H), 2.54 (s, 3H), 2.33 - 2.22 (m, 4H), 1.78 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 515.1.
41	 (<i>R</i>)-2-(((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid	
42	 (<i>R</i>)-3-(((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-2-carboxylic acid	
43	 6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




44	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.51 (br d, <i>J</i> = 6.0 Hz, 1H), 7.81 (s, 1H), 7.78 (s, 1H), 7.25 (d, <i>J</i> = 8.80 Hz, 1H), 6.98 (d, <i>J</i> = 8.80 Hz, 1H), 5.52 (m, 1H), 2.66 - 2.57 (m, 1H), 2.07 (s, 3H), 1.64 (d, <i>J</i> = 6.80 Hz, 3H), 1.39 - 1.24 (m, 4H). LCMS [M+1] ⁺ = 408.1.
45	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.95 (br s, 1H), 8.56 - 8.44 (m, 1H), 7.72 - 7.64 (m, 2H), 7.32 - 7.25 (m, 1H), 7.10 - 6.95 (m, 1H), 5.51 - 5.39 (m, 1H), 4.50 (br t, <i>J</i> = 9.2 Hz, 1H), 4.42 - 4.31 (m, 1H), 3.25 - 3.14 (m, 2H), 2.91 - 2.74 (m, 1H), 2.43 (d, <i>J</i> = 2.0 Hz, 3H), 2.07 - 2.00 (m, 1H), 1.93 - 1.84 (m, 1H), 1.76 - 1.62 (m, 5H). LCMS [M+Na] ⁺ = 541.2.
46A	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>S</i>)-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.98 (br s, 1H), 8.48 (br d, <i>J</i> = 6.8 Hz, 1H), 7.69 (s, 1H), 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.28 (d, <i>J</i> = 9.2 Hz, 1H), 6.98 (d, <i>J</i> = 9.2 Hz, 1H), 5.48 - 5.43 (m, 1H), 4.52 (br d, <i>J</i> = 12.8 Hz, 1H), 4.36 (br d, <i>J</i> = 13.6 Hz, 1H), 3.28 - 3.13 (m, 2H), 2.91 - 2.76 (m, 1H), 2.43 (s, 3H), 2.08 - 2.00 (m, 1H), 1.92 - 1.84 (m, 1H), 1.76 - 1.60 (m, 5H). LCMS [M-1] ⁻ = 517.2.





46B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>R</i>)-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.99 (br s, 1H), 8.52 (br s, 1H), 7.69 (s, 1H), 7.68 (s, 1H), 7.29 (d, <i>J</i> = 8.8 Hz, 1H), 7.06 (d, <i>J</i> = 8.8 Hz, 1H), 5.45 (m, 1H), 4.49 (br d, <i>J</i> = 12.4 Hz, 1H), 4.37 (br d, <i>J</i> = 13.6 Hz, 1H), 3.28 - 3.18 (m, 2H), 2.93 - 2.74 (m, 1H), 2.43 (s, 3H), 2.08 - 2.01 (m, 1H), 1.93 - 1.84 (m, 1H), 1.76 - 1.62 (m, 5H). LCMS [M+Na] ⁺ = 541.1.
47A	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>S</i>)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
47B	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>R</i>)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




48	 (<i>R</i>)-6-chloro-3-((1-(2-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.48 (d, <i>J</i> = 0.8 Hz, 1H), 7.39 (d, <i>J</i> = 1.6 Hz, 1H), 7.28 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.56 - 5.46 (m, 1H), 3.59 - 3.58 (m, 4H), 2.45 - 2.40 (m, 1H), 2.38 (s, 3H), 2.30 - 2.18 (m, 4H), 1.65 (d, <i>J</i> = 6.8 Hz, 3H), 1.24 - 1.19 (m, 2H), 1.17 - 1.15 (m, 2H). LCMS [<i>M</i> +1] ⁺ = 502.1.
49	 (<i>R</i>)-6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.99 (br s, 1H), 8.49 (br d, <i>J</i> = 7.2 Hz, 1H), 7.79 (s, 1H), 7.70 (d, <i>J</i> = 1.6 Hz, 1H), 7.27 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (quin, <i>J</i> = 6.4 Hz, 1H), 3.57 (br t, <i>J</i> = 4.8 Hz, 4H), 2.46 (s, 3H), 2.26 - 2.13 (m, 4H), 1.68 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +23] ⁺ = 552.1.
50	 (<i>R</i>)-2-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.70 (br s, 1H), 8.51 (br d, <i>J</i> = 4.4 Hz, 1H), 7.79 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.77 (br s, 1H), 7.67 (d, <i>J</i> = 1.6 Hz, 1H), 7.19 - 7.09 (m, 1H), 6.50 (t, <i>J</i> = 7.2 Hz, 1H), 6.44 (d, <i>J</i> = 8.4 Hz, 1H), 5.61 - 5.46 (m, 1H), 3.58 (br t, <i>J</i> = 5.6 Hz, 4H), 2.45 (s, 3H), 2.28 - 2.13 (m, 4H), 1.64 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 495.3




51	 (<i>R</i>)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.24 (s, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.69 (s, 1H), 7.66 (d, <i>J</i> = 1.6 Hz, 1H), 7.19 (dt, <i>J</i> = 1.6, 7.6 Hz, 1H), 6.59 (t, <i>J</i> = 7.6 Hz, 1H), 6.35 (d, <i>J</i> = 8.4 Hz, 1H), 5.67 - 5.46 (m, 1H), 4.04 - 3.81 (m, 4H), 2.78 (q, <i>J</i> = 7.6 Hz, 2H), 2.36 - 2.18 (m, 4H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H), 1.26 (t, <i>J</i> = 7.6 Hz, 3H). LCMS [M+1] ⁺ = 466.2.
52	 (<i>R</i>)-6-chloro-3-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
53	 (<i>R</i>)-2-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 9.07 - 8.85 (m, 1H), 7.78 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.57 (s, 1H), 7.53 (d, <i>J</i> = 1.6 Hz, 1H), 7.12 - 6.96 (m, 1H), 6.44 (t, <i>J</i> = 7.6 Hz, 1H), 6.33 (d, <i>J</i> = 8.4 Hz, 1H), 5.53 - 5.46 (m, 1H), 3.68 (br t, <i>J</i> = 4.8 Hz, 4H), 2.41 (s, 3H), 2.27 - 2.16 (m, 4H), 1.59 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 461.2.




54	 (<i>R</i>)-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.53 (br d, <i>J</i> = 7.2 Hz, 1H), 7.55 (s, 1H), 7.43 (d, <i>J</i> = 1.6 Hz, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 5.53 (m, 1H), 3.51 (m, 4H), 2.67 (s, 3H), 2.40 (s, 3H), 2.33 (s, 3H), 2.25 - 2.15 (m, 4H), 1.65 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 456.1.
55	 (<i>R</i>)-2-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.86 (dd, <i>J</i> = 1.6, 8.4 Hz, 1H), 7.53 (d, <i>J</i> = 2.0 Hz, 1H), 7.46 (s, 1H), 7.15 - 6.99 (m, 1H), 6.47 (t, <i>J</i> = 7.6 Hz, 1H), 6.38 (d, <i>J</i> = 8.8 Hz, 1H), 5.52 (q, <i>J</i> = 6.4 Hz, 1H), 4.25 - 4.04 (m, 4H), 2.36 (s, 3H), 1.63 (d, <i>J</i> = 6.8 Hz, 3H), 1.40 (s, 6H). LCMS [M+1] ⁺ = 416.1.
56	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.56 (d, <i>J</i> = 1.6 Hz, 1H), 7.53 (s, 1H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.48 (q, <i>J</i> = 6.8 Hz, 1H), 4.23 - 4.16 (m, 2H), 4.16 - 4.10 (m, 2H), 2.41 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H), 1.40 (s, 6H). LCMS [M+1] ⁺ = 451.2.


57	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.87 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.61 (s, 1H), 7.19 - 7.00 (m, 1H), 6.49 (t, <i>J</i> = 7.6 Hz, 1H), 6.41 (d, <i>J</i> = 8.4 Hz, 1H), 5.57 (q, <i>J</i> = 6.8 Hz, 1H), 3.96 - 3.87 (m, 4H), 3.83 - 3.70 (m, 4H), 2.44 (s, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 418.1.
58	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.66 (d, <i>J</i> = 1.6 Hz, 1H), 7.63 (s, 1H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 3.98 - 3.86 (m, 4H), 3.83 - 3.72 (m, 4H), 2.46 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 453.2.
59	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.87 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 7.57 (d, <i>J</i> = 1.6 Hz, 1H), 7.52 (s, 1H), 7.15 - 6.97 (m, 1H), 6.48 (t, <i>J</i> = 7.6 Hz, 1H), 6.38 (d, <i>J</i> = 8.4 Hz, 1H), 5.53 (q, <i>J</i> = 6.4 Hz, 1H), 4.90 (s, 4H), 4.68 - 4.60 (m, 4H), 2.39 (s, 3H), 1.65 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+1] ⁺ = 430.2.




60	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.60 (d, J = 1.6 Hz, 1H), 7.57 (s, 1H), 7.20 (d, J = 9.2 Hz, 1H), 7.05 (d, J = 9.2 Hz, 1H), 5.48 (q, J = 6.8 Hz, 1H), 4.91 (s, 4H), 4.72 - 4.67 (m, 2H), 4.64 - 4.59 (m, 2H), 2.43 (s, 3H), 1.72 (d, J = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 465.2.
61	 (R)-2-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (dd, J = 1.2, 8.0 Hz, 1H), 7.61 (s, 1H), 7.58 (s, 1H), 7.16 - 7.05 (m, 1H), 6.50 (t, J = 7.6 Hz, 1H), 6.38 (d, J = 8.4 Hz, 1H), 5.59 (q, J = 6.4 Hz, 1H), 3.78 (t, J = 5.6 Hz, 4H), 2.42 (s, 3H), 1.68 - 1.60 (m, 7H), 1.08 (s, 6H). LCMS [M+H] ⁺ : 444.2.
62	 (R)-6-chloro-3-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.62 (br s, 2H), 7.20 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 5.54 (q, J = 6.4 Hz, 1H), 3.81 - 3.72 (m, 4H), 2.45 (s, 3H), 1.72 (d, J = 6.8 Hz, 3H), 1.62 (t, J = 5.6 Hz, 4H), 1.08 (s, 6H). LCMS [M+H] ⁺ : 479.1.
63	 (R)-2-((1-(2-cyano-3-(4-methyl-2-methoxy-2-oxaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.89 (d, J = 7.6 Hz, 1H), 7.59 (s, 1H), 7.53 (br d, J = 3.2 Hz, 1H), 7.15 - 7.06 (m, 1H), 6.49 (br t, J = 7.2 Hz, 1H), 6.41 (d, J = 8.4 Hz, 1H), 5.55 (q, J = 6.4 Hz, 1H), 4.44 - 4.35 (m, 2H),




	(<i>R</i>)-2-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	4.28 (dd, $J = 10.8, 12.0$ Hz, 2H), 3.36 (d, $J = 0.8$ Hz, 3H), 2.40 (s, 3H), 1.65 (d, $J = 6.8$ Hz, 3H), 1.62 (s, 3H). LCMS $[M + 1] = 432.2$.
64	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CD_3OD) $\delta = 7.61$ (s, 1H), 7.58 (s, 1H), 7.22 (d, $J = 9.2$ Hz, 1H), 7.07 (d, $J = 9.2$ Hz, 1H), 5.51 (q, $J = 6.8$ Hz, 1H), 4.48 - 4.24 (m, 4H), 3.37 (s, 3H), 2.45 (s, 3H), 1.73 (d, $J = 6.8$ Hz, 3H), 1.62 (s, 3H). LCMS $[M + 1]^+ = 467.1$.
65	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	^1H NMR (400 MHz, CD_3OD) $\delta = 7.90$ (d, $J = 1.6$ Hz, 1H), 7.88 (d, $J = 1.6$ Hz, 1H), 7.91 - 7.87 (m, 1H), 7.65 (d, $J = 1.8$ Hz, 1H), 7.60 (d, $J = 0.88$ Hz, 1H), 7.10 (ddd, $J = 1.6, 7.1, 8.6$ Hz, 1H), 6.53 - 6.46 (m, 1H), 6.41 (d, $J = 8.6$ Hz, 1H), 5.60 (q, $J = 6.8$ Hz, 1H), 4.26 (br d, $J = 13.6$ Hz, 2H), 3.50 - 3.37 (m, 2H), 2.44 (s, 3H), 2.22 - 2.08 (m, 2H), 1.78 - 1.70 (m, 2H), 1.68 (d, $J = 6.8$ Hz, 3H), 1.38 (s, 3H). LCMS $[M+H]^+$: 498.1.
66	 (<i>R</i>)-2-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	^1H NMR (400 MHz, CD_3OD) $\delta = 7.66$ (s, 1H), 7.63 (br s, 1H), 7.20 (d, $J = 8.8$ Hz, 1H), 7.04 (d, $J = 9.2$ Hz, 1H), 5.54 (q, $J = 6.8$ Hz, 1H), 4.24 (br t, $J = 12.8$ Hz, 2H), 3.50 - 3.35 (m, 2H), 2.46 (s, 3H), 2.12 (dt, $J =$




	(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	4.0, 12.8 Hz, 2H), 1.73 (br d, J = 6.8 Hz, 5H), 1.37 (s, 3H). LCMS $[M+Na]^+$: 555.1.
67	 (<i>R</i>)-2-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	1H NMR (400 MHz, CD_3OD) δ = 7.88 (dd, J = 1.2, 8.0 Hz, 1H), 7.72 (s, 2H), 7.14 - 7.04 (m, 1H), 6.48 (t, J = 7.2 Hz, 1H), 6.32 (d, J = 8.4 Hz, 1H), 5.64 (q, J = 6.8 Hz, 1H), 2.72 - 2.64 (m, 1H), 2.48 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H), 1.44 - 1.32 (m, 4H). LCMS $[M+1]^+$ = 373.1.
68	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	1H NMR (400 MHz, CD_3OD) δ = 7.87 (dd, J = 1.6, 8.0 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.49 (s, 1H), 7.08 (ddd, J = 1.6, 7.2, 8.8 Hz, 1H), 6.51 - 6.44 (m, 1H), 6.37 (d, J = 8.4 Hz, 1H), 5.54 (q, J = 6.8 Hz, 1H), 3.96 - 3.88 (m, 4H), 2.38 (s, 3H), 2.10 (td, J = 3.6, 6.8 Hz, 4H), 1.64 (d, J = 6.4 Hz, 3H). LCMS $[M+H]^+$ = 402.2.
69	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	1H NMR (400 MHz, CD_3OD) δ = 7.53(s, 1H), δ = 7.50(s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 5.50 (q, J = 6.8 Hz, 1H), 4.05 - 3.77 (m, 4H), 2.40 (s, 3H), 2.10 (td, J = 3.6, 6.4 Hz, 4H), 1.71 (d, J = 6.4 Hz, 3H). LCMS $[M+Na]^+$ = 459.2.




70	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.60 (s, 1H), 7.57 (s, 1H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 4.38 - 4.14 (m, 4H), 2.66 - 2.55 (m, 2H), 2.43 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 495.1.
71	 (<i>R</i>)-2-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.87 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.59 (d, <i>J</i> = 2.0 Hz, 1H), 7.56 - 7.52 (m, 1H), 7.07 (ddd, <i>J</i> = 1.6, 7.2, 8.4 Hz, 1H), 6.50 - 6.44 (m, 1H), 6.38 (d, <i>J</i> = 8.4 Hz, 1H), 5.53 (q, <i>J</i> = 6.4 Hz, 1H), 4.36 - 4.24 (m, 2H), 4.23 - 4.13 (m, 2H), 2.65 - 2.53 (m, 2H), 2.40 (s, 3H), 1.66 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+H] ⁺ = 438.2.
72A and 72B	 2-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid OR 2-(((<i>S</i>)-1-(2-cyano-3-((<i>R</i>)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	Purified by SFC after saponification: First eluting final product (Example 72A): ¹ H NMR (400 MHz, CD ₃ OD) δ = 7.76 (br d, <i>J</i> = 7.6 Hz, 1H), 7.54 (s, 1H), 7.38 (s, 1H), 6.82 (t, <i>J</i> = 7.6 Hz, 1H), 6.34 (t, <i>J</i> = 7.2 Hz, 1H), 6.14 (d, <i>J</i> = 8.4 Hz, 1H), 5.44 (q, <i>J</i> = 6.8 Hz, 1H), 4.12 (br d, <i>J</i> = 4.0 Hz, 1H), 3.98 - 3.82 (m, 4H), 3.32 (s, 3H), 2.28 (s, 3H), 2.21 - 2.14 (m, 1H), 2.12 - 2.06 (m, 1H), 1.52 (d, <i>J</i> = 6.6 Hz, 3H). LCMS [M+1] ⁺ = 432.0.




	2-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	Second eluting final product (Example 72B): ¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.56 (d, <i>J</i> = 1.6 Hz, 1H), 7.52 (s, 1H), 7.12 (ddd, <i>J</i> = 1.6, 7.2, 8.4 Hz, 1H), 6.52 - 6.48 (t, <i>J</i> = 7.2, 1H), 6.40 (d, <i>J</i> = 8.4 Hz, 1H), 5.58 (q, <i>J</i> = 6.8 Hz, 1H), 4.24 - 4.20 (m, 1H), 4.10 - 3.98 (m, 4H), 3.42 (s, 3H), 2.40 (s, 3H), 2.32 - 2.26 (m, 1H), 2.22 - 2.12 (m, 1H), 1.66 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 432.0.
73	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	First eluting isomer: ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.55 (s, 1H), 7.53 (s, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 8.8 Hz, 1H), 5.58 - 5.48 (m, 1H), 5.52 (q, <i>J</i> = 6.4 Hz, 1H), 4.24 - 4.16 (m, 1H), 4.08 - 3.92 (m, 4H), 3.41 (s, 3H), 2.41 (s, 3H), 2.36 - 2.08 (m, 2H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1]⁺ = 467.2. Second eluting isomer: ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.56 (s, 1H), 7.54 (s, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.51 (q, <i>J</i> = 6.8 Hz, 1H), 4.23 - 4.17 (m, 1H), 4.07 - 3.92 (m, 4H), 3.42 (s, 3H), 2.42 (s, 3H), 2.33 - 2.23 (m, 1H), 2.21 - 2.08 (m, 1H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1]⁺ = 467.3.




74	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.61 - 7.52 (m, 2H), 7.19 (dd, <i>J</i> = 7.2, 9.2 Hz, 1H), 6.94 (t, <i>J</i> = 8.8 Hz, 1H), 5.70 - 5.55 (m, 1H), 3.96 - 3.75 (m, 2H), 2.42 (s, 3H), 1.69 (dd, <i>J</i> = 1.6, 6.4 Hz, 3H), 1.59 - 1.48 (m, 1H), 1.35 (s, 3H), 1.27 - 1.13 (m, 1H). LCMS [M + Na] ⁺ = 509.1.
75A and 75B	 2-(((<i>R</i>)-1-(2-cyano-3-(((<i>S</i>)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid AND  2-(((<i>R</i>)-1-(2-cyano-3-(((<i>R</i>)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	Purified by SFC prior to saponification: First eluting isomer leading to final compound 75A: ¹H NMR (400 MHz, CD₃OD) δ = 7.90 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.60 (d, <i>J</i> = 2.0 Hz, 1H), 7.55 (d, <i>J</i> = 0.8 Hz, 1H), 7.12 - 7.06 (m, 1H), 6.51 (t, <i>J</i> = 7.2 Hz, 1H), 6.34 (d, <i>J</i> = 8.4 Hz, 1H), 5.66 (q, <i>J</i> = 6.8 Hz, 1H), 3.96 - 3.80 (m, 2H), 2.41 (s, 3H), 1.63 (d, <i>J</i> = 6.8 Hz, 3H), 1.60 - 1.52 (m, 1H), 1.36 (t, <i>J</i> = 2.0 Hz, 3H), 1.22 - 1.14 (m, 1H). LCMS [M + 1]⁺ = 452.1. Second eluting isomer leading to final compound 75B: ¹H NMR (400 MHz, CD₃OD) δ = 7.91 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.59 (d, <i>J</i> = 1.6 Hz, 1H), 7.55 (s, 1H), 7.14 - 7.05 (m, 1H), 6.52 (t, <i>J</i> = 7.2 Hz, 1H), 6.34 (d, <i>J</i> = 8.4 Hz, 1H), 5.64 (q, <i>J</i> = 6.8 Hz, 1H), 3.98 (br d, <i>J</i> = 14.4 Hz, 1H), 3.77 (d, <i>J</i> = 14.8 Hz, 1H),




		2.41 (s, 3H), 1.63 (d, $J = 6.4$ Hz, 3H), 1.61 - 1.53 (m, 1H), 1.37 - 1.33 (m, 3H), 1.22 - 1.14 (m, 1H). LCMS $[M + 1]^+ = 452.1$.
76	 (<i>R</i>)-2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	^1H NMR (400 MHz, CD_3OD) δ = 7.88 (dd, $J = 1.6, 8.0$ Hz, 1H), 7.58 (d, $J = 2.0$ Hz, 1H), 7.53 (d, $J = 0.8$ Hz, 1H), 7.13 - 7.04 (m, 1H), 6.53 - 6.44 (m, 1H), 6.36 (d, $J = 8.4$ Hz, 1H), 5.59 (q, $J = 6.8$ Hz, 1H), 4.54 - 4.34 (m, 1H), 3.18 - 2.98 (m, 2H), 2.95 - 2.73 (m, 2H), 2.39 (s, 3H), 1.63 (d, $J = 6.4$ Hz, 3H). LCMS $[M+1]^+ = 438.1$.
77	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CD_3OD) δ = 7.60 (s, 1H), 7.59 (s, 1H), 7.20 (d, $J = 8.8$ Hz, 1H), 6.97 (d, $J = 9.2$ Hz, 1H), 5.61 - 5.55 (m, 1H), 4.52 - 4.43 (m, 1H), 3.20 - 3.04 (m, 2H), 2.96 - 2.76 (m, 2H), 2.44 (s, 3H), 1.71 (d, $J = 6.8$ Hz, 3H). LCMS $[M+\text{Na}]^+ = 495.1$.
78A	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CD_3OD) δ = 7.69 - 7.58 (m, 2H), 7.19 (d, $J = 9.2$ Hz, 1H), 7.02 (d, $J = 9.2$ Hz, 1H), 5.52 (q, $J = 6.8$ Hz, 1H), 4.38 - 4.20 (m, 2H), 3.56 - 3.44 (m, 1H), 3.26 - 3.16 (m, 1H), 2.46 (s, 3H), 2.42 - 2.15 (m, 3H), 1.73 (d, $J = 6.8$ Hz, 3H), 1.15 (d, $J = 6.8$ Hz, 3H). LCMS $[M+H]^+ = 501.2$.




78B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.72 - 7.58 (m, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.54 (q, <i>J</i> = 6.8 Hz, 1H), 4.42 - 4.14 (m, 2H), 3.55 - 3.41 (m, 1H), 3.26 (br dd, <i>J</i> = 11.2, 12.8 Hz, 1H), 2.46 (s, 3H), 2.43 - 2.10 (m, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H), 1.14 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 501.2.
79A	 2-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (br d, <i>J</i> = 8.0 Hz, 1H), 7.65 (s, 1H), 7.60 (br d, <i>J</i> = 7.2 Hz, 1H), 7.09 (q, <i>J</i> = 6.8 Hz, 1H), 6.53 - 6.44 (m, 1H), 6.40 (d, <i>J</i> = 8.4 Hz, 1H), 5.57 (q, <i>J</i> = 6.8 Hz, 1H), 4.37 - 4.15 (m, 2H), 3.55 - 3.42 (m, 1H), 3.29 - 3.18 (m, 1H), 2.44 (br d, <i>J</i> = 4.0 Hz, 3H), 2.40 - 2.08 (m, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H), 1.13 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 466.2.
79B	 2-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.90 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 7.68 (d, <i>J</i> = 1.6 Hz, 1H), 7.65 (s, 1H), 7.12 (dt, <i>J</i> = 1.6, 7.6 Hz, 1H), 6.52 (t, <i>J</i> = 7.6 Hz, 1H), 6.42 (d, <i>J</i> = 8.4 Hz, 1H), 5.63 - 5.51 (m, 1H), 4.39 - 4.21 (m, 2H), 3.59 - 3.48 (m, 1H), 3.26 (br dd, <i>J</i> = 10.8, 12.8 Hz, 1H), 2.47 (s, 3H), 2.44 - 2.19 (m, 3H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H),




		1.16 (d, $J = 6.8$ Hz, 3H). LCMS $[M+H]^+$: 466.2.
80	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CD_3OD) δ = 7.60 (s, 1H), 7.56 (br d, $J = 9.6$ Hz, 1H), 7.19 (dd, $J = 3.2$, 9.2 Hz, 1H), 7.04 (dd, $J = 5.2$, 9.2 Hz, 1H), 5.49 (q, $J = 6.4$ Hz, 1H), 4.45 - 4.18 (m, 3H), 3.82 - 3.62 (m, 1H), 2.82 (tt, $J = 8.0$, 16.4 Hz, 1H), 2.43 (d, $J = 2.4$ Hz, 3H), 1.73 (d, $J = 6.4$ Hz, 3H), 1.25 (d, $J = 6.4$ Hz, 3H). LCMS $[M+1]^+$ = 509.1.
81	 2-(((1<i>R</i>)-1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
82	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CD_3OD) δ = 7.68 - 7.62 (m, 2H), 7.19 (d, $J = 8.8$ Hz, 1H), 7.03 (d, $J = 8.8$ Hz, 1H), 5.55 (q, $J = 6.4$ Hz, 1H), 3.88 - 3.79 (m, 4H), 2.46 (s, 3H), 2.10 (s, 4H), 1.73 (d, $J = 6.4$ Hz, 3H). LCMS $[M+H]^+$ = 549.2.

83	 (R)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.63 (d, <i>J</i> = 3.6 Hz, 2H), 7.27 (br d, <i>J</i> = 4.4 Hz, 1H), 7.20 (d, <i>J</i> = 4.4 Hz, 3H), 7.15 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (d, <i>J</i> = 8.8 Hz, 1H), 5.56 (q, <i>J</i> = 6.4 Hz, 1H), 4.92 (br d, <i>J</i> = 4.8 Hz, 2H), 4.12 (t, <i>J</i> = 6.0 Hz, 2H), 3.12 (br t, <i>J</i> = 5.6 Hz, 2H), 2.45 (s, 3H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 521.1.
84	 (R)-2-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (d, <i>J</i> = 7.6 Hz, 1H), 7.61 (d, <i>J</i> = 10.8 Hz, 2H), 7.26 (br d, <i>J</i> = 4.4 Hz, 1H), 7.19 (d, <i>J</i> = 4.4 Hz, 3H), 7.08 (t, <i>J</i> = 7.6 Hz, 1H), 6.49 (t, <i>J</i> = 7.6 Hz, 1H), 6.39 (d, <i>J</i> = 8.4 Hz, 1H), 5.60 (q, <i>J</i> = 6.8 Hz, 1H), 4.93 (d, <i>J</i> = 6.8 Hz, 2H), 4.12 (q, <i>J</i> = 6.4 Hz, 2H), 3.13 (q, <i>J</i> = 4.8 Hz, 2H), 2.43 (s, 3H), 1.66 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+H] ⁺ = 464.2.
85	 (R)-6-chloro-3-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.67 (s, 2H), 7.62 (s, 1H), 7.59 - 7.54 (m, 1H), 7.53 - 7.49 (m, 1H), 7.15 (d, <i>J</i> = 8.8 Hz, 1H), 6.98 (d, <i>J</i> = 8.8 Hz, 1H), 5.51 (q, <i>J</i> = 6.4 Hz, 1H), 5.02 - 4.95 (m, 2H), 4.14 (t, <i>J</i> = 6.0 Hz, 2H), 3.22 - 3.15 (m, 2H), 2.47 (s, 3H), 1.71 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+23] ⁺ = 546.1.



86	 (<i>R</i>)-2-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 7.65 (s, 1H), 7.62 (br d, <i>J</i> = 10.0 Hz, 2H), 7.57 - 7.53 (m, 1H), 7.51 - 7.47 (m, 1H), 7.08 (t, <i>J</i> = 7.2 Hz, 1H), 6.50 (t, <i>J</i> = 7.6 Hz, 1H), 6.38 (d, <i>J</i> = 8.8 Hz, 1H), 5.55 (d, <i>J</i> = 6.8 Hz, 1H), 5.00 - 4.92 (m, 2H), 4.21 - 4.07 (m, 2H), 3.18 (br d, <i>J</i> = 5.2 Hz, 2H), 2.45 (s, 3H), 1.65 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+H] ⁺ = 489.2.
87	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.85 (br s, 1H), 7.66 (s, 2H), 7.36 (dd, <i>J</i> = 8.8, 6.0 Hz, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 7.13 - 7.02 (m, 2H), 6.94 (br d, <i>J</i> = 9.2 Hz, 1H), 5.52 - 5.37 (m, 1H), 4.87 (q, <i>J</i> = 16.4 Hz, 2H), 4.04 (t, <i>J</i> = 6.0 Hz, 2H), 3.08 (br t, <i>J</i> = 6.0 Hz, 2H), 2.42 (s, 3H), 1.62 (d, <i>J</i> = 6.8 Hz, 3H).
88	 (<i>R</i>)-2-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.54 (br s, 1H), 7.78 (dd, <i>J</i> = 1.6, 7.6 Hz, 1H), 7.65 (s, 1H), 7.64 (s, 1H), 7.35 (dd, <i>J</i> = 6.0, 8.4 Hz, 1H), 7.18 - 6.99 (m, 3H), 6.49 (t, <i>J</i> = 7.6 Hz, 1H), 6.43 (d, <i>J</i> = 8.0 Hz, 1H), 5.51 - 5.48 (m, 1H), 4.97 - 4.79 (m, 2H), 4.07 - 4.03 (m, 2H), 3.15 - 3.05 (m, 2H), 2.42 (s, 3H), 1.61 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 504.2.



89	 (<i>R</i>)-2-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.59 (br s, 1H), 8.50 (s, 1H), 8.35 (d, <i>J</i> = 5.2 Hz, 1H), 7.78 (d, <i>J</i> = 7.6 Hz, 1H), 7.66 (s, 1H), 7.65 (s, 1H), 7.25 (d, <i>J</i> = 4.8 Hz, 1H), 7.12 (br t, <i>J</i> = 7.6 Hz, 1H), 6.49 (t, <i>J</i> = 7.6 Hz, 1H), 6.41 (br d, <i>J</i> = 8.4 Hz, 1H), 5.49 - 5.48 (m, 1H), 4.99 - 4.88 (m, 2H), 4.11 - 4.03 (m, 2H), 3.09 (br s, 2H), 2.42 (s, 3H), 1.59 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 465.2.
90	 (<i>R</i>)-6-chloro-3-(((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.67 (d, <i>J</i> = 4.8 Hz, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 8.8 Hz, 1H), 5.53 (q, <i>J</i> = 6.4 Hz, 1H), 3.90 - 3.76 (m, 8H), 2.47 (s, 3H), 2.43 (d, <i>J</i> = 6.8 Hz, 2H), 1.74 (d, <i>J</i> = 6.4 Hz, 3H), 1.12 - 1.01 (m, 1H), 0.61 - 0.54 (m, 2H), 0.23 (q, <i>J</i> = 4.8 Hz, 2H). LCMS [M+H] ⁺ = 534.3.
91	 (<i>R</i>)-2-(((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.91 - 7.84 (m, 1H), 7.67 (s, 1H), 7.63 (s, 1H), 7.14 - 7.06 (m, 1H), 6.49 (t, <i>J</i> = 7.6 Hz, 1H), 6.41 (d, <i>J</i> = 8.4 Hz, 1H), 5.57 (q, <i>J</i> = 6.4 Hz, 1H), 3.89 - 3.76 (m, 8H), 2.45 (s, 3H), 2.42 (d, <i>J</i> = 6.8 Hz, 2H), 1.68 (d, <i>J</i> = 6.8 Hz, 3H), 1.11 - 1.00 (m, 1H), 0.60 - 0.53 (m, 2H), 0.26 - 0.19 (m, 2H). LCMS [M+H] ⁺ = 499.3.

92A and 92B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(4-(2-((<i>S</i>)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(4-(2-((<i>R</i>)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Purified by SFC prior to saponification: First eluting isomer leading to final compound 92A: ¹H NMR (400 MHz, CD₃OD) δ = 7.70 - 7.65 (m, 2H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 3.95 - 3.76 (m, 8H), 2.70 (br d, <i>J</i> = 7.2 Hz, 2H), 2.48 (s, 3H), 2.02 - 1.85 (m, 1H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H), 1.56 (m, 1H), 1.21 - 1.08 (m, 1H). LCMS [M+Na]⁺ = 592.2. Second eluting isomer leading to final compound 92B: ¹H NMR (400 MHz, CD₃OD) δ = 7.67 (s, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 3.91 - 3.74 (m, 8H), 2.70 (br d, <i>J</i> = 7.2 Hz, 2H), 2.47 (s, 3H), 1.93 (m, 1H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H), 1.56 (m, 1H), 1.19 - 1.07 (m, 1H). LCMS [M+Na]⁺ = 592.2.
93	 2-(((1<i>R</i>)-1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	




94	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
95A and 95B	 2-(((1<i>R</i>)-1-(2-cyano-3-((1<i>R</i>)-1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid AND  2-(((1<i>R</i>)-1-(2-cyano-3-((1<i>S</i>)-1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	Purified by SFC after saponification: First eluting isomer 95A: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 12.68 (br s, 1H), 8.46 (br s, 1H), 7.79 (dd, J = 1.2, 8.0 Hz, 1H), 7.69 - 7.53 (m, 2H), 7.25 - 7.07 (m, 1H), 6.50 (t, J = 7.6 Hz, 1H), 6.41 (t, J = 8.0 Hz, 1H), 5.50 (br s, 1H), 4.94 (br s, 1H), 3.97 - 3.84 (m, 2H), 3.79 (br dd, J = 6.0, 12.8 Hz, 1H), 3.48 (br dd, J = 2.4, 12.8 Hz, 1H), 3.41 - 3.40 (m, 1H), 2.41 (s, 3H), 2.18 - 2.04 (m, 1H), 1.92 - 1.65 (m, 5H), 1.61 (br d, J = 5.6 Hz, 3H), 1.53 - 1.38 (m, 2H). LCMS $[\text{M}+1]^+ = 472.2$. Second eluting isomer 95B: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 12.69 (br s, 1H), 8.47 (br s, 1H), 7.79 (dd, J = 1.6, 8.0 Hz, 1H), 7.60 (d, J = 0.8 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.21 - 7.02 (m, 1H), 6.49 (t, J = 7.6 Hz, 1H), 6.38 (dd, J = 8.4, 14.8 Hz, 1H),





		5.52 (br d, $J = 6.4$ Hz, 1H), 5.20 - 4.72 (m, 1H), 4.27 (br dd, $J = 9.6, 12.8$ Hz, 1H), 4.03 - 3.88 (m, 1H), 3.80 (br t, $J = 7.2$ Hz, 1H), 3.54 (br dd, $J = 3.2, 13.2$ Hz, 1H), 3.44 - 3.40 (m, 1H), 2.39 (s, 3H), 2.18 - 2.06 (m, 1H), 1.96 - 1.84 (m, 1H), 1.83 - 1.65 (m, 4H), 1.60 (br dd, $J = 2.4, 6.4$ Hz, 4H), 1.26 - 1.19 (m, 1H). LCMS $[M+1]^+ = 472.2$.
96A And 96B	6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1<i>H</i>-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid AND 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1<i>H</i>-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	Purified by SFC prior to saponification: First eluting isomer leading to 96A: ^1H NMR (400 MHz, CD_3OD) $\delta = 7.62$ (d, $J = 1.6$ Hz, 1H), 7.57 (s, 1H), 7.31 (d, $J = 2.0$ Hz, 1H), 7.14 (d, $J = 9.2$ Hz, 1H), 6.99 (d, $J = 8.8$ Hz, 1H), 6.02 (d, $J = 2.0$ Hz, 1H), 5.55 (q, $J = 6.8$ Hz, 1H), 5.18 - 5.06 (m, 2H), 3.86 (s, 3H), 3.53 - 3.42 (m, 1H), 2.43 (s, 3H), 2.24 - 1.95 (m, 8H), 1.69 (d, $J = 6.8$ Hz, 3H). LCMS $[M+1]^+ = 557.3$. Second eluting isomer leading to 96B: ^1H NMR (400 MHz, methanol-d_4) $\delta = 7.62$ (s, 1H), 7.59 (s, 1H), 7.36 (d, $J = 2.0$ Hz, 1H), 7.16 (d, $J = 8.8$ Hz, 1H), 7.00 (d, $J = 9.2$ Hz, 1H), 6.25 (d, $J = 1.6$ Hz, 1H), 5.53 (q, $J = 6.8$ Hz, 1H), 5.15 - 5.06 (m, 1H), 5.05 - 4.99 (m, 1H), 3.74




		(s, 3H), 3.16 - 3.07 (m, 1H), 2.84 - 2.71 (m, 2H), 2.44 (s, 3H), 2.22 - 2.09 (m, 2H), 1.97 - 1.84 (m, 2H), 1.82 - 1.73 (m, 2H), 1.72 (d, $J = 6.4$ Hz, 3H). LCMS $[M+1]^+ = 557.3$.
97A and 97B	 2-(((1R)-1-(2-cyano-7-methyl-3-((1R,5S)-3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid AND  2-(((1R)-1-(2-cyano-7-methyl-3-((1R,5S)-3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	Purified by SFC prior to saponification: First eluting isomer leading to 97A: ^1H NMR (400 MHz, CD_3OD) $\delta = 7.86$ (d, $J = 8.0$ Hz, 1H), 7.59 - 7.55 (m, 2H), 7.31 (d, $J = 1.6$ Hz, 1H), 7.07 - 6.99 (m, 1H), 6.47 (t, $J = 7.2$ Hz, 1H), 6.38 (d, $J = 8.4$ Hz, 1H), 6.02 (d, $J = 1.6$ Hz, 1H), 5.68 - 5.52 (m, 1H), 5.14 - 5.05 (m, 2H), 3.85 (s, 3H), 3.51 - 3.39 (m, 1H), 2.40 (s, 3H), 2.25 - 1.93 (m, 8H), 1.63 (d, $J = 6.8$ Hz, 3H). LCMS $[M+\text{Na}]^+ = 522.2$. Second eluting isomer leading to 97B: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) $\delta = 8.47$ (br s, 1H), 7.78 (dd, $J = 1.6, 8.0$ Hz, 1H), 7.61 (d, $J = 8.4$ Hz, 2H), 7.29 (d, $J = 2.0$ Hz, 1H), 7.11 (t, $J = 7.2$ Hz, 1H), 6.48 (t, $J = 7.2$ Hz, 1H), 6.40 (d, $J = 8.4$ Hz, 1H), 6.22 (d, $J = 1.6$ Hz, 1H), 5.52 - 5.40 (m, 1H), 5.07 - 4.95 (m, 2H), 3.65 (s, 3H), 3.07 - 3.03 (m, 1H), 2.70 - 2.62 (m, 2H), 2.40 (s, 3H), 2.14 - 2.06 (m, 2H), 1.87 - 1.79 (m, 2H), 1.75 - 1.67 (m, 2H), 1.60 (d, $J = 6.4$



		Hz, 3H). LCMS [M+23] ⁺ = 522.2.
98A and 98B	 2-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>R</i>,5<i>S</i>)-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid AND  2-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>R</i>,5<i>S</i>)-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	Purified by SFC prior to saponification: First eluting isomer leading to 98A: ¹H NMR (400 MHz, CDCl₃) δ = 8.32 - 8.05 (m, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.57 (br s, 2H), 7.24 (d, <i>J</i> = 2.0 Hz, 1H), 7.18 - 7.11 (m, 1H), 6.56 (t, <i>J</i> = 6.8 Hz, 1H), 6.44 - 6.35 (m, 1H), 6.01 (d, <i>J</i> = 2.4 Hz, 1H), 5.54 (m, 1H), 5.22 - 5.15 (m, 2H), 3.85 (s, 3H), 3.48 - 3.35 (m, 1H), 2.43 (s, 3H), 2.22 - 2.11 (m, 4H), 2.18 - 2.00 (m, 4H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1]⁺ = 522.2. Second eluting isomer leading to 98B: ¹H NMR (400 MHz, CDCl₃) δ = 8.36 - 8.13 (m, 1H), 7.98 (d, <i>J</i> = 7.6 Hz, 1H), 7.56 (s, 1H), 7.55 (s, 1H), 7.29 (d, <i>J</i> = 2.0 Hz, 1H), 7.17 (t, <i>J</i> = 7.6 Hz, 1H), 6.56 (t, <i>J</i> = 7.2 Hz, 1H), 6.39 (br d, <i>J</i> = 8.4 Hz, 1H), 6.16 (d, <i>J</i> = 2.4 Hz, 1H), 5.57 - 5.47 (m, 1H), 5.21 - 5.06 (m, 2H), 3.89 (s, 3H), 3.15 - 3.04 (m, 1H), 2.67 - 2.56 (m, 2H), 2.43 (s, 3H), 2.39 - 2.29 (m, 2H), 2.02 - 1.90 (m, 2H), 1.89 - 1.81 (m, 2H), 1.68 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+1]⁺ = 522.2.

99A and 99B	2-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>R</i>,5<i>S</i>)-3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid AND 2-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>R</i>,5<i>S</i>)-3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	Purified by SFC prior to saponification: First eluting isomer leading to 99A: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 12.68 (br s, 1H), 8.43 (br d, J = 6.4 Hz, 1H), 8.43 (br d, J = 6.4 Hz, 1H), 7.78 (dd, J = 1.6, 8.0 Hz, 1H), 7.61 (s, 1H), 7.59 (s, 1H), 7.43 (s, 1H), 7.24 (s, 1H), 7.12 - 7.04 (m, 1H), 6.49 (t, J = 7.6 Hz, 1H), 6.40 (d, J = 8.4 Hz, 1H), 5.56 - 5.44 (m, 1H), 5.06 (br s, 1H), 5.00 (br s, 1H), 3.72 (s, 3H), 3.23 - 3.10 (m, 1H), 2.40 (s, 3H), 2.16 - 2.05 (m, 2H), 2.01 - 1.82 (m, 6H), 1.59 (d, J = 6.8 Hz, 3H). LCMS $[\text{M}+23]^+ = 544.3$. First eluting isomer leading to 99B: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 12.69 (br s, 1H), 8.45 (br d, J = 6.8 Hz, 1H), 8.45 (br d, J = 6.8 Hz, 1H), 7.78 (dd, J = 1.6, 8.0 Hz, 1H), 7.64 (s, 1H), 7.61 (s, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.42 (s, 1H), 7.17 - 7.10 (m, 1H), 6.49 (t, J = 7.2 Hz, 1H), 6.40 (d, J = 8.4 Hz, 1H), 5.48 (m, 1H), 5.00 (br d, J = 2.4 Hz, 2H), 3.78 (s, 3H), 2.98 - 2.87 (m, 1H), 2.49 - 2.44 (m, 2H), 2.40 (s, 3H), 2.06 - 1.97 (m, 2H), 1.96 - 1.88 (m, 2H), 1.75 - 1.66 (m, 2H), 1.60 (d, J = 6.8
----------------------------	---	---




		Hz, 3H). LCMS [M+1] ⁺ = 522.3.
100	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
101	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
102	 6-chloro-3-(((1<i>R</i>)-1-(2-cyano-7-methyl-3-(3-(2-oxopiperidin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




103	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
104	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
105	 (<i>R</i>)-2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
106	 ¹H NMR (400 MHz, CD₃OD) δ = 7.66 (d, <i>J</i> = 2.8 Hz, 2H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 7.03 (d, <i>J</i> = 9.2 Hz, 1H), 5.57 (q, <i>J</i> = 6.8 Hz, 1H), 4.60 - 4.52 (m, 2H), 3.45 (tt, <i>J</i> = 3.6, 12.0 Hz, 1H), 3.29 - 3.22 (m, 2H), 2.98 (s, 3H), 2.47 (s, 3H), 2.34 - 2.26 (m, 2H), 2.13 - 1.95 (m, 2H), 1.72 (d, <i>J</i> =	




	(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(methylsulfonyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	6.8 Hz, 3H). LCMS [M+1] ⁺ = 529.2.
107	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxidothiophymorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.67 (d, <i>J</i> = 7.2 Hz, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 8.8 Hz, 1H), 5.55 (q, <i>J</i> = 6.8 Hz, 1H), 4.39 - 4.28 (m, 2H), 4.26 - 4.15 (m, 2H), 3.29 - 3.21 (m, 2H), 3.11 - 3.03 (m, 2H), 2.47 (s, 3H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+H] ⁺ = 485.2.
108	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-((2-methoxyethyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.56 (s, 1H), 7.54 (s, 1H), 7.17 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (d, <i>J</i> = 8.8 Hz, 1H), 5.51 (q, <i>J</i> = 6.4 Hz, 1H), 4.13 - 3.98 (m, 2H), 3.74 (t, <i>J</i> = 5.2 Hz, 2H), 3.44 (s, 3H), 3.30 (br s, 3H), 2.41 (s, 3H), 1.68 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+H] ⁺ = 455.2.
109	 2-(((1<i>R</i>)-1-(2-cyano-3-(4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	





111A and 111B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid  and 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Separated isomers by SFC before saponification: Final product from Saponification of first eluting methyl ester isomer (111A): ¹H NMR (400 MHz, CD₃OD) δ = 7.63 (d, <i>J</i> = 1.6 Hz, 1H), 7.57 (s, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 6.99 (d, <i>J</i> = 9.0 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 5.12 - 5.02 (m, 1H), 4.53 - 4.40 (m, 1H), 4.29 (q, <i>J</i> = 12.0 Hz, 1H), 2.77 (m, 1H), 2.43 (s, 3H), 2.34 (dq, <i>J</i> = 5.2, 13.6 Hz, 1H), 1.73 (d, <i>J</i> = 6.4 Hz, 3H), 1.48 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 509.1. Final product from Saponification of second eluting methyl ester isomer (111B): ¹H NMR (400 MHz, CD₃OD) δ = 7.60 (s, 1H), 7.58 (s, 1H), 7.14 (d, <i>J</i> = 8.8 Hz, 1H), 6.89 (d, <i>J</i> = 8.8 Hz, 1H), 5.59 (q, <i>J</i> = 6.8 Hz, 1H), 5.01 - 4.92 (m, 1H), 4.45 (q, <i>J</i> = 12.0 Hz, 1H, 1H), 4.31 (q, <i>J</i> = 12.0 Hz, 1H), 2.87 - 2.66 (m, 1H), 2.41 (s, 3H), 2.35 (m, 1H), 1.66 (d, <i>J</i> = 6.8 Hz, 3H), 1.49 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 509.1.
------------------------------	---	--




112A and 112B	6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid and 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (112A): ¹H NMR (400 MHz, DMSO-<i>d</i>₆) δ = 12.98 (br s, 1H), 8.45 (d, <i>J</i> = 6.8 Hz, 1H), 7.64 (d, <i>J</i> = 0.8 Hz, 1H), 7.63 (d, <i>J</i> = 1.6 Hz, 1H), 7.29 (d, <i>J</i> = 8.8 Hz, 1H), 7.01 (d, <i>J</i> = 9.2 Hz, 1H), 5.49 (quin, <i>J</i> = 6.8 Hz, 1H), 4.58 (br s, 1H), 4.32 (br d, <i>J</i> = 12.8 Hz, 1H), 4.22 (br d, <i>J</i> = 13.6 Hz, 1H), 3.46 - 3.34 (m, 2H), 3.24 - 3.11 (m, 1H), 3.00 (dd, <i>J</i> = 10.0, 12.8 Hz, 1H), 2.44 (br s, 3H), 1.82 (br d, <i>J</i> = 8.8 Hz, 3H), 1.75 - 1.66 (m, 1H), 1.64 (d, <i>J</i> = 6.4 Hz, 3H), 1.34 - 1.22 (m, 1H). LCMS [M+Na]⁺ = 503.3. Final product from Saponification of second eluting methyl ester isomer (112B): ¹H NMR (400 MHz, DMSO-<i>d</i>₆) δ = 12.98 (br s, 1H), 8.46 (d, <i>J</i> = 7.2 Hz, 1H), 7.64 (d, <i>J</i> = 0.8 Hz, 1H), 7.63 (d, <i>J</i> = 2.0 Hz, 1H), 7.29 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.48 (quin, <i>J</i> = 6.8 Hz, 1H), 4.98 - 4.43 (m, 1H), 4.34 - 4.31 (m, 1H), 4.20 (br d, <i>J</i> = 13.6 Hz, 1H), 3.46 - 3.36 (m, 2H), 3.21 (m, 1H), 2.99 (dd, <i>J</i> = 10.0, 13.2 Hz, 1H), 2.42 (s, 3H), 1.94 -
------------------------------	---	--




		1.76 (m, 3H), 1.69 (m, 1H), 1.64 (d, $J = 6.8$ Hz, 3H), 1.44 - 1.15 (m, 1H). LCMS $[M+Na]^+ = 503.3$.
113	 (<i>R</i>)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)pyrazine-2-carboxylic acid	^1H NMR (400 MHz, CDCl_3) $\delta = 8.92 - 8.74$ (m, 1H), 8.25 (br s, 1H), 7.72 (s, 1H), 7.66 (s, 1H), 7.60 (s, 1H), 6.02 (m, 1H), 4.01 - 3.81 (m, 4H), 2.50 (s, 3H), 2.32 - 2.21 (m, 4H), 1.76 (d, $J = 6.8$ Hz, 3H). LCMS $[M+H]^+ = 454.2$. LCMS $[M+Na]^+ = 476.2$.
114	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-((3-(dimethylamino)-3-oxopropyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CD_3OD) $\delta = 7.59 - 7.51$ (m, 2H), 7.24 - 7.13 (m, 1H), 6.99 (d, $J = 9.2$ Hz, 1H), 5.59 - 5.53 (m, 1H), 4.19 - 4.02 (m, 2H), 3.44 (s, 3H), 3.04 (s, 3H), 2.93 - 2.92 (m, 2H), 2.89 (s, 3H), 2.42 (d, $J = 4.4$ Hz, 3H), 1.68 (d, $J = 6.8$ Hz, 3H). LCMS $[M+1]^+ = 496.3$.
115	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-methylthiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	^1H NMR (400 MHz, CDCl_3) $\delta = 8.40$ (br d, $J = 6.8$ Hz, 1H), 7.70 (s, 1H), 7.58 (d, $J = 1.6$ Hz, 1H), 7.14 (d, $J = 8.8$ Hz, 1H), 6.94 (s, 1H), 6.80 (d, $J = 8.8$ Hz, 1H), 5.48 (quin, $J = 6.8$ Hz, 1H), 3.93 - 3.92 (m, 4H), 3.90 - 3.79 (m, 4H), 2.49 (s, 3H), 2.35 (d, $J = 0.8$ Hz, 3H), 1.72 (d, $J = 6.8$ Hz, 3H). LCMS $[M+1]^+ = 549.2$.




116	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(7,7-difluoro-5-azaspiro[2.4]heptan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.62 (s, 1H), 7.54 (s, 1H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 4.46 (dt, <i>J</i> = 6.0, 12.0 Hz, 2H), 4.23 - 4.08 (m, 2H), 2.44 (s, 3H), 1.74 (d, <i>J</i> = 6.4 Hz, 3H), 1.21 - 1.13 (m, 2H), 0.99 (br s, 2H).
117	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(1<i>H</i>-imidazol-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 8.88 (s, 1H), 8.55 (br d, <i>J</i> = 7.2 Hz, 1H), 8.17 (s, 1H), 8.00 (s, 1H), 7.97 (s, 1H), 7.44 (s, 1H), 7.27 (d, <i>J</i> = 8.8 Hz, 1H), 7.11 (d, <i>J</i> = 9.2 Hz, 1H), 5.70 - 5.60 (m, 1H), 2.57 (s, 3H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 434.2.
118	 (<i>R</i>)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.54 - 8.27 (m, 1H), 7.91 - 7.75 (m, 1H), 7.67 (s, 1H), 7.61 (d, <i>J</i> = 1.6 Hz, 1H), 7.21 - 7.09 (m, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 5.52 (quin, <i>J</i> = 6.8 Hz, 1H), 3.98 - 3.83 (m, 4H), 2.47 (s, 3H), 2.34 - 2.19 (m, 4H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 453.3.




119	 (<i>R</i>)-6-chloro-3-(((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.62 - 7.61 (m, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.55 (q, <i>J</i> = 6.8 Hz, 1H), 4.44 - 4.40 (m, 2H), 3.52 (q, <i>J</i> = 7.2 Hz, 2H), 3.38 (d, <i>J</i> = 6.0 Hz, 2H), 3.18 - 3.14 (m, 2H), 2.45 (s, 3H), 1.95 - 1.92 (m, 3H), 1.72 (d, <i>J</i> = 6.4 Hz, 3H), 1.53 - 1.49 (m, 2H), 1.20 (t, <i>J</i> = 7.2 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 509.2.
120	 3-(((1<i>R</i>)-1-(3-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.34 (br d, <i>J</i> = 5.6 Hz, 1H), 7.64 (s, 1H), 7.53 (s, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 6.73 (d, <i>J</i> = 8.8 Hz, 1H), 5.49 - 5.44 (m, 1H), 4.88 (br d, <i>J</i> = 5.6 Hz, 2H), 4.03 - 3.98 (m, 2H), 3.80 - 3.76 (m, 2H), 2.46 (s, 3H), 2.24 - 2.17 (m, 2H), 2.12 - 2.02 (m, 2H), 1.69 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + <i>Na</i>] ⁺ = 501.2.
121	 (<i>R</i>)-4-(((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.09 (d, <i>J</i> = 3.2 Hz, 1H), 7.69 (d, <i>J</i> = 1.6 Hz, 1H), 7.66 (s, 1H), 5.46 (d, <i>J</i> = 3.6 Hz, 1H), 5.30 (q, <i>J</i> = 6.8 Hz, 1H), 3.92 - 3.83 (m, 4H), 2.50 (s, 3H), 2.31 - 2.22 (m, 4H), 1.66 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ : 458.2.




122	 6-chloro-3-(((R)-1-(2-cyano-3-((3S,4R)-3,4-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.60 (d, <i>J</i> = 1.6 Hz, 1H), 7.56 (s, 1H), 7.18 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.59 - 5.39 (m, 2H), 5.37 - 5.24 (m, 1H), 4.47 - 4.24 (m, 2H), 4.23 - 4.03 (m, 2H), 2.42 (s, 3H), 1.73 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+Na] ⁺ = 495.1.
123	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoro-4,4-dimethylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.61 (d, <i>J</i> = 2.0 Hz, 1H), 7.60 - 7.57 (m, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.06 (d, <i>J</i> = 9.2 Hz, 1H), 5.48 (q, <i>J</i> = 6.4 Hz, 1H), 4.45 - 4.26 (m, 2H), 4.00 - 3.87 (m, 2H), 2.44 (s, 3H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H), 1.28 (s, 6H). LCMS [M+H] ⁺ = 501.1.
124	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-((3,3,3-trifluoropropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.63 (s, 1H), 7.57 (s, 1H), 7.22 (d, <i>J</i> = 9.2 Hz, 1H), 6.99 (d, <i>J</i> = 9.2 Hz, 1H), 5.61 - 5.52 (m, 1H), 4.01 - 3.84 (m, 2H), 2.73 - 2.60 (m, 2H), 2.43 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H).
125	 6-chloro-3-((1-(2-cyano-7-methyl-3-((3,3,3-trifluoropropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.56 (d, <i>J</i> = 1.2 Hz, 1H), 7.51 (s, 1H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 9.2 Hz, 1H), 5.59 (q, <i>J</i> = 6.4 Hz, 1H), 3.91 (dt, <i>J</i> = 2.4, 6.8 Hz, 2H), 3.03 (s, 3H), 2.94 (s, 3H), 2.82 (t, <i>J</i> = 6.8 Hz,




	(<i>R</i>)-6-chloro-3-((1-(2-cyano-3-((3-(dimethylamino)-3-oxopropyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H), 2.40 (s, 3H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 482.3.
126	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.62 (s, 1H), 7.37 (d, <i>J</i> = 2.0 Hz, 1H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 6.14 (d, <i>J</i> = 2.0 Hz, 1H), 5.55 (q, <i>J</i> = 6.8 Hz, 1H), 4.58 - 4.42 (m, 2H), 3.88 (s, 3H), 3.40 - 3.32 (m, 1H), 3.32 - 3.26 (m, 1H), 3.11 (tt, <i>J</i> = 3.6, 11.8 Hz, 1H), 2.45 (s, 3H), 2.12 (br d, <i>J</i> = 12.0 Hz, 2H), 1.90 (dq, <i>J</i> = 4.0, 12.4 Hz, 2H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 531.3.
127	 (<i>R</i>)-2-((1-(2-cyano-3-(3,3-difluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (dd, <i>J</i> = 8 Hz, 1H), 7.65 (s, 1H), 7.59 (s, 1H), 7.15 - 7.07 (m, 1H), 6.50 - 6.46 (m, 1H), 6.42 - 6.44 (m, 1H), 5.54 (q, <i>J</i> = 6.8 Hz, 1H), 4.87 - 4.76 (m, 4H), 2.43 (s, 3H), 1.69 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> +H] ⁺ = 424.3.
128	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.59 (s, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 8.8 Hz, 1H), 5.49 (q, <i>J</i> = 6.8 Hz, 1H), 4.84 - 4.76 (m, 4H), 2.44 (s, 3H), 1.72 (d, <i>J</i> = 6.4 Hz, 3H).




129	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.88 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.11 (ddd, <i>J</i> = 1.6, 7.2, 8.4 Hz, 1H), 6.54 - 6.46 (m, 1H), 6.40 (d, <i>J</i> = 8.4 Hz, 1H), 5.59 (q, <i>J</i> = 6.8 Hz, 1H), 3.87 - 3.79 (m, 4H), 2.45 (s, 3H), 2.09 (br s, 4H), 1.68 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 514.2.
130	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.60 (d, <i>J</i> = 1.6 Hz, 1H), 7.57 (s, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 9.2 Hz, 1H), 5.49 (q, <i>J</i> = 6.8 Hz, 1H), 4.74 (dd, <i>J</i> = 1.2, 10.4 Hz, 1H), 4.71 - 4.66 (m, 1H), 4.63 - 4.54 (m, 4H), 3.01 (t, <i>J</i> = 7.6 Hz, 2H), 2.43 (s, 3H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ : 465.1.
131	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.59 (d, <i>J</i> = 1.6 Hz, 1H), 7.47 (s, 1H), 7.15 (d, <i>J</i> = 8.8 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 5.47 (q, <i>J</i> = 6.8 Hz, 1H), 4.76 - 4.66 (m, 2H), 4.55 - 4.44 (m, 2H), 3.68 (m, 1H), 2.40 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + <i>Na</i>] ⁺ = 513.1.




132	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-((2-methoxyethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.56 (d, <i>J</i> = 1.6 Hz, 1H), 7.54 (s, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.00 (d, <i>J</i> = 9.2 Hz, 1H), 5.55 (q, <i>J</i> = 6.8 Hz, 1H), 3.90 - 3.75 (m, 2H), 3.72 - 3.63 (m, 2H), 3.41 (s, 3H), 2.41 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 463.1.
133	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(6-(trifluoromethyl)pyridin-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 8.43 (d, <i>J</i> = 2.8 Hz, 1H), 7.68 (s, 2H), 7.66 (d, <i>J</i> = 8.8 Hz, 1H), 7.53 (dd, <i>J</i> = 2.8, 8.8 Hz, 1H), 7.21 (d, <i>J</i> = 9.2 Hz, 1H), 7.07 (d, <i>J</i> = 9.2 Hz, 1H), 5.56 (q, <i>J</i> = 6.4 Hz, 1H), 4.09 - 3.91 (m, 4H), 3.67 (t, <i>J</i> = 5.2 Hz, 4H), 2.48 (s, 3H), 1.76 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 597.3.
134	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.52 - 8.10 (m, 1H), 7.99 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.57 (s, 1H), 7.55 (s, 1H), 7.19 (ddd, <i>J</i> = 1.6, 7.2, 8.8 Hz, 1H), 6.62 - 6.53 (m, 1H), 6.38 (d, <i>J</i> = 8.4 Hz, 1H), 5.50 (q, <i>J</i> = 6.4 Hz, 1H), 4.69 (m, <i>J</i> = 4.0 Hz, 2H), 4.68 - 4.55 (m, 4H), 3.08 - 2.93 (m, 2H), 2.43 (s, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 452.3.



135	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-((oxetan-3-ylmethyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.57 (d, <i>J</i> = 2.0 Hz, 1H), 7.55 (s, 1H), 7.21 (d, <i>J</i> = 9.2 Hz, 1H), 6.99 (d, <i>J</i> = 9.2 Hz, 1H), 5.54 (q, <i>J</i> = 6.6 Hz, 1H), 4.85 - 4.83 (m, 2H), 4.57 (t, <i>J</i> = 5.6 Hz, 2H), 4.02 - 3.86 (m, 2H), 3.52 - 3.41 (m, 1H), 2.42 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 453.2.
136	 (<i>R</i>)-3-((1-(3-(4-(1<i>H</i>-pyrazol-1-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.74 (d, <i>J</i> = 2.4 Hz, 1H), 7.68 - 7.62 (m, 2H), 7.52 (d, <i>J</i> = 2.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 8.8 Hz, 1H), 6.31 (t, <i>J</i> = 2.0 Hz, 1H), 5.57 (q, <i>J</i> = 6.8 Hz, 1H), 4.61 - 4.51 (m, 3H), 3.43 - 3.33 (m, 2H), 2.46 (s, 3H), 2.36 - 2.22 (m, 4H), 1.73 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 517.3.
137	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(<i>N</i>-methylacetamido)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.35 - 11.41 (m, 1H), 8.39 (br d, <i>J</i> = 7.2 Hz, 1H), 7.67 (br d, <i>J</i> = 5.2 Hz, 2H), 7.28 (d, <i>J</i> = 8.8 Hz, 1H), 7.11 (br d, <i>J</i> = 9.2 Hz, 1H), 5.56 - 5.43 (m, 1H), 4.67 - 4.54 (m, 1H), 4.47 (br t, <i>J</i> = 11.2 Hz, 2H), 3.25 (br s, 2H), 2.86 - 2.67 (m, 3H), 2.50 (br s, 3H), 2.45 (s, 3H), 2.13 - 2.02 (m, 2H), 1.99 - 1.85 (m, 2H), 1.68 (br d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 522.2.




138	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.68 (s, 1H), 7.66 (s, 1H), 7.52 (s, 1H), 7.33 (s, 1H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 7.07 (d, <i>J</i> = 9.2 Hz, 1H), 5.59 (q, <i>J</i> = 6.8 Hz, 1H), 4.61 - 4.51 (m, 2H), 4.50 - 4.42 (m, 1H), 3.45 - 3.35 (m, 2H), 2.48 (s, 3H), 2.33 - 2.19 (m, 4H), 2.10 (s, 3H), 1.75 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 531.2.
139	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 8.22 (s, 1H), 7.78 (s, 1H), 7.69 - 7.60 (m, 2H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 8.8 Hz, 1H), 5.57 (d, <i>J</i> = 6.4 Hz, 1H), 4.66 - 4.48 (m, 3H), 3.45 - 3.33 (m, 2H), 2.46 (s, 3H), 2.41 - 2.25 (m, 4H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + <i>H</i>] ⁺ = 585.2.
140	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-cis-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.59 (d, <i>J</i> = 2.0 Hz, 1H), 7.55 (s, 1H), 7.13 (d, <i>J</i> = 8.8 Hz, 1H), 6.94 (d, <i>J</i> = 9.2 Hz, 1H), 5.49 (q, <i>J</i> = 6.8 Hz, 1H), 4.21 - 4.10 (m, 2H), 4.05 - 3.86 (m, 4H), 3.80 (dt, <i>J</i> = 2.8, 8.8 Hz, 2H), 3.24 - 3.13 (m, 2H), 2.42 (s, 3H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +23] ⁺ = 501.2.




141	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-oxa-7-azaspiro[2.5]octan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.70 - 7.63 (m, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 5.52 (q, <i>J</i> = 6.8 Hz, 1H), 4.02 - 3.96 (m, 2H), 3.89 - 3.80 (m, 2H), 3.80 - 3.72 (m, 2H), 2.47 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H), 0.92 - 0.77 (m, 4H). LCMS [<i>M</i> +23] ⁺ = 501.2.
142	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>R</i>)-3-(methylsulfonyl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.63 (s, 1H), 7.59 (s, 1H), 7.16 (br d, <i>J</i> = 8.8 Hz, 1H), 7.02 (br d, <i>J</i> = 8.8 Hz, 1H), 5.54 (q, <i>J</i> = 6.8 Hz, 1H), 4.44 - 4.40 (m, 1H), 4.34 - 4.21 (m, 2H), 4.16 - 4.08 (m, 2H), 3.13 (s, 3H), 2.68 - 2.56 (m, 2H), 2.45 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H), 1.32 (s, 1H). LCMS [<i>M</i> + 23] ⁺ = 537.3.
143	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((3<i>S</i>,5<i>R</i>)-3,5-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.65 (d, <i>J</i> = 1.2 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 6.94 (d, <i>J</i> = 8.8 Hz, 1H), 5.60 (q, <i>J</i> = 6.8 Hz, 1H), 5.05 - 5.01 (m, 2H), 4.38 - 4.31 (m, 2H), 3.98 - 3.89 (m, 2H), 2.47 (s, 3H), 2.45 - 2.28 (m, 2H), 1.72 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 23] ⁺ = 509.1.




144	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(2,2-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.70 - 7.61 (m, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 3.97 (t, <i>J</i> = 4.8 Hz, 2H), 3.80 - 3.66 (m, 2H), 3.66 - 3.56 (m, 2H), 2.47 (s, 3H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H), 1.39 (s, 6H). LCMS [<i>M</i> + 23] ⁺ = 503.2.
145	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.44 (br d, <i>J</i> = 6.4 Hz, 1H), 7.82 (d, <i>J</i> = 2.0 Hz, 1H), 7.60 (d, <i>J</i> = 2.4 Hz, 1H), 7.16 (d, <i>J</i> = 8.8 Hz, 1H), 6.79 (d, <i>J</i> = 8.8 Hz, 1H), 5.37 (quin, <i>J</i> = 6.8 Hz, 1H), 4.99 - 4.90 (m, 4H), 4.79 - 4.72 (m, 2H), 4.70 - 4.63 (m, 2H), 1.74 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 485.1.
146	 (<i>R</i>)-6-chloro-3-((1-(7-chloro-2-cyano-3-(3,3-difluoropyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.79 (d, <i>J</i> = 2.4 Hz, 1H), 7.68 (d, <i>J</i> = 2.4 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (d, <i>J</i> = 9.2 Hz, 1H), 5.49 (q, <i>J</i> = 6.4 Hz, 1H), 4.42 - 4.15 (m, 4H), 2.66 - 2.52 (m, 2H), 1.74 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 493.1.
147 and 148		Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (147): ¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ




	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3,3-difluoro-5-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3,3-difluoro-5-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	= 7.66 (d, J = 4.0 Hz, 2H), 7.19 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.57 (q, J = 6.8 Hz, 1H), 4.58 - 4.45 (m, 2H), 3.69 - 3.53 (m, 3H), 3.06 (dd, J = 11.2, 12.8 Hz, 1H), 2.46 (s, 3H), 2.45 - 2.25 (m, 2H), 1.98 - 1.80 (m, 1H), 1.74 (d, J = 6.8 Hz, 3H). LCMS $[M + 23]^+ = 539.1$. Final product from saponification of second eluting methyl ester isomer (148): ^1H NMR (400 MHz, methanol-d_4) δ = 7.66 (s, 2H), 7.18 (d, J = 9.2 Hz, 1H), 6.99 (d, J = 9.2 Hz, 1H), 5.61 (q, J = 6.8 Hz, 1H), 4.55 - 4.49 (m, 2H), 3.67 - 3.60 (m, 2H), 3.60 - 3.48 (m, 1H), 3.11 - 3.05 (m, 1H), 2.46 (s, 3H), 2.43 - 2.42 (m, 1H), 2.32 - 2.30 (m, 1H), 1.94 - 1.89 (m, 1H), 1.71 (d, J = 6.8 Hz, 3H). LCMS $[M + 23]^+ = 539.1$.
149 and 150	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-(dimethylcarbamoyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND	Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (149): ^1H NMR (400 MHz, methanol-d_4) δ = 7.57 (d, J = 2.0 Hz, 1H), 7.53 (s, 1H), 7.18 (d, J = 9.2 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 5.51 (q, J = 6.8 Hz, 1H), 4.11 - 4.09 (m, 2H), 4.04 - 4.02 (m, 2H), 3.67 (quin, J = 6.8 Hz,




	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-(dimethylcarbamoyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	1H), 3.20 (s, 3H), 2.99 (s, 3H), 2.41 (s, 3H), 2.39 - 2.35 (m, 1H), 2.27 - 2.22 (m, 1H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1]⁺ = 508.2. Final product from saponification of second eluting methyl ester isomer (150): ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.57 (d, <i>J</i> = 1.6 Hz, 1H), 7.52 (s, 1H), 7.14 (d, <i>J</i> = 8.8 Hz, 1H), 6.97 (d, <i>J</i> = 8.8 Hz, 1H), 5.50 (q, <i>J</i> = 6.4 Hz, 1H), 4.19 - 4.15 (m, 2H), 4.08 - 4.01 (m, 2H), 3.67 (quin, <i>J</i> = 6.8 Hz, 1H), 3.21 (s, 3H), 2.99 (s, 3H), 2.41 (s, 3H), 2.41 - 2.36 (m, 1H), 2.31 - 2.20 (m, 1H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1]⁺ = 508.1.
151	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-((1<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.59 - 7.54 (m, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.01 (d, <i>J</i> = 8.8 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 4.45 (dd, <i>J</i> = 8.4, 11.2 Hz, 2H), 3.96 (t, <i>J</i> = 13.6 Hz, 2H), 2.42 (s, 3H), 2.28 (t, <i>J</i> = 3.2 Hz, 2H), 1.80 - 1.73 (m, 1H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 23]⁺ = 539.1.




152	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.39 (br d, <i>J</i> = 6.0 Hz, 1H), 7.72 (s, 1H), 7.60 (d, <i>J</i> = 1.6 Hz, 1H), 7.13 (d, <i>J</i> = 8.8 Hz, 1H), 6.77 (d, <i>J</i> = 8.8 Hz, 1H), 5.50 (quin, <i>J</i> = 6.8 Hz, 1H), 3.97 - 3.84 (m, 4H), 2.79 (q, <i>J</i> = 7.6 Hz, 2H), 2.34 - 2.20 (m, 4H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H), 1.28 (t, <i>J</i> = 7.6 Hz, 3H). LCMS [M + 23] ⁺ = 523.1
153	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((1<i>R</i>,5<i>S</i>,6<i>S</i>)-6-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.57 (d, <i>J</i> = 1.6 Hz, 1H), 7.54 (s, 1H), 7.16 (d, <i>J</i> = 9.2 Hz, 1H), 6.98 (d, <i>J</i> = 9.2 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 4.39 (d, <i>J</i> = 12.0 Hz, 2H), 4.20 (br d, <i>J</i> = 10.0 Hz, 2H), 2.41 (s, 3H), 2.36 (br dd, <i>J</i> = 2.0, 8.0 Hz, 2H), 2.01 - 1.86 (m, 1H), 1.70 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M + 23] ⁺ = 539.2.
154	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(methyl(3,3,3-trifluoropropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.60 (s, 2H), 7.17 (d, <i>J</i> = 9.2 Hz, 1H), 6.92 (d, <i>J</i> = 8.8 Hz, 1H), 5.55 (q, <i>J</i> = 6.8 Hz, 1H), 4.11 - 4.04 (m, 2H), 3.52 (s, 3H), 2.81 - 2.66 (m, 2H), 2.43 (s, 3H), 1.68 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M + 23] ⁺ = 515.2.



155 and 156	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-cyanopyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-cyanopyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (155): ^1H NMR (400 MHz, methanol-d_4) δ = 7.59 (s, 1H), 7.57 (s, 1H), 7.19 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.51 (q, J = 6.4 Hz, 1H), 4.32 - 4.04 (m, 4H), 3.55 (quin, J = 6.4 Hz, 1H), 2.58 - 2.48 (m, 1H), 2.47 - 2.37 (m, 4H), 1.73 (d, J = 6.4 Hz, 3H). LCMS $[M + 1]^+ = 462.2$. Final product from saponification of second eluting methyl ester isomer (156): ^1H NMR (400 MHz, methanol-d_4) δ = 7.59 (s, 1H), 7.56 (s, 1H), 7.19 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.51 (q, J = 6.4 Hz, 1H), 4.25 - 4.06 (m, 4H), 3.57 - 3.54 (m, 1H), 2.54 - 2.49 (m, 1H), 2.47 - 2.38 (m, 4H), 1.72 (d, J = 6.8 Hz, 3H). LCMS $[M + 1]^+ = 462.1$.
157		^1H NMR (400 MHz, methanol-d_4) δ = 7.89 (d, J = 2.4 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.55 (q, J = 6.8 Hz, 1H), 3.96 - 3.91 (m, 4H), 3.90 - 3.81 (m, 4H), 1.76 (d, J = 6.8 Hz, 3H). LCMS $[M + 23]^+ =$




	(<i>R</i>)-6-chloro-3-((1-(7-chloro-2-cyano-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	495.1
158	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.54 (d, <i>J</i> = 3.2 Hz, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.52 (q, <i>J</i> = 6.8 Hz, 1H), 4.13 - 4.03 (m, 2H), 3.91 (td, <i>J</i> = 7.6, 10.8 Hz, 1H), 3.75 - 3.59 (m, 3H), 2.67 - 2.55 (m, 1H), 2.41 (s, 3H), 2.27 - 2.16 (m, 1H), 1.99 - 1.85 (m, 1H), 1.71 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 467.3.
159	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.55 - 7.53 (m, 2H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 7.01 (d, <i>J</i> = 9.2 Hz, 1H), 5.56 - 5.47 (m, 1H), 4.07 - 4.00 (m, 2H), 4.00 - 3.93 (m, 1H), 3.78 - 3.73 (m, 2H), 3.71 - 3.62 (m, 1H), 2.60 (td, <i>J</i> = 6.8, 14.0 Hz, 1H), 2.41 (s, 3H), 2.22 - 2.19 (m, 1H), 1.95 - 1.90 (m, 1H), 1.71 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 467.1.
160	 (<i>R</i>)-3-((1-(3-(4-acetylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.68 (s, 2H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 3.90 - 3.76 (m, 8H), 2.48 (s, 3H), 2.19 (s, 3H), 1.74 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 494.0.




161	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-oxopiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, chloroform- <i>d</i>) δ = 8.43 - 8.41 (m, 1H), 7.70 (s, 1H), 7.57 (d, <i>J</i> = 1.6 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 5.50 - 5.43 (m, 1H), 4.11 (t, <i>J</i> = 6.0 Hz, 4H), 2.77 (t, <i>J</i> = 6.0 Hz, 4H), 2.49 (s, 3H), 1.72 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 465.3.
162	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1<i>H</i>)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 8.51 (s, 1H), 8.33 (d, <i>J</i> = 5.2 Hz, 1H), 7.69 (d, <i>J</i> = 1.6 Hz, 1H), 7.65 (s, 1H), 7.32 (d, <i>J</i> = 5.2 Hz, 1H), 7.08 (d, <i>J</i> = 9.2 Hz, 1H), 6.91 (d, <i>J</i> = 8.8 Hz, 1H), 5.56 - 5.50 (m, 1H), 4.98 - 4.96 (m, 2H), 4.16 - 4.12 (m, 2H), 3.21 - 3.17 (m, 2H), 2.46 (s, 3H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 500.2.
163	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1<i>R</i>,5<i>S</i>,6<i>S</i>)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.58 (s, 1H), 7.55 (s, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 8.8 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 4.24 - 4.08 (m, 4H), 3.62 - 3.32 (m, 2H), 2.43 (s, 3H), 2.08 - 2.04 (m, 2H), 1.72 (d, <i>J</i> = 6.4 Hz, 3H), 1.40 - 1.30 (m, 1H). LCMS [<i>M</i> + 1] ⁺ = 479.2.




164 and 165	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-fluoro-3-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-fluoro-3-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (164): ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.57 (d, <i>J</i> = 2.4 Hz, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.55 - 5.46 (m, 1H), 4.26 - 4.07 (m, 4H), 3.83 - 3.71 (m, 2H), 3.48 (s, 3H), 2.43 (s, 3H), 2.40 - 2.19 (m, 2H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1]⁺ = 499.0. Final product from saponification of second eluting methyl ester isomer (165): ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.57 (br d, <i>J</i> = 2.4 Hz, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.03 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 4.29 - 4.01 (m, 4H), 3.74 (d, <i>J</i> = 4.8 Hz, 1H), 3.83 - 3.70 (m, 1H), 3.48 (s, 3H), 2.43 (s, 3H), 2.39 - 2.20 (m, 2H), 1.71 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 1]⁺ = 499.1.
166	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.55 (d, <i>J</i> = 1.6 Hz, 1H), 7.51 (s, 1H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 6.99 (d, <i>J</i> = 9.2 Hz, 1H), 5.49 (q, <i>J</i> = 6.4 Hz, 1H), 4.35 - 4.30 (m, 2H), 3.94 - 3.87 (m, 2H), 3.39 - 3.31 (m, 5H), 2.40 (s, 3H), 1.78 (br s, 2H), 1.70 (d,




	7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	$J = 6.8 \text{ Hz, 3H}$, 1.06 - 1.01 (m, 1H). LCMS $[M + 1]^+ = 493.2$.
167	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((1<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	$^1\text{H NMR}$ (400 MHz, methanol- d_4) $\delta = 7.64 - 7.44$ (m, 2H), 7.20 (d, $J = 8.8 \text{ Hz}$, 1H), 7.00 (br d, $J = 9.2 \text{ Hz}$, 1H), 5.50 (q, $J = 6.4 \text{ Hz}$, 1H), 4.35 (br t, $J = 10.4 \text{ Hz}$, 2H), 3.96 - 3.87 (m, 2H), 3.53 (d, $J = 6.8 \text{ Hz}$, 2H), 2.43 (s, 3H), 1.79 (br s, 2H), 1.72 (d, $J = 6.8 \text{ Hz}$, 3H), 1.04 - 1.01 (m, 1H). LCMS $[M + 23]^+ = 501.2$.
168	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>R</i>)-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid	$^1\text{H NMR}$ (400 MHz, methanol- d_4) $\delta = 7.67 - 7.62$ (m, 2H), 7.21 (d, $J = 8.8 \text{ Hz}$, 1H), 7.05 (d, $J = 9.2 \text{ Hz}$, 1H), 5.51 (q, $J = 6.4 \text{ Hz}$, 1H), 4.27 (br d, $J = 12.8 \text{ Hz}$, 1H), 4.21 (br d, $J = 13.2 \text{ Hz}$, 1H), 4.04 (dd, $J = 1.6, 11.6 \text{ Hz}$, 1H), 3.93 - 3.77 (m, 2H), 3.30 - 3.26 (m, 1H), 2.91 (dd, $J = 10.4, 12.8 \text{ Hz}$, 1H), 2.46 (s, 3H), 1.74 (d, $J = 6.8 \text{ Hz}$, 3H), 1.27 (d, $J = 6.0 \text{ Hz}$, 3H). LCMS $[M + 23]^+ = 489.1$.
169 and 170		Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (169): $^1\text{H NMR}$ (400 MHz, methanol- d_4) $\delta = 7.61$ (d, $J = 1.6 \text{ Hz}$, 1H), 7.55 (s, 1H), 7.18 (d, $J = 9.2 \text{ Hz}$, 1H),




	6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3,3-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3,3-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	6.98 (d, $J = 9.2$ Hz, 1H), 5.49 (q, $J = 6.8$ Hz, 1H), 4.84 - 4.80 (m, 1H), 4.34 (m, 1H), 4.06 (m, 1H), 2.69 - 2.53 (m, 2H), 2.41 (s, 3H), 1.72 (d, $J = 6.4$ Hz, 3H), 1.44 (dd, $J = 2.8, 6.8$ Hz, 3H). LCMS $[M + 23]^+ = 509.1$. Final product from saponification of second eluting methyl ester isomer (170): ^1H NMR (400 MHz, methanol-d_4) $\delta = 7.59$ (s, 1H), 7.56 (s, 1H), 7.14 (d, $J = 9.2$ Hz, 1H), 6.89 (d, $J = 8.8$ Hz, 1H), 5.58 (q, $J = 6.8$ Hz, 1H), 4.77 - 4.69 (m, 1H), 4.39 - 4.29 (m, 1H), 4.13 - 4.04 (m, 1H), 2.67 - 2.53 (m, 2H), 2.41 (s, 3H), 1.66 (d, $J = 6.8$ Hz, 3H), 1.45 (dd, $J = 2.8, 6.8$ Hz, 3H). LCMS $[M + 23]^+ = 509.1$.
171 and 172	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND	Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (171): ^1H NMR (400 MHz, methanol-d_4) $\delta = 7.65 - 7.55$ (m, 2H), 7.21 (d, $J = 8.8$ Hz, 1H), 7.05 (d, $J = 9.2$ Hz, 1H), 5.51 - 5.42 (m, 1H), 4.38 - 4.19 (m, 4H), 4.15 - 4.05 (m, 1H), 3.60 (s, 3H), 2.43 (s, 3H), 1.73 (d, $J = 6.4$ Hz, 3H). LCMS $[M + 23]^+ = 525.1$.





	 6-chloro-3-(((R)-1-(2-cyano-3-((R)-3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Final product from saponification of second eluting methyl ester isomer (172): ^1H NMR (400 MHz, methanol-d_4) δ = 7.64 - 7.56 (m, 2H), 7.20 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 5.51 (q, J = 6.8 Hz, 1H), 4.36 - 4.16 (m, 4H), 4.06 (dt, J = 2.4, 12.0 Hz, 1H), 3.60 (s, 3H), 2.44 (s, 3H), 1.73 (d, J = 6.8 Hz, 3H). LCMS $[\text{M} + 1]^+ = 503.2$.
173 and 174	 3-(((R)-1-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid AND  3-(((R)-1-(3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	^1H NMR (400 MHz, methanol-d_4) δ = 7.55 (d, J = 2.0 Hz, 1H), 7.47 (s, 1H), 7.16 (d, J = 8.8 Hz, 1H), 6.97 (d, J = 9.2 Hz, 1H), 5.50 (m, 1H), 5.28 (s, 1H), 4.77 (s, 1H), 4.08 (dd, J = 1.2, 10.0 Hz, 1H), 4.04 - 4.02 (m, 1H), 3.99 - 3.95 (m, 1H), 3.76 (d, J = 10.0 Hz, 1H), 2.38 (s, 3H), 2.12 - 2.03 (m, 2H), 1.67 (d, J = 6.8 Hz, 3H). LCMS $[\text{M} + 1]^+ = 465.2$. AND ^1H NMR (400 MHz, methanol-d_4) δ = 7.63 (d, J = 1.6 Hz, 1H), 7.59 (s, 1H), 7.23 (d, J = 9.2 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 5.49 (q, J = 6.8 Hz, 1H), 5.37 (s, 1H), 4.80 (br s, 1H), 4.15 - 4.04 (m, 2H), 3.98 - 3.93 (m, 1H), 3.81 (d, J = 10.0 Hz, 1H), 2.46 (s, 3H), 2.18 - 2.03 (m, 2H), 1.73 (d, J = 6.4 Hz, 3H). LCMS $[\text{M} + 1]^+ = 465.3$.




175	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>S</i>)-3-(methylsulfonyl)pyrrolidin-1-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.62 (d, <i>J</i> = 2.0 Hz, 1H), 7.57 (s, 1H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 8.8 Hz, 1H), 5.54 (q, <i>J</i> = 6.8 Hz, 1H), 4.45 - 4.22 (m, 3H), 4.20 - 4.07 (m, 2H), 3.12 (s, 3H), 2.73 - 2.55 (m, 2H), 2.44 (s, 3H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 515.1.
176	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-fluoropyrrolidin-1-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.57 (d, <i>J</i> = 2.0 Hz, 1H), 7.55 (d, <i>J</i> = 0.8 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.55 - 5.37 (m, 2H), 4.27 - 4.16 (m, 2H), 4.15 - 4.01 (m, 2H), 2.49 - 2.21 (m, 5H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 455.2.
177	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-fluoropyrrolidin-1-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.56 (dd, <i>J</i> = 1.2, 5.6 Hz, 2H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.57 - 5.37 (m, 2H), 4.28 - 4.18 (m, 2H), 4.17 - 3.97 (m, 2H), 2.47 - 2.01 (m, 5H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> + 1] ⁺ = 455.1.




178	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((3<i>S</i>,4<i>S</i>)-3,4-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.60 (s, 2H), 7.22 - 7.15 (m, 1H), 7.01 (d, <i>J</i> = 8.8 Hz, 1H), 5.57 - 5.47 (m, 2H), 5.42 - 5.36 (m, 1H), 4.43 - 4.19 (m, 4H), 2.44 (s, 3H), 1.74 (dd, <i>J</i> = 3.6, 6.8 Hz, 3H). LCMS [<i>M</i> +Na] ⁺ = 495.1.
179	 (<i>R</i>)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.18 - 12.84 (m, 1H), 8.50 (d, <i>J</i> = 7.2 Hz, 1H), 8.49 - 8.44 (m, 1H), 7.86 (dd, <i>J</i> = 2.4, 8.8 Hz, 1H), 7.69 (s, 2H), 7.30 (d, <i>J</i> = 8.8 Hz, 1H), 7.09 (d, <i>J</i> = 9.2 Hz, 1H), 7.03 (d, <i>J</i> = 9.2 Hz, 1H), 5.48 (quin, <i>J</i> = 6.8 Hz, 1H), 3.98 - 3.88 (m, 8H), 2.44 (s, 3H), 1.68 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> + 23] ⁺ = 597.1.
180 and 181	 methyl 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-fluoro-3-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate AND	Separated isomers by SFC before saponification: Final product from saponification of first eluting methyl ester isomer (180): ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.59 - 7.51 (m, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 5.49 (q, <i>J</i> = 6.4 Hz, 1H), 4.22 - 3.92 (m, 4H), 2.42 (s, 3H), 2.39 - 2.09 (m, 2H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H), 1.67 (d, <i>J</i> = 20.4 Hz, 3H). LCMS [<i>M</i> + 1]⁺ = 491.2.




	 methyl 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-fluoro-3-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate	Final product from saponification of second eluting methyl ester isomer (181): ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.57 (s, 1H), 7.55 (s, 1H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 7.03 (d, <i>J</i> = 9.2 Hz, 1H), 5.51 (q, <i>J</i> = 6.8 Hz, 1H), 4.23 - 3.86 (m, 4H), 2.42 (s, 3H), 2.39 - 2.05 (m, 2H), 1.71 (d, <i>J</i> = 6.4 Hz, 3H), 1.66 (d, <i>J</i> = 21.2 Hz, 3H). LCMS [<i>M</i> + 1]⁺ = 491.2.
182A and 182B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(((<i>S</i>)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(((<i>R</i>)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	

183	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(N-methylacetamido)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
184	 6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(tetrahydrofuran-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
185A and 185B	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((S)-tetrahydrofuran-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid AND	




	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>R</i>)-tetrahydrofuran-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
186	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)picolinic acid	
187	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-ethyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	
188		



	(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-ethyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
189A and 189B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-2-ethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-2-ethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
190A	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>S</i>)-2-(trifluoromethyl)morpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, CD₃OD) δ = 7.71 (d, <i>J</i> = 1.6 Hz, 1H), 7.68 (s, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 6.86 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 4.47 - 4.44 (m, 1H), 4.39 - 4.35 (m, 1H), 4.29 - 4.25 (m, 1H), 4.17 (br d, <i>J</i> = 12.0 Hz, 1H), 3.97-3.90 (m, 1H), 3.48 - 3.41 (m, 1H), 3.34 - 3.33 (m, 1H), 2.47 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 543.1.





190B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>R</i>)-2-(trifluoromethyl)morpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.72 (s, 1H), 7.68 (s, 1H), 7.05 (d, <i>J</i> = 8.8 Hz, 1H), 6.85 (d, <i>J</i> = 8.8 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 4.44 (br d, <i>J</i> = 12.8 Hz, 1H), 4.39 - 4.34 (m, 1H), 4.27 (br d, <i>J</i> = 13.6 Hz, 1H), 4.19 (br d, <i>J</i> = 11.2 Hz, 1H), 3.95 (dt, <i>J</i> = 2.4, 11.6 Hz, 1H), 3.48 - 3.35 (m, 2H), 2.47 (s, 3H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 543.1.
191A and 191B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-2-(difluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-2-(difluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




192A and 192B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>S</i>)-3-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid and  6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-((<i>R</i>)-3-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
193	 3-(((1<i>R</i>)-1-(3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





194A and 194B	6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(4-((<i>R</i>)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid And 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(4-((<i>S</i>)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
195A and 195B	6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(4-((<i>R</i>)-1-methoxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid And	195A, final product from the first eluting isomer before saponification: ¹H NMR (400 MHz, methanol-<i>d</i>₄) δ = 7.63 (s, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.55 (q, <i>J</i> = 6.8 Hz, 1H), 4.51 - 4.42 (m, 2H), 3.36 (s, 3H), 3.25 - 3.18 (m, 1H), 3.17 - 3.05 (m, 2H), 2.45 (s, 3H), 2.05 - 1.97 (m, 1H), 1.84 - 1.78 (m, 1H), 1.72 (d, <i>J</i> = 6.8 Hz, 4H), 1.65 - 1.48 (m, 2H), 1.17 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i>+1]⁺ = 509.3. 195B, final product from the second eluting isomer before




	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-(4-((<i>S</i>)-1-methoxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	saponification: ^1H NMR (400 MHz, methanol-d_4) δ = 7.63 (s, 2H), 7.21 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.56 (q, J = 6.4 Hz, 1H), 4.51 - 4.41 (m, 2H), 3.36 (s, 3H), 3.23 - 3.20 (m, 1H), 3.16 - 3.06 (m, 2H), 2.45 (s, 3H), 2.00 (br d, J = 13.2 Hz, 1H), 1.86 - 1.78 (m, 1H), 1.72 (d, J = 6.8 Hz, 4H), 1.65 - 1.48 (m, 2H), 1.17 (d, J = 6.4 Hz, 3H). LCMS $[\text{M}+1]^+ = 509.3$.
196A and 196B	 196A, 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid And  196B, 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	196A, made from the enantiopure (3<i>S</i>)-3-methoxypiperidine: ^1H NMR (400 MHz, CD_3OD) δ = 7.64 (s, 2H), 7.21 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 5.57 (q, J = 6.8 Hz, 1H), 4.24 (dd, J = 3.2, 12.8 Hz, 1H), 4.00 - 3.89 (m, 1H), 3.65 - 3.55 (m, 2H), 3.47 (dd, J = 8.0, 12.8 Hz, 1H), 3.43 (s, 3H), 2.46 (s, 3H), 2.17 - 1.98 (m, 2H), 1.78 - 1.64 (m, 5H). LCMS $[\text{M} + \text{Na}]^+ = 503.2$. 196B, made from the enantiopure (3<i>R</i>)-3-methoxypiperidine: ^1H NMR (400 MHz, CD_3OD) δ = 7.64 (s, 1H), 7.61 (s, 1H), 7.14 (d, J = 8.8 Hz, 1H), 6.97 (d, J = 9.2 Hz, 1H), 5.56 (q, J = 6.8 Hz, 1H), 4.20 - 4.18 (m, 1H), 3.94 - 3.90 (m, 1H), 3.61 - 3.49 (m, 3H), 3.40 (s, 3H), 2.44 (s, 3H), 2.10



		- 2.02 (m, 2H), 1.70 (d, $J = 6.8$ Hz, 5H). LCMS $[M + Na]^+ = 503.2$.
197	 2-(((<i>R</i>)-1-(2-cyano-3-(4-(2-((<i>R</i>)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid OR 2-(((<i>R</i>)-1-(2-cyano-3-(4-(2-((<i>S</i>)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	Product generated using the first eluting isomer before saponification: 1H NMR (400 MHz, CD_3OD) $\delta = 7.90$ (d, $J = 7.6$ Hz, 1H), 7.69 (s, 1H), 7.65 (s, 1H), 7.12 (t, $J = 8.0$ Hz, 1H), 6.50 (t, $J = 7.6$ Hz, 1H), 6.42 (d, $J = 8.4$ Hz, 1H), 5.60 (q, $J = 6.8$ Hz, 1H), 3.89 - 3.81 (m, 8H), 2.71 (br d, $J = 7.2$ Hz, 2H), 2.47 (s, 3H), 1.96 - 1.93 (m, 1H), 1.69 (d, $J = 6.8$ Hz, 3H), 1.59 - 1.55 (m, 1H), 1.17 - 1.13 (m, 1H). LCMS $[M + Na]^+ = 557.2$.
198	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(oxetan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




199	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-imidazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
200	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(3-methylisoxazol-5-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	LCMS [M + H] ⁺ = 533.3
201	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-methylisoxazol-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.55 - 8.33 (m, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.14 - 7.03 (m, 1H), 6.75 (br d, J = 8.8 Hz, 1H), 5.71 (s, 1H), 5.54 - 5.44 (m, 1H), 3.92 - 3.84 (m, 4H), 3.57 - 3.50 (m, 4H), 2.47 (s, 3H), 2.35 (s, 3H), 1.70 (br d, J = 6.4 Hz, 3H). LCMS [M+Na] ⁺ = 555.2.
202	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyrrolidin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.34 (br d, J = 6.0 Hz, 1H), 7.65 (s, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.12 (d, J = 9.2 Hz, 1H), 6.79 (d, J = 8.8 Hz, 1H), 5.52 (quin, J = 6.8 Hz, 1H), 4.94 - 4.80 (m,




	(<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H), 4.52 - 4.39 (m, 2H), 3.29 - 3.15 (m, 4H), 2.51 - 2.41 (m, 5H), 2.05 - 1.94 (m, 2H), 1.90 - 1.79 (m, 6H), 1.70 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 548.3.
203	 (<i>R</i>)-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.73 (dd, <i>J</i> = 0.8, 4.8 Hz, 1H), 7.71 (d, <i>J</i> = 2.0 Hz, 1H), 7.66 (s, 1H), 7.38 (dd, <i>J</i> = 4.8, 8.8 Hz, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 5.61 (q, <i>J</i> = 6.8 Hz, 1H), 3.95 - 3.89 (m, 4H), 3.82 - 3.76 (m, 4H), 2.46 (s, 3H), 1.73 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [<i>M</i> +1] ⁺ = 419.2.
204	 (<i>R</i>)-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, methanol- <i>d</i> ₄) δ = 7.78 - 7.70 (m, 1H), 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.59 (s, 1H), 7.48 (dd, <i>J</i> = 5.2, 8.8 Hz, 1H), 7.34 (d, <i>J</i> = 8.8 Hz, 1H), 5.58 (q, <i>J</i> = 6.8 Hz, 1H), 4.40 - 4.14 (m, 4H), 2.66 - 2.53 (m, 2H), 2.43 (s, 3H), 1.75 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [<i>M</i> +Na] ⁺ = 461.2.
205	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethoxy)quinoxalin-5-yl)ethyl)amino)picolinic acid	




206	 (<i>R</i>)-3-chloro-2-cyano-6-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
207	 (<i>R</i>)-2-cyano-6-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
208	 3-(((1<i>R</i>)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
209	 (<i>R</i>)-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




210A and 210B	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>R</i>)-3,3-difluoro-4-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((<i>R</i>)-1-(2-cyano-3-((<i>S</i>)-3,3-difluoro-4-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	210A, final product formed using the first eluting isomer before saponification: ¹H NMR (400 MHz, CD₃OD) δ = 7.61 - 7.58 (m, 2H), 7.18 (d, J = 9.2 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 5.52 (q, J = 6.8 Hz, 1H), 4.43 - 4.29 (m, 3H), 4.02 (dd, J = 6.8, 10.8 Hz, 1H), 3.94 (dd, J = 5.2, 11.2 Hz, 1H), 3.80 (dd, J = 6.8, 11.6 Hz, 1H), 2.99 - 2.87 (m, 1H), 2.43 (s, 3H), 1.72 (d, J = 6.4 Hz, 3H). LCMS [M+1]⁺ = 503.2. 210B, final product formed using the second eluting isomer before saponification: ¹H NMR (400 MHz, CD₃OD) δ = 7.61 - 7.58 (m, 2H), 7.19 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.51 (q, J = 6.4 Hz, 1H), 4.40 - 4.28 (m, 3H), 4.07 (dd, J = 6.8, 10.8 Hz, 1H), 3.94 (dd, J = 5.2, 11.4 Hz, 1H), 3.82 (dd, J = 6.8, 11.4 Hz, 1H), 2.99 - 2.86 (m, 1H), 2.44 (s, 3H), 1.73 (d, J = 6.8 Hz, 3H). LCMS [M+1]⁺ = 503.2.
211A and 211B		211A, final product was synthesized using the first eluting isomer from SFC directly before saponification: ¹H NMR (400 MHz, CD₃OD) δ = 7.61 (s, 1H), 7.58 (s, 1H), 7.19 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.51 (q, J =




	6-chloro-3-(((R)-1-(2-cyano-3-((S)-3,3-difluoro-4-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((R)-1-(2-cyano-3-((R)-3,3-difluoro-4-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	6.8 Hz, 1H), 4.42 - 4.27 (m, 3H), 3.95 (dd, $J = 7.6, 10.8$ Hz, 1H), 3.78 - 3.72 (m, 1H), 3.63 (dd, $J = 7.2, 9.6$ Hz, 1H), 3.40 (s, 3H), 3.12 - 2.98 (m, 1H), 2.43 (s, 3H), 1.72 (d, $J = 6.4$ Hz, 3H). LCMS $[M+Na]^+ = 539.1$. 211B, final product was synthesized using the second eluting isomer from SFC directly before saponification: 1H NMR (400 MHz, CD_3OD) $\delta = ^1H$ NMR (400 MHz, methanol-d_4) $\delta = 7.61$ (s, 1H), 7.57 (br s, 1H), 7.19 (d, $J = 8.8$ Hz, 1H), 7.03 (d, $J = 9.2$ Hz, 1H), 5.50 (q, $J = 6.4$ Hz, 1H), 4.42 - 4.22 (m, 3H), 4.01 (br dd, $J = 7.2, 10.8$ Hz, 1H), 3.76 (dd, $J = 5.6, 9.6$ Hz, 1H), 3.64 (dd, $J = 6.8, 9.6$ Hz, 1H), 3.40 (s, 3H), 3.10 - 2.97 (m, 1H), 2.43 (s, 3H), 1.73 (d, $J = 6.8$ Hz, 3H). LCMS $[M+Na]^+ = 539.1$.
212A and 212B	 6-chloro-3-(((R)-1-(2-cyano-3-((1S,4R)-2,2-difluoro-7-azabicyclo[2.2.1]heptan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




	AND  6-chloro-3-(((R)-1-(2-cyano-3-((1R,4S)-2,2-difluoro-7-azabicyclo[2.2.1]heptan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
213	 6-chloro-3-(((R)-1-(2-cyano-3-((1R,5S,6S)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, CD₃OD) δ = 7.59 (dd, J = 1.2, 8.8 Hz, 2H), 7.22 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 8.8 Hz, 1H), 5.53 (q, J = 6.8 Hz, 1H), 4.22 - 4.08 (m, 4H), 3.47 - 3.44 (m, 2H), 3.32 (s, 3H), 2.43 (s, 3H), 2.07 - 2.04 (m, 2H), 1.74 (d, J = 6.4 Hz, 3H), 1.40 (q, J = 8.0 Hz, 1H). LCMS [M+1]⁺ = 493.1.
214	 6-chloro-3-(((1R)-1-(2-cyano-3-(6-methoxy-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




215	 6-chloro-3-(((1R)-1-(2-cyano-3-(6-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.57 (s, 1H), 7.53 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 9.2 Hz, 1H), 5.47 (q, J = 6.8 Hz, 1H), 4.55 - 4.38 (m, 1H), 4.33 (t, J = 11.6 Hz, 2H), 4.03 - 3.93 (m, 2H), 2.41 (s, 3H), 2.27 (d, J = 3.2 Hz, 1H), 2.23 (d, J = 3.2 Hz, 1H), 1.71 (d, J = 6.4 Hz, 3H). LCMS [M+23] ⁺ = 489.1.
216	 (R)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 8.43 (br s, 1H), 8.36 (br d, J = 1.2 Hz, 1H), 7.67 (d, J = 4.0 Hz, 2H), 7.44 (br d, J = 4.8 Hz, 1H), 7.17 (d, J = 8.8 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 5.51 (q, J = 6.4 Hz, 1H), 5.03 - 4.92 (m, 2H), 4.16 (br t, J = 5.2 Hz, 2H), 3.21 - 3.14 (m, 2H), 2.47 (s, 3H), 1.72 (d, J = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 500.1.
217	 (R)-6-chloro-3-((1-(2-cyano-3-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.71 (s, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.64 (d, J = 0.8 Hz, 1H), 7.54 (dd, J = 1.6, 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H), 5.53 (q, J = 6.8 Hz, 1H), 5.01 - 4.93 (m, 2H), 4.12 (t, J = 6.0 Hz, 2H), 3.20 (br t, J = 5.6 Hz, 2H), 2.46 (s, 3H), 1.71 (d, J = 6.8 Hz, 3H). LCMS [M+23] ⁺ = 546.2.




218	 (R)-6-chloro-3-((1-(2-cyano-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
219	 (R)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
220	 6-chloro-3-(((R)-1-(2-cyano-3-((3R,5R)-3,5-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	



221	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(6-methyl-5-oxo-3,4,5,6-tetrahydro-2,6-naphthyridin-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.67 (br d, <i>J</i> = 4.0 Hz, 2H), 7.51 (d, <i>J</i> = 6.8 Hz, 1H), 7.15 (d, <i>J</i> = 9.2 Hz, 1H), 6.97 (d, <i>J</i> = 9.2 Hz, 1H), 6.40 (d, <i>J</i> = 7.2 Hz, 1H), 5.52 (q, <i>J</i> = 6.4 Hz, 1H), 4.74 (s, 2H), 4.16 - 4.02 (m, 2H), 3.56 (s, 3H), 2.93 - 2.76 (m, 2H), 2.47 (s, 3H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+] ⁺ : 530.3.
222	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(7-methyl-8-oxo-3,4,7,8-tetrahydro-2,7-naphthyridin-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.65 (d, <i>J</i> = 4.4 Hz, 2H), 7.51 (d, <i>J</i> = 6.8 Hz, 1H), 7.17 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (d, <i>J</i> = 8.8 Hz, 1H), 6.31 (d, <i>J</i> = 6.8 Hz, 1H), 5.70 (q, <i>J</i> = 6.4 Hz, 1H), 4.68 (br d, <i>J</i> = 4.8 Hz, 2H), 4.10 - 4.04 (m, 2H), 3.56 (s, 3H), 3.00 (br t, <i>J</i> = 5.4 Hz, 2H), 2.46 (s, 3H), 1.69 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+H] ⁺ = 530.3.
223	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 8.64 (d, <i>J</i> = 2.4 Hz, 1H), 8.32 (dd, <i>J</i> = 2.4, 9.4 Hz, 1H), 7.86 (s, 1H), 7.84 (s, 1H), 7.16 - 7.14 (m, 1H), 7.10 - 7.06 (m, 1H), 6.75 (d, <i>J</i> = 9.6 Hz, 1H), 5.74 - 5.68 (m, 1H), 3.76 (s, 3H), 2.57 (s, 3H), 1.78 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+] ⁺ = 475.2.




224	 6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-methyl-6-oxopiperidin-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
225	 (R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(3-oxopyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
226	 6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-methyl-4-oxopyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




227	 (R)-6-chloro-3-((1-(2-cyano-3-(3,3-dimethyl-4-oxopyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
228	 6-chloro-3-(((1R)-1-(2-cyano-3-(2,2-dioxidotetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, CD₃OD) δ = 7.60 (d, <i>J</i> = 2.0 Hz, 1H), 7.58 (d, <i>J</i> = 0.8 Hz, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.50 (q, <i>J</i> = 6.8 Hz, 1H), 4.38 - 4.25 (m, 2H), 4.09 (dd, <i>J</i> = 4.4, 11.6 Hz, 1H), 4.03 (dd, <i>J</i> = 4.8, 11.6 Hz, 1H), 3.51 - 3.35 (m, 4H), 3.29 - 3.19 (m, 2H), 2.44 (s, 3H), 1.73 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+Na]⁺: 549.2.
229A and 229B	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((3aS,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid AND	229A, final product obtained using the first eluting isomer from SFC before saponification: ¹H NMR (400 MHz, CD₃OD) δ = 7.56 (s, 1H), 7.53 (s, 1H), 7.16 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (d, <i>J</i> = 8.8 Hz, 1H), 5.49 (q, <i>J</i> = 6.8 Hz, 1H), 4.18 (br dd, <i>J</i> = 6.0, 9.6 Hz, 2H), 4.06 (t, <i>J</i> = 6.4 Hz, 2H), 3.73 - 3.52 (m, 4H), 2.77 - 2.59 (m, 2H), 2.41 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz,



	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((3aR,6aR)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	3H). LCMS [M+Na]⁺: 501.1. 229B, final product obtained using the second eluting isomer from SFC before saponification: ¹H NMR (400 MHz, CD₃OD) δ = 7.57 (d, J = 2.0 Hz, 1H), 7.54 (s, 1H), 7.18 (d, J = 9.2 Hz, 1H), 7.01 (d, J = 9.2 Hz, 1H), 5.45 (q, J = 6.4 Hz, 1H), 4.13 (dd, J = 6.0, 9.6 Hz, 2H), 4.06 (t, J = 6.8 Hz, 2H), 3.75 (brt, J = 10.4 Hz, 2H), 3.62 (dd, J = 7.2, 10.4 Hz, 2H), 2.78 - 2.58 (m, 2H), 2.42 (s, 3H), 1.72 (d, J = 6.4 Hz, 3H). LCMS [M+Na]⁺: 501.1.
230	 (R)-6-chloro-3-((1-(2-cyano-3-morpholino-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
231		¹H NMR (400 MHz, CDCl₃) δ = 10.73 (s, 1H), 8.41 (br d, J = 6.4 Hz, 1H), 8.03 (d, J = 1.2 Hz, 1H), 7.80 (d, J = 1.2 Hz, 1H), 7.14 (d, J = 8.8 Hz, 1H), 6.90 - 6.54 (m, 2H), 4.04 - 3.94 (m, 4H), 3.94 - 3.87 (m, 4H), 1.75 (d, J = 6.8 Hz, 3H). LCMS




	(R)-6-chloro-3-((1-(2-cyano-7-(difluoromethyl)-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	[M+23] ⁺ : 511.1.
232	 (R)-6-chloro-3-((1-(2-cyano-7-ethoxy-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	
233	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(tetrahydro-2H-pyran-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.84 (s, 2H), 7.21 (d, J = 9.2 Hz, 1H), 7.06 (d, J = 9.2 Hz, 1H), 5.78 (d, J = 6.8 Hz, 1H), 4.23 - 4.13 (m, 2H), 3.80 - 3.64 (m, 3H), 2.57 (s, 3H), 2.25 - 2.13 (m, 2H), 2.08 - 1.98 (m, 2H), 1.79 (d, J = 6.8 Hz, 3H). LCMS [M+1] ⁺ : 452.1.
234A and 234B	 6-chloro-3-(((R)-1-(2-cyano-3-((R)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND	234A , Final product made using the first eluting isomer from SFC before saponification: ¹ H NMR (400 MHz, CD ₃ OD) δ = 7.67 (s, 2H), 7.20 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.61 (q, J = 6.8 Hz, 1H), 4.46 (br d, J = 13.6 Hz, 1H), 4.32 - 4.20 (m, 1H), 3.99 (dd, J = 4.0, 11.2 Hz, 1H), 3.70 - 3.56 (m, 2H), 3.48 (dd, J = 10.4, 12.8 Hz, 1H), 2.55 - 2.39 (m, 4H), 2.32 - 2.10 (m,




	 6-chloro-3-(((R)-1-(2-cyano-3-((S)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	2H), 1.72 (d, $J = 6.4$ Hz, 3H). LCMS $[M+Na]^+$: 539.1. 234B, Final product made using the second eluting isomer from SFC before saponification: 1H NMR (400 MHz, CD_3OD) = 7.67 (d, $J = 2.4$ Hz, 2H), 7.19 (d, $J = 9.2$ Hz, 1H), 7.01 (d, $J = 9.2$ Hz, 1H), 5.61 (q, $J = 6.8$ Hz, 1H), 4.48 (br d, $J = 13.2$ Hz, 1H), 4.36 - 4.19 (m, 1H), 3.99 (dd, $J = 4.0$, 11.2 Hz, 1H), 3.66 - 3.54 (m, 2H), 3.52 - 3.41 (m, 1H), 2.47 (s, 3H) 2.52 - 2.42 (m, 1H), 2.32 - 2.11 (m, 2H), 1.72 (d, $J = 6.8$ Hz, 3H). LCMS $[M+Na]^+$: 539.2.
235A	 6-chloro-3-(((R)-1-(2-cyano-3-((S)-2-(hydroxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	1H NMR (400 MHz, CD_3OD) δ = 7.67 (s, 2H), 7.21 (d, $J = 8.8$ Hz, 1H), 7.04 (d, $J = 9.2$ Hz, 1H), 5.55 (q, $J = 6.4$ Hz, 1H), 4.37 - 4.31 (m, 1H), 4.23 (br dd, $J = 1.6$, 13.2 Hz, 1H), 4.09 (dd, $J = 1.6$, 11.6 Hz, 1H), 3.91 - 3.78 (m, 2H), 3.74 - 3.64 (m, 2H), 3.34 - 3.33 (m, 1H), 3.08 (dd, $J = 10.4$, 13.0 Hz, 1H), 2.47 (s, 3H), 1.73 (d, $J = 6.4$ Hz, 3H). LCMS $[M+Na]^+$: 505.2.



235B	 6-chloro-3-(((R)-1-(2-cyano-3-((R)-2-(hydroxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.66 (s, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.56 (q, <i>J</i> = 6.4 Hz, 1H), 4.32 (br d, <i>J</i> = 12.8 Hz, 1H), 4.25 (br dd, <i>J</i> = 1.6, 13.2 Hz, 1H), 4.10 (dd, <i>J</i> = 1.6, 11.6 Hz, 1H), 3.93 - 3.79 (m, 2H), 3.73 - 3.62 (m, 2H), 3.34 - 3.33 (m, 1H), 3.16 - 3.08 (m, 1H), 2.47 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ : 505.2.
236A	 6-chloro-3-(((R)-1-(2-cyano-3-((S)-2-(methoxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.66 (s, 1H), 7.65 (s, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.05 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 4.31 (td, <i>J</i> = 2.0, 13.2 Hz, 1H), 4.22 (dd, <i>J</i> = 2.0, 13.2 Hz, 1H), 4.10 - 4.04 (m, 1H), 3.93 (dtd, <i>J</i> = 2.4, 5.2, 10.4 Hz, 1H), 3.86 (dt, <i>J</i> = 2.4, 11.6 Hz, 1H), 3.61 - 3.52 (m, 2H), 3.41 (s, 3H), 3.38 - 3.32 (m, 1H), 3.08 (dd, <i>J</i> = 10.4, 13.2 Hz, 1H), 2.46 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+H] ⁺ : 497.2.
236B		¹ H NMR (400 MHz, CD ₃ OD) δ = 7.69 (s, 1H), 7.68 (s, 1H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.57 (q, <i>J</i> = 6.4 Hz, 1H), 4.39 - 4.22 (m, 2H), 4.15 - 4.05 (m, 1H), 4.01 - 3.80 (m, 2H), 3.57 (dq, <i>J</i> = 5.2, 10.4 Hz, 2H), 3.42 (s, 3H), 3.34 - 3.27 (m, 1H), 3.15 (dd, <i>J</i> = 10.4, 13.2




	6-chloro-3-(((R)-1-(2-cyano-3-((R)-2-(methoxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.64 (d, J = 1.6 Hz, 1H), 7.62 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 5.55 - 5.48 (m, 1H), 4.62 - 4.58 (m, 1H), 4.14 (dd, J = 2.0, 13.6 Hz, 1H), 3.94 - 3.90 (m, 1H), 3.85 - 3.79 (m, 2H), 3.21 (dd, J = 11.2, 13.6 Hz, 1H), 2.44 (s, 3H), 1.70 (d, J = 6.8 Hz, 3H), 1.44 (d, J = 6.8 Hz, 3H), 1.29 (d, J = 6.0 Hz, 3H). LCMS [M+H] ⁺ = 497.1.
237A	 6-chloro-3-(((R)-1-(2-cyano-3-((2R,5R)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.64 (d, J = 1.6 Hz, 1H), 7.62 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 5.55 - 5.48 (m, 1H), 4.62 - 4.58 (m, 1H), 4.14 (dd, J = 2.0, 13.6 Hz, 1H), 3.94 - 3.90 (m, 1H), 3.85 - 3.79 (m, 2H), 3.21 (dd, J = 11.2, 13.6 Hz, 1H), 2.44 (s, 3H), 1.70 (d, J = 6.8 Hz, 3H), 1.44 (d, J = 6.8 Hz, 3H), 1.29 (d, J = 6.0 Hz, 3H). LCMS [M+Na] ⁺ = 503.2.
237B	 6-chloro-3-(((R)-1-(2-cyano-3-((2S,5S)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.67 (s, 1H), 7.61 (s, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 5.49 (q, J = 6.8 Hz, 1H), 4.61 - 4.58 (m, 1H), 4.14 (dd, J = 1.6, 13.6 Hz, 1H), 3.95 - 3.91 (m, 1H), 3.84 - 3.79 (m, 2H), 3.27 - 3.24 (m, 1H), 2.45 (s, 3H), 1.70 (d, J = 6.8 Hz, 3H), 1.45 (d, J = 6.8 Hz, 3H), 1.28 (d, J = 6.0 Hz, 3H). LCMS [M+Na] ⁺ = 503.2.
238A		¹ H NMR (400 MHz, CD ₃ OD) δ = 7.74 (br t, J = 2.0 Hz, 2H), 7.21 - 7.14 (m, 1H), 6.93 (d, J = 9.2 Hz, 1H), 5.70 (q, J = 6.4 Hz, 1H), 4.07 - 3.98 (m, 2H), 3.87 - 3.83 (m, 1H), 3.75 (dd, J = 2.4, 12.4 Hz, 1H), 3.58 - 3.53 (m,




	6-chloro-3-(((R)-1-(2-cyano-3-((2S,5R)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H), 2.93 (dd, <i>J</i> = 8.4, 12.4 Hz, 1H), 2.53 - 2.46 (m, 3H), 1.69 (d, <i>J</i> = 6.4 Hz, 3H), 1.26 (d, <i>J</i> = 6.4 Hz, 3H), 1.15 (d, <i>J</i> = 6.0 Hz, 3H). LCMS [M+Na] ⁺ = 503.1.
238B	 6-chloro-3-(((R)-1-(2-cyano-3-((2R,5S)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.78 - 7.72 (m, 2H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 7.03 (d, <i>J</i> = 9.2 Hz, 1H), 5.57 (q, <i>J</i> = 6.4 Hz, 1H), 4.07 - 3.98 (m, 2H), 3.95 - 3.86 (m, 1H), 3.72 (dd, <i>J</i> = 2.4, 12.4 Hz, 1H), 3.54 (dd, <i>J</i> = 9.2, 11.6 Hz, 1H), 2.94 (dd, <i>J</i> = 8.8, 12.4 Hz, 1H), 2.51 (s, 3H), 1.76 (d, <i>J</i> = 6.4 Hz, 3H), 1.26 (d, <i>J</i> = 6.4 Hz, 3H), 1.14 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+Na] ⁺ = 503.1.
239A and 239B	 3-(((R)-1-(3-((1R,6S)-2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid AND	Purified by SFC prior to saponification: First eluting isomer leading to final compound 239A: ¹H NMR (400 MHz, CD₃OD) δ = 7.61 (br d, <i>J</i> = 5.6 Hz, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.2 Hz, 1H), 5.54 (q, <i>J</i> = 6.4 Hz, 1H), 4.03 - 3.95 (m, 4H), 3.54 (td, <i>J</i> = 3.2, 12.4 Hz, 1H), 3.37 - 3.34 (m, 1H), 2.45 (s, 3H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H), 1.17 (q, <i>J</i> = 6.8 Hz, 1H), 1.04 - 1.00 (m, 1H). LCMS [M+Na]⁺ = 487.2. Second eluting isomer leading to final compound 239B: ¹H NMR (400 MHz, CD₃OD) δ = 7.61 (s, 2H), 7.20 (d, <i>J</i> = 8.8 Hz,




	 3-(((R)-1-(3-((1S,6R)-2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	1H), 7.01 (d, $J = 8.8$ Hz, 1H), 5.54 (q, $J = 6.4$ Hz, 1H), 4.04 (dt, $J = 3.6, 6.4$ Hz, 1H), 3.98 - 3.92 (m, 3H), 3.63 - 3.57 (m, 1H), 3.38 - 3.35 (m, 1H), 2.45 (s, 3H), 1.73 (d, $J = 6.8$ Hz, 3H), 1.18 (q, $J = 6.8$ Hz, 1H), 1.02 - 0.98 (m, 1H). LCMS $[M+Na]^+ = 487.2$.
240	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	1H NMR (400 MHz, $CDCl_3$) $\delta =$ 8.37 (br d, $J = 6.8$ Hz, 1H), 7.59 (s, 1H), 7.47 (d, $J = 1.6$ Hz, 1H), 7.11 (d, $J = 8.8$ Hz, 1H), 6.79 (d, $J = 9.2$ Hz, 1H), 5.48 - 5.39 (m, 1H), 4.84 - 4.76 (m, 2H), 4.71 (dd, $J = 1.2, 6.4$ Hz, 2H), 4.20 - 4.09 (m, 2H), 4.05 - 3.93 (m, 2H), 2.48 - 2.38 (m, 5H), 1.72 (d, $J = 6.8$ Hz, 3H). LCMS $[M+Na]^+ = 501.2$.
241A and 241B	 3-(((R)-1-(3-((1R,6S)-3-oxabicyclo[4.1.0]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid AND	




	 3-(((R)-1-(3-((1S,6R)-3-oxabicyclo[4.1.0]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
242	 (R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(1,4-oxazepan-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.59 (s, 2H), 7.19 (d, <i>J</i> = 9.2 Hz, 1H), 6.95 (d, <i>J</i> = 9.2 Hz, 1H), 5.52 (q, <i>J</i> = 6.8 Hz, 1H), 4.18 - 4.09 (m, 4H), 4.03 - 3.96 (m, 2H), 3.84 (t, <i>J</i> = 5.6 Hz, 2H), 2.43 (s, 3H), 2.21 - 2.11 (m, 2H), 1.69 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+] ⁺ : 467.2.
243A and 243B	 3-(((R)-1-(3-((1R,5S)-6-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid AND	243A , Final product made using the first eluting isomer from SFC before saponification: ¹ H NMR (400 MHz, CDCl ₃) δ = 8.26 - 8.20 (m, 1H), 7.53 (s, 1H), 7.40 (br s, 1H), 7.15 - 7.02 (m, 1H), 6.69 - 6.56 (m, 1H), 5.44 (br d, <i>J</i> = 4.2 Hz, 1H), 4.71 (br d, <i>J</i> = 11.6 Hz, 1H), 4.45 (br s, 1H), 4.19 (br d, <i>J</i> = 11.2 Hz, 1H), 4.06 (br d, <i>J</i> = 5.2 Hz, 1H), 3.89 (br s, 1H), 3.39 - 3.34 (m, 2H), 2.68 (br s, 1H), 2.36 (br s, 3H), 2.04 (br s,




	 3-(((R)-1-(3-((1S,5R)-6-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	1H), 1.91 (br d, $J = 11.2$ Hz, 1H), 1.62 (br s, 3H). LCMS $[M+Na]^+ = 501.1$. 243B, Final product made using the second eluting isomer from SFC before saponification: 1H NMR (400 MHz, $CDCl_3$) $\delta = 8.28$ (br d, $J = 1.6$ Hz, 1H), 7.53 (s, 1H), 7.42 (s, 1H), 7.04 (br d, $J = 7.6$ Hz, 1H), 6.71 (br d, $J = 8.8$ Hz, 1H), 5.39 (br t, $J = 6.0$ Hz, 1H), 4.66 (br d, $J = 12.0$ Hz, 1H), 4.47 - 4.45 (m, 1H), 4.27 - 4.24 (m, 1H), 4.03 (d, $J = 8.0$ Hz, 1H), 3.86 - 3.83 (m, 1H), 3.42 (br d, $J = 12.8$ Hz, 1H), 3.35 (br d, $J = 12.8$ Hz, 1H), 2.68 (br s, 1H), 2.36 (s, 3H), 2.07 - 2.04 (m, 1H), 1.94 (br d, $J = 11.2$ Hz, 1H), 1.63 (br d, $J = 6.4$ Hz, 3H). LCMS $[M+Na]^+ = 501.1$.
244A and 244B	 6-chloro-3-(((1R)-1-(2-cyano-3-((1S)-1-fluoro-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND	244A, Final product made using the first eluting isomer from SFC before saponification: 1H NMR (400 MHz, CD_3OD) $\delta = 7.58$ (br d, $J = 2.8$ Hz, 2H), 7.20 (d, $J = 9.2$ Hz, 1H), 7.02 (d, $J = 9.2$ Hz, 1H), 5.53 (q, $J = 6.4$ Hz, 1H), 4.45 (dd, $J = 13.2, 16.4$ Hz, 1H), 4.27 - 4.13 (m, 2H), 4.12 - 4.03 (m, 1H), 3.29 - 3.19 (m, 1H), 2.57 - 2.35 (m, 5H), 2.30 - 2.14 (m, 1H), 1.72 (d, $J = 6.4$ Hz, 3H), 1.53 - 1.36 (m, 1H). LCMS




	 6-chloro-3-(((1R)-1-(2-cyano-3-((1S)-1-fluoro-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	[M+Na]⁺ = 503.1. 244B, Final product made using the second eluting isomer from SFC before saponification: ¹H NMR (400 MHz, CD₃OD) δ = 7.67 - 7.52 (m, 2H), 7.19 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 9.2 Hz, 1H), 5.48 (q, J = 6.8 Hz, 1H), 4.53 (dd, J = 13.2, 16.8 Hz, 1H), 4.25 - 4.06 (m, 3H), 3.30 - 3.19 (m, 1H), 2.57 - 2.39 (m, 5H), 2.28 - 2.14 (m, 1H), 1.74 (d, J = 6.8 Hz, 3H), 1.51 - 1.37 (m, 1H). LCMS [M+Na]⁺ = 503.1.
245	 6-chloro-3-(((R)-1-(2-cyano-3-((3S,4S)-3-fluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, CDCl₃) δ = 8.35 (br dd, J = 5.6, 13.6 Hz, 1H), 7.59 (s, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.11 (dd, J = 4.8, 9.2 Hz, 1H), 6.79 (dd, J = 2.8, 8.8 Hz, 1H), 5.58 - 5.34 (m, 1H), 5.28 - 5.06 (m, 1H), 4.33 - 4.05 (m, 3H), 3.69 (td, J = 11.2, 18.8 Hz, 1H), 2.60 - 2.45 (m, 1H), 2.43 (s, 3H), 1.70 (dd, J = 6.8, 10.4 Hz, 4H), 1.32 (d, J = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 491.1.
246A		¹H NMR (400 MHz, CD₃OD) δ = 7.56 (s, 2H), 7.17 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 9.2 Hz, 1H), 5.64 - 5.37 (m, 2H), 4.96 - 4.92 (m, 1H), 4.52 - 4.36 (m, 1H), 4.31 - 4.16 (m, 1H), 2.52 - 2.34 (m, 4H), 2.20 (br dd, J =




	6-chloro-3-(((R)-1-(2-cyano-3-((2R,4S)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^{1}H NMR (400 MHz, CD_3OD) δ = 14.8, 20.0 Hz, 1H), 1.68 (d, J = 6.8 Hz, 3H), 1.51 (d, J = 6.4 Hz, 3H). LCMS $[\text{M}+\text{Na}]^+$: 491.1.
246B	 6-chloro-3-(((R)-1-(2-cyano-3-((2S,4R)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^{1}H NMR (400 MHz, CD_3OD) δ = 7.58 (s, 1H), 7.56 (s, 1H), 7.19 (d, J = 9.2 Hz, 1H), 6.99 (d, J = 9.2 Hz, 1H), 5.57 - 5.37 (m, 2H), 5.07 - 5.00 (m, 1H), 4.53 - 4.36 (m, 1H), 4.28 - 4.11 (m, 1H), 2.55 - 2.33 (m, 4H), 2.28 - 2.12 (m, 1H), 1.73 (d, J = 6.8 Hz, 3H), 1.51 (d, J = 6.4 Hz, 3H). LCMS $[\text{M}+\text{Na}]^+$: 491.2.
246C	 6-chloro-3-(((R)-1-(2-cyano-3-((2R,4R)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	^{1}H NMR (400 MHz, CD_3OD) δ = 7.56 (s, 2H), 7.17 (d, J = 9.2 Hz, 1H), 6.91 (d, J = 9.2 Hz, 1H), 5.61 - 5.37 (m, 2H), 4.98 - 4.92 (m, 1H), 4.50 - 4.36 (m, 1H), 4.31 - 4.13 (m, 1H), 2.53 - 2.33 (m, 4H), 2.16 - 2.25 (m, 1H), 1.68 (d, J = 6.8 Hz, 3H), 1.51 (d, J = 6.4 Hz, 3H). LCMS $[\text{M}+\text{Na}]^+$: 491.1.
246D		^{1}H NMR (400 MHz, CD_3OD) δ = 7.61 (s, 2H), 7.19 (d, J = 9.2 Hz, 1H), 6.94 (d, J = 9.2 Hz, 1H), 5.56 (q, J = 6.8 Hz, 1H), 5.47 - 5.28 (m, 1H), 4.82 - 4.74 (m, 1H), 4.38 - 4.21 (m, 1H), 4.19 - 4.06 (m, 1H), 2.67 - 2.54 (m, 1H), 2.44 (s, 3H), 2.12 - 1.92 (m, 1H), 1.73 (d, J = 6.4




	6-chloro-3-(((R)-1-(2-cyano-3-((2S,4S)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	Hz, 3H), 1.46 (d, $J = 6.0$ Hz, 3H). LCMS $[M+Na]^+$: 491.1.
247A and 247B	 6-chloro-3-(((1R)-1-(2-cyano-3-((1S)-1-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((1R)-1-(2-cyano-3-((1R)-1-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
248A and 248B	 6-chloro-3-(((R)-1-(2-cyano-3-((R)-3,3-difluorocyclopentyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND	

	 6-chloro-3-(((R)-1-(2-cyano-3-((S)-3,3-difluorocyclopentyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
249	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.71 - 7.57 (m, 2H), 7.20 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.52 (q, J = 6.8 Hz, 1H), 4.55 (s, 4H), 3.79 - 3.59 (m, 4H), 2.45 (s, 3H), 2.12 (t, J = 5.6 Hz, 4H), 1.72 (d, J = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 493.2.
250	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.64 (s, 2H), 7.19 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 5.55 (q, J = 6.4 Hz, 1H), 4.62 (t, J = 8.0 Hz, 2H), 3.87 - 3.70 (m, 4H), 2.55 (t, J = 8.0 Hz, 2H), 2.45 (s, 3H), 2.20 - 2.06 (m, 4H), 1.71 (d, J = 6.4 Hz, 3H). LCMS [M+1] ⁺ = 493.3.

251	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(6-oxa-2-azaspiro[3.4]octan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 10.95 - 10.41 (m, 1H), 8.37 (br d, J = 6.4 Hz, 1H), 7.59 (s, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.12 (d, J = 9.2 Hz, 1H), 6.80 (d, J = 9.2 Hz, 1H), 5.43 (quin, J = 6.8 Hz, 1H), 4.55 - 4.41 (m, 4H), 4.04 - 3.98 (m, 2H), 3.94 (t, J = 6.8 Hz, 2H), 2.44 (s, 3H), 2.36 - 2.26 (m, 2H), 1.70 (d, J = 6.8 Hz, 3H). LCMS [M+Na] ⁺ : 501.1.
252	 (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(5-oxa-2-azaspiro[3.4]octan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acidS	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.62 - 7.52 (m, 2H), 7.21 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 9.2 Hz, 1H), 5.49 (q, J = 6.8 Hz, 1H), 4.57 - 4.36 (m, 4H), 3.93 (t, J = 6.8 Hz, 2H), 2.43 (s, 3H), 2.29 - 2.20 (m, 2H), 2.06-1.99 (m, 2H), 1.71 (d, J = 6.8 Hz, 3H). LCMS [M+Na] ⁺ : 501.2.
253A and 253B	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((S)-1-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid AND	Purified by SFC prior to saponification: First eluting isomer leading to final compound 253A: ¹ H NMR (400 MHz, CD ₃ OD) δ = 7.55 (dd, J = 1.6, 10.4 Hz, 2H), 7.19 (d, J = 9.2 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 5.50 (q, J = 6.8 Hz, 1H), 4.14 - 4.01 (m, 2H), 3.99 - 3.83 (m, 4H), 2.41 (s, 3H), 2.26 - 2.02 (m, 6H), 1.71 (d, J = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 493.2.


	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((R)-1-oxa-7-azaspiro[4.4]nonan-7-yl)ethyl)amino)picolinic acid	Second eluting isomer leading to final compound 253B: ¹H NMR (400 MHz, CD₃OD) δ = 7.61 - 7.48 (m, 2H), 7.19 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 9.2 Hz, 1H), 5.50 (q, J = 6.8 Hz, 1H), 4.13 - 3.82 (m, 6H), 2.41 (s, 3H), 2.24 - 2.01 (m, 6H), 1.71 (d, J = 6.8 Hz, 3H). LCMS [M+1]⁺ = 493.2.
254A and 254B	 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((S)-2-oxa-7-azaspiro[4.4]nonan-7-yl)ethyl)amino)picolinic acid AND  6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((R)-2-oxa-7-azaspiro[4.4]nonan-7-yl)ethyl)amino)picolinic acid	Purified by SFC prior to saponification: First eluting isomer leading to final compound 254A: ¹H NMR (400 MHz, CD₃OD) δ = 7.57 (d, J = 1.8 Hz, 1H), 7.55 (s, 1H), 7.21 (d, J = 9.2 Hz, 1H), 7.05 (d, J = 9.2 Hz, 1H), 5.51 - 5.46 (m, 1H), 4.10 (td, J = 6.8, 10.8 Hz, 1H), 4.03 - 3.93 (m, 4H), 3.87 - 3.78 (m, 2H), 3.76 - 3.70 (m, 1H), 2.42 (s, 3H), 2.20 - 2.02 (m, 4H), 1.73 (d, J = 6.8 Hz, 3H). LCMS [M+H]⁺: 493.1. Second eluting isomer leading to final compound 254B: ¹H NMR (400 MHz, CD₃OD) δ = 7.57 (d, J = 1.6 Hz, 1H), 7.54 (s, 1H), 7.18 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.48 (q, J = 6.8 Hz, 1H), 4.04 (t, J = 6.8 Hz, 2H), 3.97 (t, J = 7.2 Hz, 2H), 3.94 - 3.84 (m, 2H), 3.80 - 3.70 (m, 2H), 2.42 (s, 3H), 2.17 - 1.99 (m, 4H), 1.72 (d, J = 6.8

		Hz, 3H). LCMS [M+H] ⁺ : 493.1.
255	 (R)-6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.59 (d, J = 1.6 Hz, 1H), 7.57 (s, 1H), 7.21 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 9.2 Hz, 1H), 5.47 (q, J = 6.8 Hz, 1H), 4.62 - 4.57 (m, 2H), 4.55 - 4.50 (m, 2H), 2.91 (t, J = 12.0 Hz, 4H), 2.43 (s, 3H), 1.72 (d, J = 6.8 Hz, 3H). LCMS [M+H] ⁺ = 499.3.
256	 (R)-6-chloro-3-((1-(2-cyano-3-(5,5-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.65 - 7.56 (m, 2H), 7.22 (d, J = 8.8 Hz, 1H), 7.06 (d, J = 9.2 Hz, 1H), 5.52 (d, J = 6.4 Hz, 1H), 4.74 (dd, J = 9.6, 17.6 Hz, 2H), 4.49 - 4.34 (m, 2H), 2.61 - 2.54 (m, 2H), 2.45 (s, 3H), 2.24 - 2.13 (m, 2H), 1.74 (d, J = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 499.1.
257A and 257B	 6-chloro-3-(((R)-1-(2-cyano-3-((S)-5-fluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid AND	Purified by SFC prior to saponification: First eluting isomer leading to final compound 257A: ¹ H NMR (400 MHz, CD ₃ OD) δ = 7.58 (s, 3H), 7.56 (s, 1H), 7.20 (d, J = 9.2 Hz, 1H), 7.01 (d, J = 9.2 Hz, 1H), 5.52 (q, J = 6.4 Hz, 1H), 5.11 - 4.90 (m, 2H), 4.44 (q, J = 9.6 Hz, 2H), 4.34 (d, J = 8.8 Hz, 1H), 2.42 (s, 3H), 2.34 - 2.24 (m, 1H), 2.20 - 1.96 (m, 2H), 1.86 (q, J = 9.6 Hz, 1H), 1.71 (d, J = 6.8 Hz, 3H). LCMS

	 6-chloro-3-((R)-1-(2-cyano-3-((R)-5-fluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	[M+Na]⁺ = 503.2. Second eluting isomer leading to final compound 257B: ¹H NMR (400 MHz, CD₃OD) δ = 7.60 (d, J = 2.0 Hz, 1H), 7.55 (s, 1H), 7.13 (br d, J = 9.2 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H), 5.49 (q, J = 6.8 Hz, 1H), 5.11 - 4.89 (m, 2H), 4.51 (d, J = 9.6 Hz, 1H), 4.39 (dd, J = 4.0, 9.2 Hz, 2H), 2.42 (s, 3H), 2.35 - 2.23 (m, 1H), 2.21 - 1.96 (m, 2H), 1.91 - 1.80 (m, 1H), 1.70 (d, J = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 503.1.
258	 (R)-6-chloro-3-((1-(2-cyano-3-(6-fluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, CD₃OD) δ = 7.57 (d, J = 2.0 Hz, 1H), 7.53 (d, J = 0.8 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.46 (q, J = 6.8 Hz, 1H), 5.12 - 4.93 (m, 1H), 4.54 - 4.39 (m, 4H), 2.80 - 2.68 (m, 2H), 2.56 - 2.44 (m, 2H), 2.41 (s, 3H), 1.70 (d, J = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 503.2.
259	 (R)-6-chloro-3-((1-(2-cyano-3-(6-hydroxy-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹H NMR (400 MHz, CD₃OD) δ = 7.57 (d, J = 2.0 Hz, 1H), 7.55 - 7.51 (m, 1H), 7.20 (d, J = 9.2 Hz, 1H), 7.03 (d, J = 9.2 Hz, 1H), 5.47 (q, J = 6.8 Hz, 1H), 4.50 - 4.37 (m, 4H), 4.25 - 4.16 (m, 1H), 2.70 - 2.61 (m, 2H), 2.41 (s, 3H), 2.24 - 2.15 (m, 2H), 1.71 (d, J = 6.8 Hz, 3H). LCMS [M+Na]⁺ = 501.2.

[00378] Synthesis of Examples 47A and 47B

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-((1*S*)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid and 6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid



[00379] Step A: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (180 mg, 452 μ mol, 1.00 eq.) in *N,N*-dimethylformamide (2.00 mL) were added PyBOP (706 mg, 1.36 mmol, 3.00 eq.) and *N,N*-diisopropylethylamine (292 mg, 2.26 mmol, 394 μ L, 5.00 eq.) and the mixture was stirred 25 °C for 30 minutes. To this mixture was added 1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexane (127 mg, 679 μ mol, 1.50 eq., hydrochloric acid salt) and the reaction was stirred at 25 °C for 1 hour. The mixture was then diluted with water (10.0 mL) and extracted with ethyl acetate (3 $\times$ 10.0 mL). The combined organic layers were washed with brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by *prep*-TLC (SiO₂, petroleum ether : ethyl acetate = 2:1) to give methyl 6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-

3-yl)quinoxalin-5-yl)ethyl)amino)picolinate (150 mg, 250 μ mol, 55.3% yield, 88.6% purity) as a yellow solid. LCMS $[M+Na]^+ = 553.1$.

[00380] Step B: The diastereomers of methyl 6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinate (150 mg, 88.6% purity) were separated by SFC (column: DAICEL CHIRALCEL OX (250 mm $\times$ 30 mm, 10 μ m); mobile phase: phase A: CO₂, phase B: 0.1% NH₄OH in MeOH; B%: 30%, isocratic elution mode). The desired fractions were concentrated to give methyl 6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(((1*S*)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinate and 6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(((1*R*)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinate.

[00381] First eluting isomer: White solid (50.0 mg, 84.8 μ mol, 18.7% yield, 85.0% purity), LCMS $[M+1]^+ = 531.3$ (Rt = 0.692 mins).

[00382] Second eluting isomer: White solid, (65.0 mg, 110 μ mol, 24.4% yield, 90.0% purity), LCMS $[M+1]^+ = 531.3$ (Rt = 0.688 mins).

[00383] Step C1: The first eluting methyl ester was saponified to the acid using the following procedure: To a solution of the first eluting methyl ester (49.0 mg, 92.3 μ mol, 1.00 eq.) in DMSO (0.10 mL) was added lithium chloride (39.1 mg, 923 μ mol, 18.9 μ L, 10.0 eq.), and the mixture was stirred at 130 °C for 2 hours. After completion of the reaction, the mixture was cooled to 20 °C, filtered, and the filtrate was purified directly by prep-HPLC (column: Phenomenex Luna C18 150 $\times$ 25 mm $\times$ 10 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 75%-100% phase B) to give the desired acid (Example 43A) of the first eluting ester from the previous reaction (2.31 mg, 4.43 μ mol, 4.80% yield, 99.2% purity) as a yellow solid. LCMS $[M+Na]^+ = 539.1$.


[00384] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.66 (br s, 1H), 7.60 (s, 2H), 7.24 (d, *J* = 8.8 Hz, 1H), 6.98 (br d, *J* = 8.8 Hz, 1H), 5.43 (quin, *J* = 6.8 Hz, 1H), 4.45 - 4.28 (m, 2H), 4.12 - 3.94 (m, 2H), 2.39 (s, 3H), 2.38 - 2.33 (m, 1H), 1.63 (d, *J* = 6.4 Hz, 3H), 1.43 (dd, *J* = 5.2, 8.4 Hz, 1H), 1.08 - 0.98 (m, 1H).

[00385] Step C2: The second eluting methyl ester was saponified to the acid using the following procedure: To a solution of the second eluting methyl ester (64.0 mg, 121 μ mol, 1.00 eq.) in DMSO (1.00 mL) was added lithium chloride (51.1 mg, 1.21 mmol, 10.0 eq.), and the mixture was stirred at 130 °C for 2 hours. After completion of the reaction, the mixture was cooled to 20 °C, filtered, and the filtrate was purified directly by prep-HPLC (column: Phenomenex Luna C18 150 $\times$ 25 mm $\times$ 10 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 75%-100% phase B) to give the desired acid (Example 43B) of the second eluting ester from the previous reaction (9.77 mg, 18.7 μ mol, 15.5% yield,

98.7% purity) as a yellow solid. LCMS $[M+Na]^+ = 539.2$.

[00386] 1H NMR (400 MHz, DMSO- d_6) δ = 12.96 (br s, 1H), 8.46 (br d, J = 7.2 Hz, 1H), 7.66 - 7.56 (m, 2H), 7.29 (d, J = 8.8 Hz, 1H), 7.11 - 7.01 (m, 1H), 5.60 - 5.27 (m, 1H), 4.43 (d, J = 10.8 Hz, 1H), 4.31 (br d, J = 11.6 Hz, 1H), 4.01 (td, J = 4.8, 10.4 Hz, 2H), 2.40 (s, 3H), 2.38 - 2.31 (m, 1H), 1.65 (d, J = 6.4 Hz, 3H), 1.44 (br dd, J = 6.0, 8.4 Hz, 1H), 1.04 (br t, J = 5.6 Hz, 1H).

[00387] Synthesis of Example 58



[00388] Step A: To a solution of methyl (R)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (50.0 mg, 113 μ mol, 1.00 eq.) and morpholine (14.8 mg, 170 μ mol, 14.9 μ L, 1.50 eq.) in DMF (0.50 mL) was added PyBOP (88.3 mg, 170 μ mol, 1.50 eq.) and *N,N*-diisopropylethylamine (43.9 mg, 339 μ mol, 59.1 μ L, 3.00 eq.), and the mixture was stirred at 25 $^{\circ}$ C for 1 hour. After this time, water (1.00 mL) was slowly added to the mixture and a yellow precipitate was formed. The suspension was then filtered, and the cake was collected and dried under vacuum to give methyl (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinate (52.0 mg, 111 μ mol, 98.5% yield) as a yellow solid. LCMS $[M+1]^+ = 467.2$.


[00389] Step B: To a solution of methyl (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinate (52.0 mg, 111 μ mol, 1.00 eq.) in DMSO (0.50 mL) was added lithium chloride (47.2 mg, 1.11 mmol, 22.8 μ L, 10.0 eq.), and the mixture was stirred at 120 $^{\circ}$ C for 6 hours. The mixture was then cooled to 25 $^{\circ}$ C, filtered to give a filtrate, and the filtrate was purified by prep-HPLC (column: YMC-Actus Triart C18 150 $\times$ 30 mm $\times$ 7 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 55%-85% B) to give (R)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-

yl)ethyl)amino)picolinic acid (8.93 mg, 19.3 μ mol, 17.4% yield, 98.1% purity) as a white solid. LCMS $[M+1]^+ = 453.2$.

[00390] ^1H NMR (400 MHz, CD_3OD) δ = 7.66 (d, J = 1.6 Hz, 1H), 7.63 (s, 1H), 7.19 (d, J = 9.2 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 5.53 (q, J = 6.8 Hz, 1H), 3.98 - 3.86 (m, 4H), 3.83 - 3.72 (m, 4H), 2.46 (s, 3H), 1.73 (d, J = 6.8 Hz, 3H).

[00391] Synthesis of Example 70

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00392] Step A: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (70.0 mg, 158 μ mol, 1.00 eq.), 3,3-difluoropyrrolidine (27.3 mg, 190 μ mol, 1.20 eq., hydrochloric acid salt) in DMF (0.50 mL) was added PyBOP (124 mg, 238 μ mol, 1.50 eq.) and *N,N*-diisopropylethylamine (143 mg, 1.11 mmol, 193 μ L, 7.00 eq.), and the mixture was stirred at 25 $^{\circ}\text{C}$ for 12 hours. The mixture was then cooled to 15 $^{\circ}\text{C}$, and water (2.00 mL) was slowly added for form a yellow precipitate. The suspension was filtered, and the cake was collected and dried under vacuum to give methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (70.1 mg, 144 μ mol, 90.9% yield) as a yellow solid. LCMS $[M+\text{Na}]^+ = 509.2$.


[00393] Step B: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (70.0 mg, 144 μ mol, 1.00 eq.) in DMSO (2.00 mL) was added lithium chloride (60.9 mg, 1.44 mmol, 29.5 μ L, 10.0 eq.), and the mixture was stirred at 120 $^{\circ}\text{C}$ for 12 hours. The mixture was then cooled to 25 $^{\circ}\text{C}$, and filtered to collect the filtrate. The filtrate was purified via prep-HPLC (column: Welch Xtimate

C18 150 × 25mm × 5μm; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 65%-85%B) to give (*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (8.26 mg, 17.2 μmol, 12.0% yield, 98.7% purity) as a yellow solid. LCMS $[M+Na]^+ = 495.1$.

[00394] 1H NMR (400 MHz, CD_3OD) δ = 7.60 (s, 1H), 7.57 (s, 1H), 7.19 (d, J = 9.2 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 5.50 (q, J = 6.8 Hz, 1H), 4.38 - 4.14 (m, 4H), 2.66 - 2.55 (m, 2H), 2.43 (s, 3H), 1.73 (d, J = 6.8 Hz, 3H).

[00395] Synthesis of Examples 94A and 94B

[00396] 6-chloro-3-(((1*R*)-1-(2-cyano-3-(((1*R*)-1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid and 6-chloro-3-(((1*R*)-1-(2-cyano-3-(((1*S*)-1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00397] Step A: To a solution of methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (80.0 mg, 201 μmol, 1.00 eq.) in DMF (1.00 mL) was added PyBOP (314 mg, 603 μmol, 3.00 eq.) and *N,N*-diisopropylethylamine (130 mg, 1.01 mmol, 175 μL, 5.00 eq.), and the mixture was stirred 25 °C for 30 minutes. After this time, 6-azaspiro[3.5]nonan-1-ol (42.0 mg, 302 μmol, 1.50 eq.) was added to the mixture, and the mixture was stirred at 25 °C for 1 hour. After completion of the reaction, the mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3 × 10.0 mL). The combined organic layers were washed with brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC

(SiO₂, petroleum ether:ethyl acetate = 2:1) to give methyl 6-chloro-3-(((1*R*)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (35.0 mg, 60.5 μmol, 30.1% yield, 94.9% purity) as a yellow solid. LCMS [M+1]⁺ = 521.2.

[00398] Step B: To a solution of methyl 6-chloro-3-(((1*R*)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (30.0 mg, 57.6 μmol, 1.00 eq.) in DMSO (0.50 mL) was added lithium chloride (24.4 mg, 576 μmol, 10.0 eq.), and the mixture was stirred at 130 °C for 5 hours. The mixture was then cooled to room temperature, filtered, and the filtrate was purified directly by prep-HPLC (column: Phenomenex luna C18 150 × 25 mm × 10 μm; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile, gradient: 55%-85% B) to the first eluting diastereomer (19.9 mg, 38.6 μmol, 67.0% yield, 98.5% purity) as a yellow solid, and the second eluting diastereomer (7.33 mg, 14.2 μmol, 24.7% yield, 98.4% purity) as a yellow solid.

[00399] Characterization data for the first eluting diastereomer: LCMS [M+1]⁺ = 507.2.


[00400] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.47 (br d, *J* = 5.2 Hz, 1H), 7.65 - 7.64 (m, 1H), 7.63 (br s, 1H), 7.30 - 7.27 (m, 1H), 7.05 - 6.99 (m, 1H), 5.53 - 5.39 (m, 1H), 4.99 - 4.89 (m, 1H), 3.92 - 3.69 (m, 4H), 3.51 - 3.46 (m, 1H), 2.41 (s, 3H), 2.15 - 2.05 (m, 1H), 1.90 - 1.68 (m, 5H), 1.66 - 1.64 (m, 3H), 1.53 - 1.38 (m, 2H).

[00401] Characterization data for the second eluting diastereomer: LCMS [M+1]⁺ = 507.2.

[00402] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 8.45 (t, *J* = 6.8 Hz, 1H), 7.66 - 7.57 (m, 2H), 7.27 (dd, *J* = 4.8, 8.8 Hz, 1H), 6.98 (t, *J* = 9.2 Hz, 1H), 5.55 - 5.44 (m, 1H), 5.06 - 4.85 (m, 1H), 4.21 (br dd, *J* = 13.6, 18.8 Hz, 1H), 3.94 - 3.85 (m, 1H), 3.81 (t, *J* = 7.6 Hz, 1H), 3.55 (t, *J* = 12.4 Hz, 1H), 3.47 - 3.42 (m, 1H), 2.40 (s, 3H), 2.17 - 2.06 (m, 1H), 1.94 - 1.82 (m, 1H), 1.81 - 1.68 (m, 3H), 1.67 - 1.57 (m, 5H), 1.28 - 1.18 (m, 1H).

[00403] Synthesis of Example 109A and 109B

[00404] 2-(((*R*)-1-(2-cyano-3-(((*R*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid and 2-(((*R*)-1-(2-cyano-3-(((*S*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid



[00405] Step A: To a solution of methyl (*R*)-2-(((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (90.0 mg, 248 μmol , 1.00 eq.) and 4,4-difluoro-2-methylpyrrolidine (60.2 mg, 497 μmol , 2.00 eq.) in DMF (1.00 mL) was added PyBOP (194 mg, 373 μmol , 1.50 eq.) and *N,N*-diisopropylethylamine (161 mg, 1.24 mmol, 216 μL , 5.00 eq.), and the mixture was stirred at 25 °C for 3 hours. The mixture was then poured into water (10.0 mL) and stirred for 2 mins. The suspension was filtered, and filter cake was dried in vacuum to give a residue. The residue was purified by SFC (column: DAICEL CHIRALCEL OX (250mm*30mm,10um); mobile phase: phase A: CO₂, phase B: 0.1% NH₄OH in MeOH; B%:40%) to give methyl 2-(((1*R*)-1-(2-cyano-3-(4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (100 mg, 214 μmol , 86.5% yield) as a yellow oil. LCMS $[M+1]^+ = 466.0$.

[00406] Step B: The diastereomers of methyl 2-(((1*R*)-1-(2-cyano-3-(4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoate (100 mg, 215 μmol , 1.00 eq.) was further separated by SFC (column: DAICEL CHIRALCEL OX(250mm*50mm,10um); mobile phase: phase A: CO₂, phase B: 0.1% NH₄OH in MeOH; B%:17%) to give the first eluting methyl ester isomer (40.0 mg, 85.9 μmol , 40.0% yield) as a yellow oil and the second eluting methyl ester isomer (45.0 mg, 96.7 μmol , 45.0% yield) as a yellow oil.

[00407] Step C1: To a solution of the first eluting methyl ester isomer from Step B (35.0 mg, 75.2 μmol , 1.00 eq.) in DMSO (2.00 mL) was added lithium chloride (31.9 mg, 752 μmol ,

15.4 μ L, 10.0 eq.), and the mixture was stirred at 130 °C for 8 hours. The mixture was then cooled to 25 °C, further diluted with water (20.0 mL), and extracted with ethyl acetate (20.0 mL). The combined organic layers were washed with brine (20.0 mL $\times$ 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (YMC-Actus Triart C18 150 $\times$ 30 mm $\times$ 7 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 60%-90%) to give 2-(((*R*)-1-(2-cyano-3-((*R*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid OR 2-(((*R*)-1-(2-cyano-3-((*S*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid (4.07 mg, 8.73 μ mol, 11.6% yield, 96.8% purity) as a yellow solid. LCMS $[M+1]^+ = 452.2$.

[00408] ^1H NMR (400 MHz, CD_3OD) δ = 7.88 (dd, J = 1.6, 8.0 Hz, 1H), 7.63 (d, J = 1.6 Hz, 1H), 7.58 (s, 1H), 7.12 - 7.06 (m, 1H), 6.49 (t, J = 7.6 Hz, 1H), 6.36 (d, J = 8.4 Hz, 1H), 5.56 (q, J = 6.8 Hz, 1H), 5.09 - 4.99 (m, 1H), 4.54 - 4.41 (m, 1H), 4.30 (q, J = 12.0 Hz, 1H), 2.84 - 2.72 (m, 1H), 2.42 (s, 3H), 2.39 - 2.26 (m, 1H), 1.68 (d, J = 6.8 Hz, 3H), 1.51 (d, J = 6.8 Hz, 3H).


[00409] Step C1: To a solution of the second eluting methyl ester isomer from Step B (40.0 mg, 85.9 μ mol, 1.00 eq.) in DMSO (1.00 mL) was added lithium chloride (36.4 mg, 859 μ mol, 17.6 μ L, 10.0 eq.), and the mixture was stirred at 130 °C for 8 hours. The mixture was then cooled to 25 °C, further diluted with water (20.0 mL), and extracted with ethyl acetate (20.0 mL). The combined organic layers were washed with brine (20.0 mL $\times$ 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: YMC-Actus Triart C18 150 $\times$ 30 mm $\times$ 7 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 60%-90% B) to give 2-(((*R*)-1-(2-cyano-3-((*R*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid OR 2-(((*R*)-1-(2-cyano-3-((*S*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid (6.10 mg, 13.1 μ mol, 15.3% yield, 97% purity) as a yellow solid. LCMS $[M+1]^+ = 452.2$.

[00410] ^1H NMR (400 MHz, CD_3OD) δ = 7.89 (d, J = 8.0 Hz, 1H), 7.61 (s, 1H), 7.58 (br s, 1H), 7.10 - 7.03 (m, 1H), 6.49 (t, J = 7.6 Hz, 1H), 6.33 (d, J = 8.4 Hz, 1H), 5.60 (q, J = 6.8 Hz, 1H), 4.98 - 4.90 (m, 1H), 4.46 (q, J = 13.2 Hz, 1H), 4.31 (q, J = 12.0 Hz, 1H), 2.83 - 2.68 (m, 1H), 2.41 (s, 3H), 2.38 - 2.26 (m, 1H), 1.61 (d, J = 6.8 Hz, 3H), 1.50 (d, J = 6.0 Hz, 3H).

[00411] Example 110A and 110B

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid and 6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-methoxypyrrolidin-1-yl)-

7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid



[00412] Step A: To a solution of methyl (R)-6-chloro-3-(((1R)-1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (70.0 mg, 176 μ mol, 1.00 eq.), 3-methoxypyrrolidine (35.6 mg, 352 μ mol, 2.00 eq.) in DMF (1.00 mL) was added PyBOP (137 mg, 264 μ mol, 1.50 eq.) and N,N-diisopropylethylamine (159 mg, 1.23 mmol, 215 μ L, 7.00 eq.), and the mixture was stirred at 30 °C for 2 hours. The mixture was then poured into water (10.0 mL) and stirred for 2 mins. The resulting suspension was filtered, and the filter cake was dried in vacuum to give methyl 6-chloro-3-(((1R)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (80.0 mg, 166 μ mol, 94.5% yield) as a yellow oil. LCMS [M+Na]⁺ = 503.1.

[00413] Step B: The methyl 6-chloro-3-(((1R)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (80.0 mg, 166 μ mol, 1.00 eq.) was purified by SFC (column: Welch Ultimate XB-CN 250 $\times$ 50 $\times$ 10 μ m; mobile phase: phase A: Hexanes, phase B: 0.1% NH₄OH in EtOH; gradient: 1%-40% B) to give the first eluting methyl ester isomer (40.0 mg, 83.2 μ mol, 50.0% yield) as a yellow oil and the second eluting methyl ester isomer (45.0 mg, 93.6 μ mol, 56.3% yield) as a yellow oil.

[00414] Step C1: To a solution of the first eluting methyl ester isomer from Step B (40.0

mg, 83.2 μ mol, 1.00 eq.) in DMSO (1.00 mL) was added lithium chloride (35.3 mg, 832 μ mol, 17.1 μ L, 10.0 eq.), and the mixture was stirred at 130 °C for 2 hours. The reaction was then cooled to 25 °C and adjusted to pH = 6 with hydrochloric acid (2M in water, 2.00 mL), and further diluted with water (20.0 mL). The resulting aqueous solution was extracted with ethyl acetate (20.0 mL), and the combined organic layers were washed with brine (20.0 mL $\times$ 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 60% - 90% B) to give 6-chloro-3-(((R)-1-(2-cyano-3-((R)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid OR 6-chloro-3-(((R)-1-(2-cyano-3-((S)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (2.23 mg, 4.39 μ mol, 5.28% yield, 91.9% purity) as a yellow solid. LCMS [M+1]⁺ = 467.2.


[00415] ¹H NMR (400 MHz, CD₃OD) δ = 7.55 (s, 1H), 7.53 (s, 1H), 7.20 (d, J = 9.2 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 5.58 - 5.48 (m, 1H), 5.52 (q, J = 6.4 Hz, 1H), 4.24 - 4.16 (m, 1H), 4.08 - 3.92 (m, 4H), 3.41 (s, 3H), 2.41 (s, 3H), 2.36 - 2.08 (m, 2H), 1.72 (d, J = 6.8 Hz, 3H).

[00416] Step C2: To a solution of the second eluting methyl ester isomer from Step B (10.0 mg, 20.8 μ mol, 1.00 eq.) in DMSO (1.00 mL) was added lithium chloride (8.81 mg, 208 μ mol, 4.26 μ L, 10.0 eq.), and the mixture was stirred at 130 °C for 2 hours. The mixture was then cooled to 25 °C and adjusted to pH = 6 with hydrochloric acid (2M in water, 2.00 mL), further diluted with water (20.0 mL), and the resulting aqueous solution was extracted with ethyl acetate (20.0 mL). The combined organic layers were washed with brine (20.0 mL $\times$ 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225% formic acid in water, phase B: acetonitrile; gradient: 60% - 90%B) to 6-chloro-3-(((R)-1-(2-cyano-3-((R)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid OR 6-chloro-3-(((R)-1-(2-cyano-3-((S)-3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid (1.99 mg, 4.18 μ mol, 20.1% yield, 98.1% purity) as a yellow solid. LCMS [M+1]⁺ = 467.3.

[00417] ¹H NMR (400 MHz, methanol-*d*₄) δ = 7.56 (s, 1H), 7.54 (s, 1H), 7.20 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 5.51 (q, J = 6.8 Hz, 1H), 4.23 - 4.17 (m, 1H), 4.07 - 3.92 (m, 4H), 3.42 (s, 3H), 2.42 (s, 3H), 2.33 - 2.23 (m, 1H), 2.21 - 2.08 (m, 1H), 1.72 (d, J = 6.8 Hz, 3H).

[00418] Example 260

[00419] 6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-(()-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid



[00420] Step A: To a solution of methyl methyl (*R*)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (40.0 mg, 101 μ mol, trifluoroacetic acid salt) in *N,N*-dimethylformamide (0.50 mL) were added PyBOP (78.5 mg, 151 μ mol, 1.50 eq.) and *N,N*-diisopropylethylamine (65.0 mg, 503 μ mol, 87.6 μ L, 3.00 eq.), and the mixture was stirred at 25 °C for 30 minutes. After this time, (*S*)-2-methylmorpholine (12.2 mg, 121 μ mol, 1.50 eq.) was added to the above mixture at 25 °C and the mixture was left to stir at 25 °C for 2.5 hours. After completion of the reaction, the mixture was diluted with water (5.00 mL) and extracted with ethyl acetate (5.00 mL $\times$ 3). The combined organic layers were washed with brine (5.00 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO₂, petroleum ether/ethyl acetate = 3/1) to give methyl 6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinate (25.0 mg, 52.0 μ mol, 51.7% yield) as yellow solid. LCMS [*M*+1] + = 481.2.


[00421] Step B: To a solution of methyl 6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinate (25.0 mg, 52.0 μ mol, μ mol, 1.00 eq.) in DMSO (0.80 mL) was added lithium chloride (22.0 mg, 520 μ mol 10.0 eq.), and the reaction was stirred at 120 °C for 5 hours. After completion of the reaction, the reaction mixture was cooled to 20 °C and filtered, and the filter liquor was purified by prep-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 55%-85% B) to give 6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid (5.95 mg, 12.7 μ mol, 24.4% yield, 99.7% purity) as yellow solid. LCMS [*M*+1] + = 467.1.


[00422] ¹H NMR (400 MHz, CD₃OD) δ = 7.66 (s, 2H), 7.21 (d, *J* = 8.8 Hz, 1H), 7.04 (d,

J = 8.8 Hz, 1H), 5.53 (q, J = 6.8 Hz, 1H), 4.29 - 4.19 (m, 2H), 4.05 (dd, J = 2.0, 11.6 Hz, 1H), 3.91 - 3.81 (m, 2H), 3.28 - 3.22 (m, 1H), 2.97 (dd, J = 10.0, 12.8 Hz, 1H), 2.47 (s, 3H), 1.73 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 6.0 Hz, 3H).

[00423] Examples 261A, 261B, 261C, and 261D

[00424] 6-chloro-3-(((R)-1-(2-cyano-3-((S)-3-((S)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid, 6-chloro-3-(((R)-1-(2-cyano-3-((S)-3-((R)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid, 6-chloro-3-(((R)-1-(2-cyano-3-((R)-3-((S)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid, and 6-chloro-3-(((R)-1-(2-cyano-3-((R)-3-((R)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid





[00425] To a solution of methyl (R)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (600 mg, 1.51 mmol, 1.00 eq.), *N,N*-diisopropylethylamine (975 mg, 7.54 mmol, 1.31 mL, 5.00 eq.) in *N,N*-dimethylformamide (6.00 mL) was added PyBOP (1.18 g, 2.26 mmol, 1.50 eq.), and the mixture was stirred at 25 °C for 1 hour. After this time 1-(piperidin-3-yl)ethan-1-ol (292 mg, 2.26 mmol, 1.50 eq.) was added to the mixture at 25 °C, and the reaction was further stirred at 25 °C for 12 hours. After completion of the reaction, the mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether: ethyl acetate = 1: 0 to 3: 1) to give a crude product. The crude product was then purified by *prep*-HPLC (column: Phenomenex luna C18 150 × 40mm × 15um; mobile phase: phase A: 0.225 % formic acid in

water, phase B: acetonitrile; gradient: 60%-90% B) to give the first eluting mixture of the methyl esters of 261A and 261D (100 mg, 173 μ mol, 11.5% yield) as a yellow solid and a second peak. The second peak was purified by *prep*-HPLC (column: YMC-Actus Triart C18 150 $\times$ 30mm $\times$ 7 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 63%-93% B) to give the second eluting mixture of the methyl ester of 261B and 261C (90.0 mg, 172 μ mol, 11.4% yield) as a yellow solid. LCMS $[M+1]^+ = 509.2$.

[00426] The first eluting mixture of the methyl esters of 261A and 261D (100 mg, 173 μ mol, 11.5% yield) was separated by SFC (column: DAICEL CHIRALPAK IC(250mm $\times$ 30mm,10 μ m); mobile phase: phase A: CO₂, phase B: i-PrOH (0.1%NH₃H₂O); B%: 55%, isocratic elution). The desired fractions were collected and concentrated under reduce pressure to give the methyl ester of 261A (25.0 mg, 49.1 μ mol, 3.26% yield) as a white solid and the methyl ester of 261B (43.0 mg, 82.0 μ mol, 5.43% yield) as a yellow solid.

[00427] Methyl ester of 261A: LCMS $[M+Na]^+ = 531.2$.

[00428] Methyl ester of 261D: LCMS $[M+Na]^+ = 531.2$.

[00429] The second eluting mixture of the methyl esters of 261B and 261C (90.0 mg, 172 μ mol, 11.4% yield) was separated by SFC (column: DAICEL CHIRALPAK IC (250mm $\times$ 30mm,10 μ m); mobile phase: phase A: CO₂, phase B: i-PrOH (0.1%NH₃H₂O); B%: 55%, isocratic elution). The desired fractions were collected and concentrated under reduce pressure to give the methyl ester of 261B (22.0 mg, 43.2 μ mol, 2.87% yield) as a white solid and the methyl ester of 261C (45.0 mg, 88.4 μ mol, 5.86% yield) as a white solid.

[00430] Methyl ester of 261B: LCMS $[M+Na]^+ = 531.2$.

[00431] Methyl ester of 261C: LCMS $[M+Na]^+ = 531.2$.

[00432] To a solution of methyl ester of 261A (24.0 mg, 47.1 μ mol, 1.00 *eq.*) in DMSO (0.500 mL) was added lithium chloride (20.0 mg, 472 μ mol, 9.67 μ L, 10.0 *eq.*). The reaction was stirred at 130 °C for 4 hours. After completion of the reaction, the mixture was cooled to 20 °C. Then the mixture was filtered and the filtrate was purified directly by *prep*-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 55%-85% B) to give 261A (11.3 mg, 22.6 μ mol, 48.0% yield) as a yellow solid.

[00433] ¹H NMR (400 MHz, DMSO-*d*₆) δ = 12.99 (s, 1H), 8.47 (br d, *J* = 6.4 Hz, 1H), 7.79 - 7.50 (m, 2H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 9.2 Hz, 1H), 5.46 (t, *J* = 6.8 Hz, 1H), 4.64-4.41 (m, 1H), 4.33 (br d, *J* = 12.8 Hz, 2H), 3.53 (br t, *J* = 6.4 Hz, 1H), 3.08 (br t, *J* = 11.6 Hz, 1H), 2.96 - 2.83 (m, 1H), 2.41 (s, 3H), 1.98 (br d, *J* = 10.0 Hz, 1H), 1.90 - 1.77 (m, 1H), 1.70 - 1.54 (m, 5H), 1.41 - 1.27 (m, 1H), 1.12 (d, *J* = 6.4 Hz, 3H).

[00434] LCMS $[M+Na]^+ = 517.4$.

[00435] To a solution of the methyl ester of 261B (22.0 mg, 43.2 μ mol, 1.00 eq.) in DMSO (0.500 mL) was added lithium chloride (18.3 mg, 432 μ mol, 8.86 μ L, 10.0 eq.). The reaction was stirred at 130 °C for 4 hours. After completion of the reaction, the mixture was cooled to 20 °C. Then the mixture was filtered and the filtrate was purified directly by *prep*-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 58% - 88% B) to 261B (13.5 mg, 83.0 μ mol, 61.4% yield) as a yellow solid.

[00436] ^1H NMR (400 MHz, DMSO- d_6) δ = 13.00 (br s, 1H), 8.46 (br d, J = 7.2 Hz, 1H), 7.64 (d, J = 6.0 Hz, 2H), 7.29 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 5.50 (br t, J = 6.8 Hz, 1H), 4.52 (br d, J = 11.6 Hz, 2H), 4.27 (br d, J = 12.0 Hz, 1H), 3.54 - 3.43 (m, 1H), 3.12 (br t, J = 11.6 Hz, 1H), 2.99 (dd, J = 10.4, 13.2 Hz, 1H), 2.41 (s, 3H), 1.88 - 1.73 (m, 2H), 1.71 - 1.55 (m, 5H), 1.42 - 1.29 (m, 1H), 1.10 (d, J = 6.4 Hz, 3H).

[00437] LCMS $[M+Na]^+ = 517.4$.

[00438] To a solution of the methyl ester of 261C (45.0 mg, 88.4 μ mol, 1.00 eq.) in DMSO (0.500 mL) was added lithium chloride (37.5 mg, 884 μ mol, 18.1 μ L, 10.0 eq.). The reaction was stirred at 130 °C for 4 hours. After completion of the reaction, the mixture was cooled to 20 °C. Then the mixture was filtered and the filtrate was purified directly by *prep*-HPLC (column: C18 150 $\times$ 30mm; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 62%-92% B) to 261C (12.6 mg, 25.3 μ mol, 28.6% yield) as a yellow solid.

[00439] ^1H NMR (400 MHz, DMSO- d_6) δ = 13.01 (br s, 1H), 8.45 (d, J = 7.2 Hz, 1H), 7.67 - 7.58 (m, 2H), 7.29 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 9.2 Hz, 1H), 5.50 (quin, J = 6.8 Hz, 1H), 4.52 (br d, J = 12.4 Hz, 2H), 4.26 (br d, J = 13.2 Hz, 1H), 3.48 (br t, J = 6.4 Hz, 1H), 3.19 - 3.11 (m, 1H), 2.98 (dd, J = 10.4, 13.2 Hz, 1H), 2.41 (s, 3H), 1.87 - 1.71 (m, 2H), 1.69 - 1.57 (m, 5H), 1.43 - 1.30 (m, 1H), 1.11 (d, J = 6.4 Hz, 3H).

[00440] LCMS $[M+Na]^+ = 517.4$.

[00441] To a solution of methyl 6-chloro-3-(((*R*)-1-(2-cyano-3-(((*R*)-3-(((*R*)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate (35.0 mg, 68.8 μ mol, 1.00 eq.) in DMSO (0.500 mL) was added lithium chloride (29.2 mg, 688 μ mol, 14.1 μ L, 10.0 eq.). The reaction was stirred at 130 °C for 4 hours. After completion of the reaction, the mixture was cooled to 20 °C. Then the mixture was filtered and the filtrate was purified directly by *prep*-HPLC (column: Phenomenex luna C18 150 $\times$ 25mm $\times$ 10 μ m; mobile phase: phase A: 0.225 % formic acid in water, phase B: acetonitrile; gradient: 58%-88% B) to give 261D (8.73 mg, 17.5 μ mol, 25.4% yield) as a yellow solid.

[00442] ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ = 13.04 (s, 1H), 8.49 (br d, J = 6.4 Hz, 1H), 7.71 - 7.60 (m, 2H), 7.30 (d, J = 8.8 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 5.47 (t, J = 6.8 Hz, 1H), 4.61 - 4.45 (m, 1H), 4.41 - 4.26 (m, 2H), 3.54 - 3.47 (m, 1H), 3.11 - 3.01 (m, 1H), 2.93 (dd, J = 11.6, 12.8 Hz, 1H), 2.41 (s, 3H), 2.03 - 1.95 (m, 1H), 1.89 - 1.78 (m, 1H), 1.70 - 1.55 (m, 5H), 1.40 - 1.21 (m, 1H), 1.10 (d, J = 6.4 Hz, 3H).

[00443] LCMS $[\text{M}+\text{Na}]^+ = 517.4$.

[00444] Examples 262-572

[00445] The compounds in Table 2 are prepared essentially according to the procedures set forth in the above schemes and examples.

Table 2

Example No.	Name	Structure
262	(R)-2-((1-(3-(4-(bicyclo[1.1.1]pentan-1-yl-3-d)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
263	(R)-2-((1-(2-cyano-3-((3-cyanophenyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
264	2-(((1R)-1-(2-cyano-7-methyl-3-(((tetrahydrofuran-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	

265	(R)-2-((1-(2-cyano-7-methyl-3-((oxetan-3-ylmethyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
266	(R)-2-((1-(2-cyano-3-((2-cyanoallyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
267	(R)-2-((1-(2-cyano-3-(cyclobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
268	(R)-2-((1-(2-cyano-3-((3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
269	(R)-2-((1-(2-cyano-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

270	(R)-2-((1-(2-cyano-3-(2,3-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
271	(R)-2-((1-(2-cyano-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
272	(R)-2-((1-(2-cyano-3-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
273	(R)-2-((1-(2-cyano-7-methyl-3-(piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
274	(R)-2-((1-(2-cyano-7-methyl-3-(4-methylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	






275	(R)-2-((1-(3-(azepan-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
276	(R)-2-((1-(2-cyano-7-methyl-3-(2-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
277	(R)-2-((1-(2-cyano-7-methyl-3-(2-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
278	(R)-2-((1-(2-cyano-7-methyl-3-(6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
279	(R)-2-((1-(3-(azetidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

280	2-(((1R)-1-(2-cyano-3-(2-hydroxy-8-azaspiro[4.5]decan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
281	(R)-2-((1-(2-cyano-7-methyl-3-(4-methylpiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
282	2-(((1R)-1-(2-cyano-7-methyl-3-(octahydro-2H-4,7-ethanoisoindol-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
283	2-(((1R)-1-(2-cyano-3-(6,6-dimethyl-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
284	(R)-2-((1-(2-cyano-7-methyl-3-(2-azaspiro[3.3]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

285	(R)-2-((1-(2-cyano-3-(2-azadispiro[3.1.36.14]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
286	(R)-2-((1-(2-cyano-7-methyl-3-(4-oxa-7-azaspiro[2.5]octan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
287	2-(((1R)-1-(2-cyano-7-methyl-3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
288	2-(((1R)-1-(2-cyano-3-(2-cyclopropylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
289	2-(((1R)-1-(2-cyano-3-(2-cyclopropyl-6-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

290	2-(((1R)-1-(3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
291	(R)-2-((1-(3-(3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
292	2-(((1R)-1-(3-(3-azabicyclo[3.1.0]hexan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
293	(R)-2-((1-(2-cyano-3-(6-(4-cyanophenyl)-2,6-diazaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
294	2-(((1R)-1-(2-cyano-7-methyl-3-(2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)benzoic acid	

295	2-(((1R)-1-(2-cyano-3-(2-cyclopropyl-2-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
296	2-(((1R)-1-(3-(3,6-diazabicyclo[3.1.1]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
297	(R)-2-((1-(3-(7-azabicyclo[2.2.1]heptan-7-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
298	(R)-2-((1-(3-(2-azaadamantan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
299	(R)-2-((1-(2-cyano-3-(1-(methoxymethyl)-4-methyl-2-azabicyclo[2.1.1]hexan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

300	2-(((1R)-1-(2-cyano-3-(8-((dimethylamino)methyl)-6-oxa-9-azaspiro[4.5]decan-9-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
301	(R)-2-((1-(3-(2-azabicyclo[2.2.2]octan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
302	2-(((1R)-1-(3-(2-azabicyclo[2.2.1]heptan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
303	2-(((1R)-1-(2-cyano-3-(hexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
304	2-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)-6-azabicyclo[3.2.1]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

305	(R)-2-((1-(3-(2-azabicyclo[2.1.1]hexan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
306	2-(((1R)-1-(2-cyano-7-methyl-3-(3-methylmorpholino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
307	2-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-(pyridin-3-ylmethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
308	2-(((1R)-1-(2-cyano-7-methyl-3-(2-methylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
309	2-(((1R)-1-(2-cyano-3-(2,3-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

310	2-(((1R)-1-(2-cyano-3-(3-hydroxy-2-(2-methoxyphenyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
311	(R)-2-((1-(2-cyano-3-(3,4-dihydroquinolin-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
312	2-(((1R)-1-(2-cyano-3-(3-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
313	2-(((1R)-1-(2-cyano-3-(3-hydroxy-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
314	2-(((1R)-1-(2-cyano-3-(2-(4-hydroxy-4-methyltetrahydro-2H-pyran-3-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

315	2-(((1R)-1-(2-cyano-3-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
316	2-(((1R)-1-(2-cyano-3-(5-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
317	2-(((1R)-1-(2-cyano-3-(6-hydroxyhexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
318	2-(((1R)-1-(2-cyano-3-(6-(4-cyanophenyl)-3,8-diazabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
319	2-(((1R)-1-(2-cyano-3-(6-hydroxy-6-methyl-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

320	2-(((1R)-1-(2-cyano-3-(5-(4-cyanophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
321	2-(((1R)-1-(2-cyano-7-methyl-3-(5-phenyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
322	2-(((1R)-1-(3-(7-(tert-butyl)-6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
323	(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
324	(R)-2-((1-(2-cyano-7-methyl-3-(5,6,8,9-tetrahydro-7H-imidazo[1,2-d][1,4]diazepin-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

325	(R)-2-((1-(2-cyano-7-methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
326	(R)-2-((1-(2-cyano-7-methyl-3-(4-(pyridin-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
327	(R)-2-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
328	(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
329	(R)-2-((1-(2-cyano-7-methyl-3-(4-(pyridin-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

330	(R)-2-((1-(2-cyano-7-methyl-3-(4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
331	(R)-2-((1-(3-(4-(4-(aminomethyl)phenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
332	(R)-2-((1-(2-cyano-7-methyl-3-(4-(3-methylisoxazol-5-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
333	(R)-2-((1-(2-cyano-3-(4-(3-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
334	(R)-2-((1-(2-cyano-3-(4-(2,6-dimethylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

335	(R)-2-((1-(2-cyano-7-methyl-3-(4-(o-tolyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
336	(R)-2-((1-(2-cyano-3-(4-(3-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
337	(R)-2-((1-(2-cyano-3-(4-(2-cyanopyridin-3-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
338	(R)-2-((1-(2-cyano-3-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
339	(R)-2-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-indazol-7-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

340	(R)-2-((1-(2-cyano-3-(4-(2-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
341	(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-(methylcarbamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
342	(R)-2-((1-(3-(4-(4-carbamoylphenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
343	(R)-2-((1-(2-cyano-3-(4-(4-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
344	(R)-2-((1-(2-cyano-3-(4-(4-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

345	(R)-2-((1-(2-cyano-3-(4-(8-cyanoisoquinolin-5-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
346	(R)-2-((1-(2-cyano-3-(4-(4-cyano-7-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
347	(R)-2-((1-(2-cyano-3-(4-(4-cyano-6-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
348	(R)-2-((1-(2-cyano-3-(4-(4,6-dicyanonaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
349	(R)-2-((1-(2-cyano-7-methyl-3-(4-(oxetan-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

350	(R)-2-((1-(2-cyano-7-methyl-3-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
351	(R)-2-((1-(2-cyano-3-(4-cyclopropylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
352	(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
353	(R)-2-((1-(3-(4-benzoylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
354	(R)-2-((1-(2-cyano-3-(4-(cyclopentanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

355	(R)-2-((1-(2-cyano-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
356	(R)-2-((1-(3-(4-acetyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
357	(R)-2-((1-(3-(4-(1H-pyrazol-1-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
358	(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
359	(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-3-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

360	(R)-2-((1-(3-(4-(1H-pyrazol-3-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
361	(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
362	(R)-2-((1-(2-cyano-3-(4-(4-methoxyphenyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
363	(R)-2-((1-(2-cyano-3-(4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
364	(R)-2-((1-(2-cyano-3-(4-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

365	(R)-2-((1-(3-([1,4'-bipiperidin]-1'-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
366	(R)-2-((1-(2-cyano-3-(4-(dimethylamino)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
367	(R)-2-((1-(2-cyano-3-(4-cyclopentylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
368	(R)-2-((1-(2-cyano-3-(4-cyclobutylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
369	(R)-2-((1-(2-cyano-3-(4-cyanopiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

370	(R)-2-((1-(2-cyano-7-methyl-3-(1-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
371	(R)-2-((1-(2-cyano-7-methyl-3-(1-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
372	(R)-2-((1-(2-cyano-3-(4-methoxy-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
373	(R)-2-((1-(2-cyano-3-(4-cyano-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
374	2-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

375	2-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-4-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
376	2-(((1R)-1-(2-cyano-7-methyl-3-(3-phenylpyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
377	2-(((1R)-1-(2-cyano-3-(3-(1,3-dihydroxypropan-2-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
378	2-(((1R)-1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
379	2-(((1R)-1-(2-cyano-7-methyl-3-(2-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	





380	2-(((1R)-1-(2-cyano-7-methyl-3-(spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
381	2-(((1R)-1-(2-cyano-3-(8,9-dihydroxy-6-oxa-2-azaspiro[4.5]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
382	2-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-3-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
383	2-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
384	2-(((1R)-1-(2-cyano-3-(4-(3-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	






385	2-(((1R)-1-(2-cyano-3-(4-(2-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
386	2-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
387	2-(((1R)-1-(2-cyano-3-(4-(2-cyano-5-methylphenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
388	2-(((1R)-1-(2-cyano-3-(6-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
389	2-(((1R)-1-(2-cyano-7-methyl-3-(1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

390	(R)-2-((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
391	(R)-2-((1-(2-cyano-3-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
392	(R)-2-((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
393	(R)-2-((1-(2-cyano-3-(4-cyanoisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
394	(R)-2-((1-(2-cyano-3-(5-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

395	(R)-2-((1-(2-cyano-7-methyl-3-(5-methylisoindolin-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
396	(R)-2-((1-(2-cyano-3-(5,6-dimethoxyisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
397	2-(((1R)-1-(2-cyano-7-methyl-3-(tetrahydro-1H,3H-spiro[pyrrolo[2,1-c][1,4]oxazine-4,5'-[1,3]oxazinan]-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
398	2-(((1R)-1-(2-cyano-3-(decahydro-2H-cycloocta[c]pyrrol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
399	2-(((1R)-1-(2-cyano-7-methyl-3-(8-azatricyclo[4.3.0.02,5]nonan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

400	(R)-2-((1-(3-(1H,3H,4H-3a,6a-(methanooxymethano)furo[3,4-c]pyrrol-5(6H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
401	2-(((1R)-1-(2-cyano-3-(8-hydroxy-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
402	(R)-2-((1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
403	(R)-2-((1-(2-cyano-7-methyl-3-(3-(pyridin-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
404	(R)-2-((1-(2-cyano-7-methyl-3-(3-phenylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	






405	(R)-2-((1-(2-cyano-3-(3-methoxyazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
406	(R)-2-((1-(2-cyano-3-(3-cyanoazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
407	(R)-2-((1-(2-cyano-3-(7-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
408	2-(((1R)-1-(2-cyano-3-(8-hydroxyoctahydro-2H-4,7-methanoisoindol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

409	2-(((1R)-1-(2-cyano-7-methyl-3-(5-methyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
410	2-(((1R)-1-(2-cyano-7-methyl-3-(1'-methyltetrahydrospiro[furo[3,4-b]pyrrole-3,4'-piperidin]-1(2H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
411	2-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
412	2-(((1R)-1-(2-cyano-3-(3-hydroxyoctahydro-1H-indol-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
413	2-(((1R)-1-(2-cyano-7-methyl-3-(1-methyloctahydro-2H-isoindol-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	






414	(R)-2-((1-(2-cyano-7-methyl-3-(methyl((5,6,8,9-tetrahydro-[1,2,4]triazolo[4,3-d][1,4]oxazepin-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
415	2-(((1R)-1-(2-cyano-7-methyl-3-(methyl((5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
416	(R)-2-((1-(2-cyano-3-((cyclopropylmethyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
417	2-(((1R)-1-(2-cyano-3-(((1-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
418	(R)-2-((1-(2-cyano-3-(dimethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

419	2-(((1R)-1-(2-cyano-7-methyl-3-(methyl(1-methyl-2,3-dihydro-1H-inden-2-yl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
420	2-(((1R)-1-(2-cyano-3-((2-methoxy-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
421	2-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
422	2-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
423	(R)-2-((1-(2-cyano-7-methyl-3-(tetrahydro-2H-pyran-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

424	(R)-2-((1-(2-cyano-7-methyl-3-(piperidin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
425	(R)-2-((1-(2-cyano-7-methyl-3-(1-methylpiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
426	(R)-2-((1-(2-cyano-3-(3,6-dihydro-2H-pyran-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
427	(R)-2-((1-(2-cyano-7-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
428	(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

429	(R)-2-((1-(2-cyano-3,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid	
430	(R)-2-((1-(2-cyano-3-(1-(4-cyanophenyl)piperidin-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
431	(R)-2-((1-(3-(1-acetylpiperidin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
432	(R)-2-((1-(3-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
433	(R)-2-((1-(2-cyano-3-((4-cyanophenyl)ethynyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

434	(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
435	(R)-2-((1-(2-cyano-7-methyl-3-(pyridin-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
436	(R)-2-((1-(2-cyano-7-methyl-3-(pyridin-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
437	(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
438	(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1H-imidazol-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

439	(R)-2-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-pyrazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
440	(R)-2-((1-(2-cyano-7-methyl-3-(pyridin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
441	(R)-2-((1-(2-cyano-7-methyl-3-phenylquinoxalin-5-yl)ethyl)amino)benzoic acid	
442	(R)-2-((1-(2-cyano-7-methyl-3-(p-tolyl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
443	(R)-2-((1-(2-cyano-3-(3-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

444	(R)-2-((1-(2-cyano-3-(3-(2-cyanopropan-2-yl)phenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
445	(R)-2-((1-(2-cyano-3-(3-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
446	(R)-2-((1-(2-cyano-7-methyl-3-(1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
447	(R)-2-((1-(2-cyano-3-(1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
448	(R)-2-((1-(2-cyano-7-methyl-3-(o-tolyl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

449	(R)-2-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
450	(R)-2-((1-(2-cyano-3-(2-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
451	(R)-2-((1-(2-cyano-3-(2-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
452	(R)-2-((1-(2-cyano-3-(4-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
453	(R)-2-((1-(2-cyano-3-(4-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

454	2-(((1R)-1-(2-cyano-7-methyl-3-(1-methyl-2-oxopiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
455	(R)-2-((1-(2-cyano-3-(4,4-difluorocyclohexyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
456	(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
457	(R)-2-((1-(2-cyano-3-(4-fluorophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
458	(R)-2-((1-(3-(4-chlorophenyl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

459	2-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)thio)quinoxalin-5-yl)ethyl)amino)benzoic acid	
460	(R)-2-((1-(2-cyano-7-methyl-3-((trifluoromethyl)sulfonyl)oxy)quinoxalin-5-yl)ethyl)amino)benzoic acid	
461	(R)-2-((1-(2-cyano-3-(((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
462	(R)-2-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
463	(R)-2-((1-(2-cyano-3-(((3,3-difluorocyclobutyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

464	2-(((1R)-1-(2-cyano-3-(((2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
465	2-(((1R)-1-(2-cyano-3-((1-cyclopropyl-2,2,2-trifluoroethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
466	(R)-2-(((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
467	(R)-2-(((1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
468	(R)-2-(((1-(2-cyano-7-methyl-3-(4H-thieno[3,4-c]pyrrol-5(6H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

469	(R)-2-((1-(2-cyano-3-(4-(2,2-difluoroethyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
470	(R)-2-((1-(2-cyano-7-methyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
471	(R)-2-((1-(2-cyano-3-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
472	2-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
473	2-(((1R)-1-(2-cyano-3-(2-(2-fluoroethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

474	2-(((1R)-1-(2-cyano-3-(5,5-difluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
475	(R)-2-(((1-(2-cyano-3-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
476	(R)-2-(((1-(2-cyano-3-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
477	2-(((1R)-1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)morpholino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
478	2-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

479	2-(((1R)-1-(2-cyano-3-(5-(2,2-difluoroethyl)-2,5-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
480	(R)-2-((1-(2-cyano-3-(4-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
481	(R)-2-((1-(2-cyano-7-methyl-3-(1-oxoisoindolin-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
482	(R)-2-((1-(2-cyano-3-(5,6-difluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
483	(R)-2-((1-(2-cyano-7-methyl-3-(4-methyl-3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

484	(R)-2-(((1-(2-cyano-7-methyl-3-(3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
485	2-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
486	2-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
487	(R)-2-(((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
488	2-(((1R)-1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

489	(R)-2-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
490	2-(((1R)-1-(2-cyano-3-(4,4-difluoro-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
491	2-(((1R)-1-(2-cyano-7-methyl-3-(3,4,4-trifluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
492	2-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
493	2-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-oxa-7-azabicyclo[3.3.1]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

494	2-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
495	2-(((1R)-1-(2-cyano-3-(9,9-difluoro-1-(hydroxymethyl)-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
496	2-(((1R)-1-(2-cyano-3-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
497	2-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
498	2-(((1R)-1-(2-cyano-7-methyl-3-(7,7,9,9-tetrafluoro-3-azabicyclo[3.3.1]nonan-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

499	2-(((1R)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
500	2-(((1R)-1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
501	2-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
502	2-(((1R)-1-(2-cyano-3-(4,4-difluoro-3,5-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
503	(R)-2-((1-(2-cyano-3-(7,7-difluoro-5-azaspiro[2.4]heptan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

504	2-(((1R)-1-(2-cyano-7-methyl-3-(6-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
505	2-(((1R)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
506	(R)-2-((1-(2-cyano-3-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
507	(R)-2-((1-(2-cyano-7-methyl-3-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
508	(R)-2-((1-(2-cyano-3-(1,1-dioxidothiomorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	






509	(R)-2-((1-(2-cyano-7-methyl-3-(4-(thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
510	(R)-2-((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
511	(R)-2-((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
512	(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-methylthiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
513	(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

514	(R)-2-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
515	(R)-2-((1-(2-cyano-3-(4-(2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
516	(R)-2-((1-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
517	(R)-2-((1-(2-cyano-3-(4-(2,4-difluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
518	(R)-2-((1-(2-cyano-3-(4-(4-cyano-2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

519	(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-(N-methylsulfamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
520	(R)-2-((1-(2-cyano-3-(4-(4-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
521	(R)-2-((1-(2-cyano-7-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
522	(R)-2-((1-(3-(4-(4-chlorobenzoyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
523	(R)-2-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

524	(R)-2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
525	(R)-2-((1-(2-cyano-3-(4,4-difluoro-[1,4'-bipiperidin]-1'-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
526	(R)-2-((1-(2-cyano-7-methyl-3-(4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
527	(R)-2-((1-(2-cyano-3-(1,1-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
528	2-(((1R)-1-(2-cyano-7-methyl-3-(7-methyl-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

529	2-(((1R)-1-(2-cyano-7-methyl-3-(2-oxo-1,7-diazaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
530	2-(((1R)-1-(2-cyano-3-(7,7-difluoro-2-azaspiro[4.4]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
531	2-(((1R)-1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
532	2-(((1R)-1-(2-cyano-3-(4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
533	2-(((1R)-1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	

534	2-(((1R)-1-(2-cyano-3-(4-(2-cyano-4-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
535	2-(((1R)-1-(2-cyano-3-(4-(4-fluorophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
536	2-(((1R)-1-(2-cyano-3-(4,4-difluoro-2-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
537	2-(((1R)-1-(2-cyano-3-(3,3-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
538	(R)-2-((1-(2-cyano-7-methyl-3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	






539	2-(((1R)-1-(2-cyano-3-(3,5-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
540	2-(((1R)-1-(2-cyano-3-(4-fluoro-2-(morpholine-4-carbonyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
541	2-(((1R)-1-(2-cyano-3-(6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
542	(R)-2-((1-(2-cyano-3-(4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
543	(R)-2-((1-(2-cyano-7-methyl-3-(2-methyl-4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	





544	(R)-2-((1-(2-cyano-3-(5-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
545	(R)-2-((1-(2-cyano-3-(5-(difluoromethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
546	(R)-2-((1-(2-cyano-7-methyl-3-(3-(5-(trifluoromethyl)isoxazol-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
547	(R)-2-((1-(2-cyano-3-(3-fluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
548	(R)-2-((1-(2-cyano-3-(3-(difluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

549	(R)-2-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
550	(R)-2-((1-(2-cyano-3-(5,5-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
551	(R)-2-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
552	2-(((1R)-1-(3-(7-chloro-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
553	2-(((1R)-1-(2-cyano-3-(3,3-difluoro-2-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

554	2-(((1R)-1-(3-((1-benzyl-2-oxopiperidin-3-yl)(methyl)amino)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
555	2-(((1R)-1-(2-cyano-7-methyl-3-(methyl(4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
556	(R)-2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
557	2-(((1R)-1-(2-cyano-7-methyl-3-(3-methyl-4-oxo-3,9-diazabicyclo[4.2.1]nonan-9-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid	
558	2-(((1R)-1-(2-cyano-3-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	

559	(R)-2-((1-(3-chloro-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
560	(R)-2-((1-(2-cyano-7-methyl-3-phenoxyquinoxalin-5-yl)ethyl)amino)benzoic acid	
561	(R)-2-((1-(2-cyano-3-(3-cyanophenoxy)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
562	(R)-2-((1-(3-(benzyloxy)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
563	2-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)oxy)quinoxalin-5-yl)ethyl)amino)benzoic acid	

564	(R)-2-((1-(2-cyano-3-methoxy-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
565	(R)-2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
566	(R)-2-((1-(2-cyano-3-(diethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
567	2-(((1R)-1-(2-cyano-7-methyl-3-((1-(pyridin-3-yl)ethyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	
568	2-(((1R)-1-(2-cyano-7-methyl-3-((3,3,3-trifluoro-2-methylpropyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid	





569	2-(((1R)-1-(2-cyano-3-((1-cyclopropylethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
570	(R)-2-((1-(2-cyano-3-(isobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
571	2-(((1R)-1-(2-cyano-3-(3-hydroxy-3-isopropylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	
572	2-(((1R)-1-(2-cyano-3-(1-isopropyl-7,7-dioxido-7-thia-2-azaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid	





[00446] Examples 573-846





[00447] The compounds in Table 3 are prepared essentially according to the procedures set forth in the above schemes and examples.





Table 3





Example No.	Name	Structure
573	(R)-3-((1-(3-(4-(bicyclo[1.1.1]pentan-1-yl-3-d)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
574	(R)-6-chloro-3-((1-(2-cyano-3-((3-cyanophenyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
575	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(((tetrahydrofuran-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
576	(R)-6-chloro-3-((1-(2-cyano-3-(((3,3-difluorocyclobutyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





577	(R)-6-chloro-3-((1-(2-cyano-3-((2-cyanoallyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
578	(R)-6-chloro-3-((1-(2-cyano-3-(cyclobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
579	(R)-6-chloro-3-((1-(2-cyano-3-((3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
580	6-chloro-3-(((1R)-1-(2-cyano-3-((1-cyclopropyl-2,2,2-trifluoroethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





581	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
582	(R)-6-chloro-3-((1-(2-cyano-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
583	(R)-6-chloro-3-((1-(2-cyano-3-(2,3-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
584	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





585	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4H-thieno[3,4-c]pyrrol-5(6H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
586	(R)-6-chloro-3-((1-(2-cyano-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
587	(R)-6-chloro-3-((1-(2-cyano-3-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
588	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





589	(R)-6-chloro-3-((1-(2-cyano-3-(4-(2,2-difluoroethyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
590	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
591	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
592	(R)-3-((1-(3-(azepan-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





593	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
594	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
595	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
596	(R)-3-((1-(3-(azetidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





597	6-chloro-3-(((1R)-1-(2-cyano-3-(2-hydroxy-8-azaspiro[4.5]decan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
598	(R)-6-chloro-3-((1-(2-cyano-3-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
599	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methylpiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
600	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(octahydro-2H-4,7-ethanoisoindol-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





601	6-chloro-3-(((1R)-1-(2-cyano-3-(6,6-dimethyl-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
602	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-azaspiro[3.3]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
603	(R)-6-chloro-3-((1-(2-cyano-3-(2-azadispiro[3.1.36.14]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
604	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





605	6-chloro-3-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
606	6-chloro-3-(((1R)-1-(2-cyano-3-(2-(2-fluoroethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
607	6-chloro-3-(((1R)-1-(2-cyano-3-(5,5-difluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
608	6-chloro-3-(((1R)-1-(2-cyano-3-(2-cyclopropylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





609	6-chloro-3-(((1R)-1-(2-cyano-3-(2-cyclopropyl-6-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
610	(R)-3-((1-(3-(3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
611	3-(((1R)-1-(3-(3-azabicyclo[3.1.0]hexan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
612	(R)-6-chloro-3-((1-(2-cyano-3-(6-(4-cyanophenyl)-2,6-diazaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





613	(R)-6-chloro-3-(((1-(2-cyano-3-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
614	(R)-6-chloro-3-(((1-(2-cyano-3-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
615	6-chloro-3-(((1R)-1-(2-cyano-3-(2-cyclopropyl-2-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
616	3-(((1R)-1-(3-(3,6-diazabicyclo[3.1.1]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





617	(R)-3-((1-(3-(7-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
618	(R)-3-((1-(3-(2-azaadamantan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
619	(R)-6-chloro-3-((1-(2-cyano-3-(1-(methoxymethyl)-4-methyl-2-azabicyclo[2.1.1]hexan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
620	6-chloro-3-(((1R)-1-(2-cyano-3-(8-((dimethylamino)methyl)-6-oxa-9-azaspiro[4.5]decan-9-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





621	6-chloro-3-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
622	(R)-3-((1-(3-(2-azabicyclo[2.2.2]octan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
623	3-(((1R)-1-(3-(2-azabicyclo[2.2.1]heptan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
624	6-chloro-3-(((1R)-1-(2-cyano-3-(hexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





625	6-chloro-3-(((1R)-1-(2-cyano-3-(5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
626	6-chloro-3-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)-6-azabicyclo[3.2.1]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
627	(R)-3-((1-(3-(2-azabicyclo[2.1.1]hexan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
628	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-(pyridin-3-ylmethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





629	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-methylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
630	6-chloro-3-(((1R)-1-(2-cyano-3-(2,3-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
631	(R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(1-oxoisindolin-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
632	(R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(4-methyl-3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





633	(R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
634	6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
635	6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxy-2-(2-methoxyphenyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
636	6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





637	(R)-6-chloro-3-(((1-(2-cyano-3-(3,4-dihydroquinolin-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
638	6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
639	6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxy-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
640	6-chloro-3-(((1R)-1-(2-cyano-3-(2-(4-hydroxy-4-methyltetrahydro-2H-pyran-3-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





641	6-chloro-3-(((1R)-1-(2-cyano-3-(4,4-difluoro-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
642	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3,4,4-trifluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
643	6-chloro-3-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-oxa-7-azabicyclo[3.3.1]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
644	6-chloro-3-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	

645	6-chloro-3-(((1R)-1-(2-cyano-3-(9,9-difluoro-1-(hydroxymethyl)-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
646	6-chloro-3-(((1R)-1-(2-cyano-3-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
647	6-chloro-3-(((1R)-1-(2-cyano-3-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
648	6-chloro-3-(((1R)-1-(2-cyano-3-(5-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





649	6-chloro-3-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
650	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(7,7,9,9-tetrafluoro-3-azabicyclo[3.3.1]nonan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
651	6-chloro-3-(((1R)-1-(2-cyano-3-(6-hydroxyhexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
652	6-chloro-3-(((1R)-1-(2-cyano-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





653	6-chloro-3-(((1R)-1-(2-cyano-3-(6-hydroxy-6-methyl-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
654	6-chloro-3-(((1R)-1-(2-cyano-3-(5-(4-cyanophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
655	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(5-phenyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
656	6-chloro-3-(((1R)-1-(2-cyano-3-(4,4-difluoro-3,5-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





657	3-(((1R)-1-(3-(7-(tert-butyl)-6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
658	(R)-6-chloro-3-(((1-(2-cyano-3-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
659	(R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
660	(R)-6-chloro-3-(((1-(2-cyano-7-methyl-3-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





661	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(5,6,8,9-tetrahydro-7H-imidazo[1,2-d][1,4]diazepin-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
662	(R)-6-chloro-3-((1-(2-cyano-3-(1,1-dioxidothiomorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
663	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
664	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





665	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
666	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-methylthiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
667	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyridin-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
668	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	

669	(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
670	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
671	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyridin-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
672	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





673	(R)-3-((1-(3-(4-(4-(aminomethyl)phenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
674	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
675	(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
676	(R)-6-chloro-3-((1-(2-cyano-3-(4-(2,6-dimethylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





677	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(o-tolyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
678	(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
679	(R)-6-chloro-3-((1-(2-cyano-3-(4-(2-cyanopyridin-3-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
680	(R)-6-chloro-3-((1-(2-cyano-3-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





681	(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-indazol-7-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
682	(R)-6-chloro-3-((1-(2-cyano-3-(4-(2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
683	(R)-6-chloro-3-((1-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
684	(R)-6-chloro-3-((1-(2-cyano-3-(4-(2-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





685	(R)-6-chloro-3-((1-(2-cyano-3-(4-(2,4-difluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
686	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
687	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-(N-methylsulfamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
688	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





689	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-(methylcarbamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
690	(R)-3-((1-(3-(4-(4-carbamoylphenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
691	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
692	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





693	(R)-6-chloro-3-((1-(2-cyano-3-(4-(8-cyanoisoquinolin-5-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
694	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-7-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
695	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-6-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
696	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4,6-dicyanonaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





697	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
698	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(oxetan-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
699	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
700	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyclopropylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





701	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
702	(R)-3-((1-(3-(4-benzoylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
703	(R)-6-chloro-3-((1-(3-(4-(4-chlorobenzoyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
704	(R)-6-chloro-3-((1-(2-cyano-3-(4-(cyclopentanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





705	(R)-6-chloro-3-((1-(2-cyano-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
706	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
707	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-3-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
708	(R)-3-((1-(3-(4-(1H-pyrazol-3-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





709	(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-methoxyphenyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
710	(R)-6-chloro-3-((1-(2-cyano-3-(4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
711	(R)-6-chloro-3-((1-(2-cyano-3-(4-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
712	(R)-3-((1-(3-([1,4'-bipiperidin]-1'-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





713	(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-[1,4'-bipiperidin]-1'-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
714	(R)-6-chloro-3-((1-(2-cyano-3-(4-(dimethylamino)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
715	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyclopentylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
716	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyclobutylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





717	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
718	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyanopiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
719	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
720	(R)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





721	(R)-6-chloro-3-((1-(2-cyano-3-(4-methoxy-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
722	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyano-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
723	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
724	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-4-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





725	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-phenylpyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
726	6-chloro-3-(((1R)-1-(2-cyano-3-(3-(1,3-dihydroxypropan-2-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
727	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
728	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





729	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(7-methyl-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
730	6-chloro-3-(((1R)-1-(2-cyano-3-(8,9-dihydroxy-6-oxa-2-azaspiro[4.5]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	 $C_{26}H_{27}ClN_6O_5$
731	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-oxo-1,7-diazaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
732	6-chloro-3-(((1R)-1-(2-cyano-3-(7,7-difluoro-2-azaspiro[4.4]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





733	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
734	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-3-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
735	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
736	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





737	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(3-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
738	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(2-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
739	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(2-cyano-4-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
740	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(4-fluorophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





741	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
742	6-chloro-3-(((1R)-1-(2-cyano-3-(4-(2-cyano-5-methylphenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
743	6-chloro-3-(((1R)-1-(2-cyano-3-(4,4-difluoro-2-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
744	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	

745	6-chloro-3-(((1R)-1-(2-cyano-3-(6-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
746	6-chloro-3-(((1R)-1-(2-cyano-3-(4-fluoro-2-(morpholine-4-carbonyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
747	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
748	(R)-6-chloro-3-(((1-(2-cyano-3-(4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





749	(R)-6-chloro-3-((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
750	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-methyl-4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
751	(R)-6-chloro-3-((1-(2-cyano-3-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
752	(R)-6-chloro-3-((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




753	(R)-6-chloro-3-((1-(2-cyano-3-(4-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
754	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyanoisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
755	(R)-6-chloro-3-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
756	(R)-6-chloro-3-((1-(2-cyano-3-(5-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





757	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(5-methylisoindolin-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
758	(R)-6-chloro-3-((1-(2-cyano-3-(5-(difluoromethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
759	(R)-6-chloro-3-((1-(2-cyano-3-(5,6-dimethoxyisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
760	(R)-6-chloro-3-((1-(2-cyano-3-(5,6-difluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





761	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(tetrahydro-1H,3H-spiro[pyrrolo[2,1-c][1,4]oxazine-4,5'-[1,3]oxazinan]-3'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
762	6-chloro-3-(((1R)-1-(2-cyano-3-(decahydro-2H-cycloocta[c]pyrrol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
763	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(8-azatricyclo[4.3.0.0 ^{2,5}]nonan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
764	(R)-3-((1-(3-(1H,3H,4H-3a,6a-(methanooxymethano)furo[3,4-c]pyrrol-5(6H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	





765	6-chloro-3-(((1R)-1-(2-cyano-3-(8-hydroxy-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
766	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(5-(trifluoromethyl)isoxazol-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
767	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
768	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(pyridin-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





769	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-phenylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
770	(R)-6-chloro-3-((1-(2-cyano-3-(3-methoxyazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
771	(R)-6-chloro-3-((1-(2-cyano-3-(3-fluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
772	(R)-6-chloro-3-((1-(2-cyano-3-(3-(difluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





773	(R)-6-chloro-3-((1-(2-cyano-3-(3-cyanoazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
774	(R)-6-chloro-3-((1-(2-cyano-3-(7-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
775	6-chloro-3-(((1R)-1-(2-cyano-3-(8-hydroxyoctahydro-2H-4,7-methanoisoindol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





776	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(5-methyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
777	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1'-methyltetrahydrospiro[furo[3,4-b]pyrrole-3,4'-piperidin]-1(2H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
778	6-chloro-3-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
779	6-chloro-3-(((1R)-1-(3-(7-chloro-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





780	6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxyoctahydro-1H-indol-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
781	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-methyloctahydro-2H-isoindol-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
782	6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-2-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
783	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(methyl((5,6,8,9-tetrahydro-[1,2,4]triazolo[4,3-d][1,4]oxazepin-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	

784	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(methyl((5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
785	(R)-6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
786	6-chloro-3-(((1R)-1-(2-cyano-3-(((1-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
787	(R)-6-chloro-3-((1-(2-cyano-3-(dimethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





788	3-(((1R)-1-(3-((1-benzyl-2-oxopiperidin-3-yl)(methyl)amino)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
789	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(methyl(4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
790	(R)-6-chloro-3-((1-(2-cyano-3-((3,3-difluorocyclobutyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
791	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(methyl(1-methyl-2,3-dihydro-1H-inden-2-yl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	





792	6-chloro-3-(((1R)-1-(2-cyano-3-((2-methoxy-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
793	6-chloro-3-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
794	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-methyl-4-oxo-3,9-diazabicyclo[4.2.1]nonan-9-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
795	6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





796	6-chloro-3-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
797	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(piperidin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
798	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methylpiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
799	(R)-6-chloro-3-((1-(2-cyano-3-(3,6-dihydro-2H-pyran-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





800	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
801	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
802	(R)-6-chloro-3-((1-(2-cyano-3,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid	
803	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-methyl-2-oxopiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





804	(R)-6-chloro-3-((1-(2-cyano-3-(1-(4-cyanophenyl)piperidin-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
805	(R)-3-((1-(3-(1-acetyl-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
806	(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluorocyclohexyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
807	(R)-3-((1-(3-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	

808	(R)-6-chloro-3-((1-(2-cyano-3-((4-cyanophenyl)ethynyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
809	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
810	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyridin-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
811	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyridin-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





812	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
813	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1H-imidazol-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
814	(R)-6-chloro-3-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-pyrazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
815	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyridin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	





816	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-phenylquinoxalin-5-yl)ethyl)amino)picolinic acid	
817	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(p-tolyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
818	(R)-6-chloro-3-((1-(2-cyano-3-(3-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
819	(R)-6-chloro-3-((1-(2-cyano-3-(3-(2-cyanopropan-2-yl)phenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	





820	(R)-6-chloro-3-((1-(2-cyano-3-(3-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
821	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	
822	(R)-6-chloro-3-((1-(2-cyano-3-(1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
823	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(o-tolyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	




824	(R)-6-chloro-3-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
825	(R)-6-chloro-3-((1-(2-cyano-3-(2-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
826	(R)-6-chloro-3-((1-(2-cyano-3-(2-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
827	(R)-6-chloro-3-((1-(2-cyano-3-(4-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	

828	(R)-6-chloro-3-((1-(2-cyano-3-(4-fluorophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
829	(R)-6-chloro-3-((1-(3-(4-chlorophenyl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
830	(R)-6-chloro-3-((1-(2-cyano-3-(4-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
831	(R)-6-chloro-3-((1-(3-chloro-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	

832	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)thio)quinoxalin-5-yl)ethyl)amino)picolinic acid	
833	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-phenoxyquinoxalin-5-yl)ethyl)amino)picolinic acid	
834	(R)-6-chloro-3-((1-(2-cyano-3-(3-cyanophenoxy)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
835	(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)quinoxalin-5-yl)ethyl)amino)picolinic acid	

836	(R)-3-((1-(3-(benzyloxy)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid	
837	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)oxy)quinoxalin-5-yl)ethyl)amino)picolinic acid	
838	(R)-6-chloro-3-((1-(2-cyano-3-methoxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
839	(R)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




840	(R)-6-chloro-3-((1-(2-cyano-3-(diethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
841	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((1-(pyridin-3-yl)ethyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
842	6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((3,3,3-trifluoro-2-methylpropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid	
843	6-chloro-3-(((1R)-1-(2-cyano-3-((1-cyclopropylethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




844	(R)-6-chloro-3-((1-(2-cyano-3-(isobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
845	6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxy-3-isopropylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	
846	6-chloro-3-(((1R)-1-(2-cyano-3-(1-isopropyl-7,7-dioxido-7-thia-2-azaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	




[00448] Examples 847-859




[00449] The compounds in Table 4 are prepared essentially according to the procedures set forth in the above schemes and examples.


Table 4

Example No.	Structure and Name	Spectral Data
847	 (<i>R</i>)-6-chloro-3-(((1-(2-cyano-3-(4,4-difluoroazepan-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.59 (s, 2H), 7.18 (d, <i>J</i> = 9.2 Hz, 1H), 6.96 (d, <i>J</i> = 9.2 Hz, 1H), 5.52 (q, <i>J</i> = 6.8 Hz, 1H), 4.09 - 3.99 (m, 4H), 2.55 - 2.45 (m, 2H), 2.43 (s, 3H), 2.25 - 2.10 (m, 4H), 1.70 (d, <i>J</i> = 6.4 Hz, 3H) LCMS [M+23] ⁺ : 523.2.
848	 6-chloro-3-(((<i>R</i>)-1-(2-cyano-7-methyl-3-cis-tetrahydro-1h-thieno[3,4-c]pyrrol-5(3<i>H</i>)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 8.34 (br d, <i>J</i> = 6.4 Hz, 1H), 7.58 (s, 1H), 7.47 (s, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 6.80 (d, <i>J</i> = 8.8 Hz, 1H), 5.44 (quin, <i>J</i> = 6.8 Hz, 1H), 4.30 - 4.16 (m, 2H), 3.87 (ddd, <i>J</i> = 3.6, 11.6, 12.0 Hz, 2H), 3.31 - 3.14 (m, 4H), 2.99 - 2.82 (m, 2H), 2.43 (s, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ : 517.1.
849	 (<i>R</i>)-6-chloro-3-(((1-(2,7-dimethyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.95 (s, 1H), 8.55 (br d, <i>J</i> = 7.2 Hz, 1H), 7.55 (s, 1H), 7.45 (d, <i>J</i> = 1.6 Hz, 1H), 7.31 (d, <i>J</i> = 9.2 Hz, 1H), 7.11 (d, <i>J</i> = 9.2 Hz, 1H), 5.49 (quin, <i>J</i> = 6.8 Hz, 1H), 3.81 (t, <i>J</i> = 4.8 Hz, 4H), 3.44 - 3.32 (m, 4H), 2.65 (s, 3H), 2.41 (s, 3H), 1.67 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+H] ⁺ : 442.3.

850	 (R)-6-chloro-3-((1-(7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO-d ₆) δ = 8.94 (s, 1H), 8.81 (s, 1H), 7.53 (d, <i>J</i> = 0.8 Hz, 1H), 7.41 (d, <i>J</i> = 1.6 Hz, 1H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 6.94 (br d, <i>J</i> = 8.8 Hz, 1H), 5.59 - 5.29 (m, 1H), 3.99 - 3.56 (m, 8H), 2.37 (s, 3H), 1.61 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ : 428.1.
851	 (R)-6-chloro-3-((1-(7-methyl-3-morpholino-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, CDCl ₃) δ = 10.71 (s, 1H), 8.37 (br d, <i>J</i> = 6.0 Hz, 1H), 7.76 (s, 1H), 7.55 (d, <i>J</i> = 1.6 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 6.81 (d, <i>J</i> = 8.8 Hz, 1H), 5.57 (quin, <i>J</i> = 6.8 Hz, 1H), 4.03 - 3.85 (m, 4H), 3.61 - 3.43 (m, 4H), 2.49 (s, 3H), 1.73 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 496.2.
852	 (R)-5-(1-((2-(1H-tetrazol-5-yl)phenyl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.77 - 7.67 (m, 2H), 7.63 (s, 1H), 7.22 - 7.06 (m, 1H), 6.68 (t, <i>J</i> = 7.2 Hz, 1H), 6.55 (d, <i>J</i> = 8.4 Hz, 1H), 5.66 (q, <i>J</i> = 6.8 Hz, 1H), 4.00 - 3.88 (m, 4H), 3.79 (dd, <i>J</i> = 4.0, 5.6 Hz, 4H), 2.42 (s, 3H), 1.76 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 442.2.

853	 (R)-5-(1-((2-cyanophenyl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.73 (d, <i>J</i> = 1.6 Hz, 1H), 7.64 (s, 1H), 7.37 (dd, <i>J</i> = 1.2, 7.6 Hz, 1H), 7.23 (ddd, <i>J</i> = 1.6, 7.2, 8.8 Hz, 1H), 6.68 - 6.55 (m, 2H), 5.51 (q, <i>J</i> = 6.8 Hz, 1H), 4.00 - 3.89 (m, 4H), 3.87 - 3.70 (m, 4H), 2.48 (s, 3H), 1.72 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 421.2.
854	 (R)-5-(1-((6-chloro-2-(1H-tetrazol-5-yl)pyridin-3-yl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.70 (d, <i>J</i> = 1.6 Hz, 1H), 7.66 (s, 1H), 7.14 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 8.8 Hz, 1H), 5.62 (q, <i>J</i> = 6.8 Hz, 1H), 4.02 - 3.87 (m, 4H), 3.84 - 3.71 (m, 4H), 2.44 (s, 3H), 1.82 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+Na] ⁺ = 499.2.
855	 (R)-5-(1-((6-chloro-2-cyanopyridin-3-yl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.73 (d, <i>J</i> = 1.6 Hz, 1H), 7.66 (d, <i>J</i> = 0.8 Hz, 1H), 7.24 (d, <i>J</i> = 9.2 Hz, 1H), 7.09 (d, <i>J</i> = 9.2 Hz, 1H), 5.53 (q, <i>J</i> = 6.8 Hz, 1H), 3.97 - 3.88 (m, 4H), 3.84 - 3.67 (m, 4H), 2.49 (s, 3H), 1.74 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 434.2.

856	 (<i>R</i>)-2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)-<i>N</i>-methylbenzamide	¹ H NMR (400 MHz, CD ₃ OD) δ = 7.70 (d, <i>J</i> = 1.6 Hz, 1H), 7.61 (s, 1H), 7.43 (dd, <i>J</i> = 1.2, 7.6 Hz, 1H), 7.07 - 6.98 (m, 1H), 6.52 (t, <i>J</i> = 7.6 Hz, 1H), 6.37 (d, <i>J</i> = 8.4 Hz, 1H), 5.54 (q, <i>J</i> = 6.4 Hz, 1H), 3.97 - 3.87 (m, 4H), 3.83 - 3.74 (m, 4H), 2.91 (s, 3H), 2.44 (s, 3H), 1.64 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 431.3.
857	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)-<i>N</i>-methylpicolinamide	¹ H NMR (400 MHz, CD ₃ OD) δ = 8.99 (d, <i>J</i> = 6.8 Hz, 1H), 7.66 (d, <i>J</i> = 1.6 Hz, 1H), 7.63 (dd, <i>J</i> = 0.8, 1.6 Hz, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 1H), 6.88 (d, <i>J</i> = 8.8 Hz, 1H), 5.56 - 5.48 (m, 1H), 3.94 - 3.88 (m, 4H), 3.83 - 3.72 (m, 4H), 2.92 (s, 3H), 2.45 (s, 3H), 1.69 (d, <i>J</i> = 6.4 Hz, 3H). LCMS [M+1] ⁺ = 466.2.
858	 (<i>R</i>)-6-chloro-3-((1-(2-cyano-7-methyl-3-(morpholino-<i>d</i>₈)quinoxalin-5-yl)ethyl)amino)picolinic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 9.98 (d, <i>J</i> = 7.2 Hz, 1H), 7.65 (s, 1H), 7.59 (s, 1H), 7.04 (d, <i>J</i> = 8.8 Hz, 1H), 6.72 (d, <i>J</i> = 8.8 Hz, 1H), 5.47 - 5.32 (m, 1H), 2.41 (s, 3H), 1.58 (d, <i>J</i> = 6.8 Hz, 3H). LCMS [M+1] ⁺ = 461.3.

859	 (2S,3S,4S,5R)-6-((6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinoyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid	¹H NMR (400 MHz, CD₃OD) δ = 7.70 (d, J = 10.3 Hz, 2H), 7.27 (d, J = 9.0 Hz, 1H), 7.11 (d, J = 9.1 Hz, 1H), 5.70 (d, J = 8.0 Hz, 1H), 5.58 (q, J = 6.7 Hz, 1H), 4.94 - 4.94 (m, 1H), 4.88 - 4.87 (m, 1H), 3.97 - 3.75 (m, 9H), 3.70 - 3.55 (m, 3H), 3.36 - 3.35 (m, 1H), 2.49 (s, 3H), 1.76 (d, J = 6.8 Hz, 3H). LCMS [M+1]⁺ = 629.3.
-----	---	--

[00450] EXAMPLE A

[00451] This Example illustrates that representative compounds of the invention inhibit the formation of phospho-AKT (pAKT) in a cell.

[00452] The ability of a compound of Formula (I) to inhibit the formation of pAKT was measured using alphaLISA Surefire Ultra AKT 1/2/3 (pS473) Assay Kit (#ALSU-PAKT-B50K) was obtained from Perkin Elmer (Waltham, MA).

[00453] To prepare assay plates for pAKT alphaLISA assays, cells were trypsinized, resuspended in fresh media, and viable cells were counted utilizing trypan blue exclusion. Prior to seeding, cells were washed with PBS and resuspended in HBSS (Gibco, #14025092). T47D (12,000/w), SKBR3 (12,000/w), or MKN1 (24,000/w) cells were seeded at 12 μl per well in a solid white flat bottom 384 cell culture plate (Perkin Elmer #6007680).

[00454] Immediately after seeding, cells were dosed using an Echo Liquid Handler (Beckman Coulter) with compounds at a 10.4 μM starting concentration and serially diluted (1:4) for a total of 10 concentrations. 14 vehicle (DMSO) and 14 positive control (Alpelisib @ 3.125 μM) wells were included on each assay plate. Cells were incubated with the compounds (solubilized in DMSO) for approximately 24 hours at 37 °C. After 24 hours of treatment, cells were lysed with 3 μl of the 5x lysis buffer (provided and incubated at room temperature for 15 min on a microtiter plate shaker). Once cells were sufficiently lysed, 7.5 μl of the acceptor bead mix (made using the manufacturers recommended dilutions) was added to each well and left on the microtiter plate shaker for 1 min prior to incubating plates at room temperature for 1

hour, in the absence of light. After 1 hour of incubation with the acceptor bead mix, 7.5 μ l of the donor bead mix (made using the manufacturers recommended dilutions) was added to each well and left on the microtiter plate shaker for 1 min prior to incubating plates at room temperature overnight in the absence of light. Plates were then imaged the following day using a CLARIOstar microplate reader (BMG Labtech, Germany).

[00455] Percent of control values were calculated by subtracting the average signal from the positive control (alpelisib) treated wells from all treated wells (including DMSO control wells) and then divided by the average signal from the vehicle DMSO treated control wells. Percent of vehicle control values were plotted as log(inhibitor) vs. response – Variable slope (four parameters) for curve fitting and IC₅₀ values were determined using XLfit.

[00456] The results are shown in Tables below. Key: N.D. = not determined

Table A

Inhibition of pAKT in T47D (PI3K α H1047R mutant) cells by
representative compounds of Formula (I)

Example No.	T47D (H1047R) pAKT 24 hr (IC ₅₀)	Example No.	T47D (H1047R) pAKT 24 hr (IC ₅₀)
1	39	143	
2	18.2	144	
3	9.5	145	1.4
4	843.9	146	
5	0.8	147	
6	5	148	
7	0.8	149	
8	7.7	150	
9	7.5	151	
10		152	
11		153	
12		154	
13		155	
14		156	
15		157	
16		158	3.6
17		159	2.6
18		160	4.6
19		161	4.6
20		162	1.6
21	0.5	163	6.8
22	1.9	164	2.1

23	0.7	165	5.6
24	1.3	166	1.2
25	1.2	167	4.6
26	1.8	168	
27	1142	169	
28	48.3	170	
29	117.4	171	
30	4.7	172	
31	561	173	0.3
32	10.2	174	4.4
33	4.3	175	
34	6.2	176	1.7
35	3.1	177	0.5
36	93.7	178	0.5
37	94.6	179	3.9
38		180	1.6
39		181	1.7
40		182A	
41		182B	
42		183	
43		184	
43B	16.8	185A	
43A	4.8	185B	
44	2	186	
45	6.8	187	
46A		188	
46B		189A	
48		189B	
49		190A	4.4
50		190B	17.3
51		191A	
52		191B	
53		192A	
54		192B	
55	21.6	193	
56	4.7	194A	
57	14	194B	
58	1.8	195A	0.47
59		195B	0.37
60		196A	1.2
61	38.6	196B	2.2
62	7.9	197	1.8
63	16.5	198	
64	1.3	199	
65		200	1.2

66		201	0.27
67	72	202	1.4
68	24.4	203	25.1
69	2.1	204	58.1
70	2.6	205	
71		206	
72A		207	
72B		208	
73		209	
74		210A	0.69
75A	52	210B	0.8
75B	39	211A	5.7
76		211B	2.6
77		212A	
78A		212B	
78B		213	0.91
79A		214	
79B		215	1.6
80		216	0.45
81		217	0.69
82	4.5	218	
83		219	
84		220	
85	2	221	0.88
86		222	4.2
87		223	20
88		224	
89		225	
90		226	
91		227	
92A		228	33.2
92		229A	0.55
93		229B	1.2
94		230	
94A		231	1.3
94B		232	
95A		233	0.17
95B		234A	2.8
96A		234B	3.6
96B		235A	2
97A		235B	1.8
97B		236A	0.89
98A		236B	3.6
98B		237A	4.3
99A		237B	6.1

99B		238A	10.4
100		238B	3.5
101		239A	1
102		239B	0.4
103		240	1.6
104		241A	
105		241B	
106		242	0.28
107		243A	0.34
108		243B	0.52
109A		244A	1.2
109B		244B	1.3
110A		245	1.1
110B		246A	0.69
111A		246B	1.8
111B		246C	0.97
112A		246D	6.8
112B		247A	
113	10420	247B	
114	11	248A	
115	1	248B	
116	15	249	1.7
117	66	250	1.2
118		251	1.1
119		252	2.7
120	2.4	253A	5.6
121		253B	5.8
122	1.3	254A	
123	66.8	254B	
124	1.9	255	3.7
125	2.7	256	0.11
126	0.8	257A	4.8
127	8.4	257B	6.7
128	1.4	258	2.99
129	18.8	259	1.5
130		260	1.9
131	2.2	261A	3.2
132	0.9	261B	2.6
133	0.8	261C	2.1
134	10.9	261D	1.2
135	19.2	847	1.8
136	0.7	848	1.7
137	1.3	852	
138	0.8	853	
139	2.1	854	

140		855	
141		856	
142		857	

Table B

Inhibition of pAKT in SKBR3 (PI3K α wild type) cells by
representative compounds of Formula (I)

Example No.	SKBR3 (WT) pAKT IC ₅₀ (nM)
1	>10000

[00457] Example B

[00458] This Example illustrates that representative compounds of the invention decrease the viability of cells.

[00459] The ability of a compound of Formula (I) to decrease the viability of cells was measured using CellTiter-Glo 2.0 (CTG) Luminescent Cell Viability Assay (#G9241) obtained from Promega (Madison, WI).

[00460] To prepare assay plates for viability assays, cells were trypsinized, resuspended in fresh media, and viable cells were counted utilizing trypan blue exclusion. T47D, SKBR3, or MKN1 cells were seeded at 1000 cells in 30 μ l per well in a solid white flat bottom 384 cell culture plate (Perkin Elmer #6007680) and incubated at 37 °C overnight.

[00461] Assay day 1, cells were dosed using an Echo Liquid Handler (Beckman Coulter) with compounds at a 10 μ M starting concentration and serially diluted (1:4) for a total of 10 concentrations. Cells were incubated for approximately 72 hours with the compounds (solubilized in DMSO) at 37 °C. After 72 hours of treatment, cell plates were equilibrated to room temperature before adding 15 μ l of CTG to each well, plates were then covered in aluminum foil to protect from light, incubated at room temperature for 30 minutes on a microtiter plate shaker, and luminescence readings were collected using a CLARIOstar microplate reader (BMG Labtech, Germany). Percent of vehicle control values were plotted as log(inhibitor) vs. response – Variable slope (four parameters) for curve fitting and IC₅₀ values were determined using XLfit.

Table C

Viability in T47D (PI3Kα H1047R mutant) cells by
representative compounds of Formula (I)

Example No.	T47D (H1047R mutant) Viability IC ₅₀ (nM)	Example No.	T47D (H1047R mutant) Viability IC ₅₀ (nM)
1	456.4	143	
2	631.4	144	
3	170.4	145	90
4	9328	146	
5	37.3	147	
6	294.2	148	
7	59.8	149	
8	34.1	150	
9	65.1	151	
10	71.6	152	
11	64	153	
12	159.9	154	
13		155	
14		156	
15	119.5	157	
16		158	88.1
17		159	70.3
18		160	85.8
19		161	47.6
20		162	35
21	32.1	163	190.9
22	79.3	164	55
23	61.9	165	97
24	44.2	166	38.6
25	175	167	150
26	51.5	168	45.8
27	10000	169	108.5
28	2142	170	93.3
29	3477	171	177.5
30	183	172	169.8
31	10000	173	26.8
32	264.7	174	36.6
33	91.4	175	344.1
34	48.2	176	34.5
35	166.2	177	19.4

36	1170	178	24.4
37	588	179	77.3
38		180	57.8
39	2681	181	44
40		182A	
41		182B	
42		183	
43		184	
43B	271.1	185A	
43A	99	185B	
44	156.6	186	
45	115.4	187	
46A		188	
46B		189A	
48	95.3	189B	
49		190A	271
50		190B	764
51		191A	
52		191B	
53		192A	
54		192B	
55	422	193	
56	128.3	194A	
57	164.6	194B	
58	24	195A	84.1
59	140.4	195B	100.1
60	21.1	196A	62.1
61	512.6	196B	61.4
62	219.7	197	105.3
63	254.4	198	
64	44	199	
65	455.7	200	17.2
66	78	201	10.5
67	686.6	202	76.4
68	391.4	203	559
69	50.2	204	393
70	31	205	
71	276	206	
72A	297.7	207	
72B	96.3	208	
73		209	
74	95	210A	135.1
75A	701	210B	120.8
75B	720	211A	78
76	324	211B	2.7

77	77	212A	
78A	125.5	212B	
78B	84.4	213	61
79A	251.8	214	
79B	176.5	215	28
80		216	48
81		217	64
82	121	218	
83	60.7	219	
84	343	220	
85		221	147
86	270	222	225
87	88.7	223	1026
88	365	224	
89	63.2	225	
90		226	
91		227	
92A		228	368.2
92		229A	16.6
93		229B	18.6
94		230	
94A		231	25.8
94B		232	
95A		233	84.4
95B		234A	73
96A		234B	85
96B		235A	183
97A		235B	262
97B		236A	52.8
98A		236B	217
98B		237A	137
99A		237B	152
99B		238A	216.4
100		238B	116.7
101		239A	39
102		239B	22
103		240	16
104		241A	
105		241B	
106	98.1	242	35
107	215.6	243A	62
108		243B	50
109A		244A	57
109B		244B	89
110A	297.7	245	63

110B	96.3	246A	35
111A		246B	61
111B		246C	46
112A		246D	158
112B		247A	
113	1169	247B	
114	189.6	248A	
115	31.3	248B	
116	201.5	249	16
117	497.8	250	37
118	382.6	251	11
119	59.9	252	119
120	56.4	253A	197
121	651	253B	113
122	33.8	254A	
123	273	254B	
124	126.2	255	170
125	163	256	310
126	24.8	257A	139
127	296.3	257B	189
128	120.6	258	86
129	330.4	259	75
130	65.6	260	73.8
131		261A	79
132		261B	98
133		261C	78
134		261D	76
135		847	59
136		848	90
137		852	1435
138		853	4337
139		854	52
140		855	1078
141		856	3445
142		857	722

Table D

Viability in SKBR3 (PI3K α wild type) cells by representative
compounds of Formula (I)

Example No.	SKBR3 (WT) Viability IC ₅₀ (nM)	Example No.	SKBR3 (WT) Viability IC ₅₀ (nM)
1	10000	143	
2	10000	144	
3	10000	145	9955
4	10000	146	
5	3967	147	
6	10000	148	
7	10000	149	
8	3617	150	
9	3405	151	
10	10000	152	
11	10000	153	
12	10000	154	
13		155	
14		156	
15	10000	157	
16		158	
17		159	
18		160	
19		161	
20		162	
21	10000	163	
22	5320	164	
23	10000	165	
24	10000	166	
25	10000	167	
26	9802	168	
27	10000	169	
28	10000	170	
29	10000	171	
30	10000	172	
31	10000	173	
32	10000	174	
33	7433	175	
34	10000	176	
35	8287	177	
36	10000	178	

37	10000	179	
38		180	
39	6231	181	
40		182A	
41		182B	
42		183	
43		184	
43B	4032	185A	
43A	10000	185B	
44	10000	186	
45	10000	187	
46A		188	
46B		189A	
48	10000	189B	
49		190A	10000
50		190B	10000
51		191A	
52		191B	
53		192A	
54		192B	
55	10000	193	
56	10000	194A	
57	10000	194B	
58	3502	195A	10000
59	10000	195B	10000
60	10000	196A	10000
61	10000	196B	10000
62	7084	197	10000
63	9806	198	
64	10000	199	
65	10000	200	5468
66	7678	201	7809
67	2774	202	9925
68	10000	203	2225
69	9650	204	1853
70	9650	205	
71	10000	206	
72A	10000	207	
72B	10000	208	
73		209	
74	10000	210A	10000
75A	10000	210B	10000
75B	10000	211A	6902
76	10000	211B	6805
77	8611	212A	


78A	7061	212B	
78B	10000	213	9552
79A	10000	214	
79B	10000	215	10000
80		216	10000
81		217	10000
82	5028	218	
83	10000	219	
84	10000	220	
85		221	10000
86	10000	222	10000
87	9253	223	10000
88	10000	224	
89	10000	225	
90		226	
91		227	
92A		228	10000
92		229A	3080
93		229B	4923
94		230	
94A		231	10000
94B		232	
95A		233	10000
95B		234A	10000
96A		234B	10000
96B		235A	10000
97A		235B	10000
97B		236A	10000
98A		236B	10000
98B		237A	8170
99A		237B	3799
99B		238A	10000
100		238B	10000
101		239A	10000
102		239B	7256
103		240	7986
104		241A	
105		241B	
106	10000	242	8259
107	10000	243A	2861
108		243B	10000
109A		244A	10000
109B		244B	10000
110A	10000	245	5512
110B	10000	246A	10000

111A		246B	4916
111B		246C	3399
112A		246D	6216
112B		247A	
113		247B	
114		248A	
115		248B	
116		249	6652
117		250	4888
118		251	10000
119		252	5265
120		253A	6848
121		253B	5139
122		254A	
123		254B	
124		255	10000
125		256	10000
126		257A	3738
127		257B	10000
128		258	8705
129		259	10000
130		260	
131		261A	10000
132		261B	10000
133		261C	10000
134		261D	10000
135		847	4937
136		848	7679
137		852	10000
138		853	10000
139		854	4380
140		855	6895
141		856	3564
142		857	2014

[00462] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be incorporated within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated herein by reference for all purposes.

What is claimed is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or deuterated form thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1$ - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or 2-carboxy-3,4,5-trihydroxytetrahydro-2H-pyran-6-yl;

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^5 is hydrogen, $-OR^{20}$, $-SR^{20}$, C_1 - C_6 alkyl, halogen, hydroxy, cyano, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy(C_1 - C_6)alkyl, cyano, amino, mono- or di(C_1 - C_3) alkyl amino, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), 3-8 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, phenyl, 3-8 membered heterocyclyl and heteroaryl is optionally independently substituted with 1-3 of halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, oxo, cyano, amino, mono- or di(C_1 - C_3) alkyl amino,

wherein R^{20} is aryl, aryl(C_1 - C_6)alkyl, 5-7 membered heteroaryl or 5-7 membered heteroaryl(C_1 - C_6)alkyl, wherein each aryl and heteroaryl is optionally independently substituted with one to four of C_1 - C_6 alkyl, halogen, hydroxy, cyano,

haloC₁₋₃ alkyl, hydroxy C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, cyano, amino, or mono- or di(C₁₋₃) alkyl amino;

R^{5A} represents NR⁷R⁸, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), phenyl, or 5-6 membered heteroaryl, wherein each C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), phenyl and heteroaryl is optionally independently substituted with 1-3 of halogen, halo(C₁₋₃ alkyl), hydroxy, oxo, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₆ alkanoyl, cyano, amino, or mono- or di(C₁₋₃) alkyl amino;

R⁷ represents H or C₁₋₃ alkyl;

R⁸ represents H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), 3-8 membered heterocyclyl, 3-8 membered heterocyclyl(C₁₋₆) alkyl, phenyl(C₁₋₆)alkyl or 5-6 membered heteroaryl(C₁₋₆)alkyl, wherein each C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₃ alkyl), phenyl, heteroaryl and 3-8 membered heterocyclyl is optionally independently substituted with 1-3 of halogen, halo(C₁₋₃ alkyl), hydroxy, oxo, C₁₋₃ alkyl, C₁₋₃ alkoxy, cyano, amino, mono- or di(C₁₋₃) alkyl amino, amino- or mono- or di(C₁₋₃) alkylaminocarbonyl, -SO₂R¹⁶, -SO₂(NR¹⁶)₂, or -NR¹⁷SO₂R¹⁶ wherein each R¹⁶ is independently C₁₋₆ alkyl and R¹⁷ is C₁₋₆ alkyl; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group or fused ring system and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and wherein each ring Q is optionally substituted, on an aromatic or non-aromatic

portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁₋₆ alkyl optionally substituted with C₁₋₃ alkoxy, (ii) C₁₋₆ alkoxy, (iii) C₃₋₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁₋₃ alkyl, (ix) hydroxy C₁₋₆ alkyl, (x) amino, (xi) mono- or di(C₁₋₆ alkyl) amino where one alkyl is optionally substituted with oxo, (xii) C₁₋₆ alkanoyl optionally substituted with 1 or 2 of C₁₋₃ alkyl, C₁₋₃ alkoxy, C₃₋₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁₋₃ alkyl, hydroxy C₁₋₃ alkyl, amino, mono- or di(C₁₋₆ alkyl) amino, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl, wherein each C₁₋₃ alkyl and C₃₋₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino,

and wherein each cycloalkyl, phenyl and heteroaryl on the alkanoyl is optionally substituted with C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, amino, hydroxy, or cyano, (xii) C₃-C₆ cycloalkyloxy, (xiii) phenyl, (xiv) phenyl(C₁-C₃ alkanoyl), (xv) 5-7 membered heterocyclyl, or (xvi) 5-6 membered heteroaryl, wherein each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, mono- or di(C₁-C₃ alkyl)amino, amino(C₁-C₃) alkyl, mono- or di(C₁-C₃ alkyl)amino(C₁-C₃) alkyl, or amino- or mono- or di(C₁-C₃) alkylaminocarbonyl.

2. A compound according to claim 1, wherein R⁶ and R^{6A} represent hydrogen.
3. A compound according to claim 1, wherein one of R⁶ and R^{6A} represents hydrogen and the other represents C₁-C₆ alkyl.
4. A compound according to claim 1, wherein one of R⁶ and R^{6A} represents hydrogen and the other represents C₁-C₆ alkyl.
5. A compound according to claim 1, wherein R⁶ and R^{6A} independently represent C₁-C₆ alkyl.
6. A compound according to any of claims 1-5, wherein R¹ is H.
7. A compound according to any of claims 1-5, wherein R¹ is CH₃.
8. A compound according to any of claims 1-5, wherein R¹ is H or CH₃.
9. A compound according to any of claims 1-8, wherein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups.
10. A compound according to any of claims 1-8, wherein R² is phenyl or a 5-7 membered heteroaryl, each of which is substituted with 1, 2 or 3 R¹² groups, and at least one R¹² group is -C(O)OR^A.

11. A compound according to any of claims 1-8, wherein R^2 is phenyl, pyridinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl or pyrimidinyl, each of which is optionally substituted with 1-5 R^{12} .
12. A compound according to any of claims 1-8, wherein R^2 is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R^{12} .
13. A compound according to any of claims 1-8, wherein R^2 is phenyl or pyridinyl, each of which is optionally substituted with 1-5 R^{12} , and at least one R^{12} group is $-C(O)OR^A$.
14. A compound according to any of claims 1-10, wherein R^3 is C_1 - C_3 alkyl, wherein the alkyl group is unsubstituted, substituted with 1-5 halo groups, or perfluorinated.
15. A compound according to any of claims 1-10, wherein R^3 is C_1 - C_3 alkyl, wherein the alkyl group is unsubstituted, substituted with 1-5 halo groups, or perfluorinated.
16. A compound according to any of claims 1-10, wherein R^3 is C_1 - C_3 alkyl.
17. A compound according to any of claims 1-10, wherein R^3 is ethyl or R^3 is methyl.
18. A compound according to any of claims 1-17, wherein R^5 is hydrogen, C_1 - C_3 alkyl, halo C_1 - C_3 alkyl, halogen, cyano, C_3 - C_6 cycloalkyl, or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl).
19. A compound according to any of claims 1-17, wherein R^5 is phenyl or 5-6 membered heteroaryl, wherein each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1-3 of halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino.
20. A compound according to any of claims 1-17, wherein R^5 is hydrogen, C_1 - C_3 alkyl, halo C_1 - C_3 alkyl, halogen, cyano, cyclopropyl, or cyclopropyl(C_1 - C_2 alkyl).
21. A compound according to any of claims 1-17, wherein R^5 is methyl, ethyl, cyclopropyl or cyano.
22. A compound according to any of claims 1-17, wherein R^5 is methyl or cyano.

23. A compound according to any of claims 1-17, wherein R⁵ is C₁-C₃ alkyl, halogen, cyano, cyclopropyl, or cyclopropyl(C₁-C₂ alkyl).
24. A compound according to any of claims 1-17, wherein R⁵ is hydrogen, halogen, hydroxy, cyano or amino.
25. A compound according to any of claims 1-17, wherein R⁵ is phenyl or 5-6 membered heteroaryl, where each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1-3 of halogen, hydroxy, C₁-C₂ alkyl, C₁-C₂ alkoxy, cyano, amino, or mono- or di(C₁-C₂) alkylamino.
26. A compound according to any of claims 1-17, wherein R⁵ is phenyl or 5-6 membered heteroaryl, where each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1 or 2 of halogen, hydroxy, C₁-C₂ alkyl, C₁-C₂ alkoxy, cyano, amino, or mono- or di(C₁-C₂) alkylamino.
27. A compound according to any of claims 1-26, wherein R² is optionally substituted phenyl.
28. A compound according to any of claims 1-26, wherein R² is optionally substituted pyridinyl.
29. A compound according to any of claims 1-27, wherein R⁴ is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl or cyano.
30. A compound according to any of claims 1-27, wherein R⁴ is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl or cyano.
31. A compound according to any of claims 1-27, wherein R⁴ is fluoro, chloro, methyl, cyclopropyl or cyano.
32. A compound according to any of claims 1-27, wherein R⁴ is fluoro, methyl or cyano.
33. A compound according to any of claims 1-32, wherein R^{5A} represents C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl);

34. A compound according to claim 1-32, wherein R^{5A} represents NR^7R^8 .
35. A compound according to claim 34, wherein R^7 is hydrogen and R^8 represents hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl).
36. A compound according to claim 34, wherein R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is a 3-7 membered monocyclic heterocyclyl group, and the heterocyclyl group is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.
37. A compound according to claim 34, wherein R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is a 3-7 membered monocyclic heterocyclyl group, and the heterocyclyl group is fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen atoms and the remainder carbons, wherein the fused heterocyclyl group is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_6 alkyl, amino, mono- or di-(C_1 - C_6 alkyl) amino, or phenyl or phenyl(C_1 - C_3 alkanoyl) where each phenyl is optionally substituted with C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C_1 - C_3 alkyl)amino.
38. A compound according to claim 34, wherein R^7 and R^8 together with the nitrogen to which they are attached form a 3-7 membered monocyclic heterocyclyl group, and the heterocyclyl group forms a spirocyclic ring system having up to 10 total ring members with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, wherein the spirocyclic ring system is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl,



cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, or phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di-(C₁-C₃ alkyl)amino.

39. A compound according to claim 34, wherein R⁷ and R⁸ together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, or phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di-(C₁-C₃ alkyl)amino.

40. A compound according to claim 34, wherein R⁷ and R⁸ together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₃ alkyl) amino.

41. A compound according to claim 34, wherein R⁷ and R⁸ together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl group, each of which is optionally substituted with 1-4 R⁹ groups, wherein each R⁹ is independently methyl, ethyl, methoxy, ethoxy, cyano, fluoro, chloro, trifluoromethyl, cyclopropyl, or cyclopropylmethyl.


42. A compound according claim 1, wherein the compound is of formula (II) or (III)




wherein n is 0, 1, 2, 3 or 4; and

m is 0, 1, 2 or 3.

43. A compound according claim 42, wherein the compound is of formula (II-A)



44. A compound according claim 42, wherein the compound is of formula (III-A)



45. A compound according to any one of claims 42 to 44 or a pharmaceutically acceptable salt thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

each R^{12} is independently C_1 - C_4 alkyl; $-OR^A$, $-C(O)OR^A$, $(C_1$ - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and


R^3 is C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl; and

R^4 is H, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, cyano, or halo, wherein each C_1 - C_3 alkyl is optionally substituted with 1-5 halo groups.

46. A compound according to any of claims 42-45 wherein R³ is C₁-C₃ alkyl.
47. A compound according to any of claims 42-45 wherein R³ is methyl.
48. A compound according to any of claims 42-47 wherein R⁴ is H, C₁-C₃ alkyl, C₃-C₄ cycloalkyl or cyano.
49. A compound according to any of claims 42-47 wherein R⁷ is hydrogen and R⁶ represents hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl).
50. A compound according to any of claims 42-47 wherein R^{5A} represents NR⁷R⁸ and R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, and ring Q is a C₁-C₆ heterocyclyl
51. A compound according to any of claims 42-47 wherein R^{5A} represents NR⁷R⁸ and R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, and ring Q is aziridinyl, azetidiny, pyrrolidinyl, piperazinyl, morpholinyl, piperidinyl, or azepanyl, each of which is optionally substituted with 1-2 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, phenyl, 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di(C₁-C₃ alkyl)amino.
52. A compound according to any of claims 42-47 wherein R^{5A} represents NR⁷R⁸ and R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, and ring Q is aziridinyl, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or azepanyl, each of which is optionally substituted with 1, 2, 3 or 4 halogens.
53. A compound according to any of claims 42-47 wherein R^{5A} represents NR⁷R⁸ and R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, and ring Q is a 5-6 membered monocyclic heterocyclyl group fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen atoms and the remainder carbons, and the fused ring system is optionally substituted, on either ring, with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano,

hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino.

54. A compound according to any of claims 42-47 wherein R^{5A} represents NR⁷R⁸ and R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, where ring Q is a group of the formula:



wherein

each ring A is a 3-6 membered carbocyclic ring or 3-6 membered heterocyclic ring,
m is 0, 1, 2, 3, or 4;

n is 0, 1 or 2;

p and r are independently 1 or 2, provided that the sum of p and r is 2 or 3;


each R¹⁰ and R¹¹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, cyano, hydroxy, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, C₃-C₆ cycloalkyl, phenyl or 5-6 membered heteroaryl, where each cycloalkyl, phenyl and heteroaryl is optionally substituted with 1-3 of halogen, hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di-(C₁-C₃) alkyl amino.

55. A compound according to any one of claims 42-47, wherein R⁷ and R⁸ together with the nitrogen to which they are attached form a piperidiny, piperaziny or morpholinyl group, each of which is optionally substituted with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₆ alkyl, amino, mono- or di-(C₁-C₆ alkyl) amino, or phenyl or phenyl(C₁-C₃ alkanoyl) where each phenyl is optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, amino, or mono- or di-(C₁-C₃ alkyl)amino.

56. A compound according to any one of claims 42-47, wherein R⁷ and R⁸ together with the nitrogen to which they are attached form a piperidiny, piperaziny or morpholinyl group, each of which is optionally substituted with 1-4 R⁹ groups, wherein each R⁹ is independently C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₃ alkyl) amino.

57. A compound according to any one of claims 42-47, wherein R^7 and R^8 together with the nitrogen to which they are attached form a piperidiny, piperaziny or morpholiny group, each of which is optionally substituted with 1-4 R^9 groups, wherein each R^9 is independently methyl, ethyl, methoxy, ethoxy, cyano, fluoro, chloro, trifluoromethyl, cyclopropyl, or cyclopropylmethyl.

58. A compound of Formula (IV):



or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, deuterated form, or tautomer thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3$ alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^5 is C_1 - C_2 alkyl, cyclopropyl, bromo, chloro, fluoro, cyano, or trifluoromethyl;

R^{5A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;

R^7 represents H or C_1 - C_3 alkyl;

R⁸ represent H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl) wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl and C₃-C₆ cycloalkyl(C₁-C₃ alkyl) is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is


a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁-C₆ alkyl, (ii) C₁-C₆ alkoxy, (iii) C₃-C₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C₁-C₃ alkyl, (ix) hydroxy C₁-C₆ alkyl, (x) amino, (xi) mono- or di-(C₁-C₆ alkyl) amino, (xii) C₂-C₆ alkanoyl optionally substituted with 1 or 2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo, halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆ alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xiii) C₃-C₆ cycloalkyloxy, or (xiv) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

59. A compound of Formula (IV-A):



(IV-A)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, deuterated form, or tautomer thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3 \text{ alkyl})-OR^A$, $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^{5A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;

R^7 represents H or C_1 - C_3 alkyl;

R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or

R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is


a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1 - C_6 alkyl, (ii) C_1 - C_6 alkoxy, (iii) C_3 - C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halo C_1 - C_3 alkyl, (viii) hydroxy C_1 - C_6 alkyl, (ix) amino, (x) mono- or di- $(C_1$ - C_6 alkyl) amino, (xi) C_2 - C_6 alkanoyl optionally substituted with 1 or 2 of C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_3 alkyl, amino, or mono- or di- $(C_1$ - C_6 alkyl) amino, wherein each C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C_3 - C_6 cycloalkyloxy, or (xiii) phenyl, phenyl(C_1 - C_3 alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C_1 - C_3 alkyl, C_1 - C_3 alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di- $(C_1$ - C_3 alkyl)amino.

60. A compound of Formula (IV-B):



or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, deuterated form, or tautomer thereof, wherein:


R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

- each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1$ - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;
- each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and
- R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;
- R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;
- R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;
- R^{6A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;
- R^7 represents H or C_1 - C_3 alkyl;
- R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or
- R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is
- a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or
- with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and
- wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1 - C_6 alkyl, (ii) C_1 - C_6 alkoxy, (iii) C_3 - C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C_1 - C_3 alkyl, (ix) hydroxy C_1 - C_6 alkyl, (x) amino, (xi) mono- or di(C_1 - C_6 alkyl) amino, (xii) C_2 - C_6 alkanoyl optionally substituted with 1 or 2 of C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_3 alkyl, amino, or mono- or di(C_1 - C_6 alkyl) amino, wherein each C_1 - C_3 alkyl or C_3 - C_6 cycloalkyl on the alkanoyl is

optionally substituted with halogen, hydroxy or amino, or (xii) C₃-C₆ cycloalkyloxy, or (xiii) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

61. A compound of Formula (IV-C):



(IV-C)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, deuterated form, or tautomer thereof, wherein:

R¹ is H, C₁-C₃ alkyl, or C₃-C₆ cycloalkyl;

R² is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R¹²;

each R¹² is independently C₁-C₄ alkyl, -OR^A, -C(O)OR^A, (C₁-C₃ alkyl)-OR^A, -C(O)N(R^A)₂, cyano, or halogen;

each R^A is independently H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl; and

R³ is C₁-C₃ alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl;

R⁴ is H, halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ alkenyl, C₂-C₃ alkynyl, or C₅-C₆ cycloalkenyl or cyano, wherein each C₁-C₃ alkyl and C₃-C₆ cycloalkyl is optionally substituted with 1-5 halo groups;

R⁶ and R^{6A} independently represent H or C₁-C₆ alkyl;

R^{6A} represents NR⁷R⁸, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl or 5-6 membered heteroaryl, wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl(C₁-C₃ alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino;

R⁷ represents H or C₁-C₃ alkyl;

R⁸ represent H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl(C₁-C₃ alkyl) wherein each C₁-C₆ alkyl, C₃-C₆ cycloalkyl and C₃-C₆ cycloalkyl(C₁-C₃ alkyl) is optionally substituted with 1-3 of halogen, halo(C₁-C₃ alkyl), hydroxy, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, amino, or mono- or di(C₁-C₃) alkyl amino; or

R⁷ and R⁸ together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring

members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon

or hetero atoms, forms a spirocyclic ring system having up to 10 total ring

members, wherein the ring members are carbons or 1 or 2 hetero atoms

selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic

portion, with 1-4 R⁹ groups, wherein each R⁹ is independently (i) C₁-C₆ alkyl,

(ii) C₁-C₆ alkoxy, (iii) C₃-C₆ cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii)

halogen, (viii) halo C₁-C₃ alkyl, (ix) hydroxy C₁-C₆ alkyl, (x) amino, (xi) mono-

or di-(C₁-C₆ alkyl) amino, (xii) C₂-C₆ alkanoyl optionally substituted with 1 or

2 of C₁-C₃ alkyl, C₁-C₃ alkoxy, C₃-C₆ cycloalkyl, cyano, hydroxy, oxo,

halogen, halo C₁-C₃ alkyl, hydroxy C₁-C₃ alkyl, amino, or mono- or di-(C₁-C₆

alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is

optionally substituted with halogen, hydroxy or amino, or (xiii) C₃-C₆

cycloalkyloxy, or (xiv) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered


heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7

membered heterocyclyl and 5-6 membered heteroaryl is optionally

substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy,

cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

62. A compound of Formula (IV-D):



(IV-D)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, deuterated form, or tautomer thereof, wherein:

R^1 is H, C_1 - C_3 alkyl, or C_3 - C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1-C_3 \text{ alkyl})-OR^A$, $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^{5A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;

R^7 represents H or C_1 - C_3 alkyl;

R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or

R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is


a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group

is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1-C_6 alkyl, (ii) C_1-C_6 alkoxy, (iii) C_3-C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halo C_1-C_3 alkyl, (viii) hydroxy C_1-C_6 alkyl, (ix) amino, (x) mono- or di- (C_1-C_6) alkyl amino, (xi) C_2-C_6 alkanoyl optionally substituted with 1 or 2 of C_1-C_3 alkyl, C_1-C_3 alkoxy, C_3-C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1-C_3 alkyl, hydroxy C_1-C_3 alkyl, amino, or mono- or di- (C_1-C_6) alkyl amino, wherein each C_1-C_3 alkyl or C_3-C_6 cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C_3-C_6 cycloalkyloxy, or (xiii) phenyl, phenyl(C_1-C_3 alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C_1-C_3 alkyl, C_1-C_3 alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di- (C_1-C_3) alkyl amino.

63. A compound of Formula (IV-E):



(IV-E)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, deuterated form, or tautomer thereof, wherein:

R^1 is H, C_1-C_3 alkyl, or C_3-C_6 cycloalkyl;

R^2 is phenyl or a 5-6 membered heteroaryl group, wherein each phenyl and heteroaryl is optionally substituted with 1-5 R^{12} ;

each R^{12} is independently C_1 - C_4 alkyl, $-OR^A$, $-C(O)OR^A$, $(C_1$ - C_3 alkyl)- OR^A , $-C(O)N(R^A)_2$, cyano, or halogen;

each R^A is independently H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl; and

R^3 is C_1 - C_3 alkyl optionally substituted, polysubstituted or persubstituted with fluoro, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl;

R^4 is H, halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkenyl, C_2 - C_3 alkynyl, or C_5 - C_6 cycloalkenyl or cyano, wherein each C_1 - C_3 alkyl and C_3 - C_6 cycloalkyl is optionally substituted with 1-5 halo groups;

R^H is bromo, chloro or fluoro,

R^6 and R^{6A} independently represent H or C_1 - C_6 alkyl;

R^{6A} represents NR^7R^8 , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl or 5-6 membered heteroaryl, wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl), phenyl and heteroaryl is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino;

R^7 represents H or C_1 - C_3 alkyl;

R^8 represent H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) wherein each C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl and C_3 - C_6 cycloalkyl(C_1 - C_3 alkyl) is optionally substituted with 1-3 of halogen, halo(C_1 - C_3 alkyl), hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyano, amino, or mono- or di(C_1 - C_3) alkyl amino; or

R^7 and R^8 together with the nitrogen to which they are attached form ring Q, wherein ring Q is

a 3-8 membered monocyclic heterocyclyl group, wherein the heterocyclyl group is optionally fused to an aromatic or non-aromatic ring containing 3-6 ring members of which 1 or 2 are optionally nitrogen, oxygen or sulfur atoms and the remainder carbons, or

with a carbon atom from the monocyclic heterocyclyl group and additional carbon or hetero atoms, forms a spirocyclic ring system having up to 10 total ring members, wherein the ring members are carbons or 1 or 2 hetero atoms selected from nitrogen, sulfur and oxygen atoms, and

wherein each ring Q is optionally substituted, on an aromatic or non-aromatic portion, with 1-4 R^9 groups, wherein each R^9 is independently (i) C_1 - C_6 alkyl, (ii) C_1 - C_6 alkoxy, (iii) C_3 - C_6 cycloalkyl, (iv) cyano, (v) hydroxy, (vi) oxo, (vii) halogen, (viii) halo C_1 - C_3 alkyl, (ix) hydroxy C_1 - C_6 alkyl, (x) amino, (xi) mono- or di-(C_1 - C_6 alkyl) amino, (xii) C_2 - C_6 alkanoyl optionally substituted with 1 or 2 of C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_3 - C_6 cycloalkyl, cyano, hydroxy, oxo, halogen, halo C_1 - C_3 alkyl, hydroxy C_1 - C_3 alkyl, amino, or mono- or di-(C_1 - C_6

alkyl) amino, wherein each C₁-C₃ alkyl or C₃-C₆ cycloalkyl on the alkanoyl is optionally substituted with halogen, hydroxy or amino, or (xii) C₃-C₆ cycloalkyloxy, or (xiii) phenyl, phenyl(C₁-C₃ alkanoyl), 5-7 membered heterocyclyl, or 5-6 membered heteroaryl where each phenyl, 5-7 membered heterocyclyl and 5-6 membered heteroaryl is optionally substituted with one to four C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, oxo, amino, or mono- or di(C₁-C₃ alkyl)amino.

64. A compound according to claim 1, which is:

2-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(((2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid;

2-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(5-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-7-fluoro-3-(4-fluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2,7-dicyano-3-(4-fluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methoxyquinoxalin-5-yl)ethyl)amino)benzoic acid;

5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid;

2-chloro-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid;

2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid;

3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-2-carboxylic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(3-(difluoromethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(1-(fluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid ;

2-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

or a pharmaceutically acceptable salt thereof.

65. A compound according to claim 1, which is:

(*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*S*,4*S*)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,4*R*)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,4*S*)-6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*S*,4*R*)-6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(((*S*)-2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(((*R*)-2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid;

(*R*)-2-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(5-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*S*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-fluoroquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*S*)-2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2,7-dicyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*S*)-2-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(7-chloro-2-cyano-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2-cyano-7-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methoxyquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid;

(*R*)-2-chloro-5-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiazole-4-carboxylic acid;

(*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid;

(*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-2-carboxylic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-((1*S*)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*R*)-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*)-1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyclopropyl-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(3-(4,4-difluoropiperidin-1-yl)-7-methyl-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-3-((1-(3-(4,4-difluoropiperidin-1-yl)-2,7-dimethylquinoxalin-5-yl)ethyl)amino)-6-methylpicolinic acid;

(*R*)-2-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-dimethylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3-methoxy-3-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methyl-4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-cyclopropyl-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(3-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-3-(((2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((*R*)-1-(2-cyano-3-(((*S*)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((*R*)-1-(2-cyano-3-(((*R*)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-((3,3-difluorocyclobutyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-3-(4,4-difluoro-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-3-(3,3-difluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1*H*)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(3,4-dihydroisoquinolin-2(1*H*)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1*H*)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(6-cyano-3,4-dihydroisoquinolin-2(1*H*)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(4-(2-((*S*)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(4-(2-((*R*)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-3-(4-(2-(2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-3-(1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-3-((1*R*)-1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-3-((1*S*)-1-hydroxy-6-azaspiro[3.5]nonan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-5-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-5-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*)-3-(1-methyl-1*H*-pyrazol-5-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*)-3-(1-methyl-1*H*-pyrazol-5-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-3-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*)-3-(1-methyl-1*H*-pyrazol-3-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*)-3-(1-methyl-1*H*-pyrazol-3-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-4-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*)-3-(1-methyl-1*H*-pyrazol-4-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*)-3-(1-methyl-1*H*-pyrazol-4-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-3-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(1-methyl-1*H*-pyrazol-4-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(3-(2-oxopiperidin-1-yl))-8-azabicyclo[3.2.1]octan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

or a pharmaceutically acceptable salt thereof.

66. A compound according to claim 1, which is:

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(methylsulfonyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxidothiomorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-((2-methoxyethyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((1*R*)-1-(2-cyano-3-(4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-4,4-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)pyrazine-2-carboxylic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-((3-(dimethylamino)-3-oxopropyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-methylthiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(7,7-difluoro-5-azaspiro[2.4]heptan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(1*H*-imidazol-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((1*R*)-1-(3-(3-oxa-8-azabicyclo[3.2.1]octan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(*R*)-4-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)thiophene-3-carboxylic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((3*S*,4*R*)-3,4-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoro-4,4-dimethylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-((3,3,3-trifluoropropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-((3-(dimethylamino)-3-oxopropyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-3-(3,3-difluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-((2-methoxyethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(6-(trifluoromethyl)pyridin-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-2-((1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-((oxetan-3-ylmethyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(3-(4-(1*H*-pyrazol-1-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(*N*-methylacetamido)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-methyl-1*H*-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-(trifluoromethyl)-1*H*-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-*cis*-tetrahydro-1*H*-furo[3,4-*c*]pyrrol-5(3*H*)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-oxa-7-azaspiro[2.5]octan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*R*)-3-(methylsulfonyl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((3*S*,5*R*)-3,5-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(2,2-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(7-chloro-2-cyano-3-(3,3-difluoropyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3,3-difluoro-5-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3,3-difluoro-5-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-(dimethylcarbamoyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-(dimethylcarbamoyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*,6*R*)-6-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((1*R*,5*S*,6*S*)-6-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(methyl(3,3,3-trifluoropropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-cyanopyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-cyanopyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(7-chloro-2-cyano-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(3-(4-acetylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-oxopiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,5*S*,6*S*)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-fluoro-3-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-fluoro-3-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,5*S*,6*R*)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,5*S*,6*R*)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*R*)-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3,3-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3,3-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((*R*)-1-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

3-(((*R*)-1-(3-((1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-3-(methylsulfonyl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-fluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-fluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((3*S*,4*S*)-3,4-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

methyl 6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-fluoro-3-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate

methyl 6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-fluoro-3-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinate

6-chloro-3-(((*R*)-1-(2-cyano-3-(((*S*)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(((*R*)-2,2-difluoro-1-methylcyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(*N*-methylacetamido)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-7-methyl-3-(tetrahydrofuran-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-tetrahydrofuran-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*R*)-tetrahydrofuran-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-ethylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-ethyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-ethyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-2-ethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-2-ethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-2-(trifluoromethyl)morpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*R*)-2-(trifluoromethyl)morpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-2-(difluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-2-(difluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*S*)-3-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-((*R*)-3-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((1*R*)-1-(3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(4-((*R*)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(4-((*S*)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(4-((*R*)-1-methoxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-(4-((*S*)-1-methoxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

2-(((*R*)-1-(2-cyano-3-(4-(2-((*R*)-2,2-difluorocyclopropyl)acetyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(oxetan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1*H*-imidazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(3-methylisoxazol-5-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-methylisoxazol-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-(trifluoromethoxy)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-chloro-2-cyano-6-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(*R*)-2-cyano-6-((1-(2-cyano-3-(4,4-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

3-(((1*R*)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-3-(((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3,3-difluoro-4-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3,3-difluoro-4-(hydroxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*S*)-3,3-difluoro-4-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3,3-difluoro-4-(methoxymethyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*S*,4*R*)-2,2-difluoro-7-azabicyclo[2.2.1]heptan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,4*S*)-2,2-difluoro-7-azabicyclo[2.2.1]heptan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((1*R*,5*S*,6*S*)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(6-methoxy-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1*R*)-1-(2-cyano-3-(6-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-(((1-(2-cyano-3-(3,4-dihydro-2,6-naphthyridin-2(1*H*))-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-(((1-(2-cyano-3-(7-cyano-3,4-dihydroisoquinolin-2(1*H*))-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3,3-difluoropyrrolidin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((3R,5R)-3,5-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(6-methyl-5-oxo-3,4,5,6-tetrahydro-2,6-naphthyridin-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(7-methyl-8-oxo-3,4,7,8-tetrahydro-2,7-naphthyridin-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-methyl-6-oxopiperidin-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-oxopyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-methyl-4-oxopyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3,3-dimethyl-4-oxopyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2,2-dioxidotetrahydro-1H-thieno[3,4-c]pyrrol-5(3H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((3aS,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((3aR,6aR)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-morpholino-7-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-(difluoromethyl)-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-ethoxy-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(tetrahydro-2H-pyran-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((R)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-2-(hydroxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((R)-2-(hydroxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-2-(methoxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((R)-2-(methoxymethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2R,5R)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2S,5S)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2S,5R)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2R,5S)-2,5-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((R)-1-(3-((1R,6S)-2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

3-(((R)-1-(3-((1S,6R)-2-oxa-5-azabicyclo[4.1.0]heptan-5-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((R)-1-(3-((1R,6S)-3-oxabicyclo[4.1.0]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

3-(((R)-1-(3-((1S,6R)-3-oxabicyclo[4.1.0]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1,4-oxazepan-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((R)-1-(3-((1R,5S)-6-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

3-(((R)-1-(3-((1S,5R)-6-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((1S)-1-fluoro-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((1S)-1-fluoro-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((3S,4S)-3-fluoro-4-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2R,4S)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2S,4R)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2R,4R)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((2S,4S)-4-fluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((1S)-1-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((1R)-1-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((R)-3,3-difluorocyclopentyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-3,3-difluorocyclopentyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(6-oxa-2-azaspiro[3.4]octan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-5-(1-((6-chloro-2-(hydroxymethoxy)pyridin-3-yl)amino)ethyl)-7-methyl-3-(5-oxa-2-azaspiro[3.4]octan-2-yl)quinoxaline-2-carbonitrile

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((S)-1-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((R)-1-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((S)-2-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-((R)-2-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,5-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-5-fluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((R)-5-fluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6-fluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6-hydroxy-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-7-methyl-3-(()-2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)picolinic acid;;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-3-((S)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((S)-3-((R)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((R)-1-(2-cyano-3-((R)-3-((S)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-3-((*R*)-3-((*R*)-1-hydroxyethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoroazepan-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-cis-tetrahydro-1*H*-thieno[3,4-*c*]pyrrol-5(3*H*)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(2,7-dimethyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-6-chloro-3-((1-(7-methyl-3-morpholino-2-(trifluoromethyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(*R*)-5-(1-((2-(1*H*-tetrazol-5-yl)phenyl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile;

(*R*)-5-(1-((2-cyanophenyl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile;

(*R*)-5-(1-((6-chloro-2-(1*H*-tetrazol-5-yl)pyridin-3-yl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile;

(*R*)-5-(1-((6-chloro-2-cyanopyridin-3-yl)amino)ethyl)-7-methyl-3-morpholinoquinoxaline-2-carbonitrile;

(*R*)-2-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)-*N*-methylbenzamide;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)-*N*-methylpicolinamide;

(*R*)-6-chloro-3-((1-(2-cyano-7-methyl-3-(morpholino-*d*8)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(2*S*,3*S*,4*S*,5*R*)-6-((6-chloro-3-(((*R*)-1-(2-cyano-7-methyl-3-morpholinoquinoxalin-5-yl)ethyl)amino)picolinoyl)oxy)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-carboxylic acid; or

a pharmaceutically acceptable salt thereof.

67. A Compound according to claim 1 which is

(*R*)-2-((1-(3-(4-(bicyclo[1.1.1]pentan-1-yl-3-*d*)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-((3-cyanophenyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(((tetrahydrofuran-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-((oxetan-3-ylmethyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-((2-cyanoallyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(cyclobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-((3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(2,3-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-methylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(azepan-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(2-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(2-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(azetidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-hydroxy-8-azaspiro[4.5]decan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-methylpiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(octahydro-2H-4,7-ethanoisindol-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6,6-dimethyl-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(2-azaspiro[3.3]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(2-azadispiro[3.1.36.14]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-oxa-7-azaspiro[2.5]octan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-cyclopropylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-cyclopropyl-6-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-(3-azabicyclo[3.1.0]hexan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(6-(4-cyanophenyl)-2,6-diazaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-methylmorpholino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-cyclopropyl-2-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-(3,6-diazabicyclo[3.1.1]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(7-azabicyclo[2.2.1]heptan-7-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(2-azaadamantan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(1-(methoxymethyl)-4-methyl-2-azabicyclo[2.1.1]hexan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(8-((dimethylamino)methyl)-6-oxa-9-azaspiro[4.5]decan-9-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(3-(2-azabicyclo[2.2.2]octan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-(2-azabicyclo[2.2.1]heptan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(hexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)-6-azabicyclo[3.2.1]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(3-(2-azabicyclo[2.1.1]hexan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3-methylmorpholino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-(pyridin-3-ylmethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-methylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2,3-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-hydroxy-2-(2-methoxyphenyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(3,4-dihydroquinolin-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-hydroxy-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-(4-hydroxy-4-methyltetrahydro-2H-pyran-3-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(5-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6-hydroxyhexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6-hydroxy-6-methyl-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(5-(4-cyanophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(5-phenyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-(7-(tert-butyl)-6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(5,6,8,9-tetrahydro-7H-imidazo[1,2-d][1,4]diazepin-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(pyridin-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(pyridin-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(3-(4-(4-(aminomethyl)phenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(3-methylisoxazol-5-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-(3-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-(2,6-dimethylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(o-tolyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(3-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(2-cyanopyridin-3-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-indazol-7-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(2-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-(methylcarbamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-(4-carbamoylphenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(8-cyanoisoquinolin-5-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-cyano-7-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-cyano-6-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4,6-dicyanonaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(oxetan-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-cyclopropylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-benzoylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(cyclopentanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-acetylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-(1H-pyrazol-1-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-3-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-(1H-pyrazol-3-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-methoxyphenyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-([1,4'-bipiperidin]-1'-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(dimethylamino)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-cyclopentylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-cyclobutylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-cyanopiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(1-oxa-7-azaspiro[3.5]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-methoxy-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-cyano-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-4-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3-phenylpyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-(1,3-dihydroxypropan-2-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-oxa-7-azaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(8,9-dihydroxy-6-oxa-2-azaspiro[4.5]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-3-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(3-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(2-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(2-cyano-5-methylphenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-cyanoisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(5-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(5-methylisoindolin-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(5,6-dimethoxyisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(tetrahydro-1H,3H-spiro[pyrrolo[2,1-c][1,4]oxazine-4,5'-[1,3]oxazinan]-3'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(decahydro-2H-cycloocta[c]pyrrol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(8-azatricyclo[4.3.0.0^{2,5}]nonan-8-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(3-(1H,3H,4H-3a,6a-(methanooxymethano)furo[3,4-c]pyrrol-5(6H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(8-hydroxy-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(3-(pyridin-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(3-phenylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(3-methoxyazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(3-cyanoazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(7-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(8-hydroxyoctahydro-2H-4,7-methanoisoindol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(5-methyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1'-methyltetrahydrospiro[furo[3,4-b]pyrrole-3,4'-piperidin]-1(2H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-hydroxyoctahydro-1H-indol-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1-methyloctahydro-2H-isoindol-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(methyl((5,6,8,9-tetrahydro-[1,2,4]triazolo[4,3-d][1,4]oxazepin-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(methyl((5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-((cyclopropylmethyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(((1-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(dimethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(methyl(1-methyl-2,3-dihydro-1H-inden-2-yl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-((2-methoxy-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(tetrahydro-2H-pyran-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(piperidin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-methylpiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3,6-dihydro-2H-pyran-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3,7-dimethylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(1-(4-cyanophenyl)piperidin-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(1-acetylpiperidin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-((4-cyanophenyl)ethynyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(pyridin-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(pyridin-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-1H-imidazol-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-pyrazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(pyridin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-phenylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(p-tolyl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3-(2-cyanopropan-2-yl)phenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(o-tolyl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(2-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(2-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1-methyl-2-oxopiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4,4-difluorocyclohexyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-fluorophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-chlorophenyl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)thio)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(((1-fluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(((3,3-difluorocyclobutyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(((2,2-difluorocyclopropyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-((1-cyclopropyl-2,2,2-trifluoroethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4H-thieno[3,4-c]pyrrol-5(6H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(2,2-difluoroethyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-(2-fluoroethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(5,5-difluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)morpholino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(1-oxoisoindolin-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(5,6-difluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-methyl-3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(3,3-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4,4-difluoro-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3,4,4-trifluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-oxa-7-azabicyclo[3.3.1]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(9,9-difluoro-1-(hydroxymethyl)-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(7,7,9,9-tetrafluoro-3-azabicyclo[3.3.1]nonan-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4,4-difluoro-3,5-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(7,7-difluoro-5-azaspiro[2.4]heptan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(6-(trifluoromethyl)-3-azabicyclo[3.1.0]hexan-3-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(1,1-dioxidothiomorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(4-methylthiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-(2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-(((1-(2-cyano-3-(4-(2,4-difluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-cyano-2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(4-(N-methylsulfamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(4-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(4-(4-chlorobenzoyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(2-oxo-[1,4'-bipiperidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4,4-difluoro-[1,4'-bipiperidin]-1'-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(1,1-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(7-methyl-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-oxo-1,7-diazaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(7,7-difluoro-2-azaspiro[4.4]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(2-cyano-4-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-(4-fluorophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4,4-difluoro-2-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,3-difluoro-2-methylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,5-difluoropiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(4-fluoro-2-(morpholine-4-carbonyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(6,6-difluoro-2-azabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(2-methyl-4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(5-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(5-(difluoromethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(3-(5-(trifluoromethyl)isoxazol-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3-fluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3-(difluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(5,5-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-(7-chloro-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,3-difluoro-2-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(3-((1-benzyl-2-oxopiperidin-3-yl)(methyl)amino)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(methyl(4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-((3,3-difluorocyclobutyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-(3-methyl-4-oxo-3,9-diazabicyclo[4.2.1]nonan-9-yl)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-chloro-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-7-methyl-3-phenoxyquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(3-cyanophenoxy)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(3-(benzyloxy)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)oxy)quinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-methoxy-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(4-(ethoxymethyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(diethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-((1-(pyridin-3-yl)ethyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-7-methyl-3-((3,3,3-trifluoro-2-methylpropyl)amino)quinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-((1-cyclopropylethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-2-((1-(2-cyano-3-(isobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(3-hydroxy-3-isopropylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

2-(((1R)-1-(2-cyano-3-(1-isopropyl-7,7-dioxido-7-thia-2-azaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)benzoic acid;

(R)-3-((1-(3-(4-(bicyclo[1.1.1]pentan-1-yl-3-d)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-((3-cyanophenyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(((tetrahydrofuran-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(((3,3-difluorocyclobutyl)methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-((2-cyanoallyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(cyclobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-((3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((1-cyclopropyl-2,2,2-trifluoroethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2,3-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4H-thieno[3,4-c]pyrrol-5(6H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(2,2-difluoroethyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(azepan-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(6-azaspiro[2.5]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(azetidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-hydroxy-8-azaspiro[4.5]decan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methylpiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(octahydro-2H-4,7-ethanoisindol-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(6,6-dimethyl-3-azabicyclo[3.2.0]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-azaspiro[3.3]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2-azadispiro[3.1.36.14]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-(2-fluoroethyl)morpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(5,5-difluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-cyclopropylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-cyclopropyl-6-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(3-azabicyclo[3.1.1]heptan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

3-(((1R)-1-(3-(3-azabicyclo[3.1.0]hexan-3-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6-(4-cyanophenyl)-2,6-diazaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-cyclopropyl-2-methylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((1R)-1-(3-(3,6-diazabicyclo[3.1.1]heptan-6-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-3-((1-(3-(7-azabicyclo[2.2.1]heptan-7-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-3-((1-(3-(2-azaadamantan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1-(methoxymethyl)-4-methyl-2-azabicyclo[2.1.1]hexan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(8-((dimethylamino)methyl)-6-oxa-9-azaspiro[4.5]decan-9-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-(fluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(2-azabicyclo[2.2.2]octan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

3-(((1R)-1-(3-(2-azabicyclo[2.2.1]heptan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(hexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)-6-azabicyclo[3.2.1]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(2-azabicyclo[2.1.1]hexan-2-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-(pyridin-3-ylmethyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-methylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2,3-dimethylmorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxoisindolin-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-methyl-3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-oxopiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxy-2-(2-methoxyphenyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3,4-dihydroquinolin-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxy-3-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(2-(4-hydroxy-4-methyltetrahydro-2H-pyran-3-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4,4-difluoro-3-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3,4,4-trifluoropiperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-oxa-7-azabicyclo[3.3.1]nonan-7-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(9,9-difluoro-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(9,9-difluoro-1-(hydroxymethyl)-3-azabicyclo[3.3.1]nonan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(5-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(5,5-difluoro-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(7,7,9,9-tetrafluoro-3-azabicyclo[3.3.1]nonan-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(6-hydroxyhexahydro-3,5-methanocyclopenta[b]pyrrol-1(2H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(6-hydroxy-6-methyl-3-azabicyclo[3.1.1]heptan-3-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(5-(4-cyanophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(5-phenyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4,4-difluoro-3,5-dimethylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((1R)-1-(3-(7-(tert-butyl)-6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(5,6,8,9-tetrahydro-7H-imidazo[1,2-d][1,4]diazepin-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1,1-dioxidothiomorpholino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-methylthiazol-2-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyridin-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(pyridin-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(4-(4-(aminomethyl)phenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(2,6-dimethylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(o-tolyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(2-cyanopyridin-3-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(3-cyano-1-methyl-1H-indazol-7-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(2-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(2,4-difluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-2-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-(N-methylsulfamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-fluorophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(4-(methylcarbamoyl)phenyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(4-(4-carbamoylphenyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyanophenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-2-methylphenyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(8-cyanoisoquinolin-5-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-7-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-cyano-6-hydroxynaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4,6-dicyanonaphthalen-1-yl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(oxetan-3-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyclopropylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(4-benzoylpiperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(3-(4-(4-chlorobenzoyl)piperazin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(cyclopentanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(1-methyl-1H-pyrazol-3-yl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(4-(1H-pyrazol-3-yl)piperidin-1-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(4-methoxyphenyl)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-methoxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-hydroxypiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-([1,4'-bipiperidin]-1'-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluoro-[1,4'-bipiperidin]-1'-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-(dimethylamino)piperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyclopentylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyclobutylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(4-(trifluoromethyl)piperidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyanopiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-oxa-8-azaspiro[4.5]decan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1,1-difluoro-6-azaspiro[2.5]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-methoxy-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyano-4-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-(pyridin-4-yl)pyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-phenylpyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-(1,3-dihydroxypropan-2-yl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-oxa-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidin]-1'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(7-methyl-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(8,9-dihydroxy-6-oxa-2-azaspiro[4.5]decan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-oxo-1,7-diazaspiro[4.4]nonan-7-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(7,7-difluoro-2-azaspiro[4.4]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1,1,2,2-tetrafluoro-6-azaspiro[3.4]octan-6-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-3-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-(trifluoromethyl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(2-methyl-4-phenylpiperazin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(3-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(2-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(2-cyano-4-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(4-fluorophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(4-cyanophenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-(2-cyano-5-methylphenyl)-2-methylpiperazin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4,4-difluoro-2-methylpiperidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(6-hydroxy-2-azabicyclo[2.2.2]octan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(4-fluoro-2-(morpholine-4-carbonyl)pyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(2-methyl-4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-fluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyanoisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(5-methylisoindolin-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5-(difluoromethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,6-dimethoxyisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(5,6-difluoroisoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(tetrahydro-1H,3H-spiro[pyrrolo[2,1-c][1,4]oxazine-4,5'-[1,3]oxazinan]-3'-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(decahydro-2H-cycloocta[c]pyrrol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(8-azatricyclo[4.3.0.0^{2,5}]nonan-8-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(1H,3H,4H-3a,6a-(methanooxymethano)furo[3,4-c]pyrrol-5(6H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(8-hydroxy-6-azaspiro[3.4]octan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(5-(trifluoromethyl)isoxazol-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(pyridin-2-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-(pyridin-3-yl)azetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(3-phenylazetidin-1-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-methoxyazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-fluoroazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-(difluoromethyl)azetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-cyanoazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(7-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(8-hydroxyoctahydro-2H-4,7-methanoisoindol-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(5-methyl-2-azabicyclo[2.2.1]heptan-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1'-methyltetrahydrospiro[furo[3,4-b]pyrrole-3,4'-piperidin]-1(2H)-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(1-(hydroxymethyl)isoindolin-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(3-(7-chloro-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxyoctahydro-1H-indol-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-methyloctahydro-2H-isoindol-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-2-methylazetidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(methyl((5,6,8,9-tetrahydro-[1,2,4]triazolo[4,3-d][1,4]oxazepin-3-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(methyl((5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)methyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-((cyclopropylmethyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(((1-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(dimethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

3-(((1R)-1-(3-((1-benzyl-2-oxopiperidin-3-yl)(methyl)amino)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(methyl(4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-((3,3-difluorocyclobutyl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(methyl(1-methyl-2,3-dihydro-1H-inden-2-yl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((2-methoxy-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(3-methyl-4-oxo-3,9-diazabicyclo[4.2.1]nonan-9-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(piperidin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methylpiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3,6-dihydro-2H-pyran-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3,7-dimethylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-(1-methyl-2-oxopiperidin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1-(4-cyanophenyl)piperidin-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(1-acetylpiperidin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4,4-difluorocyclohexyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-((4-cyanophenyl)ethynyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyridin-2-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyridin-3-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1-methyl-1H-imidazol-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-pyrazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(pyridin-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-phenylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(p-tolyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-(2-cyanopropan-2-yl)phenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(1H-pyrazol-4-yl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(o-tolyl)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(1-(4-cyanophenyl)-1H-imidazol-4-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(2-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-methoxyphenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-fluorophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(3-(4-chlorophenyl)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(4-cyanophenyl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(3-chloro-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)thio)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-phenoxyquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(3-cyanophenoxy)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-3-((1-(3-(benzyloxy)-2-cyano-7-methylquinoxalin-5-yl)ethyl)amino)-6-chloropicolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((tetrahydrofuran-3-yl)oxy)quinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-methoxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-hydroxy-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(diethylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((1-(pyridin-3-yl)ethyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-7-methyl-3-((3,3,3-trifluoro-2-methylpropyl)amino)quinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-((1-cyclopropylethyl)amino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

(R)-6-chloro-3-((1-(2-cyano-3-(isobutylamino)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(3-hydroxy-3-isopropylpyrrolidin-1-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid;

6-chloro-3-(((1R)-1-(2-cyano-3-(1-isopropyl-7,7-dioxido-7-thia-2-azaspiro[3.5]nonan-2-yl)-7-methylquinoxalin-5-yl)ethyl)amino)picolinic acid; or
a pharmaceutically acceptable salt thereof.

68. A pharmaceutical composition comprising a compound or salt according to any of claims 1-67 together with a pharmaceutically acceptable carrier, excipient or diluent.

69. A method of treating a disease or disorder associated with modulation of phosphoinositide 3-kinase (PI3K), comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 67 or a pharmaceutical composition of claim 68.

70. The method of claim 69, wherein the PI3K is PI3K α .

71. The method of claim 69 or claim 70, wherein the PI3K associated with the disease or disorder has a H1047R mutation.

72. The method of any one of claims 69 to 71, wherein the disease or disorder is a cancer.

73. The method of claim 69, wherein the cancer is endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, head and neck cancer, breast cancer, brain cancer, or prostate cancer.

74. The method of any one of claims 69 to 71, wherein the disease or disorder is CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), or PIK3C α -related overgrowth syndrome (PROS).

75. A method of inhibiting phosphoinositide 3-kinase (PI3K), comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 67 or a pharmaceutical composition of claim 68.

76. A method of treating cancer or a disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 67 or a pharmaceutical composition of claim 68.

77. The method of claim 72, wherein the cancer is endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, head and neck cancer, breast cancer, brain cancer, or prostate cancer.

78. A method of treating cancer comprising administering a compound according to any of claims 1 to 67 or a pharmaceutical composition of claim 68 and a KRAS inhibitor to a patient in need thereof, wherein the cancer is breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

79. A method treating cancer comprising administering a compound according to any of claims 1-67 or a pharmaceutical composition of claim 68 and a mutant selective KRAS inhibitor to a patient in need thereof, wherein the cancer is breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

80. A compound according to any of claims 1-67 or a pharmaceutical composition of claim 68 for use in the treatment of cancer in combination with a KRAS inhibitor, wherein the cancer is breast cancer, uterine carcinosarcoma, uterine endometrial carcinoma, colorectal adenocarcinoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, bladder carcinoma, lung squamous cell carcinoma, brain glioma, adrenocortical carcinoma, liver hepatocellular carcinoma, sarcoma, prostate adenocarcinoma, kidney renal cell carcinoma, lung adenocarcinoma, ovarian cystadenocarcinoma, glioblastoma multiforme, melanoma.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2024/028261

A. CLASSIFICATION OF SUBJECT MATTER					
INV.	C07D241/44	C07D401/04	C07D401/12	C07D401/14	C07D403/04
	C07D417/12	C07D491/18	C07D491/20	C07D498/20	A61P35/00
	A61K31/498				
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) C07D					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
X	WO 2023/078401 A1 (FOCHON BIOSCIENCES LTD [CN]) 11 May 2023 (2023-05-11) examples 4a, 4b, 16a, 16b -----				1 - 80
X	WO 2017/060406 A1 (JANSSEN PHARMACEUTICA NV [BE]) 13 April 2017 (2017-04-13) pages 1-4 - page 232; compound 167 -----				1
Y	WO 2018/178280 A1 (JANSSEN PHARMACEUTICA NV [BE]) 4 October 2018 (2018-10-04) page 1; examples -----				1 - 80
Y	WO 2018/178280 A1 (JANSSEN PHARMACEUTICA NV [BE]) 4 October 2018 (2018-10-04) page 1; examples -----				1 - 80
X, P	WO 2024/026419 A1 (BLACK DIAMOND THERAPEUTICS INC [US]; ARNAUTOVA YELENA [US] ET AL.) 1 February 2024 (2024-02-01) examples -----				1 - 80
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.					
* Special categories of cited documents :					
"A" document defining the general state of the art which is not considered to be of particular relevance			"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E" earlier application or patent but published on or after the international filing date			"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)			"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"O" document referring to an oral disclosure, use, exhibition or other means			"&" document member of the same patent family		
"P" document published prior to the international filing date but later than the priority date claimed					
Date of the actual completion of the international search 26 June 2024			Date of mailing of the international search report 11/07/2024		
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016			Authorized officer Lauro, Paola		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2024/028261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2023078401 A1	11-05-2023	NONE	
WO 2017060406 A1	13-04-2017	AU 2016335086 A1	12-04-2018
		BR 112018007068 A2	23-10-2018
		CA 2999818 A1	13-04-2017
		CN 108349946 A	31-07-2018
		EA 201890906 A1	28-09-2018
		EP 3359533 A1	15-08-2018
		ES 2905673 T3	11-04-2022
		IL 258513 A	31-05-2018
		JP 6912460 B2	04-08-2021
		JP 2018535199 A	29-11-2018
		KR 20180061258 A	07-06-2018
		MA 45896 A	19-06-2019
		US 2019062311 A1	28-02-2019
		US 2020079763 A1	12-03-2020
		WO 2017060406 A1	13-04-2017
WO 2018178280 A1	04-10-2018	AU 2018246321 A1	14-11-2019
		BR 112019020309 A2	28-04-2020
		CA 3054107 A1	04-10-2018
		CN 110461827 A	15-11-2019
		EA 201992296 A1	12-02-2020
		EP 3601254 A1	05-02-2020
		ES 2925176 T3	14-10-2022
		IL 269598 A	28-11-2019
		JP 7053654 B2	12-04-2022
		JP 2020512352 A	23-04-2020
		KR 20190133729 A	03-12-2019
		US 2020181132 A1	11-06-2020
		WO 2018178280 A1	04-10-2018
WO 2024026419 A1	01-02-2024	NONE	